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Besides its use as primary coagulants in water treatment1 or as antibacterial agents,2 cationic 
polymers hold great promise in treating human diseases in the 21st century. They have proven to 
be versatile tools in the field of biomedical applications, in particular for gene delivery systems or 
point-of-care diagnostics.3 Some of these so-called “pharmapolymers” already entered the market 
or are currently in different stages of clinical studies, which are discussed in Chapter 2. 
Without doubt, gene delivery represents the most prominent application field of polycations. 
Although viral vectors have superior transduction capabilities, their clinical applications are 
limited due to their immunogenic and oncogenic potentials.4-5 To circumvent this problem, 
numerous non-viral gene delivery systems have been investigated, which include cationic 
molecules like lipids,6 peptides7 and polymers.8 Among those, synthetic polymers have been 
established as promising alternatives since they offer several advantages, such as easy large scale 
production, simple storage conditions, non-significant batch-to-batch variations and numerous 
possibilities for chemical modifications to achieve the desired properties.9-10 
While electrostatically interacting with the negatively charged phosphate groups of the genetic 
material, the cationic polymers form so-called polyplexes (see Figure 1.1A).11 The condensation 
of oligonucleotides is often described in the literature by the nitrogen/phosphate ratio (N/P ratio) 
of the respective polyplexes (polymer/nucleic acid). Besides the condensation of 
oligonucleotides, the complexation results in the shielding of negative charges and the 
“protection” of nucleic acids from enzymatic degradation under in vitro and in vivo conditions. 
This is essential for a successful gene delivery mechanism.12 The formed complexes are able to 
enter the cell by different endocytotic uptake mechanisms summarized by Durzynska et al. 
(Figure 1.1B).13 Once entered into endosomes, protons accumulate on the cationic functional 
sites of the polymer initiated by the proton pump vacuolar-type H+-ATPase (V-ATPase). 
The influx of chloride anions, which comes along with the proton accumulation, results in an 
increase of the ion concentration and, simultaneously, in an osmotic swelling of the endosome. 
Furthermore, the internal charge repulsion leads to the expansion of the polymeric network 
(“proton-sponge effect”).14 Finally, the endosome membrane ruptures and the cargo is released 
into the cytosol. It has been reported that this local rupture, forced by the protonation of amines,15 
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is essential for the polyplex release, rendering the pH responsive release an important criterion 
for the design of gene delivery systems.16 
Although immense effort has been put into the investigation of the uptake mechanism through the 
nucleus membrane, the uptake of oligonucleotides is still widely unknown and represents the 
major limitation for the efficient gene transfer with non-viral systems. 
 
 
Figure 1.1. A) Polyplex formation of cationic polymers with genetic material (e.g. DNA, RNA). B) Gene delivery 
mechanism of DNA. 
 
The described process requires polymer systems with precisely designed properties which range 
from the condensation and protection of the genetic material to specific delivery, uptake and 
expression of the desired genes. Among the investigated systems, poly(ethylene imine) (PEI) is 
one of the most successfully and widely studied vectors and has been used as the gold standard 
for gene transfection (1st generation).8, 17 Linear (LPEI) and branched (BPEI) architectures exist 
and possess one of the highest cationic charge density potentials of all organic macromolecules.18 
Every third atom is an amine, of which every sixth nitrogen is protonated under physiological 
conditions19 which turns PEI into a useful tool to form toroidal complexes that are readily 
endocytosed by cells.20-21 Thereby, transfection efficiencies similar to viral vectors can be 
achieved.22 Obtained by the ring-opening polymerization (ROP) of unsubstituted aziridines, 
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BPEI features a branched structure including primary, secondary and tertiary amine groups 
(Figure 1.2A).23 However, the lack of control during the synthesis limits the investigation of 
structure-property relationships.24 For this reason, along with the high cytotoxicity of branched 
structures,18 the linear form, which possesses solely secondary amine functionalities, is often 
desired. One opportunity to synthesize LPEI is the ROP of N-substituted aziridines and 
subsequent deprotection (Figure 1.2B).25-27 
 
 
Figure 1.2. Schematic representation of the synthesis of A) branched PEI by ring-opening polymerization of 
aziridines and B) linear PEI by ring-opening polymerization of N-functionalized aziridines.  
 
However, the most common synthesis method uses poly(2-oxazoline)s (POx) as starting 
materials, which show a stealth effect similar to poly(ethylene glycol) (PEG).28 The living 
character of the cationic ring-opening polymerization (CROP) of 2-oxazolines, which was 
described in 1966 by four different research groups,29-32 allowed the design of well-defined POx 
and, later on, LPEI, with narrow dispersities and the access to highly functional systems. 
The CROP is performed under inert conditions and can be mainly subdivided into three steps. 
The first step is the initiation of the 2-substituted oxazoline with an electrophile, e.g. methyl 
tosylate or methyl triflate (Scheme 1.1A). The formed oxazolinium species exhibits a weakened 
C-O-bond which allows the nucleophilic attack of the nitrogen of another monomer. This results 
in a ring-opening followed by the formation of a carbonyl group. This propagation step can be 
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repeated until the desired chain length is achieved. The addition of a nucleophile, e.g. water, 
terminates the polymerization. 
LPEI is obtained by the acidic33-34 or basic35-36 hydrolysis of poly(2-alkyl-2-oxazoline)s, whereas 
methyl or ethyl side chains have been established as fast and simple moieties for a controlled 
hydrolysis (Scheme 1.1B, m = n). The reaction time for acidic hydrolysis ranges from a few 
hours to several days (depending on the POx side chain), while the basic hydrolysis is even 
slower using a conventional heating procedure. In recent years, microwave-assisted synthesis 
approaches resulted in a renaissance of POx. Besides the tremendous acceleration of the 
polymerization from days/hours to minutes,37 the acceleration of the hydrolysis of POx could be 
established.38-39  
 
 
Scheme 1.1. Schematic representation of the A) mechanism for the cationic ring-opening polymerization (CROP) of 
poly(2-oxazoline)s and B) (partial) hydrolysis of poly(2-oxazoline)s. 
 
Besides enabling for the full hydrolysis of POx, the microwave irradiation supports the tailored 
partial hydrolysis to yield poly(2-alkyl-2-oxazoline-stat-ethylene imine)s (P[Ox-stat-EI]) with 
defined monomer ratios (Scheme 1.1B, m < n).38, 40 The partial hydrolysis of POx represents a 
unique opportunity to overcome the major drawbacks that come along with the net positive 
charge of PEI/polyplexes, comprising poor water solubility (at room temperature), severe 
cytotoxicity, aggregation and undesired non-specific interactions with cellular and non-cellular 
components, particularly in vivo.41 A further powerful strategy is the post-hydrolysis chemical 
modification, comprising the transformation of the amine group of PEI via alkylation, 
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ring-opening of epoxides and carbonates, conjugate addition and acylation, among others.24 
Starting from commercially available LPEI, the design of biodegradable and more biocompatible 
LPEI – currently an ongoing challenge – via simple one-pot modification is described in 
Chapter 3. 
An additional challenge to impart functionality for specific applications is to attach functional 
groups via N-acylation to the LPEI backbone. The resulting polymers are obtained by a 
post-polymerization modification and exhibit POx-like structures (pseudo-POx).42 
The installation of alkene functionalities enables the subsequent application of the thiol-ene 
photo-addition to attach specific functional groups. Chapter 4 describes the introduction of 
functional groups to the LPEI backbone, comprising primary amine groups for gene delivery 
applications and D-fructose moieties with selectivity for the GLUT5 transporter system in human 
breast cancer cells. Furthermore, the conjugation of glutathione moieties to the cationic backbone 
allows the transport of genetic material and, simultaneously, the passage through an hCMEC/D3 
endothelial cell layer mimicking the highly selective blood-brain barrier within a microfluidically 
perfused biochip. The general structures of different generations of LPEI (1st, 2nd and 
3rd generation) which are mentioned in the following chapters, are depicted in Figure 1.3. 
 
 
Figure 1.3. Schematic overview of different generations of linear poly(ethylene imine) (LPEI). Compared to the 
original LPEI (1st generation), the 2nd generation LPEI contains functional monomer units (black or blue) besides the 
ethylene imine units (blue). The 3rd generation LPEI describes the presence of multiple functional units comprising 
cationic functionalities (blue), cell viability increasing functional groups (black) as well as a third group of 
functionalities (orange, e.g. primary amine functionalities or targeting molecules). 
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While poly(2-oxazoline)s show no binding affinity to genetic material since they contain 
exclusively nitrogen in forms of amide functionalities, the use of suitable amine group containing 
2-oxazoline monomers results in copolymers with excellent deoxyribonucleic acid (DNA) 
binding affinities which are described in Chapter 5. Notably, the absence of chain transfers and 
termination reactions using CROP under optimal conditions results in a high end-group fidelity 
that can be used to synthesize block copolymers by sequential addition of different monomers. 
The overall aim of this thesis is the development of a versatile platform for the preparation of 
cationic polymers for biomedical applications, in particular gene delivery, based on POx. 
The convenient modification of these starting materials enables a straightforward tuning of the 
properties of the final cationic polymers and, thus, the application in various research fields. 
In future, this knowledge can be further applied for the straightforward preparation of various 
functional cationic systems. Even more complex systems seem to be accessible with the 
presented, convenient modification techniques. 
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Parts of this chapter will be published in: P1) C. Englert, J. C. Brendel, T. C. Majdanski, T. Yildirim, S. Schubert, 
M. Gottschaldt, N. Windhab, U. S. Schubert, Adv. Healthcare Mater., submitted (2017/06/06). 
 
The administration of genes is one of the main tasks within the area of pharmaceutical 
applications of cationic polymers. Since the early 1960s, controlled gene delivery has gained 
increasing interest and developed from macroscopic devices and implants to microscopic and 
nanoscopic systems.43 The term “cationic pharmapolymers” covers synthetic cationic polymers 
based on an artificially produced polymeric backbone which are used for the administration of 
genes. They represent a useful alternative to liposomes, metal-organic frameworks (MOFs) and 
natural polymers (such as dextran, chitosan, hyaluronic acid) among others to fulfill the criteria 
of drug storage and delivery. On average, one out of 5,000 compounds that entered pre-clinical 
studies becomes an approved product after 10 years from the idea to the market entry.44 
Cationic polymers that received market approval or are at least under clinical investigations are 
based on the polymer class of poly(ethylene imine) (PEI) and mainly occur in forms of 
nanoparticulate drug carriers. Different PEI formulations and modifications which allow 
overcoming the toxicity issues of pure PEI reveal promising results in clinical phases (Table 2.1). 
The hydrolysis of tailored poly(2-ethyl-2-oxazoline)s (PEtOx) results in linear PEI (LPEI) which 
is sold in a formulation under the trade name jetPEI®. One representative example is the polyplex 
SNS01-T, which is dissolved in a special buffer system and possesses a molar mass (Mn) around 
22,000 g mol-1. It contains a B-cell specific expression plasmid deoxyribonucleic acid (pDNA) as 
well as a small interfering ribonucleic acid (siRNA). The latter suppresses the hypusinated 
eukaryotic translation initiation factor 5A (eIF5A) which was found to sensitize myeloma cells to 
apoptosis (clinical phase II).45 Another transfection agent based on jetPEI® is CYL-02, which is 
currently in clinical phase II for pDNA delivery. CYL-02 is intratumorally administered using 
endoscopic ultrasound in patients with pancreatic cancer and sensitizes cancer cells to 
chemotherapy.46 Another system that uses the jetPEI® technology is the polyplex formation with 
pDNA, BC-819. The complex is intravenously administered and targets cancer cells that usually 
express the H19 gene (activation of diphtheria toxin A leads to cell death), whereas healthy cells 
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are not affected. In this way, BC-819 works as a “search and destroy” unit. For 2016, BioCancell 
announced the start of pivotal bladder cancer trials (phase III).47 In addition, the company is 
working on a dual-DTA (diphtheria toxin A) expression system named BC-821 driven by the two 
core promoters H19 and the promoter segment IGF2-P4.48 The system has the benefit of 
providing enhanced cell-killing potential as well as the increasing chance that at least one of the 
promoters will be active in any tumor. 
The significant cytotoxicity of PEI is a tremendous challenge in the process of becoming an FDA 
approved product. The chemical modification of PEI represents a suitable tool to increase its 
biocompatibility. One pDNA/PEI-based formulation using this approach already entered clinical 
phase II.49 In contrast to the former described formulations, EGEN-001 is based on low molar 
mass branched PEI (BPEI) which is covalently linked with poly(ethylene glycol) methyl ether 
and cholesterol.50 EGEN-001 is directly injected into cancerous tissue where the local 
concentration of interleukin 12 (IL-12) is increased in the tumor microenvironment. IL-12 is one 
of the most active immunocytokines leading to a robust local and systemic immune response to 
cancer.51 In 2014, Celsion Corp. acquired the EGEN Inc. including the product candidate 
EGEN-001, which was renamed as “GEN-1”. Currently, the TheraSilenceTM technology platform 
is used to advance EGEN-RNA-002, which is in preclinical development for the treatment of 
lung disease by the delivery of a RNA sequence.52 Another representative based on modified PEI 
is DermaVir® (phase II). It is a topical application that contains a pDNA expressing all HIV 
proteins except integrase to induce T-cell mediated immune responses with broad specifity. The 
pDNA is formulated with a mannosylated jetPEI® in a glucose solution to target antigen-
presenting cells (Langerhans cells - precursors of dendritic cells) and to protect the DNA from 
intracellular degradation.53 DermaVir-transduced cells migrate from the skin to the draining 
lymph node and interdigitate as DermaVir-expressing, antigen-presenting dendritic cells. 
Besides nanocarrier formulations, PEI has found its way to clinical studies even in a 
hydrogel-based device. The product, which is marketed under the trade name Aquatrix IITM by 
Hydromer Inc., consists of two separate aqueous solutions comprising poly(vinyl pyrrolidone) 
(PVP) and either chitosan or PEI.54 Pharmaceutical ingredients can be loaded into the drug 
delivery matrices by the addition to the aqueous solution prior to the network formation. 
 19 
2  POLY(2-OXAZOLINE) DERIVED PHARMAPOLYMERS OF THE 21ST CENTURY 
Poly(2-oxazoline)s (POx) represent another polymer class that possesses significant potential for 
drug delivery applications and can be used as the precursor for the synthesis of cationic polymers 
(e.g. LPEI). POx are a rather new emerging class of synthetic polymers which has not been under 
clinical investigation so far. In October 2015, Serina Therapeutics started to recruit participants 
for a clinical phase I study of their POx-drug conjugate SER-214 (Table 2.1).55 SER-214 is a 
PEtOx polymer conjugate of the FDA (Food and Drug Administration)-approved dopamine 
antagonist rotigotine, which displayed an impressive efficacy in vivo.56 Its continuous 
dopaminergic stimulation profile represents a powerful tool in the treatment of Parkinson’s 
disease. Beyond, Serina Therapeutics’ POx polymer technology represents a unique injectable 
platform technology with distinct advantages in drug delivery applications. Latest investigations 
point through an enhanced interest in future POx-based materials. It could be shown that the 
cellular uptake is influenced by the choice of the oxazoline monomer and architecture.57-58 
Furthermore, in vivo studies revealed a low immune response as well as an increased circulation 
of POxylated proteins.59 Luxenhofer et al. have recently summarized POx drug- and protein-
conjugates and their preclinical results.60 
The coupling of small molecule drugs, such as Ara-C or antibiotic ciprofloxacin, to POx resulted 
in similar behavior as comparable poly(ethylene glycol) (PEG) conjugates. The latter represent 
probably the most well-known examples for polymer conjugates. In contrast, the properties and 
the functionality of POx can be altered with a relative ease and render this polymer class a highly 
versatile alternative. 
 
Table 2.1. Poly(2-oxazoline) derived pharmapolymers on the market or in clinical trials. 
Name Form Polymer system Drug Indication/Use Status 
SNS01-T Polyplex LPEI (jetPEI®) pDNA, siRNA Multiple myeloma Phase II  (NCT01435720) 
CYL-02 Polyplex LPEI (jetPEI®) pDNA Pancreatic adenocarcinoma 
Phase II  
(NCT02806687) 
BC-819/PEI  
(DTA-H19) Polyplex BPEI pDNA 
Bladder cancer, ovarian 
cancer, pancreatic 
adenocarcinoma 
Phase II  
(NCT00595088) 
EGEN-001  
(GEN-1) Polyplex 
Cholesterol and 
PEG-modified PEI pDNA 
Ovarian, tubal, colorectal 
peritoneal cancer 
Phase II  
(NCT01118052) 
DermaVir® 
(LC002) Polyplex 
Mannosylated LPEI 
(jetPEI®) DNA HIV vaccine 
Phase II  
(NCT00711230)  
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Aquatrix II
TM Hydrogel PVP-Chitosan, PVP-PEI 
Broad range of 
cosmetic and drug 
ingredients 
Drug delivery matrices  
(i.e. transdermal) Market 
SER-214 Polymer-drug conjugate POx Rotigotine Parkinson's Disease 
Phase I 
(NCT02579473) 
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Parts of this chapter have been published in: P2) C. Englert, M. Hartlieb, P. Bellstedt, K. Kempe, C. Yang, 
S. K. Chu, X. Ke, J. M. Garcı́a, R. J. Ono, M. Fevre, R. J. Wojtecki, U. S. Schubert, Y. Y. Yang, J. L. Hedrick, 
Macromolecules 2015, 48, 7420-7427; P3) C. Englert, M. Fevre, R. J. Wojtecki, W. Cheng, Q. Xu, C. Yang, X. Ke, 
M. Hartlieb, K. Kempe, J. M. García, R. J. Ono, U. S. Schubert, Y. Y. Yang, J. L. Hedrick, Polym. Chem. 2016, 7, 
5862-5872. 
 
3.1 Simple one-pot modifications of commercial linear poly(ethylene imine) 
Commercially available linear poly(ethylene imine) (LPEI), which can be purchased e.g. from 
Polysciences, is commonly obtained by acidic hydrolysis of methyl-initiated 
poly(2-ethyl-2-oxazoline) (PEtOx). The main differences to self-made LPEI are the high 
dispersity, which results from the commercial precursor PEtOx, and the contents of uncleaved 
N-acyl groups (up to 10%).24 However, commercial LPEI (in particular with 
Mw = 25,000 g mol-1) represents still the status quo new transfection agents have to compete 
with.  
One opportunity to simply modify commercial LPEI (1) in a one-pot reaction was previously 
described by MacDonald and co-workers.61 The authors reported the oxidation of the secondary 
amine groups of branched PEI (BPEI) by hydrogen peroxide via the following intermediate 
species: Hydroxylamine (Scheme 3.1b),62 nitrone (c),63 and oxaziridine (d).64 The ring-opening of 
the oxaziridine leads to a Beckmann-type rearrangement product and, subsequently, to the 
formation of a stable amide group (e). In this way, the structure of BPEI can be converted into a 
poly(glycine)-like structure with potential biocompatibility and biodegradability. The previous 
report mentioned the possible partial chain degradation (visible by the occurrence of carboxylic 
acid and aldehyde) which may occur from the oxidation (and subsequent hydrolysis) of the 
primary amines. For this reason, the oxidation of linear PEI was investigated since the polymer 
possesses no primary amine functionalities and can be characterized more easily. 
 22 
3  LINEAR POLY(ETHYLENE IMINE)S – MODIFICATION & APPLICATION 
 
 
Scheme 3.1. Schematic representation of the oxidation mechanism of a secondary amine (a) via hydroxylamine (b), 
nitrone (c), and oxaziridine (d) intermediates to form the final amide group (e), as proposed by MacDonald et al..61  
 
Initial experiments focused on the identification of the optimal reagents and conditions to control 
the oxidation process. The influence of several parameters like time, temperature and 
concentration was investigated as well as the nature of the oxidizing agents. 
Surprisingly, common oxidizing agents such as oxone, m-chloroperoxybenzoic acid (mCPBA), 
or the White catalyst (palladium coordination complex) were outperformed by hydrogen peroxide 
when surveying the degree of oxidation (DO), which was calculated by proton NMR 
spectroscopy (for details see Chapter 3.2). Its simplicity together with the efficient purification 
process of the oxidized material (i.e. by precipitation in diethyl ether, centrifugal concentration 
with a molar cut-off of 3,000 g mol-1 followed by freeze-drying) makes this procedure 
straightforward. The oxidation of 1 is performed in methanol and turns it into a partially oxidized 
poly(ethylene imine-stat-glycine) (P(EI-stat-Gly)) consisting of unaffected ethylene imine and 
newly formed glycine units (Scheme 3.2A). Copolymers with different degrees of oxidation 
(20 to 85%, 2 to 5) were synthesized and their structures are summarized in Table 3.1A. 
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Scheme 3.2. Schematic representation of simple one-pot modifications of commercial linear poly(ethylene imine) 
(LPEI). A): H2O2, MeOH, r.t.. B): < 0.5 equiv. paraformaldehyde (pF), H2O, 90 °C, 15 h. C): > 0.5 equiv. pF, H2O, 
90 °C, 15 h. D): Glycidol, MeOH, r.t., 20 h. 
 
A second approach for a facile one-pot reaction is the carbohydrate-like modification of 1. 
Previously, considerable efforts have been made to install carbohydrate-containing moieties on 
PEI due to their non-toxicity as well as their potential to target cells exhibiting carbohydrate-
receptors. Amongst others, galactose,65 mannose66 and oligo-maltose67 have been grafted 
successfully onto PEI. However, in most cases multiple step syntheses or harsh experimental 
conditions were required with often poor control over the composition. A facile and more 
economical modification strategy represents the installation of hydroxyl moieties in close 
proximity to the PEI backbone, in an effort to mimic the vicinal diols of sugars. Towards this 
goal, 1 was modified by a single-step reaction with hemiaminal moieties using paraformaldehyde 
(Scheme 3.2B and C) and by ring-opening of glycidol (Scheme 3.2D), i.e. reagents which are 
commercially available. The functionalization with different equivalents of paraformaldehyde 
(pF) per amine functionality (0.15 to 1.2 equiv.) was performed for 15 h at 90 °C in water and 
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resulted in copolymers with varying compositions (Table 3.1B). While the reaction of 1 with 
< 0.5 equiv. pF led to polymeric systems consisting of ethylene imine and hemiaminal units 
(6, 7), N-methylation of the PEI backbone occurred for higher pF contents (> 0.5 equiv.) 
(8 to 10). 
 
Table 3.1. Parameters for A) 1 and oxidized samples 2 to 5 and B) functionalized LPEI’s 6 to 15. 
 
 
 
 
 
 
 
a “b” indicates the degree of oxidation (DO). 
b Determined by 1H NMR (calculated from LPEI 6,500 g mol-1,68 ratio of PEI and Gly). 
c Determined by SEC (eluent: DMAc + 0.21% LiCl, calibration against polystyrene standard). 
d All samples are hardly soluble in the SEC eluent DMAc. Unfortunately, there is no calibration standard available  
  for cationic polymers like LPEI and derivatives. 
 
3.2 Characterization of modified linear poly(ethylene imine)s 
In general, the characterization of cationic polymers, in particular LPEI and its derivatives, 
represents a tremendous challenge due to numerous interactions with column materials. In the 
cases presented above, the main challenge was to demonstrate the absence of polymeric 
degradation products. In the following different characterization methods are discussed which 
allowed to elucidate the molecular structures of the copolymers synthesized. 
Proton nuclear magnetic resonance spectroscopy (1H NMR). One of the simplest, fastest and 
often applied characterization techniques in polymer chemistry is the 1H NMR. In particular, 
it can be used for the calculation of the polymer composition by comparing the integrals of the 
signals of different monomer units. For example, the DO of the oxidized P(EI-stat-Gly)s was 
 
  Composition [%] Mn [g mol-1] 
# Abbr. a ba NMRb SECc,d 
1 LPEIa ~95  6500 1100 
2 
P(EIa-stat-Glyb) 
80 20 6900 1500 
3 60 40 7300 1400 
4 33 67 7900 1700 
5 15 85 8200 1600 
 
 
# Abbr. Equivalents of funct. Agent 
6 P(EI-stat-Hem) 0.15 
7 0.30 
8 
P(EI-stat-Hem-stat-MetEI) 
0.50 
9 0.75 
10 1.20 
11 
P(EI-stat-Glyc) 
0.15 
12 0.30 
13 0.50 
14 0.75 
15 1.20 
 
A B 
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calculated from the integration of the 1H NMR signals of the copolymer 
backbones via equation 1, where B is the integral of the Gly, A the integral of the ethylene imine, 
and D the integral of the remaining EtOx units at 1 ppm after incomplete hydrolysis 
(provided that A << F). 
DO = (

	
)
	

     (1) 
A comparison of the 1H NMR spectra of the precursor 1 and 2 to 5 is depicted in Figure 3.1A. 
A higher H2O2 concentration resulted in an increasing integral of signal C (7.9 ppm) which 
represents the formed amide group. Its appearance is rather surprising and cannot be used for 
quantification of the DO due to proton exchange processes in D2O. A further evidence for a 
successful oxidation is the downfield shift of the signal A (EI) to the signal B (Gly). Previous 
kinetic investigations allowed the adjustment of defined DOs (2: 20, 3: 40, 4: 67, 5: 85%) 
via temperature and time controlled reaction. The development of the DO over the time is 
presented in Figure 3.1B for different temperatures ranging from –20, 0, and 8 to 18 °C. 
The molar masses for 1 in Table 3.1A, and, therefore, for the oxidized copolymers 2 to 5, are 
based on literature reported values. Indeed, commercial LPEI (Polysciences, 
Mw = 25,000 g mol-1) has been investigated by several research groups and revealed molar 
masses (Mn) below 10,000 g mol-1.68 
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Figure 3.1. A) 1H NMR spectra of 1 and oxidized samples 2 to 5 (D2O, 400 MHz). B) Kinetic studies of the 
oxidation of 1 at different temperatures with a 4-fold excess of H2O2. Degrees of oxidation were calculated from 
1H NMR spectra (D2O, 400 MHz).  
 
In the case of the carbohydrate-mimicking modifications, various concentrations of pF and 
glycidol, respectively, were used to synthesize copolymers with different compositions. 
Using pF, the copolymers 6 to 10 were obtained (Figure 3.2A). An increasing signal C occurred 
with higher concentration of pF, which is attributed to hemiaminal species. With 0.5 equivalents 
of pF or higher (8 to 10), methylation of the backbone was observed.69 The methyl group could 
be identified by DEPT 135/90 NMR experiments (distorsionless enhancement by polarisation 
transfer) and is the result of an Eschweiler-Clarke-type rearrangement, whereas the iminium 
intermediate (in the form of a secondary amine) is reduced to the corresponding tertiary 
amine.33, 70 This side reaction limits the amount of hemiaminal moieties that can be attached. 
Using glycidol to modify 1 through a straightforward ring-opening reaction under mild and 
catalyst free conditions71 yielded copolymers 11 to 15. 1H NMR spectroscopy was used once 
again to track the impact of the increasing epoxide concentration (Figure 3.2B).  
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Figure 3.2. 1H NMR spectra of 1 modified with varying contents of A) paraformaldehyde resulting in 6 to 10, 
respectively (D2O, 400 MHz) and, B) glycidol resulting in 11 to 15 (D2O, 400 MHz). 
 
Diffusion-ordered NMR spectroscopy (DOSY NMR). DOSY NMR represents a helpful technique 
to confirm the presence of a single (polymeric) species, as indicated by a defined diffusion 
coefficient and, furthermore, the absence of degradation processes leading to lower molar mass 
species. Using literature values, the molar mass of LPEI could be determined by DOSY NMR as 
4,200 g mol-1 by the help of the Mark-Houwink equation.72 A DOSY NMR spectrum for the 
oxidized sample 4 is presented in Chapter 3.3, Figure 3.5B. 
Size exclusion chromatography (SEC). The poor solubility in common solvents and the known 
interactions of the cationic polymers with the column material hinder a successful determination 
of molar masses of the polymeric samples by SEC, a commonly used method for the 
characterization of polymers. However, 1 to 5 could be dissolved in N,N-dimethylacetamide 
(DMAc) at low concentrations and the SEC traces indicate a successful modification without 
degradation (Figure 3.3A). A missing calibration for cationic polymers complicates a 
determination of accurate molar masses (see Table 3.1A). Due to the molar masses (Mn) 
< 10,000 g mol-1, asymmetric field flow fractionation (AF4) coupled to a MALLS (multi-angle 
laser light scattering) detector cannot be used for a successful determination of the molar masses. 
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Fourier transform infrared spectroscopy (FTIR). FTIR represents a straightforward and efficient 
method to investigate the vibrations of different bonds. The IR spectra of polymers 1 to 5 
are shown in Figure 3.3B and can be interpreted with regard to literature reports about 
polyglycine.73-75 The main vibration at 1660 cm-1 results from the carbonyl stretching vibration of 
the newly formed glycine unit.76 Potential degradation products, e.g. carboxylic acid derivatives, 
are expected to occur at wavenumbers over 1700 cm-1,77 however, they were not observed. 
Increasing DOs lead from nearly no carbonyl vibrations (for 1) to intense carbonyl bands (2 to 5). 
The vibration at 1600 cm-1 is likewise attributed to the amide mode. The CH2 bending and 
wagging modes of the formed glycine result in vibrations between 1440 and 1340 cm-1. 
 
 
Figure 3.3. A) Size exclusion chromatography traces of 1 to 5 (N,N-dimethylacetamide, 0.21% LiCl). B) IR spectra 
of 1 and oxidized samples 2 to 5 in the wavenumber range from 1200 to 2000 cm-1. 
 
3.3 Biocompatibility and -degradability 
As previously mentioned, one important parameter of a polymer candidate for biomedical 
applications is its biocompatibility, which describes the ability to be in contact with a living 
system without producing an adverse effect.78 For this purpose, in vitro studies were performed 
on chosen modified PEIs (2 to 12) to evaluate their cell viability in the model mammalian cell 
line human embryonic kidney 293 (HEK 293). The copolymers were compared to commercial 
LPEI which induces a toxic effect (cell viability < 80%) already at very low concentrations 
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(< 6.25 µg mL-1). The oxidized LPEIs (2 to 5) show cell viability up to a concentration of 
25 µg mL-1 (Figure 3.4A). Apparently, the degree of oxidation (DO) strongly influences the cell 
viability. While cell viability values drop below 60% after incubation with 2 at 50 µg mL-1 
for 48 h, an oxidation degree of 85% (5) still does not induce harmful effects even at higher 
concentrations (200 µg mL-1). Unfortunately, the modification of LPEI with pF (6 to 10) and 
glycidol (11, 12), respectively, did not allow for a significant improvement of the 
biocompatibility for lower degrees of functionalization (Figure 3.4B). But the use of more than 
0.5 equiv. pF (vs. -NH) induced N-methylation of the backbone, which increased the cell viability 
by lowering the net positive charge of 1.79 A crucial fact for the similar toxicity of pF-modified 
copolymers 6 to 9 compared to 1 is the instability of hemiaminal moieties at acidic pH values, 
releasing formaldehyde under endosomal conditions. As expected, the increase of the glycidol 
content resulted in decreasing cytotoxicities. 
 
 
Figure 3.4. Cytotoxicity of A) 1, oxidized samples 2 to 5 and B) functionalized samples 6 to 10 and 11, 12 by MTT 
assay on HEK 293 cells. 
 
Another important parameter for biomedical applications is the interaction of polymers with 
serum proteins. Therefore, DLS measurements were performed after treatment with fetal bovine 
serum (FBS) (Figure 3.5A). The starting LPEI (1) could not be investigated since its addition to 
serum immediately resulted in a precipitation of protein components. The Z-average values of the 
investigated copolymers 2 to 5 were indistinguishable from pure FBS (untreated control sample) 
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and, therefore, indicated no further aggregation as well as polymer stability in the presence of 
serum proteins over 48 h. This behavior only demonstrates the absence of serum coagulation, 
while an interaction of protein and polymer is still possible. 
 
 
Figure 3.5. A) Serum stability by time-dependent DLS measurements of FBS in the presence of oxidized 
samples 2 to 5. B) DOSY NMR of oxidized sample 4 before (blue) and after treatment with 6 mol L-1 aqueous 
hydrogen chloride (orange) and peptidase (trypsin) (green). The solvent signal was used for calibration 
(D2O, 400 MHz, 25 °C). 
 
Besides the described cytotoxicity of LPEI, the non-biodegradability represents another challenge 
that must be overcome. Different literature reports have claimed biodegradable PEI derivatives 
via end-group modification of PEI80-82 or side chain functionalization with degradable linkers.83 
However, none of these reports describe the full degradation of the polymer backbone. 
The incorporation of a defined number of amide groups in the backbone of LPEI via oxidation 
would enable biodegradation. To investigate the decomposition behavior, copolymer 4 with a DO 
of 67% was chosen as a model system and subjected to acidic (6 M hydrochloric acid) and 
enzymatic (trypsin) conditions. Diffusion-ordered NMR spectroscopy (DOSY NMR) was utilized 
to confirm successful degradation (Figure 3.5B). While the unmodified polymer 1 revealed 
no changes under these conditions, the copolymer 4 exhibited increased diffusion coefficients as 
well as a fractionation of the signals. Furthermore, the 1H NMR spectra revealed sharp and 
undefined signals. Further evidence is given by the reduction of the peak intensity of the amide 
bond at 7.9 ppm, which completely disappears upon treatment with hydrochloric acid. 
 31 
3  LINEAR POLY(ETHYLENE IMINE)S – MODIFICATION & APPLICATION 
At the same time, the intensity of the sharp signal at 8.45 ppm increases, which is probably 
attributed to degradation products. 
In summary, the specific improvement of the (bio)-properties, such as biodegradation and 
biocompatibility, was demonstrated and helps to overcome the main drawbacks of 
commercial LPEI.
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Parts of this chapter have been published in: P4) C. Englert, A. M. Schwenke, S. Hoeppener, C. Weber, 
U. S. Schubert, Adv. Polym. Sci. 2015, 274, 209-240; P5) T. Bus, C. Englert, M. Reifarth, P. Borchers, M. Hartlieb, 
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M. Gottschaldt, Macromol. Biosci. 2017, 17, 1600502. 
 
4.1 Post-polymerization modification of linear poly(ethylene imine) 
One opportunity to install different functionalities on a linear poly(ethylene imine) (LPEI) 
backbone is the hydrolysis of functional poly(2-oxazoline)s (POx), where parts of the functional 
groups are cleaved off and form ethylene imine units. Since most of the POx functional groups, 
e.g. alkene functionalities, do not withstand the acidic or basic hydrolysis, the 
post-polymerization modification of LPEI via N-acylation represents a meaningful alternative. 
As a result, poly(2-oxazoline)-like structures (pseudo-POx) are obtained. To enable reproducible 
modification steps including detailed characterization and evaluation, the precursor LPEI was 
synthesized in our lab in a well-controlled manner using a microwave synthesizer.  
Microwave-assisted synthesis approaches have been reported frequently over the last years. 
Amongst others, they can be used for the synthesis of well-defined high molar mass poly(2-alkyl-
2-oxazoline) (PAlkOx) under inert conditions and their subsequent hydrolysis. In particular, 
the hydrolysis has been the focus of numerous literature reports. Besides an acceleration of the 
reaction, the degree of hydrolysis can be easily controlled using different reaction conditions. 
Using 2-methyl- (MeOx) or 2-ethyl-2-oxazoline (EtOx), the microwave irradiation allows the 
synthesis of LPEI with EI contents up to 99% and chain lengths of 200 (Table 4.1).39 An increase 
of the reaction temperature (up to 180 °C) while using comparatively low acid concentrations has 
proven to significantly accelerate the full hydrolysis.40 Furthermore, the use of an ethanol-water 
mixture enables the differentiation of the hydrophilic poly(2-methyl-2-oxazoline) (PMeOx) and 
poly(2-ethyl-2-oxazoline) (PEtOx).84 The tailored hydrolysis of statistical or block copolymers, 
consisting of different 2-alkyl-2-oxazoline monomer units, allows the synthesis of copolymers 
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with defined compositions. While the hydrophilic oxazoline units show an enhanced hydrolysis 
rate, the cleavage of the hydrophobic part is almost inhibited. The different properties of the 
monomers can be used to synthesize block copolymers, such as poly(2-phenyl-2-oxazoline-block-
ethylene imine) which exhibits thermoresponsive micellization behavior.85  
 
Table 4.1. Overview of microwave-assisted hydrolysis of poly(2-oxazoline)s. 
 
 
Precursor architecture R1 R2 (a1 + b1) [units] c [%]* a2 [% ] b2 [% ] Hydrolysis conditions Ref. 
Homopolymer CH3 - 5-200 99 1 - HCl (16 wt%), 100 °C 38 C2H5 
Homopolymer C2H5 - 10-200 99 1 - HCl (16 wt%), 130 °C 39 
Homopolymer C2H5 - 30, 500 95 5 - HCl (3 wt%), 180 °C 40 
Homopolymer 
C2H5 
- 100 
95 5 - 
HCl (16 wt%), 160 °C 86 
n-C9H19 87 13 - 
Homopolymer 
CH3 
- 100 
95 5 - 
HCl (12 wt%), 100 °C, EtOH:H2O 4:1 84 
C2H5 22 68 - 
C6H5 13 87 - 
Block copolymer CH3 
C2H5 a1 = 50 b1 = 50 48 37 15 
C6H5 a1 = 60 b1 = 15 78 18 4 
Statistical copolymer 
CH3 C6H5 a1 = 60 b1 = 40 
98 2 0 HCl (16 wt%), 100 °C 
85 
59 21 20 NaOH 
Block copolymer 
84 16 0 HCl (16 wt%), 100 °C 
42 36 23 NaOH 
* The maximum degree of hydrolysis can be determined only within the limits of the 1H NMR accuracy. 
 
In order to fulfill the requirements for genetic interactions, well-defined high molar mass 
PEtOx (16) was synthesized with a degree of polymerization of 575 (Ð = 1.3), as starting 
material.28 Subsequently, the homopolymer was hydrolyzed in 6 M hydrochloric acid at 100 °C 
under microwave irradiation (Scheme 4.1A).38 Kinetic studies were performed in order to obtain 
cationic polymers with desired contents of EI. The partial hydrolysis resulted in 
 34 
4  PSEUDO-POLY(2-OXAZOLINE)S – SYNTHESIS & APPLICATION 
poly(2-ethyl-2-oxazoline-stat-ethylene imine) with an EI content of 46% (17), while the full 
hydrolysis provided LPEI with > 95% EI content (24). 
 
 
Scheme 4.1. Schematic representation of the synthesis of different pseudo-poly(2-oxazoline)s (16 to 29). 
A) 6 M HCl, µW, 100 °C, 100 min. B), E) and J) N-succinimidyl-4-pentenate, 4-N,N-dimethylamino-pyridine, 
pyridine, 80 °C, 20 h. C) and K): 2-(Boc-amino)ethanethiol, 2,2-dimethoxy-2-phenylacetophenone, MeOH, 365 nm, 
r.t., 20 h. D) and M): Trifluoro acetic acid, CH2Cl2, 20 h, r.t.. F): 2,2-Dimethoxy-2-phenylacetophenone, MeOH, 
365 nm, r.t., 18 h. G): 2 M HCl, THF/H2O, 40 °C, 12 h (grey circle = deprotected D-fructose). 
H) and L): Irgacure® 2959, milli-Q H2O, 365 nm, r.t., 17 h. 
 
Using N-succinimidyl-4-pentenate, a post-polymerization modification was performed to install 
2-butenyl-2-oxazoline (ButEnOx) units on the PEI backbone (Scheme 4.1B, E, J).42 
Different polymer compositions were obtained by using P(EtOx-stat-EI) (17) or LPEI (24) as 
starting material for the modification. In all cases, the presence of alkene functionalities enables 
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their application in thiol-ene photo-addition reactions and the simple attachment of various target 
molecules. Three different copolymers of P(EtOx-stat-EI-stat-ButEnOx) (18 to 20) with varying 
contents of secondary amines and ButEnOx (1:3, 1:2, 1:1) were obtained from 17, while the EtOx 
content remained constant (54%). An overview of the different polymer compositions is given in 
Table 4.2. The installation of primary amine functionalities was performed likewise by thiol-ene 
click reaction. For this purpose, 2-(boc-amino)ethanethiol was used to modify 18 to 20 
(Scheme 4.1C, D), resulting in P(EtOx-stat-EI-stat-AmButOx) after deprotection (21 to 23). 
The post-polymerization modification of 24 allowed the synthesis of P(EI-stat-ButEnOx) 
containing an EI content of 73% (25) as well as the homopolymer P(ButEnOx) (28). 
The copolymer 25 was functionalized with a protected thio-fructose (Scheme 4.1F), which was 
obtained by a five-step synthesis (not shown). However, full conversion of the alkene 
functionalities could not be achieved even after stepwise photo-addition. One reason might be the 
steric hindrance of the bulky side chains (isopropylidene protecting groups). Deprotection 
resulted in P(EI-stat-ButEnOx-stat-FruButOx) (26) with 16% D-fructose content (Scheme 4.1G). 
By using the same copolymer 25 as a precursor, L-glutathione (GSH) moieties were attached 
via the previously described thiol-ene photo-addition (Scheme 4.1H). Surprisingly, in this case 
the final polymer P(EI-stat-GluButOx) (27) contained no unmodified ButEnOx (as observed for 
26). Limited solubility properties of GSH require the photoinitiator Irgacure® 2959 to be used to 
run the click reaction in water. In another approach, polymer 28 was modified in a first step with 
primary amine moieties (2-(boc-amino)ethanethiol) (Scheme 4.1K), followed by the introduction 
of GSH using the previously described synthesis of 27 (Scheme 4.1L). The deprotection 
(Scheme 4.1M) resulted in the final polymer P(ButEnOx-stat-AmButOx-stat-GluButOx) (29). 
All modified PEI based products were water soluble. 
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Table 4.2. Parameters for pseudo-poly(2-oxazoline)s and their precursors (16 to 29) with a DP of 575. 
  Composition [%] NMR
a AF4 SEC 
# Name a b c d e f Mn  [g mol-1] 
Mn  
[g mol-1] Ð 
Mn  
[g mol-1] Ð 
16 PEtOxa 100      57,000 57,000 1.2 69,000
b 1.3 
17 P(EtOxa-stat-EIb) 54 46     42,100 31,300 1.3 48,000
b 1.3 
18 
P(EtOxa-stat-EIb-stat-
ButEnOxc) 
54 12 34    58,100 25,500 1.4 36,000
b 2.1 
19 54 17 29    55,800 30,900 1.3 34,500
b 1.6 
20 54 23 23    53,000 30,400 1.3 36,000
b 1.6 
21 
P(EtOxa-stat-EIb-stat-
AmButOxd) 
54 12  34   73,200 35,300 1.7 30,500
b 1.6 
22 54 17  29   68,600 43,700 1.7 39,000
b 1.6 
23 54 23  23   63,100 30,500 1.6 31,500
b 1.5 
24 LPEIb <5 >95     24,800 9,900 1.4 n.d. n.d. 
25 P(EIb-stat-ButEnOxc) <5 73 27    37,500 n.d. n.d. 31,400
c 1.2 
26 P(EIb-stat-ButEnOxc-stat-FruButOxe) <5 73 11  16  59,600 n.d. n.d. 9,800
b 1.2 
27 P(EIb-stat-GluButOxf) <5 73    27 85,200 21,000 2.0 n.d. n.d. 
28 P(ButEnOxc) <5  >95    71,900 n.d. n.d. 44,000
c 1.5 
29 
P(ButEnOxc-stat- 
AmButOxd -stat- 
GluButOxf) 
<5  10 82  8 122,300 63,300 1.8 n.d. n.d. 
 
a Determined by 1H NMR (calculated from PEtOx: 57,000 g mol-1 (ratio of tosylate and CH2-CH3 signal)) 
b SEC: DMAC, 0.21% LiCl, against PS; c SEC: CHCl3/iPrOH/NEt3 94:2:4, against PS 
n.d. – not determined, due to insolubility in SEC eluent or undesired interactions with the column/membrane 
 
4.2 Characterization of pseudo-poly(2-oxazoline)s 
As already mentioned, the characterization of cationic polymers represents a significant 
challenge. However, the installation of hydrophilic moieties on the pseudo-POx backbone allows 
a more comprehensive characterization as for modified commercial LPEI (Chapter 3.2). 
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Size exclusion chromatography (SEC) and asymmetric field flow fractionation (AF4). 
SEC represents a suitable method to determine the molar masses of polymeric species. Another 
well-established method for the detailed characterization is AF4 (RC membrane with molar mass 
cut-off 10,000 g mol-1). Both methods were used to investigate the synthesized copolymers and 
the respective precursors. In some cases, the different solubilities of both species limited the 
choice of the characterization method. The SEC traces for the synthesis of the copolymer 22 and 
the corresponding precursors 16, 17 and 19 are shown in Figure 4.1. In general, the molar masses 
determined by SEC (ranging from 9,800 to 69,000 g mol-1) are lower than the calculated values 
by 1H NMR (24,800 to 122,300 g mol-1) (see Table 4.2). One explanation is the presence of 
cationic amine units (primary and secondary) as well as alkene functionalities, which leads to 
undesired column and membrane interactions, and, therefore, to a change in the elution behavior. 
Additionally, suitable SEC calibration standards for cationic systems are not available. 
 
 
Figure 4.1. Size exclusion chromatography traces of the starting homopolymer 16 and the corresponding copolymers 
17, 19 and 22 (N,N-dimethylacetamide, 0.21% LiCl, calibration: polystyrene). 
 
Proton nuclear magnetic resonance spectroscopy (1H NMR). A useful characterization method to 
determine the polymer composition is 1H NMR spectroscopy. The installation of primary amine 
functionalities starts with the partial hydrolysis of PEtOx (16), confirmed by the presence of 
EtOx as well as EI units (copolymer 17, Figure 4.2A). Since the signals of the EtOx side chain 
(A, B) and the backbone (C) remain constant during the modification steps, they can be used as 
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reference. The successful modification with N-succinimidyl-4-pentenate is shown by the proton 
signals of the double bond that appear at 5.9 ppm (-HC=CH2, signal H) and 5.1 ppm 
(-HC=CH2, signal I) for the copolymer 20. The signals H, D (EI backbone) and A (methyl 
protons of the EtOx side chain) are used to calculate the composition of the formed copolymers. 
Within the next step – the photo-addition of 2-(boc-amino)ethanethiol – the double bond signals 
disappear and the protected copolymer boc23 is obtained. Besides the signals of the newly 
formed CH2 groups at 2.40 (signal I´) and 1.70 ppm (signal H´), a singlet of the 
tert-butyloxycarbonyl (boc) protecting group is obtained at 1.50 ppm (signal L). After treatment 
with trifluoroacetic acid and precipitation in diethyl ether, the successful deprotection of boc23 is 
confirmed by the disappearance of the protecting group to yield the final copolymer 
P(EtOx-stat-EI-stat-AmButOx) (23). 
The successful installation of alkene moieties on LPEI (24) yielded the copolymer 25 
(27% degree of functionalization, Figure 4.2B). Its composition was calculated from the integrals 
of the signals of the double bond (signal H) and the signals of the EI backbone (signal D). 
Since the EI units are not used for further modifications, their content remains constant (73%) 
during the following reactions. The successful attachment of 1-O-(2-mercapto-ethyl)-2,3:4,5-di-
O-isopropylidene-β-D-fructopyranoside (for a schematic representation of the structure 
see Scheme 4.1) is shown by the appearance of D-fructose related signals between 4.6 and 3.4 
ppm and the decrease of the signals of the double bond after thiol-ene photo-addition (iso26, 
Figure 4.2B). After treatment with hydrochloric acid, neutralization, and dialysis against water 
(cut-off: 3,500 g mol-1) the signals of the isopropylidene protecting groups between 1.5 and 
1.1 ppm (signal L) disappeared, indicating the successful deprotection and formation of the 
final copolymer P(EI-stat-ButEnOx-stat-FruButOx) (26). The cleavage of the protecting group 
resulted in the formation of a hemiketal structure and, therefore, in an equilibrium of pyranoses, 
furanoses and an open-chain form which turns the interpretation of the spectra into a challenging 
task. However, two-dimensional NMR spectroscopy, in particular heteronuclear single quantum 
coherence NMR (HSQC NMR), can be utilized to assign the signals according to the literature.87 
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Figure 4.2. Comparison of the 1H NMR spectra of A) the starting homopolymer 16 (PEtOx), the precursors 17, 20 
and boc23 and the final product 23 (¤ side product N-hydroxysuccinimide) (300 MHz, MeOD) and B) the precursor 
copolymer 25, the protected D-fructose copolymer iso26 and the final product 26 (600 MHz, DMSO-d6). 
 
In contrast to the sugar-functionalization, the attachment of L-glutathione (GSH) to the 
copolymer 25 resulted in the disappearance of the alkene functionalities and confirmed the 
quantitative functionalization (27). Besides the additional protons observed after the thiol-ene 
photo-addition (signal H´ and I´), the signals of GSH can be assigned to the respective protons 
(Figure 4.3A). The specific signal for the CH group of the cysteine unit appears at 4.54 ppm 
(signal H). A second approach was the attachment of side chains bearing primary amine groups 
and GSH moieties to PButEnOx (28). The synthesis of the homopolymer 
(functionalization > 95%) was confirmed by the disappearance of the signals assigned to the EI 
backbone (between 3.70 and 3.20 ppm) (Figure 4.3B). The successful preparation of the 
copolymer 29 after stepwise thiol-ene click reaction of GSH and 2-(boc-amino)ethanethiol is 
shown by the CH2 signals nearby the amine group at 2.8 ppm, the signal of the boc-protecting 
group which disappears after deprotection (1.4 ppm) and the specific GSH protons. 
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Figure 4.3. Comparison of the 1H NMR spectra of A) the starting homopolymer 24 (LPEI), the precursor 25 and the 
final product 27 (¤ side product N-hydroxysuccinimide) (400 MHz, MeOD/D2O) and B) the precursor copolymer 28 
and the final product 29 (400 MHz, MeOD/D2O). 
 
Diffusion-ordered NMR spectroscopy (DOSY NMR). To confirm the successful photo-addition of 
the targeting molecules (D-fructose and L-glutathione, respectively) to the polymer sidechain as 
well as the formation of a single (polymeric) species, DOSY NMR was utilized. The attachment 
of D-fructose to the copolymer 25 resulted in a single diffusion coefficient for copolymer 26 
which proves the absence of degradation (Figure 4.4A). In combination with a shift to a higher 
coefficient, indicating a decrease of the hydrodynamic radius of the polymer in solution, 
a successful installation of the sugar units was confirmed. The deprotection of the single 
D-fructose molecule resulted in decomposition and, therefore, hindered the determination of the 
diffusion coefficient. 
In contrast, the GSH decorated polymer 27 exhibited a lower diffusion coefficient compared to 
copolymer 25 (Figure 4.4B). The single GSH molecule has an increased mobility compared to 
the polymeric species and, therefore, displayed a significantly higher diffusion coefficient. 
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Figure 4.4. Diffusion ordered NMR spectra of A) the precursor 25 (green) and the final product 26 (orange) 
(600 MHz, DMSO-d6, 25 °C) and B) L-glutathione (red), the precursor 25 (green) and the final product 27 
(400 MHz, D2O, 25 °C). 
 
4.3 Application as DNA interactive materials 
Bio- and hemocompatibility. As mentioned before, biocompatibility represents a critical 
parameter for PEI-based copolymers as potential non-viral vectors in biomedical applications. 
Their cationic charge density, molar mass as well as degree of branching represent key 
parameters for the interaction with the cellular membranes and, consequently, the initiation of 
apoptosis.88-89 The impact of tailored functionalization of LPEI was investigated in the 
non-cancerous fibroblast cell-line L929, routinely used for toxicity screenings. One option to 
reduce the cytotoxicity of LPEI is the introduction of EtOx units as shown for 17 (oxazoline 
content of 54%), the precursor for the polymers 21 to 23. While LPEI (24) led to poor cell 
viability at low concentrations (IC50 ~ 4.0 µg mL-1) in agreement with literature reports,90 
21 to 23 revealed no cytotoxicity after 24 h using polymer concentrations up to 0.5 mg mL-1 
(IC50 > 0.5 mg mL-1) (shown for 23 in Figure 4.5A). This improvement is attributed to the 
introduced EtOx units and is consistent with literature reports.91 The D-fructose conjugated 
polymer 26 shows an improved biocompatibility as well. No significant reduction of the cell 
viability in mouse fibroblast L929 cells was observed after 24 h treatment with 26 (16% fructose) 
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for all tested concentrations (IC50 > 0.5 mg mL-1). The impact of the sugar moieties on the cell 
viability as well as the benefit of low sugar contents attached to the polymer backbone have been 
reported.65-67 The installation of 27% L-glutathione resulted in a strong reduction of the 
cytotoxicity. The copolymer 27 revealed no cytotoxic effects (relative viability ≥ 85%) using 
polymer concentrations up to 150 µg mL-1 and an IC50 value of ~ 270 µg mL-1. The replacement 
of the ethylene imine units by flexible primary amine containing side chains as in the case of the 
copolymer 29 led to an increased cytotoxicity (IC50 value of ~ 44 µg mL-1) as compared to 27. 
Blood compatibility represents another important parameter for biomedical applications, 
in particular for in vivo studies. It was investigated by assessment of the hemolytic activity and 
the aggregation of erythrocytes. All investigated copolymers did not show any hemolytic activity 
in a concentration range from 10 to 50 µg mL-1 (Figure 4.5B). A slight hemolysis (2.4% 
hemoglobin release) was observed at higher concentrations for 26 (100 µg mL-1). In contrast, 
24 (LPEI) revealed an increased interaction with the cellular membranes of the blood cells 
resulting in hemoglobin releases above 2% (50 to 100 µg mL-1). Moreover, it resulted in a strong 
agglomeration of erythrocytes. In the presence of certain polymers, irreversible erythrocyte 
aggregation can occur due to the membrane interactions forming bridges between the polymers 
and the erythrocytes, which results in an increase of the blood viscosity and can be dangerous for 
vital organs.92 The latter was not observed with EtOx containing copolymers 21 to 23, 
D-fructose conjugated 26 as well as GSH conjugated 27 (data not shown). In contrast, 
GSH conjugated 29 revealed distinct interactions with cellular membranes of erythrocytes 
leading to aggregation. Obviously, the type of amines within the polymer side chain is a crucial 
factor for the interaction with cells, in particular with the plasma membrane, and is therefore 
linked to the biocompatibility properties. In the literature, primary amines are reported to display 
an increased affinity to cellular membranes compared to secondary amines, indicated by a higher 
toxicity.93 
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Figure 4.5. Bio- and hemocompatibility. A) Relative viability of L929 cells after 24 h incubation with the respective 
polymers 23 (primary amine), 24 (LPEI), 26 (D-fructose), 27 (GSH) and 29 (GSH & primary amine) at indicated 
concentrations as well as IC50 values. B) Hemolysis assay of erythrocytes after incubation with respective polymers 
at indicated concentrations. Triton X-100 was used as positive and PBS as negative control. A value < 2% hemolysis 
is classified as non-hemolytic, 2 to 5% as slightly hemolytic and values > 5% as hemolytic. Values represent the 
mean ± S.D. (n = 3). ¤ Hemoglobin release of 24 describes the mean of the different functionalization approaches (as 
well as the S.D.). 
 
Characterization of the polyplexes. The efficient delivery of nucleic acids (e.g. plasmid DNA) 
into cells depends on several parameters. They comprise the compact condensation of genetic 
material, the masking of negative charges, the prevention of degradation, the cell uptake and the 
efficient dissociation from the polymer after transfer into the cellular cytoplasm or nucleus. 
To investigate the polyplex formation, in particular the binding affinity of the copolymers with 
plasmid DNA (pDNA), ethidium bromide quenching assays (EBA) were performed. 
Therefore, polyplexes of the copolymers 21 to 23, 26, 27 and 29 were formed at different 
nitrogen (polymer) to phosphate (pDNA) ratios (N/P). Due to the electrostatic and hydrophobic 
interactions between the polymer and the nucleic acid, ethidium bromide is excluded from its 
binding sites within the oligonucleotides resulting in a reduction of fluorescence intensity that 
correlates with the affinity for complexation.94-95 The copolymers 21 to 23 revealed decreasing 
fluorescence below 40% relative fluorescence units (RFU, exemplified for 23 in Figure 4.6A). 
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A plateau indicates a stable polyplex formation at N/P ratios from 5 to 40 comparable to the gold 
standard LPEI (24, ~ 25% RFU). Since the precursors 16 and 17 did not form appropriate 
complexes, it can be assumed that the presence of EtOx units hinders a strong binding of pDNA 
to the secondary amines of the PEI backbone. Obviously, the more flexible side chains of 21 to 
23 (containing primary amine functionalities) compensate the reduced complexation affinity. 
Notably, the combination of EI and AmButOx seems to be beneficial, since a comparable 
copolymer P(MeOx-stat-AmButOx) without EI units revealed a reduced pDNA complexation 
behavior in a previous study.93 The sugar-conjugated copolymer 26 did not reach a fluorescence 
intensity plateau within the displayed N/P ratios (57% RFU at N/P 40). The smaller content of 
amine functionalities combined with bulky side chains hinders the tight attachment to the pDNA. 
However, 26 was able to form polyplexes with pDNA, as this RFU was also reported for other 
transfection polymers.93 The GSH-conjugated copolymers 27 and 29 revealed a stable polyplex 
formation at N/P ratios from 20 to 40 reaching 45% and 30% RFU, respectively. 
The copolymer 29 revealed strong polyplex formation even comparable to LPEI (24). One reason 
could be the presence of primary amines attached through flexible side chains, which are easily 
accessible for the pDNA and known to promote its complexation.10 
Besides the strong binding of pDNA, a fast and efficient release from the copolymers is 
necessary for the efficient delivery of nucleic acids. For this purpose, the heparin dissociation 
assay was used to analyze the stability and the dissociation properties of the formed 
polyplexes.96-97 Heparin is a sulfated glycosaminoglycan with multiple negative charges in the 
polymer chain. It competes with the pDNA of the polyplex and forces the release of the nucleic 
acid. Increasing amounts of heparin displace the genetic material of the polyplex. The released 
pDNA is able to rebind free ethidium bromide (from the polyplex formation) causing an increase 
of the fluorescence intensity (Figure 4.6B). For all investigated polyplexes, the pDNA was 
released very fast at low heparin concentrations (10 U mL-1) to nearly 100% RFU. One exception 
are the copolymers 21 to 23, achieving only 80% dissociation. The use of an alternative 
competitor, in particular poly(methacrylic acid) (DP = 200), resulted in a full dissociation of the 
polyplex. In contrast, LPEI (24) required increased amounts of the anionic competitor heparin 
(40 U mL-1) for almost full dissociation, which underlines the stability of 24/pDNA polyplexes. 
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Figure 4.6. Polyplex formation and stability with pDNA using the polymers 23, 24, 26, 27 and 29. A) Complexation 
affinity (ethidium bromide quenching assay) of respective polymers at indicated N/P ratios. B) Dissociation assay of 
polyplexes formed at N/P 20 (26), 30 (23), 40 (27,29) using heparin (0 to 60 U mL-1). Values represent the mean 
± S.D. (n = 3). 
 
Another task on the way to an efficient delivery is the determination of the sizes and zeta 
potentials of the polyplexes. The internalization of polyplexes into cells via the endocytic 
pathway requires defined sizes and charges of the complexes. In the literature, sizes of polymeric 
nanocarriers up to 200 nm are recommended.58, 98 The here formed polyplexes reveal favorable 
sizes between 100 and 200 nm with the exception of 27 (Table 4.3). As expected for cationic 
polymers, the calculated zeta potentials are between 18 and 33 mV evidencing their 
cationic nature. An explanation for the negative zeta potential of the GSH conjugated 
copolymer 27 (–7 mV) could be the presence of GSH carboxylic acid moieties at the outside of 
the polyplex. In contrast, the inversion of charge is not obtained for copolymer 29 (33 mV) where 
the lower content of GSH and the side chains with more flexible primary amines reduce the effect 
of the anionic GSH functionalities. 
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Table 4.3. Size and surface charge (zeta potential) measured in 20 mM 4-(2-hydroxyethyl)piperazine-1-
ethanesulfonic acid (HEPES) and 5% (w/v) glucose, pH value 7.2 of pDNA complexes of 21 to 24, 26, 27 and 29 at 
defined N/P ratios measured by dynamic light scattering. 
# z-Average [d/nm] PDI Zeta potential [mV] N/P ratio 
21 158 ± 1 0.23  27 ± 0.3 
30 22 143 ± 1 0.21  23 ± 0.1 
23 154 ± 1 0.23  23 ± 0.1 
24  132 ± 28 0.24  28 ± 2.7 
20 
26 165 ± 1 0.26  18 ± 0.4 
27 282 ± 5 0.38  –7 ± 0.1 
29 117 ± 1 0.31 33 ± 1.5 
 
The investigated polyplexes were used in the following investigations to fulfill particular 
requirements, including the proof of high transfection efficiency and careful examination of the 
uptake mechanism, the successful targeting of human breast cancer cells and the passage through 
the blood-brain barrier. In all cases, polymer concentrations < 10 µg mL-1 are used for the 
preparation of the polyplexes, which are in an acceptable range below the cytotoxicity-inducing 
concentrations (cf. Figure 4.5A). 
Gene delivery agents. Gene therapy describes the treatment of human diseases by the transport of 
genetic material to specific cells of the patient. Recent developments enabled the identification of 
numerous disease-causing genes. The use of cationic polymers as gene delivery agents offers the 
opportunity to circumvent biological barriers. The combination of primary and secondary amines 
as well as non-charged EtOx units should turn the copolymers 21 to 23 into promising candidates 
as non-viral gene delivery agents (3rd generation PEIs). They were investigated for their 
transfection efficiency (TE) using human embryonic kidney (HEK) cells and pDNA encoding the 
enhanced green fluorescence protein gene (egfp). Flow cytometry was utilized to determine the 
TE and to analyze all viable cells (propidium iodide staining) which successfully express EGFP. 
A well-known side effect is the unwanted interaction of cationic polymers with serum proteins. 
Serum proteins attach to the surface of the polyplexes (shielding) and, therefore, inhibit the 
cellular uptake process.99-100 As a consequence, the cells were transfected in serum-reduced 
media (OptiMEM) and serum-containing media (RPMI1640 supplemented with 10% FBS). 
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The latter offers test conditions more comparable to an in vivo situation and represents an 
established method to test the performance of polymers. High TEs over 60% were observed 
under serum-reduced conditions for polyplexes of 22 and 23 at N/P ratios 30 to 50 (Figure 4.7). 
Comparable values were obtained for 24 (LPEI) at N/P 20. Interestingly, the egfp transfection 
level of 21 to 23 at N/P 50 in serum-containing media did not change significantly compared to 
transfection in OptiMEM. In contrast, the TE for 24 decreased continuously for increasing N/P 
ratios (N/P > 20) due to its cytotoxicity and the influence of serum proteins. The combination of 
high cell viability (no cyto- and hemotoxicity) and impressive transfection performance even in 
serum containing media underlines the immense potential of 22 and 23 as preferable gene 
delivery vectors. In particular 23 withstands a comparison to LPEI (24), the literature known 
‘gold standard for transfection’. 
 
 
Figure 4.7. Transfection efficiency of LPEI (24) and copolymers 21 to 23 for adherent HEK cells in serum reduced 
(OptiMEM, orange) and serum containing media (RPMI + 10% FBS, green) at different N/P ratios after 24 h. Values 
represent the mean ± S.D. (n = 3). 
 
To understand the outstanding transfection performance of the prepared copolymers, the uptake 
mechanism was investigated. For this purpose, polyplexes formed with YOYO-1 labeled pDNA 
were used for an uptake kinetic in order to detect the internalization within cells by flow 
cytometry. The polymers 21 to 23 and LPEI (24) revealed a fast and time-dependent cellular 
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uptake. In detail, almost 90% of measured cells internalized the polyplexes after 4 h. 
Nevertheless, the quantities (mean fluorescence intensities, MFI) differ significantly. 
Higher internalized polyplex concentrations were detected using the copolymers 21 to 23 
compared to 24. Most probably, the enhanced complexation with pDNA as well as the excellent 
cellular uptake is based on the presence of primary amine functionalities while the oxazoline 
content possesses reduced membrane interactions. By performing a temperature-dependent 
uptake study (4 °C and 37 °C) of YOYO-1 stained polyplexes as well as using a proton pump 
inhibitor (bafilomycin), the involvement of the endosomal uptake and release as critical steps 
during the transfection mechanism could be confirmed. Deeper insights into the uptake 
mechanism were obtained with microscopic studies including confocal microscopy (data not 
shown), structured illumination microscopy (SIM) and high-angular annular dark-field scanning 
transmission electron microscopy (HAADF-STEM) (shown for copolymer 23 in Figure 4.8). 
Fluorescence imaging of cells, in particular SIM images, revealed a co-localization of 
pDNA-bound 23 polyplexes (blue, Cy5-labeled) within the lysosomes/late endosomes (red, RFP 
labeling). The detection of the YOYO-signal within the cytoplasm that was not co-localized with 
lysosomal structures indicates a successful dissociation of the polyplexes. Taking the low 
concentration of heparin into account, which is required to destabilize the polyplex 
(see Figure 4.6B), an efficient release of pDNA into the cytoplasm can be assumed. 
The polyplexes of 23 are mainly localized within the endosome in close vicinity to the endosomal 
membrane (Figure 4.8A-C). An explanation could be the strong interaction between the polyplex 
and the cytoplasmic membrane at the time of the cellular uptake or a strong interaction with the 
endosomal membrane caused by the acidification. In order to study the interaction of the 
polymers with the endosomal membrane in more detail, STEM on embedded sections was 
performed. EM images revealed an uptake of single 23 polyplexes into vesicles with sizes of 
200 to 500 nm (n > 10 vesicles of different sections were analyzed) and confirmed the close 
vicinity between the polyplex and the endosomal membrane. An uptake event induced by cilia 
(hair-like structure on the cell body) was observed (Figure 4.8D-F), supporting an 
energy-dependent uptake, such as by macropinocytosis. Compared to the uptake under 
non-inhibited conditions, the use of the inhibitor 5-(N-ethyl-N-isopropyl)amiloride resulted in 
only 30% of cells that internalized 23 polyplexes after 4 h and no detection of polyplexes within 
the cytoplasm. 
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Figure 4.8. High resolution imaging. A) Structured illumination image of 23 based polyplexes taken up by HEK 
cells (deconvolved data). White arrows indicate co-localization of 23-pDNA polyplexes within lysosomes. B-C) 
Magnified view of the yellow and red, dash-lined frame in A: 23-Cy5 polyplex within the endosome. 63 × Oil Obj. 
1.4 NA. Grey: Hoechst. Red: Lysosomal membrane (RFP). Green: Plasmid DNA labeling (YOYO-1). Blue: Polymer 
labeling (Cy-5). D-F) HAADF-STEM image of 23 based polyplexes taken up by HEK cells. The following letters 
corresponds to cell organelles: N = cell nucleus, M = mitochondria, E = endosomal compartment, P = polyplex. 
 
The outstanding properties of 21 to 23 are based on the tailored combination of oxazoline units 
and different amine functionalities. The presence of EtOx subunits shields the formed polyplexes 
from aggregation caused by protein interactions prior to uptake. This could explain the efficient 
cellular uptake and the high transfection efficiency of the respective copolymers. Besides the 
installation of primary amine functionalities, the alkene functionalities of the pseudo-POx can be 
used for the attachment of specific targeting molecules. 
Human breast cancer cell targeting. Human breast cancer is one of the main leading death causes 
for woman nowadays. The expression of GLUT5 in these cells has been controversially discussed 
in the literature. While Gowrishankar et al. argued against the overexpression in all breast cancer 
tissues,101 Nualart and co-workers claimed that GLUT5 is overexpressed in 85% out of 33 tested 
breast cancer cell lines,102 also confirmed for estrogen-receptor positive MCF-7 and 
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triple-negative MDA-MB-231.103 Therefore, high molar mass LPEI (24) was modified with 
D-fructose moieties (26) in order to combine the selectivity of the sugar unit for the GLUT5 
transporter104 with the delivery potential of LPEI for genetic material. The cell-type dependent 
cytotoxicities and specific cellular uptake (MDA-MB-231 breast cancer vs. non-cancer L929 cell 
line/primary human cell line HUVEC) of the designed copolymer 26 and the precursor LPEI (24) 
were investigated. Using the alamarBlue assay, the precursor 24 reveals a concentration 
dependent cytotoxicity for all cell lines (Figure 4.9A). As already described before, the 
D-fructose-conjugated copolymer 26 shows no significant reduction of the cell viability in mouse 
fibroblast L929 cells. Furthermore, no cytotoxicity was observed in the primary human 
endothelial HUVEC cells after 24 h treatment for all tested polymer concentrations 
(IC50 > 500 µg mL-1). Interestingly, its cytotoxicity against breast cancer cell line MDA-MB-231 
is concentration-dependent (IC50 ~ 35 µg mL-1). Obviously, the fructose-modification results in a 
highly enhanced biocompatibility for the non-cancer cell line L929 as well as the primary human 
cell line HUVEC on one hand and in the selective toxicity for the breast cancer cell line 
MDA-MB-231 on the other hand. 
The cellular uptake of the polyplexes of 24 (LPEI), the respective precursor 25 
(without D-fructose) and the final 26 into L929, HUVEC and MDA-MB-231 cells is depicted in 
Figure 4.9B. The uptake was measured after 1 h (a time point at which no cytotoxicity was 
observed) at different polymer concentrations by flow cytometry. Polyplexes based on 
polymer 24 revealed a strong uptake in all tested cell types indicating no cell specifity. 
In contrast, polyplexes of 25 can be detected in MDA-MB-231 and HUVEC cells at N/P 20. 
Higher N/P values resulted in pDNA uptake in all three cell lines. The polyplexes of 26 show an 
enhanced uptake in MDA-MB-231 cells at N/P 50 even outperforming 24 and, even more 
important, the precursor 25 (no D-fructose). Indeed, the uptake of 26 into L929 is more than 
doubled for the MDA-MB-231 cells. These results indicate a positive influence of D-fructose 
towards cell specific gene delivery into breast cancer cells. Non-cancer cell lines L929 and 
HUVEC efficiently take up polyplexes of 24 and 25, but with a reduced efficiency as compared 
to 26. Overall, specific delivery of pDNA into MDA-MB-231 cells can be obtained with 
D-fructose targeted polyplexes. 
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Figure 4.9. A) Cell-type dependent cytotoxicity assay of starting polymer 24 and the final polymer 26 using 
alarmaBlue. Non-treated cells served as 100% relative viability. Cells were treated 24 h with the indicated 
concentrations of the polymers. B) Uptake study. Polyplexes formed with YOYO-1 labeled pDNA were incubated 
with L929, HUVEC, and MDA-MB-231 cells in OptiMEM for indicated time points using the copolymers 24, 25 
and the fructose conjugated polymer 26 at indicated N/P ratios. The amount of cells (%), which have taken up pDNA 
relative, as well as the mean fluorescence intensity (MFI) of all viable cells compared to pDNA control without 
polymers were depicted. Values represent the mean ± S.D. (n ≥ 3); * represents statistical significant difference in 
MFI to 26 N/P 50 of L929 and HUVEC; ANOVA, p-value < 0.01. 
 
Crossing the blood-brain barrier. Targeted gene delivery to the central nervous system is another 
challenge in pharmaceutical formulations since its access is strictly limited through the highly 
selective blood-brain barrier (BBB).105 The tripeptide L-glutathione (GSH), a well-known 
antioxidant, has been studied as a potential candidate to facilitate the receptor-mediated 
transcytosis of nanocarriers.106-108 In this context, high molar mass LPEI (24) was functionalized 
with GSH moieties to enable the transport of genetic material and, simultaneously, the passage 
through the BBB. The copolymers 27 and 29, containing 73% of secondary (27) or 82% of 
primary amine groups (29), respectively, were investigated for their ability to cross an 
hCMEC/D3 endothelial cell layer mimicking the BBB within a microfluidically perfused biochip 
(see Figure 4.10A). The cells were cultured on a suspended membrane within a MOTiF biochip 
that was shown to enable an improved culture of endothelial cells under physiological perfusion 
conditions.109 The membrane served as a cell substrate that is perfused from the apical side of the 
cell layer. 
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Figure 4.10. Performance of LPEI (24), the precursor 25 and the GSH-conjugated polyplexes 27 and 29 in a 
microfluidically supported biochip assay mimicking permeability of the BBB. A) Chip geometry. Schematic 
illustration of hCMEC/D3 cultured on top of a porous membrane within the chip. GSH-coupled nanocarriers are 
perfused on the apical side and passage through the cell layer was investigated basolateral. B) Passage of the 
respective polyplexes through BBB-like hCMEC/D3 cell layer over time. C) Top: Microscopic images display 
polyplex uptake (green) with the hCMEC/D3 cells (nuclei stained with DAPI (blue)) under a physiologic shear stress 
of 4 dyn cm-2. Bottom: Quantificational analysis of polyplexes at the cellular barrier. * significances vs. 27; 
*** p < 0,001; n = 3; scale bar 100 nm. 
 
The biochip model enables the exact determination of the total amount of polyplexes that crossed 
the endothelial barrier as well as the quantification of nanoparticles taken up by the endothelial 
layer. The pure YOYO-1 labeled pDNA (without nanocarrier) was used to prove the 
imperviousness of the model system since no pDNA passed through the membrane. 
This underlined the need for a nanocarrier. The precursor 25 was used for comparative purposes 
to demonstrate the need of glutathione moieties for a successful passage. To elucidate the trans-
endothelial transport of the different polyplexes, their enrichment in the lower chamber 
underneath the endothelial barrier of the biochip was measured (Figure 4.10B). The polyplex of 
LPEI (24) exhibited a surprising increase of translocation through the endothelial layer after 
30 min perfusion, remaining at this level for up to 60 min of perfusion. Although the final 
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concentration of the investigated polyplex 24 (0.5 µg mL-1) was still in an acceptable range below 
the cytotoxicity-inducing concentration, a possible explanation for the translocation are the flow 
conditions. They lead to an increased total amount of polyplexes presented to the cells within the 
incubation time compared to the static culture conditions. An induced leakage of the hCMEC/D3 
cell layer could be an explanation to the unexpected polyplex passage. For the polyplex of 
polymer 27, a continuously increasing transport through the layer was observed reaching a 
maximum at 60 min. In contrast, the precursor polyplex 25 without GSH modification showed 
only minimal passaging which supports the assumption of GSH-facilitated transcytosis. 
Surprisingly, the GSH-modified polyplex 29 revealed minimal passaging likewise. 
Uptake studies revealed a fast polyplex uptake of 29 in HEK cells which can be explained by the 
strong interaction of 29 with the cellular membrane induced by the primary amine functionalities. 
Microscopic studies confirmed these interactions by showing the highest uptake into the 
endothelial cell layer (Figure 4.10C, top) which prevents the passage to the lower chamber. 
Polymer 29 is supposed to adhere to cells in in vivo studies and might be partly internalized by 
endothelial blood vessel cells, followed by cargo release instead of passing the cell layer. 
In contrast, 24 and 25 revealed a lower enrichment, while 27 exhibited the weakest enrichment 
within the layer. An image analysis of the polyplexes at the cellular barrier is depicted in 
Figure 4.10C (bottom). The amounts of uptaken polyplexes into the cell layer is in accordance 
with the amounts of passed polyplexes through the hCMEC/D3 cell layer. The GSH-conjugated 
copolymer 27 showed no interaction neither with HEK cells in uptake studies nor endothelial 
cells, but was able to pass the BBB. This renders this polymer a promising candidate as a BBB 
nanocarrier and demonstrates the strong influence of the polymeric design/composition for a 
BBB carrier balancing the GSH content, DNA binding potential and cellular interactions. 
In conclusion, the ease of modification of secondary amine groups enables the introduction of 
double bonds and, furthermore, the installation of different functional molecules via thiol-ene 
photo-addition. Thus, modified POx could be used for enhanced gene delivery, human breast 
cancer cell targeting and the passage of a blood-brain barrier model with respect to the targeted 
delivery of genetic material. 
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Parts of this chapter have been published in: P8) M. Hartlieb, D. Pretzel, C. Englert, M. Hentschel, K. Kempe, 
M. Gottschaldt, U. S. Schubert, Biomacromolecules 2014, 15, 1970-1978; P9) M. N. Leiske, M. Hartlieb, C. Paulenz, 
D. Pretzel, M. Hentschel, C. Englert, M. Gottschaldt, U. S. Schubert, Adv. Funct. Mater. 2015, 25, 2458-2466; 
P10) M. Hartlieb, D. Pretzel, M. Wagner, S. Höppener, P. Bellstedt, M. Görlach, C. Englert, K. Kempe, 
U. S. Schubert, J. Mater. Chem. B, 2015, 3, 1748-1759. 
 
5.1 Diversity of poly(2-oxazoline)s 
Besides the established hydrolysis of poly(2-alkyl-2-oxazoline)s (PAlkOx) to create amine 
functionalities in the polymer backbone, cationic moieties can be installed in the side chain via 
post-polymerization modification (described in Chapter 4.1). Another alternative approach is the 
use of amine groups bearing 2-oxazoline monomers in a living cationic ring-opening 
polymerization (CROP) (see Scheme 1.1A) to synthesize DNA interactive materials. Since the 
nucleophilic nitrogen would terminate the living cationic chain-end of the polymer,110 the amine 
group in the oxazoline side-chain has to be protected to obtain polymerizable monomers. 
Cesana et al. were the first who described the synthesis of such cationic POx.111 
The monomer 2-(4-((tert-butoxycarbonyl)amino)butyl)-2-oxazoline (BocOx) (the schematic 
representation of the chemical structure can be found in Scheme 5.1) was synthesized, following 
a protocol described in the literature.112 Despite the tert-butoxycarbonyl (boc)-protecting group, 
the formed amide of the BocOx can still react with small electrophilic compounds such as methyl 
cation, which is typically used as initiating species. As a consequence, its polymerization has to 
be performed in a two-step initiation process. First, an 2-ethyl-2-oxazoline (EtOx) oligomer is 
produced mixing methyl tosylate and three equivalents of EtOx at 140 °C. The formed active 
species, the oxazolinium group (see Scheme 1.1A), reveals a significantly larger steric hindrance 
as compared to the methyl cation. Subsequently, BocOx can be added and polymerized. 
In order to introduce versatile solubility (particularly in water) and biocompatibility, BocOx was 
copolymerized with EtOx. Kinetic investigations resulted in similar slopes of the pseudo first 
order kinetic plots which demonstrated similar reactivities of both monomers.112 The addition of 
both monomers in a defined ratio to the active EtOx oligomer, and subsequent microwave-
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assisted polymerization37 and deprotection with trifluoro acetic acid (TFA) resulted in statistical 
copolymers P(EtOx-stat-AmOx) (30 to 35, Scheme 5.1). The synthesis of block copolymers, 
which are the basis for micellar structures, was performed by starting with the polymerization of 
EtOx followed by the chain extension of the living polymer with BocOx, the boc-protected 
precursor of the cationic AmOx segment. Deprotection after termination of the polymerization 
gave the block copolymers P(EtOx-b-AmOx) (36 to 40, Scheme 5.1). 
 
 
Scheme 5.1. Schematic representation of the copolymerization of EtOx and BocOx and subsequent deprotection to 
yield statistical (30 to 35) as well as block copolymers (36 to 40). Polymerization conditions: µW, 140 °C, 
acetonitrile. Deprotection conditions: Trifluoro acetic acid, CH2Cl2, 60 °C, Amberlyst A21. 
 
Copolymers of different contents were prepared by changing monomer-to-initiator ratios 
([M]/[I]) and polymerization times (Table 5.1). While the overall degree of polymerization (DP) 
for the statistical copolymers 30 to 35 was kept constant at around 50 repeating unis, the amine 
content was varied from 10 to 33%. For the block copolymers 36 to 40, the total DP was kept 
around 100 with varying amine contents (5 to 29%). The length of the polymers was determined 
from 1H NMR investigations directly after polymerization by comparing the tosylate initiator 
signal to the integral of the total polymer backbone. The experimental ratios of the monomers 
within the final polymer were calculated from the 1H NMR spectra of the purified samples. 
Size exclusion chromatography (SEC) of the copolymers revealed Mn values around 
5,000 g mol-1 for the copolymers 30 to 35 and values around 10,000 g mol-1 for 36 to 40, while 
the dispersity (Ð) values ranged from 1.13 to 1.34. However, a precise determination of both 
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values is challenging due to a lack of cationic SEC standards, as well as potential column 
interactions. 
 
Table 5.1. Parameters for statistical (30 to 35) and block poly(2-oxazoline) copolymers (36 to 40). 
   Composition [%] NMR
a SECb 
# Name DP a b Mn [g mol-1] Mn [g mol-1] Ð 
30 
P(EtOxa-stat-AmOxb) 
48 90 10 5,000 8,100 1.26 
31 46 85 15 4,900 8,200 1,24 
32 41 78 22 4,400 8,700 1,25 
33 53 73 27 5,900 9,500 1,23 
34 48 67 33 5,400 9,400 1,24 
35 46 80 20 4,900 9,300 1.13 
36 
P(EtOxa-b-AmOxb) 
118 95   5 12,000 14,500 1.34 
37 102 90 10 10,600 16,800 1.23 
38 90 82 18 9,700 16,100 1.22 
39 105 78 22 11,400 18,100 1.23 
40 90 71 29 10,100 15,600 1.30 
 
a Determined by 1H NMR (calculated from the ratio tosylate/backbone signals directly after polymerization (crude)  
b SEC: DMAC, 0.21% LiCl, against polystyrene 
 
5.2 Application as DNA interactive materials 
The isolation and purification of nucleic acids from highly complex samples, such as blood and 
feces,99 is of paramount importance for DNA-based detection methods in modern clinical 
diagnostics,100 genetic analysis,104 and pathogen detection.101 To date, a wide range of DNA 
purification and extraction techniques have been investigated but an universal purification 
method is still missing.102 Solid phase extraction (SPE) represents a well-established and easily 
adaptable purification method firstly described by McCormick.113 Although it allows the 
effective separation of nucleic acids from proteins without generating toxic by-products, there are 
still remaining issues that have to be overcome, such as the intensive washing procedures, the 
limited loading capacity of the silica matrix, as well as the limitation of the extraction 
efficiency.114 
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A highly promising approach is the reversible binding of genetic materials within a 
three-dimensional hydrogel matrix. Although insoluble due to cross-linking, hydrogels are able to 
incorporate water up to a multitude of their own mass, which allows the diffusion of guest 
molecules. Besides a large surface area for binding targeted molecules, these networks can be 
tailored in pore size and chemical functionality. For instance, the incorporation of cationic 
functionalities into the network enables the electrostatic interaction with negatively charged 
DNA. Changes of the pH value, temperature or ionic strength are commonly used methods to 
support the elution of the genetic material from the hydrogel. 
Matrix supported poly(2-oxazoline)-based hydrogels. The statistical copolymers 30 to 34 were 
used to generate hydrogels and matrix supported hydrogels by cross-linking some of the primary 
amine groups with epichlorohydrin (ECH). The preparation of supported structures was 
performed by soaking polyethylene (PE) or polypropylene (PP) filer materials in a 
copolymer/ECH solution. Heating resulted in cross-linking and, therefore, the formation of a 
bead-like structure of the gel phase. This could be attributed to a lower critical solution 
temperature (LCST) behavior of the copolymers, and, therefore, phase separation, prior to 
gelation. The swelling behavior, the ratio of hydrogel per composite, as well as the ability to 
absorb and release DNA were tested. Cy5 (Abs. 649 nm, Em. 670 nm) labeled DNA can be 
detected and quantified by microscopic and spectroscopic techniques tracking the fluorescence of 
the attached dye. Using fluorescence microscopy, the uptake and stimulated release of the genetic 
material from PP-based composites by heparin could be investigated and is shown for 
copolymer 33 in Figure 5.1. The first row displays the autofluorescence of the swollen hydrogel 
(buffer solution) which is bound to the substrate. A bright fluorescence of the composite is visible 
after the addition of DNA followed by a washing step (A). The treatment with a 
6 mg mL-1 heparin solution (a polyanion which is able to replace the DNA) resulted in a partial 
release of the bound DNA (B). In contrast, the pure PP-matrix showed no change at analogue 
treatment. 
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Figure 5.1. Schematic representation of the DNA uptake and release (by heparin) of PP-based cross-linked 
composite 33 (PP: Green, Polymer: Blue, Cross-linker: Orange) and pure PP-matrix. Cy5-labeled DNA (red) was 
used to measure fluorescence microscopy of the treated samples. 
 
Although the release of DNA using heparin represents an efficient method, it suffers from 
drawbacks like the inhibition of the polymerase chain reaction (PCR) at higher heparin 
concentrations. As a consequence, different stimuli like pH value or temperature were 
investigated, as well as decreasing heparin concentrations (see Figure 5.2A). The first two did not 
lead to a sufficient release. As expected, the increase of the heparin concentration resulted in an 
enhanced DNA release. The detection of the low amounts of DNA in biological samples requires 
multiplication using a PCR of the genetic material. Therefore, the naturally thermostable enzyme 
polymerase is used to amplify a few copies of a specific sequence of the genetic material.115-116  
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PCR studies revealed that the recovered DNA, which was released at heparin concentrations up 
to 1 mg mL-1, could be amplified (Figure 5.2B). In these cases, the heparin concentration seems 
to be low enough that the majority of the heparin is entrapped within the network and does not 
disturb the subsequent PCR. 
 
 
Figure 5.2. DNA uptake and release of PP-matrix supported hydrogels. A) Quantification of DNA release depending 
on temperature, pH value and heparin concentration, and B) gel electrophoresis of PCR products from release eluates 
at varying heparin concentrations. 
 
Poly(2-oxazoline)-based multilayers. To combine the advantages of a hydrogel matrix with 
diffusion independent, surface mediated processes, cationic polymer layers were covalently 
attached to a surface (glass and PP) by a so-called layer-by-layer (LbL) technique.117 Although 
the covalent immobilization of POx on glass substrates has been described in the context of anti-
fouling coatings,118 its bioanalytical potential has not been reported so far. The functionalization 
of the glass surface comprises the cleaning and activation by plasma and the attachment of an 
epoxide group bearing siloxane monolayer (3-glycidyloxypropyl trimethoxysilane, GOPTMS) 
(Scheme 5.2). Subsequently, a monolayer of the amine containing block copolymer 35 was 
attached via the ring-opening reaction of the epoxide.119 To obtain multilayers, the remaining 
amine groups were partially functionalized with ECH, the epoxide rings regenerated (alkaline 
conditions) and reacted with a second layer of 35 as described before. This cycle can be repeated 
several times to install a defined number of POx coatings on the surface with specific film 
thicknesses.  
 60 
5  POLY(2-OXAZOLINE)S – SYNTHESIS & APPLICATION 
 
 
Scheme 5.2. Schematic representation of the deposition of 35 on substrates by layer-by-layer immobilization. 
 
The successful layer deposition was shown by contact angle (CA), thermogravimetric analysis 
(TGA) and reflectometric interference spectroscopy (RIFS)120 measurements. Finally, the LbL 
deposition was successfully proven for the stepwise attachment of three polymer layers by using 
fluorescently labeled 35 (Fluorescein-NHS-ester). All coatings steps could be tracked by confocal 
laser scanning microscopy (CLSM) measurements. To investigate the ability of POx multilayers 
on a PP chip to absorb genetic material in a reversible manner, Cy5-labeled DNA strands were 
used. Each reaction step was followed by a purification treatment with DMF as well as water. 
The CLSM measurements did not show an efficient uptake behavior within the first 5 min for one 
POx multilayer which can be attributed to a low degree of swelling (Figure 5.3A). In contrast, PP 
chips with two layers revealed an increase of the fluorescence up to 5 min incubation time while 
three layers resulted in a constant increase in emission up to 2 h. It can be assumed that the DNA 
absorption behavior depends on the number of polymer layers. To investigate the ability of a 
controllable DNA release, which is necessary for a subsequent polymerase, PP chips were loaded 
with DNA for 1 hour and subjected to a temperature dependent washing process (Figure 5.3B). 
Temperatures of 65 °C or higher resulted in a release of 40% of the initially bound DNA which is 
in accordance to the conditions of PCR experiments (57 to 95 °C). Since there is no significant 
 61 
5  POLY(2-OXAZOLINE)S – SYNTHESIS & APPLICATION 
difference for two and three POx layers, the PCR experiments were conducted using POx double 
layers. 
 
 
Figure 5.3. A,B) Adsorption and release of Cy5 labeled DNA by POx (35) multilayers. A) Time dependent uptake 
of labeled genetic material determined by mean fluorescence of POx multilayers after treatment. B) Temperature 
dependent release of POx multilayers loaded with DNA for 1 h displayed as percentage of the initially bound DNA 
amount. C) Box-plot of qPCR experiments, performed in POx coated (35) reaction vessels. The tubes were loaded 
with genetic material from cell lysates at different temperatures and the ct value of the amplification was recorded. 
 
In order to create a model system similar to industrial requirements, PCR-tubes (RoboStrip PP 
white 8-well strips low profile) were coated using unlabeled POx 35. After successful binding of 
DNA (from Escherichia coli BL21), a specific primer (for LacZ-Gene) and a PCR master mix 
was added to the tube and subjected to qPCR. The working principle of the “lab in a tube” 
approach is depicted in Figure 5.4. The surface binding of DNA revealed positive results for the 
specific E. coli-target LacZ-gene and the PCR product showed the same melting point as the 
positive control. In order to develop a simple and low-cost system, DNA binding has to be 
performed directly from a cell lysate tolerating other (charged) cellular components instead of 
using purified genetic material. To this end, E. coli suspension was heated to 95 °C to lyse the 
cells. A defined amount of cell lysate was filled in different tubes coated with 35 and incubated 
for 1 h. The samples were incubated at different temperatures ranging from 25 to 65 °C 
(Figure 5.3C). For all temperatures, E. coli DNA could be detected with the desired melting point 
around 87.3 °C. Increasing temperature results in a decrease of the ct value of the qPCR, and 
therefore, a faster amplification process.  
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The “lab in a tube” model displays a promising tool for bioanalytics since it enables the 
collection of DNA samples from biological materials, and allows the purification, amplification 
and detection within one coated PCR tube. 
 
 
Figure 5.4. Working principle of the “lab in a tube” approach. Cells are lysed by heat treatment and genetic material 
is adsorbed in POx surface coatings. After addition of a specific primer and a PCR master mix, amplification and 
detection is accomplished in a qPCR process. 
 
Core cross-linked nanogels. Another challenge is the use of amine containing copolymers for the 
encapsulation of drugs. A widely studied dosage form for the administration of hydrophobic 
compounds is the polymeric micelle121 which is formed via the aqueous self-assembly of block 
copolymers consisting of hydrophobic and hydrophilic segments.122 As reported recently, the 
cross-linking of such systems prevents a disassembly and a component exchange even below the 
critical micelle concentration (CMC).123 Nanogels combine the beneficial properties of hydrogels 
(tissue-like structure, stimuli responsiveness) and nano-assemblies (solubility properties, such as 
nanoparticles or micelles) in the nanometer size range. To obtain nanogels, different approaches 
have been established. Besides the inverse emulsion124 and the polymerization induced phase 
separation,125 an elegant way is the cross-linking of self-assembled structures. Up to date, only a 
limited number of reports described the synthesis and the potential of covalently cross-linked 
POx micelles, comprising the stabilization via epoxide-amine cross-linking,126 light-mediated 
cross-linking,127-128 thiol-yne chemistry,129-130 electron beam irradiation131 as well as the use of a 
disulfide bond linker (reversible system).132 
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The copolymers 36 to 40, consisting of the neutral hydrophilic EtOx and the cationic AmOx 
block, were self-assembled in organic solvents (Figure 5.5). Since both blocks are readily water 
soluble, these structures have to be cross-linked to transfer them into aqueous solution. Therefore, 
glutaraldehyde was used to synthesize core-crosslinked nanogels. As reported in the literature, a 
full conversion of the amine groups is not possible133 and residual aldehydes have to be quenched 
by low molar mass amines. Besides a stabilization of the self-assembled structure, this strategy 
can be used to simultaneously incorporate drug molecules or fluorescence labels. The nanogel 
structures of 36 to 40 were quenched with diethylamine (DEA) and loaded with 
6-amino fluorescein (6AF), respectively, and could be transferred to aqueous medium. 
In addition, the reversibility of this system allows a later disassembly of the network.134 
 
 
Figure 5.5. Schematic representation of the self-assembly of 40 followed by cross-linking and quenching 
(diethylamine) or loading (6-amino fluorescein, 6AF). 
 
The self-assembly and subsequent loading of cross-linked copolymer 40 in chloroform (41) and 
isopropanol (42), respectively, was followed by DLS measurements and AF4 experiments 
(Table 5.2). Distributions in water are in the same size range as in organic solvents while the PDI 
values of the quenched systems increased slightly, evidencing aggregation caused by 
unconsumed aldehyde groups in the core. However, the values are still in the acceptable range for 
synthetic nano-sized objects. The presence of free amine groups was confirmed by positive zeta 
potentials for all samples. Besides the calculation of the molar masses of specific polymers, AF4 
can be used to determine the hydrodynamic radius (Rh, only DLS) and the radius of gyration (Rg, 
multi-angle laser light scattering (MALLS)). The sample 41 revealed a similar Rh value as 
obtained by DLS measurement. In contrast, for 42, the obtained value is smaller than the size 
obtained from DLS measurement. This could be due to the AF4 separation technique, which 
examines single colloidal structures instead of taking also small fractions of aggregates into 
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account (DLS investigation). Furthermore, AF4 enables the characterization of the particle shape 
by the ratio of Rg and Rh (ρ = Rg/Rh). For 41, no Rg value could be determined since the value 
was too small for detection (MALLS detector limit: ~ 15 nm).135 The obtained ρ ratio below 0.8 
describes a hard sphere and, therefore, a compact structure like a micellar architecture.136 A larger 
ratio (~ 1.0), as obtained for 42, is usually attributed to soft and less dense structures, such as 
vesicles.136 The vesicular morphology of 42 is supported by the block architecture of 
P(EtOx-b-AmOx) and the fact, that the radius of the assembly is longer than the fully stretched 
polymer chain (32 nm length). The proposed structures were visualized via cryo transmission 
electron microscopy (cryoTEM) measurements and facilitate the interpretation of micelles and 
vesicles in good agreement to the results of DLS and AF4 measurements. 
 
Table 5.2. Characterization for cross-linked nanostructures (DLS: 5 mg mL-1, size indication in radius). Polymer 40 
served as precursor for the assemblies. The content of fluorescein was determined by the absorbance at 470 nm. 
   DLS in water  AF4   
# Solvent for self-assembly 
Capping 
agent Size, Rh [nm] PDI ζ [mV] 
 Rg Rh ρ Content of capping agent [wt%] 
41 CHCl3 6AF 15 0.20 +17  - 20 <0.8  29 
42 iPrOH 6AF 50 0.18 +23  40 40 1.00  29 
 
To investigate the cytotoxicity of the assembled structures 41 and 42, routine XTT assays were 
performed using the established L929 cell line. After 24 h of incubation, 41 revealed a lower 
biocompatibility only for the highest concentration of micelles (5 mg mL-1) while the vesicular 
structures did not show any cytotoxicity within the investigated concentration range 
(Figure 5.6A). However, the concentration range of potential applications is far below the border 
to cytotoxicity in both cases. Another challenge is the time and concentration dependent cellular 
uptake of 41 and 42, which is quantified by flow cytometric measurements. Increasing sample 
concentrations resulted in higher fluorescence intensities indicating a concentration dependent 
uptake (Figure 5.6B). The vesicular structure 42 revealed a stronger increase of fluorescence, in 
particular for higher concentrations which could be attributed to an increased cellular 
accumulation/association compared to micelles 41 (three-fold uptake at 0.5 mg mL-1). The same 
trend could be observed for the time-dependent uptake over 24 h (Figure 5.6C). 
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Figure 5.6. A) Cell viability of L929 mouse fibroblasts after incubation with micelles (42)/vesicles (44) up to 
5 mg mL-1 for 24 hours. B) Flow cytometry investigation on the concentration and time dependent uptake of 6AF 
containing micelles/vesicles by L929 mouse fibroblasts at 37 °C. For the concentration dependent uptake, cells were 
investigated over an incubation time of 24 h using micelle/vesicle concentrations in the range between 0.05 and 
0.5 mg mL-1. C) For the time dependent uptake, cells were incubated between 0.5 and 24 h with micelles/vesicles 
with a concentration of 0.5 mg mL-1. 
 
Confocal laser scanning microscopy (CLSM) was performed to elucidate the cellular 
internalization and intracellular localization of micelles and vesicles in L929 cells. 
Figure 5.7 shows a representative distribution of the fluorescent vesicle 42 in the context of 
cellular structures in detached cells revealing three main observations: 1) Since the 6AF labeled 
structures (green) are exclusively detectable within the stained cell membrane (orange), 
CLSM images are in favor of an intracellular localization (Figure 5.7, a1 to a3); 2) within the 
nuclear compartment (blue), no vesicles are observed (Figure 5.7, b1 to b3), and 3) co-localization 
of the vesicles and stained acidic endosomes (red) occurs (Figure 5.7, c1 to c3). Since only intact 
nanostructures can be detected by fluorescence in an intracellular environment, the studies clearly 
suggest an endosomal location, and, therefore, an internalization by endocytosis can be assumed. 
In the future, the self-assembling structures should enable the administration of drugs, 
e.g. cytostatic. 
In conclusion, the combination of POx and amine bearing side chains results in challenging 
polymer systems which can be used to design various functional materials. 
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Figure 5.7. Representative CSLM images of detached L929 cells after 24 h incubation at 37 °C with vesicles 42 at 
0.1 mg mL-1. Cell membranes (a2), cell nuclei (b2), or late endosomes/lysosomes (c2) were specifically stained and 
correlated with the fluorescence signal of 6AF labeled vesicles (a1, b1 and c1). Superimposition of both channels 
(a3, b3 and c3) proves an intracellular (a3) but extra-nuclear (b3) localization of the vesicles and their apparent 
co-localization with endosomal structures (c3). Scale bar: 10 µm. 
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The treatment of human diseases by the efficient and specific delivery of drugs or genetic 
material to target cells of the patient is one major task of current and future biomedical research. 
Besides the well-established delivery systems of lipids, peptides and natural-occurring polymers, 
synthetic polymers represent promising alternatives with numerous opportunities of modification. 
Since they enable the circumvention of biological barriers, cationic polymers play a crucial role 
for biomedical applications, in particular gene delivery. They can electrostatically interact with 
the negatively charged phosphate groups of nucleic acids (e.g. deoxyribonucleic acid) and 
eventually protect them from enzymatic degradation. The formed polyplexes are able to enter the 
cell and to release the cargo to the site of action. 
Within the last decades, poly(ethylene imine) (PEI) has emerged as the state-of-the-art of gene 
delivery agents. The linear form (LPEI) is thereby preferred, since it shows reduced cytotoxicity 
and enhanced synthesis control compared to the branched form. Poly(2-oxazoline)s (POx) 
represent ideal starting materials for the production of LPEI, since they can be easily converted 
into cationic polymers bearing primary, secondary and tertiary amine functionalities. The fast and 
efficient cationic ring-opening polymerization of 2-oxazolines enables the synthesis of 
well-defined POx and tolerates numerous functionalities as 2-substitutents of the monomers. 
Furthermore, it allows the introduction of different end-groups which can be exploited for 
post-polymerization modification processes. The acidic hydrolysis of poly(2-alkyl-2-oxazoline) 
results in the cleavage of propionic acid and the formation of secondary amine functionalities. 
The degree of hydrolysis can be well-controlled by using microwave-assisted synthesis 
approaches. Although the fully hydrolyzed polymer, LPEI, reveals remarkable properties 
concerning polyplex formation, major drawbacks such as poor water solubility, severe 
cytotoxicity, and undesired non-specific interactions with cellular and non-cellular components 
have to be overcome. The present thesis deals with the modification of cationic polymers based 
on POx to enhance their biological properties and introduce targeting sites, while maintaining the 
efficiency for biomedical applications (Figure 6.1).  
One powerful tool to turn LPEI into a biocompatible polymer is its one-pot modification with 
hydrophilic moieties. As an alternative to well-established carbohydrates which mostly require 
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multi-step syntheses, hydroxyl moieties (carbohydrate-mimetics), i.e. paraformaldehyde and 
glycidol, can be installed in a close proximity to the polymer backbone to improve the 
biocompatibility. A second approach is the oxidation of secondary amine groups in the LPEI 
backbone using hydrogen peroxide. The conversion of the functional groups into amides turns the 
polymer into a biocompatible and biodegradable material. The described modification represents 
a useful technique for future synthesis approaches. 
 
 
Figure 6.1. Schematic overview of the various cationic polymer structures obtained by the modification of 
poly(2-oxazoline) and their biomedical application fields. 
 
Besides enhancing the biocompatibility and the transport of genetic material, the specific drug 
targeting using PEI derivatives represents a major challenge. Since the hydrolysis conditions of 
POx prevent the simultaneous presence of secondary amine groups and alkene functionalities, 
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LPEI was modified via N-acylation (pseudo-POx) followed by the attachment of targeting 
molecules or functional groups. The attachment of L-glutathione moieties allows the successful 
crossing of polyplexes through the hCMEC/D3 endothelial cell layer mimicking the 
blood-brain barrier (BBB), which usually limits the transportation of genetic material, within a 
microfluidically perfused biochip. The modification with D-fructose enables the specific delivery 
of genetic material into human breast cancer cells (i.e. MDA-MB-231) while revealing cell-type 
specific cytotoxicities. The combination of partially hydrolyzed PEtOx and the subsequent 
installation of primary amine groups in the polymer side chain results in non-viral gene delivery 
agents that even outperform LPEI. Their endosomal release could be identified and investigated 
in detail by super-resolution and electron microscopy.  
Another approach to obtain cationic polymers with strong affinity for nucleic acids is the 
introduction of amine functionalities to the side chain of 2-oxazoline monomers prior to the 
polymerization. The obtained statistical and block copolymers can be used for the design of 
hydrogels, nanogels and surface coatings, which are utilized for either pathogen detection or drug 
delivery. 
In summary, the convenient modification of cationic polymers made from POx results in high 
functional polymer systems which can serve as platform materials for various biomedical 
applications. The present work will be the basis for further tailor-made polymer systems and will 
encourage researchers to continue the investigation of modified cationic polymers. In particular, 
the combination of drug delivery and cell specific targeting is of tremendous interest for the 
future treatment of human diseases and has to take the next step from bench to bedside. 
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Die Behandlung von verschiedenen Krankheitsbildern durch den effizienten und zielgerichteten 
Transport von Wirkstoffen oder genetischem Material zum gewünschten Wirkungsort stellt eine 
Hauptaufgabe innerhalb der heutigen und der zukünftigen biomedizinischen Forschung dar. 
Neben den etablierten Transportsystemen wie Lipiden, Peptiden und natürlichen Polymeren 
haben sich insbesondere synthetische Polymere mit ihren zahlreichen 
Modifizierungsmöglichkeiten als vielversprechende Alternativen hervorgetan. Eine besondere 
Bedeutung kommt dabei kationischen Polymeren im Hinblick auf biomedizinische 
Anwendungen, im Speziellen für den Gentransfer, zu. Die elektrostatische Wechselwirkung ihrer 
positiven Ladungen mit den negativ geladenen Phosphatgruppen der Nukleinsäuren 
(z.B. Desoxyribonukleinsäure) führt zur Komplexbildung und gleichzeitig zur Abschirmung des 
genetischen Materials, welches unter Anderem vor einem enzymatischen Abbau schützt. Die auf 
diese Weise gebildeten Polyplexe ermöglichen den Transport von Nukleinsäuren in die Zellen 
und deren Freisetzung am entsprechenden Wirkungsort. 
In den letzten Jahrzehnten hat sich Poly(ethylenimin) (PEI) zum „Goldstandard“ für den 
Gentransfer entwickelt. Dabei wird die lineare (LPEI) gegenüber der verzweigten Form (BPEI) 
bevorzugt, da sie neben einer reduzierten Zytotoxizität auch eine einfachere Kontrolle der 
Synthese zulässt. Poly(2-oxazoline) (POx) stellen das ideale Ausgangsmaterial für die 
Herstellung von LPEI dar, da sie verhältnismäßig einfach in kationische Polymere mit primären, 
sekundären und tertiären Aminfunktionalitäten umgewandelt werden können. Die schnelle und 
effiziente kationische Ringöffnungspolymerisation von 2-Oxazolinen ermöglicht die Synthese 
von gut definierten POx und toleriert gleichzeitig zahlreiche Funktionalitäten in 2-Position der 
Monomere. Weiterhin erlaubt sie die Einführung von verschiedenen Endgruppen, die zur 
anschließenden Modifizierung genutzt werden können. Die saure Hydrolyse von Poly(2-alkyl-2-
oxazolinen) resultiert in der Abspaltung von Propionsäure und der Ausbildung von sekundären 
Amingruppen. Der Hydrolysegrad kann dabei durch einen mikrowellenunterstützten 
Syntheseansatz gut kontrolliert werden. Obwohl das vollständig hydrolysierte Polymer, LPEI, 
außerordentlich gute Eigenschaften bezüglich einer Polyplexbildung zeigt, existieren zahlreiche 
Nachteile wie eine schlechte Wasserlöslichkeit, hohe Zytotoxizität sowie unspezifische 
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Wechselwirkungen mit zellulären und nicht-zellulären Bestandteilen. Die vorliegende Arbeit 
beschäftigt sich mit der Modifizierung von kationischen Polymeren basierend auf POx mit dem 
Ziel der Verbesserung ihrer biologischen Eigenschaften und der gezielten Einführung von 
Funktionalitäten für spezielle biomedizinische Anwendungen (Figure 7.1). 
 
 
Figure 7.1. Schematische Übersicht über die verschiedenen kationischen Polymere, die durch Modifizierung von 
Poly(2-oxazolinen) erhalten wurden und ihre biomedizinischen Anwendungsgebiete. 
 
Eine Möglichkeit LPEI in ein biokompatibles Polymer umzuwandeln ist die einstufige 
Modifizierung mit hydrophilen Resten. Als eine Alternative zu bereits etablierten 
Kohlenhydraten, welche meistens Mehrstufensynthesen erfordern, können Hydroxylreste, 
im Speziellen Paraformaldehyd und Glycidol, in unmittelbarer Nähe des Polymer-Rückgrates zur 
Verbesserung der Biokompatibilität angebracht werden. Ein zweiter Ansatzpunkt ist die 
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Oxidation von sekundären Amingruppen im LPEI-Rückgrat mittels Wasserstoffperoxid. 
Die Umwandlung dieser Funkionalitäten in Amidgruppen resultiert in biokompatiblen und 
gleichzeitig bioabbaubaren Polymeren. Die beschriebene Modifikation stellt eine vielseitig 
anwendbare Technik für zukünftige Syntheseansätze dar.  
Neben den genannten Aspekten der Biokompatibilität und Bioabbaubarkeit stellt die 
zielgerichtete Anreicherung und Freisetzung eines Wirkstoffes am gewünschten Wirkungsort 
unter Verwendung von PEI-Derivaten eine weitere Herausforderung dar. Da die 
Hydrolysebedingungen von POx die gleichzeitige Anwesenheit von sekundären Amin- und 
Alkenfunktionalitäten verhindern, musste ein alternativer Syntheseweg gefunden werden. 
Dabei wird LPEI zunächst mittels N-Acylierung modifiziert (Pseudo-POx) und anschließend 
erfolgt die Einführung von Zielmolekülen oder weiteren funktionellen Gruppen. 
Die Funktionalisierung mit L-Glutathionresten ermöglicht dabei die erfolgreiche Passage von 
Polyplexen durch die hCMEC/D3 Endothelzellschicht innerhalb eines mikrofluidischen 
Biochips. Dieser dient als Modell der Blut-Hirn-Schranke, die für gewöhnlich den Transport von 
genetischem Material verhindert. Die Modifikation von LPEI mit D-Fructose hingegen erlaubt 
den gezielten Transport von genetischem Material in menschliche Brustkrebszellen 
(im Speziellen MDA-MB-231) und weist dort zellspezifische Zytotoxizität auf. Weiterhin kann 
die Kombination aus partiell hydrolysiertem Poly(2-ethyl-2-oxazolin) mit primären 
Aminfunktionalitäten in der Polymerseitenkette als nicht-viraler Gentransporter verwendet 
werden. Dieser zeigte verbesserte Eigenschaften gegenüber dem Goldstandard LPEI. 
Die endosomale Freisetzung konnte mittels hochauflösender Konfokal- und 
Elektronenmikroskopie untersucht und nachgewiesen werden. 
Ein weiterer Ansatzpunkt für kationische Polymere mit ausgeprägter Bindungsaffinität für 
Nukleinsäuren ist die Einführung von Aminfunktionalitäten in die Seitenkette von 
2-Oxazolinmonomereinheiten. Die anschließend synthetisierten Copolymere (Block und 
statistisch) dienen als Ausgangsmaterial für das Design von Hydrogelen, Nanogelen und 
Oberflächenbeschichtungen, die sowohl für die Detektion von Krankheitserregern als auch für 
den gezielten Wirkstofftransport eingesetzt werden können. 
Zusammenfassend konnte gezeigt werden, dass die einfache Modifikation von kationischen 
Polymeren in hochfunktionalisierten Polymersystemen resultieren kann. Diese können als 
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Plattform für zahlreiche biomedizinische Anwendungen genutzt werden. Die vorliegende Arbeit 
stellt die Basis für zukünftige maßgeschneiderte Polymersysteme dar und soll Wissenschaftler 
ermutigen, entsprechende Forschungen weiter voran zu treiben. Insbesondere die Kombination 
aus Wirkstofftransport und zellspezifischen Zielmolekülen ist von fundamentalem Interesse für 
die zukünftige Behandlung von humanen Krankheitsbildern und hat den entscheidenden Schritt 
von der Laborbank zum klinischen Einsatz noch vor sich. 
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BocOx    2-(4-((tert-Butoxycarbonyl)amino)butyl)-2-oxazoline 
BPEI    Branched poly(ethylene imine) 
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Graphical abstract 
 
Abstract 
The administration of drugs, as a main challenge of pharmaceutical and medicinal applications, has certainly 
benefited from the application of synthetic polymers. However, despite an enormous effort to develop new 
materials for drug delivery applications, only few of them have entered the market due to the hurdles of 
regulation, production, cost efficiency and both industrial’s and patients’ acceptance. In this review, we summarize 
all these classes of synthetic polymers, which are on the market as well as the latest developments in clinical trials, 
and describe their application in polymer-drug conjugates, as excipients, in nano-/microscopic and macroscopic 
drug carriers, as polymeric coatings, or as polymeric drugs. Our intention is to create a link between the underlying 
chemical structures, the properties of the polymers, and their area of application, where they are often just known 
by their trade names or abbreviations. In addition selected types of synthetic polymers are highlighted that feature 
interesting properties and have the potential to make it to the market in future. 
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1. Introduction 
 
The administration of drugs is one of the main tasks within the area of pharmaceutical and medicinal applications. 
Drugs are defined as "articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of 
disease" and "articles (other than food) intended to affect the structure or any function of the body of man or 
other animals” by the Federal Food, Drug, and Cosmetic Act (FD&C Act). Starting in the early 1960s, controlled drug 
delivery research has broadened and has developed from macroscopic devices and implants (1970s and 1980s) to 
microscopic (1980s and 1990s) as well as nanoscopic systems.[1] Besides liposomes, nanocrystals, bio-compatible 
metal-organic frameworks and others, polymeric materials represent a useful option to fulfill the challenges of drug 
storage and delivery. They can be subdivided into natural, pseudo-synthetic and synthetic macromolecules. 
The latter offer several advantages compared to natural polymers like an easier synthesis of large quantities, 
nonsignificant batch-to-batch variations and countless possibilities for modifications to achieve the desired 
properties. These factors turn polymers into very promising candidates to solve numerous problems in drug 
administration. 
In this review, we introduce the term ‘Pharmapolymers’, which describes synthetic polymers used during the 
administration of drugs. They are based on an artificially made polymeric backbone, excluding chemically modified 
natural polymer species plus dendrimers, which do not reveal a distribution in the number of repeating units per 
molecule (molar mass distribution). The first part comprises an overview of potential polymer classes, which are 
discussed concerning their suitability (structure, properties etc.) as potential drug delivery systems. This represents 
the basis for the following parts of the work. To be considered as drug delivery system, the polymer structure has 
to fulfill at least parts of the following requirements: Biocompatibility, biodegradability or complete chemical 
inertness as well as sufficient control over its synthetic structure. In 1999, Uhrich et al. already reviewed polymeric 
systems for controlled drug delivery.[2] Almost two decades later, this work misses completeness and the modern 
developments of the polymer classes applied nowadays. The second part summarizes all pharmapolymers which 
are currently or have previously been on the market subdivided according to their form of appearance. In addition, 
we included materials which are currently undergoing clinical trials. The main routes of drug administration 
discussed here are oral, topical and by injection (intravenous, intramuscular, subcutaneous). The third section 
highlights recent progress in research and exemplarily describes a few chosen in vivo studies to emphasize future 
prospects of pharmapolymers in drug delivery applications. On average, only one out of 5,000 compounds that 
enters pre-clinical studies (and only one out of 10 that enters clinical studies) becomes an approved drug after 
10 years from the starting idea to the market approval.[2] The clinical phases necessary for market approval and a 
short description are listed in Table 1.  
The present study is the most comprehensive summary of established synthetic polymers in drug administration 
so far, comprising far more than 100 polymeric products on the market and 70 under clinical investigations. 
Our intent is to provide a link between chemical structures as well as properties of the polymers and their area of 
application, where they are often just known by their trade names or abbreviations. Even so, the authors apologize 
in advance for all omissions since it is nearly impossible to keep track of the whole wealth of materials applied in 
drug delivery. 
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Table 1. Overview of clinical trial phases. 
Phase Primary goal Secondary goal Participants Duration Special Features 
Preclinical Checking for preliminary safety, efficacy and pharmacokinetic information (in vitro & in vivo) - 
Several 
years  
Phase 0 Pharmacokinetics  (i.e. oral bioavailability and half-life of the drug) 10  
Often skipped for 
phase I, subtherapeutic, 
doses too low to cause 
any therapeutic effect 
Phase I Checking for safety 
Establish the max. tolerated 
dose, determine side effects, 
determine the metabolism and 
pharmacologic actions of drugs 
20 to 100 Several  months 
Often first time tested in 
humans, subtherapeutic 
with ascending doses 
Phase II Checking for efficacy Determine the common short-term side effects and risks Several hundred 
Up to 2 
years 
Therapeutic doses, 
“Proof of concept” 
Phase III Confirm findings in large patient population 
Evaluate the overall risk-
benefit ratio 300 to 3,000 1 to 4 years 
Usually randomized 
controlled trials, pivotal 
studies for drug licensing 
Phase IV Testing long-term safety in diverse patient population 
Identify additional, unusual 
side effects 
“Real-life patients”,  
several thousands Ongoing  
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2. Polymer classes 
The Food and Drug Administration (FDA) is a federal agency of the United States Department of Health and Human 
Services, which is responsible for the monitoring of trading and safety standards in the food and drug industries in 
the United States. A large number of different polymer types are used in pharmaceutical research and applications 
nowadays, whether in an early scientific stage or already in FDA approved formulations. To fulfill specific 
requirements, often different polymer classes have to be combined to create smart solutions for specific problems. 
The following chapter discusses the most important polymer classes including individual representatives of 
pharmapolymers. All structures of homopolymer systems mentioned later in the application Chapter 3 or the 
future prospects Chapter 4 are marked in bold and can be found in Table 2. 
 
2.1 Polyethers 
The term polyether generally describes polymers that contain the ether functional group in their main chain. 
Although there are several FDA approved polyethers, they all reveal one major drawback: They lack 
biodegradability (referring to the degradation of the polymer backbone, independent of the molar mass of the 
respective polymer species).  
Among them, poly(ethylene glycol) (PEG) (also poly(ethylene oxide) (PEO) for Mn >20,000 g mol-1) represents 
probably the most well-known polyether in pharmaceutical applications. The oldest[3] and most frequently used 
method to synthesize PEG in laboratory and industrial scale is via anionic ring-opening polymerization of ethylene 
oxide[4] resulting in polymers with a wide range of possible molar masses and very low dispersities.[5] Cationic 
polymerization is also feasible, with the drawback of broad molar mass distribution due to backbiting reactions.[6] 
A variety of functionalized PEGs are offered from commercial sources, with different α and/or ω functionalities, 
e.g. methoxy groups, amines, or thiols. Furthermore, side group functionalized PEG derivatives are known in 
literature, e.g. functionalized with furfuryl.[7] PEG has several interesting advantages for pharmaceutical 
applications. It is water soluble, even at higher molar masses,[8] non-ionic, non-toxic and biocompatible. 
Furthermore, it was already approved by the FDA for different applications in foods, cosmetics and 
pharmaceuticals.[9] The success of PEG in the biomedical area started with the covalent decoration of bio(active) 
molecules,[10] often named PEGylation,[11] which will be described in detail in Chapter 3.1.1. One outstanding 
property of PEG is the so-called “stealth-effect”, discovered in 1990 for modified liposomes.[12] It describes the 
ability to protect molecules or nanoscopic objects against unspecific interactions with blood components 
(e.g. opsonization), by attaching specific proteins to the surface.[13] Until now, PEG is still regarded as the gold 
standard for stealth behavior. Furthermore, renal filtration was found to be decreased by the attachment of PEG 
which comes along with an increase of the molar masses. These two points lead to significantly elongated in vivo 
blood circulation times of formulations associated with PEG.[13-14] Besides all the advantages of PEG a few 
drawbacks have to be addressed as well.[15] With increasing molar mass of the polymers, PEG tends to accumulate 
within certain organs, which has to be avoided.[16] If, however, the applied product contains oligomers 
below 400 g mol-1 or becomes fragmented, toxic species can be produced by oxidation in vivo.[17] A second issue 
concerns the possibility of an immune response due to compliment C activation, which can lead to hypersensitive 
reactions and, consequently, to an anaphylactic shock.[18] Furthermore – despite the established large scale 
production – the anionic polymerization technique requires still an high effort, in particular considering the highly 
toxic and explosive monomer and the purification of the polymer for pharmaceutical applications (formaldehyde 
and 1,4-dioxane can occur as side products, which need to be excluded from pharmacological grade PEG). 
Nevertheless, PEG remains the most commonly used polymer in drug administration and can be considered as the 
standard. 
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Poly(propylene glycol) (PPG) (also named poly(propylene oxide): PPO) represents another polyether which is 
applied for drug delivery. The common way to synthesize PPG is anionic ring-opening polymerization with an 
alcoholate as initiator and a base as catalyst resulting in the atactic product. The change of the catalyst enables the 
synthesis of the isotactic product. However, like most mono-substituted epoxides, the monomer tends to induce 
chain transfer reactions during the polymerization limiting the maximum molar mass (Mn) of the resulting polymer 
to approximately 6,000 g mol-1.[4-5] The water solubility of the polymer is, compared to PEG, reduced considerably, 
which causes an lower critical solution temperature (LCST) between 15 and 42 °C depending on the molar mass[19] 
(LCSTPEG ≈ 100 °C),[20] whereas the biocompatibility is even more distinct as for PEG.[21] The polymer appears mostly 
as a central, non-ionic, hydrophobic, non-toxic segment in PEG-b-PPG-b-PEG block copolymers named 
poloxameres, which are also known by their trade names Pluronic®, Synperonic® and Kolliphor® (a subgroup are 
poloxamines consisting of an ethylene diamine core). The commercial products are available in various 
compositions. The polymerization of the block copolymer is similar to the PPG homopolymer synthesis. After the 
homopolymer is formed, ethylene oxide is added to the reaction, which then grows from both sides of the PPG 
homopolymer. The resulting products often contain admixtures, e.g homopolymer, di- and triblock polymers, which 
can be removed by chromatographic fractionation. Poloxameres are increasing the rate of wound and burn healing, 
which is the reason why they can be found in skin healing creams and skin substitutes. Furthermore, they form 
micelles in aqueous solution, making them attractive for drug delivery applications. 
 
Poly(glycerol) (PG) represents an alternative for PEG and PPG in terms of solubility- and biological behavior. PG’s 
are produced by anionic[22] or cationic[23] ring-opening polymerization of glycidol leading to branched polymer 
architectures. Using anionic ring-opening polymerization, high molar mass polymers comprising a relatively narrow 
distribution (up to 700,000 g mol-1 at dispersities of below 1.4) can be synthesized.[24] The main advantage of PG 
compared to PEG is the presence of hydroxyl groups at the main chain, which can be utilized to introduce 
additional functionalities to the polymer backbone.[25] If the alcohol group on the monomer is protected, a linear 
polymerization with molar masses (Mn) up to 30,000 g mol-1 can be accomplished.[26] Both, linear and 
hyperbranched PGs are fully biocompatible,[27] revealing even better profiles compared to PEG.[28] Similar to PEG, 
modifications with PG lead to an elongated circulation time.[29] A rather well-known example is poly(glycerol) 
polyricinoleate (PGPR) as food additive being considered by the FDA as general recognized as safe (GRAS) for 
human consumption (Code of Federal Regulations: 21 CFR 172.854). Several other poly(glycerol) esters are known 
for their application as emulsifier in food, cosmetics and pharmaceutical preparations. 
 
2.2 Poly(ethylene imine)s 
Poly(ethylene imine)s (PEI) are characterized by the presence of amine group functionalities within the polymer 
backbone, which determine their chemical and physical behavior. PEI reveals one of the highest cationic-charge-
densities of all organic macromolecules.[30] Every third atom is an amine group of which every sixth nitrogen atom is 
protonated under physiological conditions.[30] This high charge density enables the interaction with the phosphate 
groups of genetic material leading to the formation of toroidal complexes that are readily endocytosed by cells.[31] 
This feature makes PEI a highly efficient vector for delivering oligonucleotides in vitro and in vivo.[32] It occurs in two 
different forms: Linear and branched PEI. 
Branched poly(ethylene imine) (BPEI) can be synthesized by the ring-opening polymerization of unsubstituted 
aziridine as described in 1944 by Jones et al. leading to uncontrolled branching and chains with primary, secondary, 
and tertiary amine groups.[33] Increasing molar masses result in higher degrees of branching and, to this end, cross-
linking becomes more likely. The handling of explosive and toxic aziridine requires safety precautions, which are 
often not applicable in most chemistry laboratories. The molar masses of commercially available BPEI cover the 
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complete range up to 750,000 g mol-1 (Mw), however, no dispersities are reported. The exact determination of the 
number average molar mass Mn of PEI is extremely complex and has been in the focus of several literature 
reports.[31a, 34] The synthesis of linear poly(ethylene imine) (LPEI) via hydrolysis of poly(2-alkyl-2-oxazoline)s was 
first described in the 1960s.[35] Therefore, linear 2-methyl or 2-ethyl substituted poly(2-oxazoline)s (POx) are mainly 
used as precursors. The hydrolysis can be performed under acidic[35b, 36] or basic conditions[35b, 37] and results in 
products hydrolyzed up to 97%. The molar mass of LPEI and its distribution is limited by the respective POx 
precursor. However, the living character of the cationic polymerization of POx (see Chapter 2.7) produces 
well-defined polymers with controlled molar masses and low dispersities, which comply with the biological 
demands for LPEI (Mn up to 25,000 g mol-1, Ð < 1.2).[38] LPEI can be purchased in the range from 400 to 
250,000 g mol-1 (Mw). The robust polymerization protocols tolerate a variety of comonomers, initiators, and 
quenchers, including allyl and aryl groups enabling the selective introduction of various functionalities to the LPEI 
backbone.[39] An alternative is the controlled partial hydrolysis of the amide bonds which has been studied in the 
last decades.[40] A further approach to LPEIs is the controlled polymerization of N-substituted aziridines followed by 
the deprotection of the amines.[37a] However, this route comes along with unwanted side reactions due to the 
harsh conditions or incomplete cleavage.[41] None of the products based on PEI have been approved by the FDA so 
far, which is mainly related to its cytotoxicity. 
 
2.3 Polyesters 
Polyester describe a class of polymers containing the ester functional group in their main chain which renders most 
of these polymers biodegradable.  
One of the earliest polymers was poly(caprolactone) (PCL) synthesized by the Carothers team in the 1930’s. PCL is 
a non-toxic, biodegradable, semi-crystalline aliphatic polyester, which is approved by the FDA for several 
applications, e.g. drug delivery systems, sutures, long-term implants and adhesion barriers as well as new tissue 
scaffold host systems. It is hydrophobic, but soluble in several solvents, can be blended with a variety of other 
materials and degrades very slowly under physiological conditions (from months to years) compared to other 
polyesters.[42] The main reason for the extended degradation time is the lack of enzymes suitable to hydrolyze the 
ester in the human body.[43] Furthermore, the hydrolysis time of PCL depends on the physical and chemical 
properties of the polymer, in particular the crystallinity and the molar mass. However, this degradation profile 
makes PCL very attractive for long term drug delivery devices or implants.[44] PCL degrades into 6-hydroxyhexanoic 
acid, which is less acidic than degradation products from other polyesters reducing the effect of autocatalysis 
occurring with the hydrolysis of polyesters. Besides the degradability, PCL exhibits a high permeability for most 
drug molecules. Furthermore, functional groups can be introduced for example by copolymerization, which enables 
an adjustment of several properties, including hydrophilicity, adhesivity and biocompatibility.[45] PCL can be 
synthesized in several ways, such as by anionic, cationic, coordination or free radical ring-opening polymerization 
(ROP) processes first described by Carothers for PLA. The most common synthesis routes comprise the ring-opening 
polymerization using metal catalysts which have to be removed afterwards and the often used polycondensation. 
A well-known catalyst for ROP is stannous octoate due to its high efficiency and its approval by the FDA as food 
additive.[46] The reported molar masses (Mn) range from 530 to 630,000 g mol-1.[47] Numerous strategies to improve 
the degradation and mechanical properties of PCL, such as copolymerization and blending with different polymers, 
are described in literature.[42a, 44e, 48] The exceptional compatibility of PCL in blends is utilized to improve the 
material properties by mixing PCL with polysaccharides, PLA, chitosan and many more.[48-49] 
Poly(lactic acid) (PLA) and poly(glycolic acid) (PGA) are aliphatic polyesters approved by the FDA for a wide range 
of applications. These materials are well-established in pharmaceutical industry as drug carriers and traditionally 
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applied as suture material.[50] Major advantages are their biocompatibility, biodegradability and their mechanical 
strength.[51] The degradation products are further non-toxic and can be cleared or consumed within bioprocesses 
occurring in the body, which makes them a powerful tool for in vivo delivery. Similar to PCL, the material properties 
such as degradation rate and mechanical strength depend on the structural features of the polymer including 
crystallinity and chain length.[52] High molar mass species are obtained by ROP[53] using stannous octoate as 
catalyst.[50b, 51a] Additional metal-free methods including enzymatic techniques are under investigation for the 
polycondensation of PLA.[52b, 54] PLA represents a stiff and hard polymer revealing versatile properties depending on 
the tacticity and molar mass. Compared to PGA it comprises an extra methyl group, and, therefore, a stereocenter, 
which results in three possible products: Poly(L-lactic acid) (PLLA), poly(D-lactic acid) (PDLA) and the mixture of 
both, poly(D-lactic acid-co-L-lactic acid) (PDLLA). PLLA and PDLA are semi-crystalline, while PDLLA is amorphous and, 
consequently, reveals the fastest degradation rate.[50c, 52b] Nevertheless, the hydrophobic methyl side group 
increases the steric hindrance and shields the ester bond from hydrolysis by water which results in a decreased 
degradation time compared to PGA. In consequence, PLA is a promising material for long term applications.[55] 
PGA has been known since 1954 as potential low cost fiber forming, highly crystalline polymer.[50b] However, the 
high sensitivity towards hydrolysis and the poor solubility in organic solvents limits its use for pharmaceutical 
applications.[47, 51b] The respective copolymer poly(lactic-co-glycolic acid) (PLGA) is probably the best established 
and studied polymer for pharmaceutical applications and tissue engineering. 
Poly(oxalate)s (PO) represent another subgroup of polyesters, which is prepared by the ester interchange reaction 
of diols with the diester of the oxalic acid. In 1980, Shalaby et al. filed a patent for the preparation of polyalkylene 
oxalates from different aliphatic diols.[56] Since that time, POs and copoly(oxalate)s have been reported only a few 
times in literature. They represent a family of biocompatible and biodegradable polymers, which degrade 
hydrolytically (and comparatively rapid) into non-toxic products that can easily be removed from the body.[57] 
Oxalate-based polymers allow a facile control over their biodegradability, crystallinity and mechanical strength. 
Their hydrolytic stability and their mechanical properties are mainly influenced by the composition and 
hydrophobicity of the incorporated diol. Compared to the commercial biodegradable polymers PCL or PLGA, they 
exhibit faster degradation kinetics. This turns POs into useful materials for medical grade plastics and devices 
(e.g. syringes and scrub brushes).[58] Garcia and Miller established the oxalate metathesis polymerization using diols 
from renewable sources and without the need of any solvents. They obtained POs with molar masses (Mn) ranging 
from 40,000 to 70,000 g mol-1.[58] Despite its biocompatibility and degradability none of the polymers in this class is 
yet approved by the FDA. 
Poly(butylene terephthalate) (PBT) is obtained by the ester interchange reaction of 1,4-butanediol and 
terephthalic acid and subsequent polycondensation. Its resistance to solvents, heat and mechanical strongness 
turns PBT into a basic module in many electronic devices and home appliances. Considering biomedical application 
PBT has not gained much attention, yet. 
 
2.4 Polycarbonates 
Polycarbonates (PC) are a group of thermoplastic polymers containing carbonate links in their backbone, firstly 
discovered in 1898 by Alfred Einhorn.[59] After 50 years without commercialization, Schnell (Bayer AG, Germany) 
patented the synthesis of linear PCs in 1953.[60] In the same year, Fox (General Electric Company, USA) synthesized 
independently a branched PC.[61] Since the late 50’s, PCs became frequently used in commercial applications. 
The excellent biocompatibility, non-toxic degradation products and the absence of autocatalytic degradation 
processes render aliphatic PCs interesting polymeric materials.[62] The polymers are commonly synthesized by 
polycondensation methods (step growth), as performed by the phosgenation of hydroxyl compounds or the 
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transesterification of diols with lower dialkyl carbonates.[63] Another approach is the utilization of CO2 and oxiranes 
to produce “green” PCs (up to 100,000 g mol-1, Ð < 1.2) via an addition polymerization,[64] whereas the low 
reactivity of CO2 requires very efficient catalysts.[65] However, these polymerization techniques suffer from 
drawbacks such as the poor control over molecular parameters and broad molar mass distributions.[66] A suitable 
preparation method to obtain well-defined PC is the ring-opening polymerization (ROP) of cyclic carbonates (chain 
growth, “living”), which can be performed by both cationic and anionic polymerization. The ROP allows the control 
of molar masses (Mn) with low dispersities (30,000 g mol-1, Ð < 1.1[67]) at fast polymerization rates and facilitates 
the formation of more complex architectures like block polymers[68] and star shaped polymers.[69] Furthermore, in 
contrast to polycondensation, no by-products are obtained from the polymerization. Compared to aliphatic 
polyesters (i.e. PCL or the copolymer PLGA), polycarbonates are degraded in vivo by surface erosion.[70] 
Their degradation does not cause an acidic environment, which may occur during polyester degradation and might 
be hazardous for loaded drugs or healthy tissues. PC resins are solely FDA approved for use as articles or 
components of articles intended for use in producing, manufacturing, packing, processing, preparing, treating, 
packaging, transporting, or holding food in accordance with defined conditions (21 CFR 177.1580). Nowadays, the 
design of functional cyclic carbonate monomers has gained increasing interest, comprising hydroxyl,[71] carboxyl,[72] 
amine,[73] alkene[74]/alkyne,[75] halogen,[76] azido[77] and sugar[78] pendant groups. 
 
2.5 Poly(amino acid)s 
Synthetic polypeptides are based on the same peptide bonds present in natural proteins and, therefore, exhibit a 
good biodegradability and excellent biocompatibility. Nevertheless, they are prepared by purely synthetic reaction 
processes and therefore included in this review.[79] As almost all types of amino acids can be applied for the 
polymerization, a large variety of different functionalities such as ionic or stimuli responsive side groups are 
accessible and complex superstructures including micelles and gels can be formed.[80] In 1906, Hermann Leuchs first 
reported the synthesis and polymerization of α-amino acid N-carboxyanhydrides (NCAs).[81] Since this time, NCAs 
have gained increasing interest for the synthesis of homo- and copolymers as well as cyclic polypeptides. A large 
number of reviews can be found dealing with the immense variety of synthetic procedures.[82] Nowadays, the most 
established way to obtain synthetic polypeptides is the ring-opening polymerization (ROP) of NCAs using amine-
based initiators. Remarkable reactions have been developed to synthesize polypeptides and polypeptide-based 
copolymers with controlled molar masses and dispersities as well as complex architectures. Deming and co-workers 
reached macromolecules with Mn up to 500,000 g mol-1 (Ð < 1.2) by applying different transition-metal-based 
initiators in a living ROP.[83] Conventional amines as initiators allow the synthesis of polypeptides with 
100,000 g mol-1 and comparable dispersities.[84] Side reactions can further be suppressed using ammonium chloride 
functionalized macro-initiators[85] or an organosilicon.[86] The functionalization of polypeptides has gained 
increasing attention in recent years. The introduction of various functional groups or stimuli-sensitive moieties to 
the side chains of the polypeptides render them particularly appealing for the design and development of multi-
functional active biomaterials. The functionalization is mainly achieved by two approaches: I) The one-step ROP of 
NCA monomers, already containing the desired functional moieties or II) the post-polymerization modification of 
polypeptides. Reported modifications comprise click chemistry, in particular alkyne-azide cycloadditions and thiol-
ene reactions, controlled free-radical polymerizations, aminolysis and transesterifications, which have extensively 
been reviewed.[82c, 87] The modularity of using unnatural amino acid derivatives as monomers leads to a versatility 
of polymer structures with molecular and physical properties far from those of proteins. Trifunctional amino acids, 
such as glutamic acid, lysine and aspartic acid, are often used to achieve structural viability within the respective 
polymer, in particular poly(glutamic acid) (PGluA),[88] poly(lysine)[89] or poly(aspartic acid).[90] The FDA classifies 
chosen poly(amino acid)s under the GRAS status for different food applications. 
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2.6 Poly(peptoid)s 
In 1982, Farmer and Ariens introduced the term “peptoid” as a peptidomimetic/pseudopeptide that is able to 
mimic the biological action of peptides while not resembling them structurally.[91] One decade later, Bartlett and 
co-workers defined them more specifically as oligomers of N-substituted glycine (poly(α-peptoids)).[92] 
Nowadays, most reports of peptoids, e.g. those indexed in PubMed, refer to the mentioned N-substituted glycines 
or respective poly(β-/γ-peptoids). In both cases, side chains are attached to the amide nitrogen and make the 
polymer resistant to protease degradation.[93] Poly(peptoid)s (PoP) are particularly interesting due to their 
convenient synthesis, chemical diversity and biological relevance. They can be synthesized in a sequence defined 
(stepwise) or statistical (chain growth) manner.[94] They are routinely obtained in a stepwise procedure, particularly 
the submonomer solid phase synthesis developed by Zuckermann et al.,[95] and have been reviewed 
continuously.[96] This two-step sequence method does not require the protection of the backbone and a variety of 
primary amines (most of them commercially available) can be incorporated.[97] Monodisperse PoPs of 100 
monomer units (Mn = 8,500 g mol-1) have been synthesized by coupling together two submonomer-synthesized 50-
mers.[98] The submonomer method represents a relatively inexpensive route compared to the preparation of the 
corresponding α-peptides.[99] Microwave heating can be used to accelerate the submonomer synthesis and 
increases the efficiency of coupling sterically hindered and electrostatically deactivated amines.[100] An alternative 
approach for their synthesis is the (living) ring-opening polymerization of N-substituted N-carboxyanhydride (NCA) 
monomers in solution or from solid substrates.[94b, 96b, 101] This chain growth polymerization yields PoPs with degrees 
of polymerization >100, but with limited sequence control.[102] Their structural similarity compared to peptides, 
their resistance against protease, the proteolytic stability, the convenient synthesis and their superior 
biocompatibility make PoPs an interesting class of materials for a variety of applications, e.g. as transfection and 
therapeutic agents,[103] diagnostic agent[104] and lung surfactant mimetic.[105] Optionally, they can be incorporated 
into polypeptides at specific sites.[106] Luxenhofer and co-workers could recently show the degradation of PoPs via 
oxidative degradation under biologically relevant conditions.[107] This polymer class is not yet approved by the FDA.  
 
2.7 Poly(2-oxazoline)s 
Concerning biocompatible, hydrophilic polymers, poly(2-oxazoline)s (POx) gained increasing attention.[15] This class 
of polymers was introduced in 1966 by four independent research groups.[35, 108] The polymers are prepared by a 
cationic ring-opening polymerization (CROP) of 2-substituted oxazolines resulting in repeating amide functionalities 
at the interface between polymer backbone and side chain. Since 2004, the microwave assisted synthesis is most 
commonly used to shorten reaction times from days to minutes.[109] As the CROP is not as sensitive as most anionic 
polymerization methods, the production of POx in a lab scale is comparably convenient, and a large variety of 
possible functionalization strategies can be applied.[110] Besides the variation of start- and end-groups, the 
2-substitution of the monomer can be modulated within the borders of tolerated functionalities in a CROP. The 
achievable molar mass strongly depends on the used monomer. POx derivatives bearing short side chains (methyl 
or ethyl) are reported to be biocompatible[111] and even feature a stealth effect similar to PEG 
(see Chapter 3.1.2),[112] which turns these polymers into highly favorable materials for biomedical applications.[113] 
By the incorporation of longer side chains, the solubility behavior can be tailored creating systems being 
thermoresponsive or water insoluble.[114] Just as PEG, POx is not biodegradable. A degradation of the amide group 
leads to an abstraction of the side group rather than a decomposition of the backbone and, hence, the formation of 
linear poly(ethylene imine) (see Chapter 2.2). Since 2016, poly(2-ethyl-2-oxazoline) is approved by the FDA as 
indirect additive used in food contact substances (21 CFR 175.105).  
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2.8 Poly(N-acrylamide)s 
Poly(N-acrylamide)s describe a polymer class that bear amide functionalities in the side chain. There is a large 
variety of monomers commercially available, however, the most commonly applied and studied polymers are 
doubtlessly poly(N-(2-hydroxypropyl)methacrylamide) and poly(N-isopropylacrylamide). Furthermore, poly(2-
acrylamido-2-methylpropane sulfonate) is utilized. 
Poly(N-(2-hydroxypropyl)methacrylamide) (PHPMA) is a hydrophilic, chemically and hydrolytically stable, 
biocompatible polymer, often described simply as “HPMA” in literature. Moreover, it mimics living tissue and 
features a well-established safety profile in the human body. Its hydroxyl group functionalities allow the convenient 
conjugation of drugs and targeting molecules. However, PHPMA-based polymers are nonbiodegradable, which 
limits their use for some pharmaceutical applications.[115] Otherwise, they are hydrophilic and known to be non-
toxic in the rat, even at higher doses (30 g kg-1).[116] PHPMA can be synthesized by conventional free radical 
polymerization of N-(2-hydroxypropyl) methacrylamide or by several controlled radical polymerization techniques 
including atom transfer radical polymerization (ATRP) and reversible addition-fragmentation chain transfer (RAFT) 
polymerization.[117] Other techniques include the post-polymerization modification of poly(pentafluorophenyl 
methacrylate) (PPFMA), which contains activated ester side chains, by reacting with 1-amino-2-propanol.[118] 
Compared to the free radical polymerization, controlled radical polymerization techniques provide access to a vast 
number of macromolecular architectures including PHPMA copolymers with improved control over the molar mass 
and dispersity.[119] Despite the extensive research effort spent on PHPMA, none of the materials has yet been 
approved by the FDA. 
Poly(N-isopropylacrylamide) (PNIPAAm) is one of the most intensively studied temperature responsive polymers 
of the past four decades.[120] The PNIPAAm homopolymer exhibits a lower critical solution temperature (LCST) of 
around 33 °C in aqueous solution, which is close to the body temperature.[121] In addition, the LCST of PNIPAAm can 
be easily tuned by copolymerizing various functional monomers to alter the polymer backbone.[122] When the 
temperature is lower than the LCST, PNIPAAm is water soluble due to a complex H-bond network along the 
PNIPAAm chains. In contrast, at temperatures above the LCST PNIPAAm becomes water insoluble because of the 
destroyed H-bond network and the release of water molecules.[123] Due to this reversible transition in water, its 
good biocompatibility and low toxicity, PNIPAAm-based polymers are found in numerous biological and biomedical 
applications including controlled drug release, tissue engineering, bio-detection, bio-separation, smart microfluidic 
devices and biochips.[123-124] However, PNIPAAm is not biodegradable which limits its use in some pharmaceutical 
applications.[125] PNIPAAm can be synthesized by a variety of polymerization techniques including conventional free 
radical polymerization, ATRP, and RAFT polymerization of N-isopropylacrylamide.[120a, 126] Although an enormous 
progress has been made, to the best of our knowledge, there is no FDA approval of PNIPAAm-based materials, nor 
are there any materials under clinical investigation for drug delivery. 
 
2.9 Polyphosphoesters 
Polyphosphoesters are constructed by repeating phosphoester groups (-POR’-O-R-O-)n in the main chain. They can 
be subdivided into polyphosphites, polyphosphonates, polyphosphoramidates and polyphosphates.[127] 
Among them, polyphosphates (PP) (R’ = OR1) represent the most important class of polymers, due to their 
structural similarity with nucleic and teichoic acids.[128] Inorganic PPs are salts or esters of polymeric oxoanions built 
on tetrahedral phosphate (PO4) units and occur as linear or branched forms, or cyclic ring structures. They are 
commonly synthesized by dehydration of orthophosphate (PO43-) at an elevated temperature. Other methods 
include an olefin metathesis reaction via an acyclic diene and the ring-opening metathesis polymerization.[129] 
13 
 
A variety of synthetic methods has been summarized by Wang et al..[130] PP can be found in all bacterial, fungal, 
plant or animal life forms. PP was first isolated from yeast by Lieberman[131] in 1888 and has been reviewed 
frequently since the 80’s.[132] The numerous and different biological functions and their biocompatibility have made 
these materials the subject of several research areas investigating the substitution for adenosine triphosphate 
(ATP) in kinase reactions,[133] chelation of metals,[134] or their role in the physiological regulation of growth, 
development, stress, and deprivation.[135] PPs allow for numerous opportunities of modifications due to the 
pentavalent nature of the phosphorus atoms. Examples for such modifications are the introduction of 
double[136]/triple bonds,[137] hydroxy[138] and amine groups[139] to the side chain or polymer backbone. Since Yan and 
co-workers reported the synthesis of highly pure hyperbranched polyphosphates (HBPPs) via the self-condensing 
ring-opening polymerization, this method attracted considerable attention.[140] The convenient modification of the 
side group of the cyclic phosphate monomers resulted in a variety of structures and functionalities.[128] 
Well-defined PPs with approximately 30,000 g mol-1 (Mn) can be synthesized with dispersities Ð < 1.1[141] while also 
high molar mass PPs are possible (Mn = 150,000 g mol-1).[142] Under physiological conditions, PPs can degrade into 
non-toxic, low molar mass species through the hydrolysis or enzymatic cleavage of the phosphate bond. The FDA 
classifies chosen PPs used in food under the GRAS status. They can be found in all types of food including baby 
food, meat, seafood and cheese according to the stipulated rules (food industry: < 5000 pm,[143] meat: 
< 0.5% weight of the final product[144]). Polyphosphates have shown to stabilize the protein structure, form a 
surface layer coagulated protein around meat or to retain the natural moisture of seafood. 
 
2.10 Polysiloxanes 
Materials composed of a backbone of alternating silicon and oxygen atoms with two alkyl or aryl moieties attached 
to the tetravalent silicon (-R2Si-O-) are generally referred to as silicon polymers.[145] They can be considered as 
hybrid materials due to the combination of polar inorganic siloxane bonds (-Si-O-) in the backbone and organic alkyl 
or aryl side chains. Since the invention of the so-called “Direct Synthesis” of methylchlorosilane by Rochow and 
Müller (also called “Müller-Rochow-Process”) in the early 1940s, polysiloxanes have been prepared industrially. 
This large scale production of silicon polymers is realized by an equilibration polymerization of cyclic and linear 
oligosiloxanes in the presence of an acid or a base as catalyst.[146] The method enables easy scale-up and cost 
effective production. However, it does not provide a good control over molar masses of the polymers and their 
dispersity. Only with the development of an ionic ring-opening polymerization using cyclic oligosiloxanes as 
monomers, well-defined polysiloxanes with defined molar masses and narrow dispersities became accessible.[147] 
Compared to the carbon-based polymers, silicon polymers feature superior physical and chemical properties in 
terms of thermal and oxidative stability, as well as flexibility combined with a low thermal glass transition 
temperature.[148]  
Poly(dimethylsiloxane) (PDMS), for pharmaceutical applications better known as “dimethicone”, bears two methyl 
groups on each silicon atom and represents the most prominent member of the silicone family. It is used in various 
pharmaceutical applications due to its excellent biocompatibility, low toxicity, optical transparency, gas 
permeability, high thermal stability, elasticity and low production costs.[149] However, due to the extreme 
hydrophobicity, PDMS-based materials suffer from low wettability and biofouling problems.[150] In consequence, 
increasing concerns arise about the safety of PDMS polymers in long term applications in blood contacting 
environments. To overcome these limitations, the focus of recent silicon related research has been concentrated 
on modifications to enhance the hydrophilicity and anti-fouling capability.[151] PDMS is not biodegradable in 
processes occurring in vivo; however, it slowly degrades within the environment to yield silica, carbon dioxide and 
water as non-toxic degradation products.[152] The FDA approved the use of PDMS in foods (except milk), cosmetic 
and pharmaceutical products (21 CFR 173.340). 
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2.11 Poly(vinyl ester/alcohol/ether)s 
Poly(vinyl esters/alcohols/ethers) are all based on the polymerization of a vinyl group linked to an adjacent oxygen 
group. Poly(vinyl ester)s comprise polymer species, which are mainly prepared by free radical polymerization of 
vinyl esters. Technically important is poly(vinyl acetate) (PVAc). More than one decade ago, the preparation of 
well-defined PVAc by controlled radical polymerization (Mn = 50,000 g mol-1, Ð < 1.4) by “macromolecular design 
via interchange of xanthate”/reversible addition-fragmentation chain-transfer (MADIX/RAFT) polymerization 
became popular.[153] PVAc reveals a glass transition temperature (Tg) around room temperature. Since it is rather 
brittle below the Tg, plasticizers are usually added for improved flexibility. The homopolymer is often applied as 
adhesive in water-based emulsions. To overcome its stiffness, PVAc is often copolymerized with other monomers. 
Furthermore, PVAc can be partially or fully hydrolyzed to obtain the water-soluble poly(vinyl alcohol) (PVA). 
It cannot be prepared by polymerization of the respective monomer vinyl alcohol since it is unstable. Depending on 
the length of the initial PVAc and the degree of hydrolysis under acidic or alkaline conditions, PVA with molar 
masses (Mn) from 20,000 to 400,000 g mol-1 can be obtained with varying solubility, tensile strength and 
adhesiveness.[154] It has a number of desirable properties like mechanical strength and high elasticity that make it a 
useful pharmapolymer. The hydroxyl groups are suitable for cross-linking (e.g. with ethylene glycol 
diglycidyl ether[155] or glutaraldehyde[156]) to create hydrogel networks with low or high swelling behavior in water. 
They have been well-established as drug delivery carriers. The FDA approved PVA for various uses, e.g. as indirect 
food additive in products, which are in contact with food (21 CFR 177.1670), as diluent in color additive mixtures 
for coloring shell eggs (21 CFR 73.1) and as ophthalmic demulcent (21 CFR 349.12).[154] Several microorganisms are 
able to degrade PVA as well as PVAc through enzymatic processes. The degradation by human enzymes has not 
been reported so far. The copolymer poly(ethylene-co-vinyl acetate) (PEVA) is often used in drug delivery research 
to slowly release a compound. Furthermore, it reveals only little or no reaction after implantation. 
Since 1930, poly(vinyl ether)s (PVE) have been produced on an industrial scale. PVEs are polymers bearing the 
functional ether group in the side chain. They are made from the respective vinyl ethers via chain-growth 
polymerization. The functional versatility of the starting material allows the incorporation of alkyl or amine 
moieties. Different synthesis routes and industrial processes are described in literature.[157] Probably the most 
important PVE is the amphipathic butyl- and amine modified one (PBAVE) that has shown remarkable 
performances in trial experiments. 
 
2.12 Poly(N-vinyl amide)s 
Poly(N-vinyl amide)s describe a polymer class that comprises amide functionalities in the side chain. Compared to 
poly(N-acryl amide)s, the amide group is linked to the polymer backbone through the nitrogen atom. The most 
prominent representative is poly(vinyl pyrrolidone) (PVP). 
Linear PVP was first synthesized by Reppe in 1939 as one of the numerous products originating from acetylene 
chemistry. It is a water soluble, non-ionic, biocompatible and stable polymer, which is not metabolized by the 
organism.[158] In the very beginning during World War II, it was mainly used as plasma expander.[159] Today, it is well 
established in several products of cosmetic and pharmaceutical industry, e.g. as binder in pills. A special feature of 
PVP, also known as “povidone”, is its possibility to form strong hydrogen bonds, which also explains its good 
solubility properties in water. Furthermore, the hydrogen bond formation enables complexation of polar 
compounds which increases the water solubility and the bioavailability, as reported for acetaminophen.[160] 
The complex formation constants as well as solubility properties were furthermore determined for several other 
substances.[161] It could be shown that PVP, similar to PEG, increases the water solubility and blood circulation time 
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for liposomes.[162] PVP is approved by the FDA for numerous applications, e.g. in food for human consumption 
(21 CFR 173.55). A reported method to synthesize PVP in laboratory scale is MADIX/RAFT polymerization. 
In industrial scale, it is synthesized by free radical polymerization in most cases, whereat a broad range of molar 
masses can be obtained. The commercially available polymers comprise ranges (Mw) from 2,000 to 
2,500 × 103 g mol-1.[163] In order to achieve high molar masses, a polymerization in aqueous solution is commonly 
applied using hydrogen peroxide as initiator. Organic solvents generally lead to low molar mass PVP. 
Using hydrogen peroxide as initiator, the solvent for the polymerization is of high importance for the final product, 
since it is responsible for the polymer end group. Other possibilities to create different functional endgroups 
include the usage of suitable transfer agents or specific chain capping agents. Post modifications are also possible 
but difficult to control, and the products are hard to purify. Another way to alter or to improve the polymer 
properties of PVP is copolymerization.[160] The synthesis is performed by radical polymerization in an organic 
solvent similar to the synthesis of the linear homopolymer. A frequently used comonomer is vinyl acetate 
(polymer: copovidone). The amount of vinyl acetate increases the hygroscopicity of the product, allowing the 
preparation of less brittle films, which is preferable for the use as soluble binder or film-forming agent.[161] 
One opportunity to obtain water insoluble PVP is cross-linking, resulting in so-called crospovidone. The ways to 
synthesize cross-linked PVP are versatile, reaching from the use of cross-linking agents or cross-linking monomers 
to subsequent cross-linking with peroxides. A well-known way to obtain highly cross-linked products is the so-called 
“popcorn polymerization”. This method uses either an alkali hydroxide, yielding some bifunctional monomers, or a 
small amount of bifunctional monomers for cross-linking.[161, 164] The mechanism of this polymerization method is 
not well-determined, since it was primary observed as a side reaction in radical polymerization processes. It could 
be found that this polymerization starts by a highly reactive nucleus initiating the whole process, similar to the 
formation of popcorn.[165] Infrared measurements revealed that there is no structural difference between the 
cross-linked PVP obtained by popcorn polymerization and the linear PVP, but a difference was observed for 
chemically cross-linked PVP. Therefore the cross-linking of PVP via popcorn polymerization is essentially of a 
physical nature.[161] The cross-linked PVP is widely used in beverage and pharmaceutical industry. The good 
adsorptive properties are used to remove polyphenols or azo dyes from beverages. A rather well-known example in 
the pharmaceutical industry is the PVP-iodine complex which is used as disinfectant, also known as betaisodona 
and with several other trade names. Furthermore, crospovidone shows beneficial disintegration properties, thus it 
is used as additive in tablets promoting their break up and, therefore, speed up the drug release from solid dosage 
forms.[161, 166] 
 
2.13 Poly(allylamine)s 
Poly(allylamine) (PAAm) is a cationic polymer obtained from the radical or cationic polymerization of allylamine. 
While the backbone contains no nitrogen, as described for poly(ethylene imine), the polymer side chain contains 
primary amine groups which can be converted into secondary or tertiary amine functionalities. This turns PAAm 
into a highly promising gene delivery agent.[167] Poly(allylamine hydrochloride) in combination with an anionic 
polyelectrolyte (e.g. poly(styrene sulfonate)) can be used to form layer-by-layer adsorbed films.[168] 
 
2.14 Poly((meth)acrylate)s 
Poly(acrylate)s and poly(methacrylate)s are synthetic polymers of acrylic and methacrylic acids or their esters, 
respectively.[169] They are prepared on an industrial scale by free radical polymerization applying a variety of 
different methods, which include bulk, solution, suspension, and emulsion polymerization.[170] 
Poly(meth)acrylates can also be synthesized by various controlled radical polymerization techniques, which allow 
16 
 
a better control over molar mass, dispersity, polymer composition, and polymer architecture compared to 
free radical polymerization.[171] Poly(methacrylate)s generally display a higher glass transition temperature (Tg) and 
a lower decomposition temperature than the corresponding poly(acrylate)s.[172] The properties of 
poly(meth)acrylates can conveniently be tuned by varying the molecular structure of the ester side chain. These 
modifications enable access to polymers spanning the whole range from water to oil soluble or from brittle to 
elastic. The FDA has approved the safety of poly(meth)acrylates in several pharmaceutical applications, e.g. as basic 
components of food contact surfaces (21 CFR 177.1010). 
Poly(acrylic acid) (PAA) and poly(methacrylic acid) (PMAA), bearing a carboxylic acid unit on every second carbon 
atom of the main chain, are water soluble, weak anionic polyelectrolytes.[173] Besides their linear form they can be 
cross-linked by several cross-linking agents. The backbone of PAA and PMAA are not biodegradable, but they 
exhibit a low toxicity and excellent biocompatibility.[160] In aqueous solution, PAA and PMAA display a reversible 
coil-to-globule transition at pH 5. At lower pH values, these polymers undergo a transition to a compact globular 
conformation. However, if the pH value is increased, the chains expand into a fully solvated coil conformation due 
to the ionization of the carboxyl groups.[174] This reversible ionization of PAA and PMAA enables the formulation of 
pH- and ionic strength responsive materials. For instance, PAA-based hydrogels swell rapidly when placed in an 
aqueous environment due to the ionization of carboxyl groups. This feature makes PAA and its sodium salt 
(poly(sodium acrylate)) the most prominent materials for super absorbers, which are applied in diapers and 
membranes for hemodialysis or ultrafiltration.[175] Concerning drug delivery applications, PAA provides sufficient 
flexibility and excellent bioadhesion properties. Hence, they are frequently used for oral and mucosal contact 
applications such as tablets, oral suspensions and bioadhesives. An advantage of PAA is the convenient 
modification of the carboxyl side chains with alcohols or amines to introduce additional functionalities. 
In consequence, drugs and/or bioactive molecules can easily be attached to the PAA backbone in accordance with 
the concept of Ringsdorf.[176] Poly(2-hydroxyethyl methacrylate) (PHEMA) represents another water soluble, 
biocompatible poly(methacrylate) modified with hydroxyl functionalities in each repeating unit. These hydroxyl 
groups enable the material to form strong hydrogen bonds and make it very hydrophilic without need for charged 
side chains. As a consequence, PHEMA is often used as the main material for contact lenses. Moreover, the 
hydroxyl functionality of PHEMA can further be modified in post-polymerization reactions to conjugate any bio-
active molecule. 
Poly(methyl methacrylate) (PMMA) represents probably one of the best-known poly(methacrylate)s containing a 
methyl ester functionality at the side chain, which makes this material hydrophobic and non-soluble in water. 
PMMA was first developed in 1928 by Röhm, Chalmers and Bauer. The first commercial product was brought to the 
market in 1933 by the Rohm and Haas company under the trademark “Plexiglas®”.[177] In the following years, 
PMMA rapidly became the most important plastic glass due to its excellent transparency and ease of production. 
Concerning pharmaceutical applications, PMMA is characterized by an excellent biocompatibility, convenient 
processability, low toxicity, minimal inflammatory reactions with tissues, and low production costs.[178] Being 
nonbiodegradable and fracture resistant, it is an essential material for implant materials, in particular in case of 
long term applications. PMMA-based materials have further found application in dermal fillers, bone cements, 
intraocular lenses and membranes in dialyzers for hemodialysis.[179] However, there are some limitations to the use 
of PMMA, which are related to its brittleness and shrinkage, the generation of voids during processing steps, a lack 
of adherence to bone tissue, and the heat created by the exothermic reaction during cement polymerization, which 
can damage bone tissue.[180] To overcome these problems, alternative poly(meth)acrylates are currently under 
investigation, in particular for use as long term implant materials. One example is poly(n-butyl methacrylate) 
(PBMA), which possesses a butyl ester at the side chain. This material features a lower toxicity, a higher fracture 
toughness, and a better fatigue life, while reducing the exothermic effects compared to PMMA.[181] 
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Another important modification of poly(methacrylate) is poly(2-dimethylaminoethyl methacrylate) (PDMAEMA), 
which contains an ionizable tertiary amine group. In water it may be protonated and becomes a weak cationic 
polyelectrolyte depending on the pH value. The pKa value of the polymer depends on the composition as well as 
the molar mass, whereas values between 7 and 8 have been reported. Additionally, PDMAEMA exhibits LCST 
behavior in water depending on the molar mass of the polymer and the pH value of the solution.[182] However, the 
positive charge on the polymer causes these materials to be quite cytotoxic, which, in combination with the lack of 
biodegradability, limits its use in pharmaceutical applications.[183] Concerning drug delivery systems, the monomer 
DMAEMA is so far only applied as comonomer in combination with other methacrylates or methacrylic acid to 
modulate the overall charge and create a defined pattern for dissolution at specific pH values. Apart from changing 
the ester functionality or its alkyl moiety, physicochemical properties of the poly(meth)acrylates can also be altered 
by copolymerizing different functional monomers and by varying the monomer composition of the polymers. 
Incorporating the ionizable segments in the backbone of the polymers, such as amine and/or carboxyl groups, can 
render a tunable pH-dependent water solubility to the corresponding polymers. Accordingly, they are used for 
pH-dependent drug release applications due to salt formation.[184] These copolymers are more commonly known as 
EUDRAGIT® polymers in pharmaceutical industry and described in Chapter 3. 
Furthermore, in addition to hydrogen and methyl groups, some other functionalities can be installed on the 
α-position of the acrylic backbone. For instance, acrylates with a nitrile group are called cyanoacrylates. 
Various alkyl groups can be added to the ester group, e.g. methyl, butyl, or hexyl. Cyanoacrylates polymerize 
rapidly in the presence of traces of water by an anionic polymerization mechanism to corresponding 
poly(cyanoacrylate)s. Therefore, they are commonly used as instant adhesives or “superglues”.[185] For medical 
adhesive applications, cyanoacrylates with long alkyl groups are preferred since poly(cyanoacrylate)s with short 
groups can irradiate the tissues. Poly(cyanoacrylate)s, in particular poly(isobutyl cyanoacrylate) and 
poly(isohexyl cyanoacrylate), have also been used in drug delivery applications. The installation of the heavier 
element fluorine on the α-position results in α-fluoroacrylates. Poly(α-fluoroacrylate)s can be obtained by the free 
radical polymerization of the α-fluoroacrylate.[186] Compared to the conventional (meth)acrylates these polymers 
exhibit better thermal and chemical stabilities. These polymers are mainly used for optical applications, but also 
found to be useful in cross-linked copolymers as polymer sequestrant. 
 
2.15 Polyacrylonitriles 
Polyacrylonitriles (PAN) are synthetic, semicrystalline organic polymers consisting of nitrile units attached to the 
carbon backbone. First synthesized in 1930 by Fikentscher and Heuck (IG Farben, Ludwigshafen),[187] it took more 
than 16 years for establishing the large scale production of PAN (brand name Orlon®) by Du Pont®.[188] Commercial 
PAN with high molar mass is synthesized by free radical polymerization of acrylonitrile. As a result, the control of 
the molar mass distribution is limited and high dispersities are obtained (Mn < 106 g mol-1, Ð > 3). More controlled 
processes like the ATRP and the RAFT polymerization enable the control of the molar mass distribution for molar 
masses (Mn) up to 100,000 g mol-1 (ATRP[189]: Ð < 1.3; RAFT[190]: 60,000 g mol-1, Ð = 1.2 to 1.4). In many cases, 
various vinyl monomers are copolymerized to modify the structure for final applications.[191] Anionic polymerization 
has been applied for the polymerization of PAN as well,[192] but this method results in branched structures, which 
affects the mechanical behavior of the PAN.[193] In general, the active nitrile groups in PAN can be converted to 
other functional groups like carboxyls (via hydrolysis)[194] and amines (via reduction),[195] which subsequently 
facilitate further modifications. Recently, Nataraj et al. reviewed the application of PAN-based nanofibers in various 
fields.[196] Several investigations have demonstrated that the relatively poor biocompatibility of the conventional 
PAN could be improved by bulk or surface modification.[197] Another simple and low-cost alternative modification is 
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blending.[198] The FDA approved the use of PAN in the production of semi-rigid and rigid acrylic plastics, which are 
intended for use in contact with food (21 CFR 177.1010). 
 
2.16 Polyurethanes 
Discovered 75 years ago, polyurethanes (PU) represent a versatile polymer class based on a modular structure 
which is generated by the combination of a variety of polyols and isocyanates as building blocks.[199] The urethane 
groups are formed in the polymer backbone by the polyaddition of respective isocyanates and alcohol groups. 
The chemical nature of the building blocks, the reaction sequence as well as the ratio of the OH/isocyanate 
components determines the properties of the polymers. Polyols with molar masses (Mn) larger than 1,000 g mol-1 
are used to make soft and elastic PUs (e.g. PEG-diols) while short chains result in hard, rigid PUs (e.g. dipropylene 
glycol). The latter can be further supported by cross-linkages. The most common used isocyanates are aromatic 
diisocyanates (e.g. toluene and methylene diphenyl diisocyanate) since they reveal higher reactivity compared to 
aliphatic isocyanates (e.g. hexamethylene diisocyanates). Often the reaction of three components, in particular a 
diisocyanate, a bifunctional polyol and a dihydroxy chain extender, is described to form linear, segmented 
copolymers consisting of alternating hard and soft segments. The structural diversities and tailorable properties 
(e.g. biodegradability, blood compatibility, hydrophilicity) make these materials extremely versatile for 
bioapplications and other high-tech products.[200] Doubtless, the most prominent application for PUs are foams of 
different nature. The FDA approved PU resins for use as basic components of food contact surfaces 
(21 CFR 177.1680). Other materials, which are closely related to PUs, are polyureas (often summarized as 
polyurethanes); these are the product of the addition of isocyanates with amines.[201] In general PUs for biomedical 
applications are mainly found in gels of various sizes. 
 
2.17 Polystyrenes 
Polystyrenes (PS) are synthetic aromatic polymers made from the styrene monomers. The first commercially 
available polymers were manufactured by the company I. G. Farben in 1931.[202] The most prominent applications 
are the PS foams. Pioneering work on its polymerization was done by Natta (1960) and Ishihara (1986) who 
reported the synthesis of iso- (phenyl groups on the same side) and syndiotactic polystyrenes (phenyl groups on 
alternating sides of the backbone). The latter is commonly prepared in a so-called Ziegler-Natta-polymerization.[203] 
This kind of polymerization uses metallocene catalysts in order to control the orientation of the monomer in the 
moment of addition.[204] Further synthesis routes comprise radical, anionic as well as cationic polymerization. 
The syndiotactic PS exhibits a crystallization rate, which is around two orders of magnitude larger than the isotactic 
form. Several routes for the synthesis of functional materials are described in literature, comprising in situ 
functionalization, post-polymerization modification or the application of pre-functionalized monomers.[205] 
For instance, the introduction of sulfonic acid groups in the para-position of the benzene ring turns the resulting PS 
into the water soluble poly(styrene sulfonic acid). Different cross-linking agents have been incorporated into the 
PS resins, including the most commonly applied divinylbenzene, but also other monomers have been used to adjust 
different solvation properties (e.g. dimethacrylate, tetraethylene glycol).[206] Basically, PS is hard and rather brittle 
and occurs in the solid or foam state. It is a widely used plastic for packaging where hygiene is important. Above its 
glass transition temperature (100 °C) it becomes liquid, while cooling down results in rigidity again. Using this 
temperature behavior, PS can be processed via extrusion, molding or vacuum forming.[207] PS is approved by the 
FDA as food packaging material (21 CFR 177.1640) updated in 2013 by the Plastics Foodservice Packaging 
Group.[208] 
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2.18 Polyanhydrides 
Polyanhydrides are commonly obtained by the dehydration reaction between diacids by either melt 
polycondensation or solution polymerization to form the functional group (-O-CO-R-CO-). Different structures, their 
characterization and biocompatibility have extensively been reviewed.[209] The polymers were prepared with the 
intention to obtain a material that should degrade within the time range of their application due to the presence of 
the most reactive functional group available for degradation on the basis of passive hydrolysis.[210] They degrade 
in vivo into non-toxic monomer counterparts, which can be eliminated from the body as metabolites. High molar 
mass polyanhydrides (Mn up to 30,000 g mol-1) can be synthesized by utilizing heterogenic coordination 
catalysts.[211] Often used monomers are the naturally occurring sebacic acid (poly(sebacic 
acid), FDA: 21 CFR 175.105) and the 1,3-bis(4-carboxyphenoxy)-propane (poly(bis-(p-carboxyphenoxy)propane). 
While aromatic polyanhydrides can fragment after exposure to water, resulting in a rapid release of water-soluble 
drugs, copolymers prepared from fatty acids (e.g. sebacic acid) show controlled degradation rates from days to 
years. The copolymer poly(styrene-co-maleic anhydride) was approved by the FDA as indirect food additive for use 
as articles or components of articles that contact food items (21 CFR 177.1820).  
Containing the functional groups in the side chain, poly(maleic anhydride) represents another form of 
polyanhydrides made from maleic anhydride in the presence of free radical catalysts and various organic bases, 
among others.[212] It is mainly used as comonomer, e.g., for the polymerization with styrene (poly(styrene-co-maleic 
anhydride)). A unique feature is the preparation of almost perfectly alternating copolymers which are the first 
polymers that were used for drug conjugates. 
 
2.19 Polyolefins 
Polyolefins describe a class of polymers obtained from a simple alkene (olefin) as monomer. These materials are 
produced in million ton scales and are the most common plastics used in commodity products. Besides radical 
processes or the frequently used coordination polymerization, the living alkene polymerization method catalyzed 
by transition metal complexes is becoming more and more popular to synthesize polyolefins with a precise molar 
mass control as well as a wide array of polymer architectures.[213] Their properties are mainly determined by their 
molar mass and degree of crystallinity (from liquid-like to rigid plastics). All practical or commercial relevant 
polyolefines are poly-α-olefins. The FDA approved poly(ethylene) for use as basic component of food contact 
surfaces (21 CFR 177.1520). It represents the simplest representative and most common plastic, which is made 
from ethylene in the presence of the Ziegler-Natta catalyst.[214] 
Further often used olefins are poly(isobutylene) (by cationic polymerization of isobutylene),[215] the non-reactive 
fluoropolymer poly(vinylidene fluoride) (PVDF) (by radical polymerization of vinylidene difluoride)[216] and 
poly(hexafluoropropylene) (PHFP). Bisfunctional polyolefins like poly(octa-1,7-diene) can be used for cross-linking 
reactions to obtain network architectures. 
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3. Polymers in pharmaceutical applications 
The following chapter describes different forms of applications of pharmapolymers which are already available on 
the market or currently undergoing clinical trials. The current clinical status and the respective NTC number 
(clinicaltrials.gov identifier) usually refer to the official webpage https://clinicaltrials.gov/. In some cases, the 
availability and the approved indication of use for the applied materials vary between countries. The described 
forms of appearance include polymer-drug conjugates, drug carrier systems in scales ranging from nano- to 
macroscopic size, polymers as coatings and matrix excipients as well as polymeric drugs. 
 
3.1 Polymer-drug conjugates 
The conjugation to polymers is a well-established technique to improve the properties of therapeutically active 
substances. In the last decades, numerous polymers have been tested for this purpose. The cytostatic agents that 
have been mainly used for preparing polymer-drug conjugates are doxorubicin (DOX), camptothecin (CPT), 
paclitaxel (TXL) and platinum complexes (Figure 1), but also other, more specialized drugs are conjugated. 
 
 
Figure 1. Schematic representation of the structures of the most common cytostatic agents used for preparing polymer-drug conjugates. 
A) Literature reported conjugation sites (marked in red) and B) selected examples for platinum complexes. 
 
3.1.1 PEG conjugates  
One of the first and probably the most well-known example is the attachment of poly(ethylene glycol) (PEG), also 
called PEGylation. In drug delivery, PEGylation can be subdivided into three categories: The attachment of PEG to 
proteins, to small drug molecules and to other polymers. The latter is often related to the formation of 
nanocarriers, which are described in detail in Chapter 3.2. With the attachment of PEG chains, some of the 
beneficial properties of this polymer are transferred to the pharmacological active compounds, which can improve 
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the accessibility of drugs in biological systems.[15, 217] Pioneered by Davis and his colleagues, the first PEGylation was 
successfully demonstrated on a protein.[10a] The initial goal was the protection from destruction during the delivery 
process. As an unexpected finding, the authors observed that the PEGylation improved the pharmacokinetic and 
pharmacodynamics of the protein.[218] Similar observations are found for small drug molecules, which often suffer 
from poor solubility and, therefore, low bioavailability. The attachment of PEG strongly improves their properties 
by adapting the beneficial properties of the PEG polymer. 
PEGylation of proteins. Since the first PEGylation of a protein, a variety of accessible functional groups on protein 
surfaces has been explored as potential linking sites. In general, the functionalization with PEG introduces several 
advantageous properties compared to the native protein. PEGylated proteins show an improved pharmacokinetic 
and pharmacodynamic, which is related to an increased water solubility, an increased stability, shielding from 
metabolic enzymes, a reduced immunogenicity and retarded renal clearance (due to stealth behavior) leading to an 
elongated blood circulation time.[11b] Depending on the molar mass of the attached PEG chains, the clearance by 
the kidneys can also be circumvented.[15, 218-219] The conjugation additionally reduces the immunogenicity of the 
native protein, increases its stability and prolongs the biological half-life which helps to reduce the frequency of 
administration. In the last decade, several new conjugation methods have been developed, allowing a more 
effective and selective attachment of PEG polymers. The PEGylation techniques of proteins can be separated into 
first and second generation.[220] The first generation is performed using short PEGs (Mn = 5,000 to 12,000 g mol-1) 
being randomly bound to the protein surface. A disadvantage when using a PEG-diol is the formation of a high 
content of protein dimers, trimers and even fully cross-linked materials. In consequence, the α-methylated mPEGs 
are preferred to avoid this problem, although minor contaminations with PEG-diol are still present.[221] As activation 
agents or linkers between the protein and the PEG chains, cyanuric chloride, tresyl chloride and many more 
compounds are applied.[11a, 222] The second generation of PEGylation improved the selectivity of the attachment to 
specific areas of the protein while reducing the influences on the protein structure. Common groups for 
functionalization are maleimide targeting free thiol groups, NHS activated acids reacting with amines, 
benzotriazoles, which create a pH-responsive linkage, and aldehydes such as propionaldehyde. Furthermore, 
second generation PEGs allow an easier purification and removal of remaining PEG-diol, e.g. in the case of PEG with 
activated acids up to 97% of the remaining diol content can be removed by ion-exchange chromatography.[218] 
PEGylation techniques forming disulfide bridges enable the site specific PEGylation to the few free cysteine 
residues on the protein surface, which minimizes the loss of biological activity, but preserves the low 
immunogenicity. A rather new method is described by DeFrees et al. called glycopegylation. This method basically 
uses enzymes for N-acetylgalactosamine (GalNAc) glycosylation at specific serine and threonine residues, which 
subsequently conjugate to salic acid conjugated PEG by enzymatic transfer.[223] These improvements on the 
conjugation methods allow the synthesis of drug conjugates with well-defined amounts of PEG and selective 
binding to non-active parts of the protein.[224] A more detailed overview on different protein PEGylation techniques 
is given by Roberts et al..[11d]  
Considering the above mentioned improvements on the synthesis, in particular the excellent selectivity of 
conjugation and the general benefits like the improved pharmacokinetics, it is not surprising that a number of 
PEGylated proteins already entered the market and several new materials are in clinical trials. Overall, thirteen 
different PEGylated proteins are nowadays approved and commercialized (Table 3). The first clinically approved 
PEGylated protein drug was the enzyme Adagen® (Enzon Pharmaceuticals). After its approval, several other 
PEGylated protein drugs found their way to commercialization and entered clinical trials within a short period of 
time. A milestone in the pharmaceutical development was certainly the approval of Macugen®, being the first 
approved aptamer used as therapeutic agent in humans.[225] The latest protein drug that has been approved by the 
Food and Drug Administration (FDA, Nov. 2015) is the PEGylated full length Factor VIII (Adynovate®) for use in 
patients aged 12 years and older suffering from haemophilia A and.[226] Once approved by the FDA or European 
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Medicines Agency (EMA), established PEGylated proteins are investigated in clinical trials. Due to the large number 
of clinical studies, only a selection of investigated diseases can be found in Table 3. 
 
Table 3. PEGylated proteins and small drugs on the market approved by the FDA and EMA as well as their use for other diseases. 
TRADE NAME CONJUGATE  INDICATION/USE MANCUFACTURER Mn (PEG) (g mol
-1)  
[# of PEGs/drug molecule] 
CURRENT  
CLINICAL TRIALS ON … 
PROTEIN 
Adagen® PEG-Adenosine Deaminase SCID
[a] Enzon Pharmaceuticals 
5,000 
[11 to 17] 
Severe combined 
immunodeficiency disease 
Oncaspar® PEG-Asparaginase  Leukaemia Enzon Pharmaceuticals 
5,000 
[69 to 82] 
Various cancers (neoplasms, 
multiple myeloma) 
PegIntron®, 
ViraferonPeg® 
PEG-Interferon-α2b Hepatitis C Schering-Plough 12,000 [1] 
Hepatitis B, various cancers 
(e.g. fallopian tube-, ovarian-, 
peritoneal cavity cancer, 
neoplasm, melanoma), HIV 
Infection 
PEG-Interferon-α2a  Hepatitis C Hoffman-La Roche 40,000 [1 branched] 
Hepatitis B, various cancers 
(e.g. kidney cancer, leukemia), 
HIV infection 
Somavert® 
PEG-Human growth 
hormone mutein 
antagonist 
Acromegaly Pfizer  5,000 [4 to 6] 
Different neoplasms 
(colorectal, lung, breast, 
prostatic) 
Neulasta® PEG-G-CSF[b] Neutropenia Amgen® 20,000 [1] 
Various cancers  
(e.g. breast cancer) 
Macugen® 
(Pegaptanib) 
PEG-anti-VEGF 
aptamer WARMD 
OSI 
Pharmaceuticals/ 
Pfizer  
40,000 
[1 branched] 
Wet age related macular 
degeneration 
Mircera® PEG-Erytropoietin AACKD Hoffman-La Roche 30,000 [1] 
Various cancers  
(e.g. breast, prostate cancer, 
lymphoma, neoplasms) 
Cimzia® PEG-anti-TNF Fab[c] 
Rheumatoid 
arthritis & 
Crohn's disease 
(RACD) 
UCB Cares® 40,000 [1 branched] RACD  
Krystexxa® 
(Pegloticase) PEG-Uricase  Chronic gout Horizon Pharma 
10,000 
[9 per homo-tetramer (4)] Chronic kidney disease stage 5 
Omontys® Peginesatide AACKD Affymax/Takeda[d] 40,000 [1 branched] 
Anaemia associated with 
chronic kidney disease 
Lonquex® 
(Lipegfilgrastim) 
Glycopegylated  
G-CSF Neutropenia
[e] TEVA 20,000 [1] 
Various cancers (e.g. breast, 
ovarian cancer) 
Plegridy® PEG-interferon beta 1a  
Relapsing 
multiple sclerosis 
(RMS) 
BiogenTM 20,000 [1] RMS 
Adynovate® 
PEG-Factor VIII 
(full-length 
Coagulation Factor 
VIII) (BAX 855) 
Haemophilia A[a] Shire 20,000 [2] 
Different blood diseases  
(von Willebrand Disease, 
thrombosis) 
SMALL DRUG 
Moventig®  
(EU: Movantik®) 
(Naloxegol) 
PEG-Naloxone[b] Opioid-induced constipation AstraZeneca 
< 1,000  
[1]  
[a] Only approved by the FDA, [b] G-CSF: Granulocyte-colony stimulating factor, [c] approved for different disease in U.S. and E.U. (Nektar®), 
[d] withdrawn by Takeda, [e] Only approved by the EMA. 
 
Selected PEGylated protein drugs in clinical trials. Due to the high number of materials in clinical trials, we only like 
to highlight a few materials in late stages of clinical testing (phase III) used for different kinds of diseases (Table 4). 
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Inherent bleeding disorder due to a deficiency or dysfunction of coagulation proteins is called haemophilia (A in 
case of Factor VIII, B in case of Factor IX). The only treatment of haemophilia patients is the intravenous injection of 
the deficient coagulation factors, prophylactic or in case of acute trauma. A drawback of native coagulates is their 
short half-life (FVIII 8: 12 h, FIX 18: 24 h) and the resulting frequent need for administration. In comparison, 
PEGylated FVIII and FIX show extended half-life and increased blood concentration after injection.[227] Besides the 
FDA approved PEGylated recombinant Factor VIII several other products are currently undergoing clinical trials 
including PEGylated Factor IX proteins. These drugs differ mainly in the way of PEG-binding, the chain length of the 
PEG or the modification of the protein (mutant Factor VIII (K1804C)).[227b, 227c, 228] The aim of these modifications is 
of course an increased activity.[229] Two conjugates are currently undergoing clinical trials in phase III (N8-GP and 
N9-GP).[230] The effects of these products are discussed in detail in literature.[227c, 231] Age related macular 
degeneration (AMD) is a medical condition causing blurred or impeded vision on focused objects, which in case of 
the more common wet AMD is related to the formation of abnormal blood vessels in the middle part of the retina. 
Initiated by the approval of the previously mentioned Macugen®, further PEGylated protein aptamers are under 
investigation, such as Fovista®. In contrast to Macugen®, Fovista® is developed to inhibit the platelet-derived 
growth factor (PDGF) and, therefore, the formation of abnormal vessel growth. For the treatment of AMD, it is 
combined with ranibizumab, an anti-Vascular Endothelial Growth Factor (anti-VEGF), and just passed the clinical 
trials phase II and entered phase III showing significantly improved results compared to native ranibizumab.  
Patients with an inactive recombinant phenylalanine ammonia lyase suffer from an enrichment of phenylalanine 
(Phe) or hyperphenylalaninemia, which is mainly caused by a recessive gene disorder and results in mental 
retarding, if not recognized and treated timely.[232] A possible treatment is an enzyme substitution therapy. 
However, injections of pure phenylalanine ammonia-lyase (PAL) have only a short half-life and low activity in gastric 
secretions. In consequence, research focused on the development of more efficient forms realized by site-directed 
mutagenesis and PEG modifications. As a result, the concentration of Phe in blood could be decreased significantly 
and the symptoms are diminished.[233] Another PEGylated protein that reached phase III clinical trials is 
Peglispro,[234] a PEGylated insulin for the application as long term drug for diabethis mellitus patients. It could be 
shown that Peglispro has improved pharmakokinetic and pharmakodynamic profiles and, preferentially, hepatic 
versus peripheral action compared to insulin glargine. Nevertheless, end of 2015 the development of the project 
was discontinued by the supplier Lilly due to late stage observations regarding liver fat changes leading to 
unresolved questions.[235] 
 
Table 4. PEGylated proteins under active clinical trials in phase III. 
NAME PEGYLATED PROTEIN INDICATION/USE MANUFACTURER Mn (PEG) (g mol
-1)  
[# of PEGs/drug molecule] 
IDENTIFIER 
NUMBER 
N8-GP Glycopegylated recombinant coagulation Factor VIII (K1804C) Haemophilia A Novo Nordisk® 40,000 [1] NCT01489111 
N9-GP PEGylated recombinant Factor IX Haemophilia B Novo Nordisk® 40,000 [1] NCT02141074 
Fovista® PEGylated anti-platelet-derived growth factor  
Age related macular 
degeneration 
Ophthotech/ 
Nektar® 40,000 [1 branched] e.g. NCT01944839 
Pegvaliase PEGylated recombinant PAL enzyme[a] Phenylketonuria BioMarin® 20,000 [1] NCT01819727 
[a] PAL: Phenylalanine ammonia lyase. 
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PEGylation of small molecule drugs. In comparison to proteins, small molecules provide only a limited number of 
reactive side chains that are suitable for modifications. The lack of functional side groups in linear PEGs makes the 
coupling capacity of small molecules a critical issue. In order to improve the loading capacity, different 
architectures were investigated, e.g. forked, multi-arm, star-like and dendritic or branched polymers for the 
conjugation of small molecule drugs.[236] [217b, 237] Despite the immense research effort, it took a comparably long 
time for PEGylated small molecule drugs to enter the market. Small molecule drugs, such as antitumor agents, 
often suffer from poor solubility, high toxicity, rapid excretion and untargeted biodistribution. Therefore, 
conjugation of PEG represents an obvious way to improve their profiles. However, until now PEG-Naloxone 
(Moventig®) is, to the best of our knowledge, the first and only marketed PEGylated small molecule drug (approved 
by FDA and EMA) (Table 3). PEG-Naloxone is applied for treatment of opioid-induced constipation and approved for 
adult patients with chronic non-cancer pain.[217a] Being approved in 2014, Moventig® entered the market 
comparably late considering that PEGylation of proteins is performed for decades. Li et al. summarized 20 to 25 
PEGylated small molecules at different stages of development and several research examples which show that 
PEGylated small molecules principally have improved properties. However, those examples failed in clinical trials 
due to a reduced activity, an inherent instability or their toxicity.[237b] Nevertheless, with the first approval of a 
PEGylated small drug we are confident that further examples will follow. 
A list of PEGylated small molecule drugs undergoing clinical trials is given in Table 5. NKTR-181 is a PEGylated 
agonist for the µ-opioid receptor developed by Nektar®. Currently, it undergoes clinical trials in phase III.[238] 
Modified opoids are the most common medication types to treat chronic pain. In preclinical and clinical trials, the 
PEG modified drug revealed a slower uptake by the central nervous system (CNS) due to a reduced crossing of the 
blood-brain barrier (BBB), resulting in fewer CNS related side effects.[239] The aim of NKTR-181 is the treatment of 
patients with chronic low back pain (SUMMIT-07).[240] 
Etirinotecan pegol comprises the prodrug irinotecan which is conjugated to a 20,000 g mol-1 four arm PEG by a 
degradable linker. Irinotecan is widely used as chemotherapeutical agent.[241] After enzymatic hydrolysis of the 
linker, it metabolizes into SN38, a potent topoisomerase I inhibitor and the active moiety of irinotecan, resulting in 
a 1000-fold increased activity in comparison to irinotecan itself.[242] The conjugation to PEG using slowly 
hydrolysable linkers based on esters aims at an application as long-acting agent with continuous and targeted drug 
release. In consequence, the concentration of SN38 is reduced in the plasma and undesired side effects are 
diminished.[243] As a result of the beneficial properties observed in phase II, Etirinotecan pegol is now undergoing 
clinical trials in phase III for advanced breast cancer and brain metastases in the US (OnzealdTM).[243] In addition to 
this trial, further studies in different stages are currently ongoing to test its use for other cancerous diseases. 
In phase II of clinical trials, toxic side-effects associated with common chemotherapies appeared less frequent or 
were completely absent.[244] These preliminary results make etirinotecan pegol an attractive and interesting 
candidate for chemotherapies in the future. Other PEGylated small molecules produced by Nektar® are in earlier 
stages of clinical trials (I and II), including EZN-2208 for advanced solid tumors/lymphoma, and NKTR-171 for 
neuropathic pain.[238, 245] 
 
Table 5. PEGylated small molecule drugs undergoing active clinical trials. 
NAME PEGYLATED DRUG INDICATION/USE MANUFACTURER 
Mn (PEG) (g mol-1)  
[# of PEGs/drug molecule] STATUS 
NKTR-181 n.a. Neuropathic pain Nektar® < 1,000 Phase III  (e.g. NCT01619839) 
NKTR-102 
(US: OnzealdTM) 
Etirinotecan 
pegol (SN38) Several cancer Nektar® 20,000 [1 four-arm] 
Phase III  
(e.g. NCT01492101) 
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Figure 2. Schematic representation of the 
chemical structure of poly(styrene-co-maleic 
anhydride/acid/ester). 
EZN-2208 SN38 Several cancer Enzon Pharmaceuticals 40,000 [1 four-arm] Phase II  (e.g. NCT00520637) 
NKTR-171 n.a. Neuropathic pain Nektar® < 1,000 Phase I[246] 
n.a.: not applicable. 
 
3.1.2  Non-PEG conjugates 
Some limitations of PEGylation have emerged specifically including an increased occurrence of immunogenic 
reactions and the accumulation in tissues which is a result of the nondegradability.[247] Hypersensitivity has been 
observed in some cases, which diminishes the benefits of PEGylation in case of some patient populations.[248] 
Even though PEG is not biodegradable, degradation occurred under certain circumstances (light, heat etc.) with the 
possibility of a build-up of toxic side products while stored.[15] Nevertheless, PEG is currently still the most tested 
and best understood polymer available with the longest clinical track record, but research efforts have increased to 
develop alternative materials addressing these limitations of PEG and adding further functionalities to 
polymer-drug conjugates. The number of potential alternatives for PEGylation has increased tremendously in the 
last years.[249] Requirements for potential substitutes for PEG include a high water-solubility, non-toxicity, 
non-immunogenicity, low accumulation during a therapy and clearance from the body.[250] Besides natural 
polymers such as heparin, dextran, chitosan, hyaluronic acid and human serum albumin, several synthetic polymers 
have emerged as suitable conjugate alternatives to PEG. In the following chapter we focus on these synthetic PEG 
alternatives and summarize all materials which entered clinical trials or the market already (Table 6). 
Poly(styrene-co-maleic anhydride). The conjugation of poly(styrene-co-maleic anhydride) to the antitumor protein 
neocarzinostatin (SMANCS) was the first clinically approved polymer-drug conjugate (Zinostatin Stimalmer®) and is 
to this date the only non-PEG polymer-protein therapeutic that made it to 
the market. Maeda et al. reported the synthesis of SMANCS in the late 
1970’s. The copolymer consisting of styrene and maleic anhydride (SMA) 
was partially modified (30 to 50%) with butanol which was found to 
provide considerable hydrophobicity (Figure 2). Once added into aqueous 
solution, the residual anhydrides open and quickly form the acid. The 
modified SMA polymer chains were covalently linked to neocarzinostatin 
(NCS).[251] This characteristic enables dispersion in the phase-contrast 
agent lipiodol used in lymphangiography and, therefore, local 
administration through the feeding artery of the primary cancer, in particular liver cancer, of patients.[252] With the 
aid of X-ray, a precise localization of SMANCS to tumor tissue became realizable. Preclinical studies revealed the 
highest tumor-blood ratio (> 2.500) of the prodrug location ever reported for targeting approaches.[253] 
Maeda mentioned for the first time the importance of passive tumor targeting by the “enhanced permeability and 
retention effect” (EPR effect) describing that molecules of certain sizes (Mn = 30,000 to 50,000 g mol-1)[254] tend to 
accumulate preferentially in tumor tissue not in normal tissue.[255] Recently, lipiodol has been proven to be 
essential for the anti-tumor activity of SMANCS.[256] The protein conjugate successfully passed the clinical phases 
with high response rates (36 to 40%).[257] SMANCS received its approval for the market in 1990 (Japan) as part of 
the treatment of hepatocellular carcinoma and is distributed by Astellas Pharma (formerly Yamanouchi).[258] 
The highest chance of success is given in a 'patient-individualized treatment' (dose per tumor size/area) and 
follow-up treatments are only administered if the tumor is not regressing. Despite the efforts made to develop 
novel polymer carriers, the modified copolymer SMA remains the only commercialized synthetic alternative to PEG. 
However, a few other types of polymers or their drug conjugates, respectively, have been evaluated in clinical 
studies and mainly comprise poly(N-(2-hydroxypropyl)methacrylamide) (PHPMA) and poly(glutamic acid) (PGluA). 
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Poly(N-(2-hydroxypropyl)methacrylamide) (PHPMA). Testing conjugates of the PHPMA with anthracyclines, the 
homopolymers and respective copolymers were found to be chemically inert in biological media and showed no 
immunogenic response.[259] The first polymer-drug conjugate that entered clinical trials was the PHPMA conjugate 
PK1 (FCE28068), which included doxorubicin (DOX) covalently bound by a tetrapeptide linker.[116] The peptide 
(Gly-Phe-Leu-Gly) is stable in the plasma, but can be cleaved off by lysosomal enzymes of tumor cells[260] enabling 
the controlled release of the DOX within the tumor cell.[261] In addition, the conjugate has shown to concentrate 
within the solid tumor models of rats.[262] After phase I studies revealed signs of activity and a 5-fold decrease in 
toxicity compared to the pure anthracycline,[116] phase II trials on application for breast, non-small cell lung and 
colon cancer were initiated. Positive responses were indicated for breast and for non-small cell lung, while none 
were observed in case of colorectal cancer. A related compound to PK1, named PK2 (FCE28069), was modified by 
incorporation of a galactosamine group, which was designed to increase the uptake in liver tumor cells by 
interaction with the asialoglycoprotein receptor. After the PHPMA-DOX-galactosamine conjugate was investigated 
in preclinical studies,[263] the phase I trial revealed that the maximum tolerated dose (MTD) was reduced to 
approximately half the value of PK1, although the molar mass and the loading ratio were similar.[264] An increased 
uptake due to the hepatic targeting was confirmed by planar imaging and single photon emission computed 
tomography (SPECT) with 123I-labeled PK2, while the conjugate without galactosamine (PK1) revealed no effect. 
However, despite showing promising results, both clinical studies (PK1 and PK2) were discontinued for undisclosed 
reasons. 
For decades, platinum complexes have represented a major class of chemotherapeutics, which have been used for 
the treatment of solid tumors. Although numerous different Pt analogues have been investigated in preclinical and 
clinical studies, cis-, carbo-, and oxaliplatin are the only metal-based anticancer agents in routine clinical use. 
Recently, the drug conjugates AP5280 and AP5286 have entered clinical trials. A diamine platinum(II) (AP5280) or a 
diaminocyclohexane platinum(II) (AP5286) moiety, respectively, are bound to a dicarboxylate ligand that is linked 
to PHPMA via the tetrapeptide spacer Gly-Phe-Leu-Gly.[265] This cathepsin B sensitive linker has already been 
mentioned for PK1 and PK2. For AP5280, preclinical studies revealed a high antitumor efficiency and increased MTD 
compared to the established clinical standards cis- and carboplatin.[266] In the case of AP5286, we can only refer to a 
handful of references that claim phase I trials that are currently ongoing.[236, 267] Abeona Therapeutics 
(formerly Access Pharmaceuticals) has decided to focus on a third generation polymer which is based on an 
improved polymer carrier.[115] ProLindacTM (AP5346) represents a 25,000 g mol-1 (Mw) polymer delivery vehicle 
based on PHPMA, to which a diaminocyclohexane (DACH) platinum is conjugated.[268] The pH-sensitive linker causes 
a more rapid release of the platinum in environments of low pH value, as it is typically found in many tumor sites. 
ProLindacTM is currently in clinical development phase II in cancer patients with solid tumors. The phase I/II 
monotherapy study on patients with recurrent ovarian cancer has been completed and demonstrated efficiency 
and safety.[268-269] This opens the field for further clinical studies of ProLindacTM in combination with other 
chemotherapeutic agents, e.g. TXL.[270] Two other PHPMA conjugates, which entered clinical phase I trials, are 
bound to TXL or CPT, respectively. In the case of TXL (PNU-166945), the drug is conjugated to the PHPMA backbone 
via the previously mentioned enzymatically degradable tetrapeptide linker. One patient with advanced breast 
cancer had a partial response. The study had to be discontinued due to severe neurotoxic effects observed in 
additional rat studies.[271] PNU-166148 is a copolymer consisting of HPMA, very few units of 
N-(2-hydroxypropyl)methacryloyl glycinamide and methacrylamide units, to which CPT is bound through the 
degradable Gly-6-amino-hexanoyl-Gly spacer (Figure 3). The conjugate was developed by Pharmacia and Upjohn to 
overcome problems in the clinical delivery of CPT, which are related to the limited solubility of the active form 
(closed lactone ring) or the poor activity of the more soluble open ring form. With conjugation of the closed form of 
CPT to the copolymer, the solubility was maintained while the drug can be released by the pH-dependent or 
enzymatic degradation of the linker. There are three different phase I studies described in literature.[272] 
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The obtained results revealed changes in the pharmacokinetics of CPT with a prolonged half-life for both carrier-
bound and released-CPT. However, the studies lacked answers to 
potential pharmacodynamic benefits, and revealed no sign of 
significant antitumor activity. The toxicities of the studied conjugates 
were similar to the pure compound CPT. Therefore, Pharmacia and 
Upjohn decided to discontinue further clinical development of 
PNU-166148. 
All PHPMA conjugates which have been investigated in clinical 
studies are exclusively applied for cancer treatment. Although 
PHPMA is well-established as a biocompatible drug carrier and a 
promising alternative to PEG, protein conjugates of this polymer 
class are less developed. However, in recent years, the research on 
PHPMA copolymers for the treatment of non-cancerous diseases has increased tremendously (see Chapter 4). 
These innovative and promising developments in the rational design, synthesis, and evaluation of novel PHPMA 
copolymer-drug conjugates have been highlighted elsewhere.[273] 
Poly(glutamic acid) (PGluA). PGluA represents a well-established type of polymer which frequently appears in 
clinical studies. The conjugate with TXL (CT-2103) is one of the few successful polymer-drug conjugates to date 
which is known under the name OpaxioTM (formerly as XyotaxTM, CTI BioPharma). It has already successfully 
finished phase III trials where it proved its efficacy against ovarian and non-small cell lung cancer in combination 
with other standard chemotherapeutics.[274] OpaxioTM features an extremely high loading capacity (~37 wt% TXL) 
compared to other polymer conjugates. Key advantages of the material are the inherent biodegradability of the 
polymer backbone and the related release of TXL or its derivatives in vitro and in vivo by enzymatic cleavage in the 
presence of cathepsin B.[275] In 2006, CTI BioPharma planned a new phase III study of 1,500 women suffering from 
ovarian cancer with the aim to improve survival rates. Two years later, CTI announced that the European Medicines 
Agency (EMA) has accepted to review CTI's Marketing Authorization Application for OpaxioTM for first-line 
treatment of patients with non-small cell lung cancer.[276] We expect that OpaxioTM will be on the market for the 
treatment of different types of cancer in the near future. In a similar manner, CPT was conjugated to 
PGluA (CT-2106) and the polymer-drug conjugate has already finished a phase I study (advanced solid 
malignancy).[277] According to an exclusive record, a phase II study on the treatment of advanced metastatic ovarian 
cancer was completed, but no results were published so far (NCT00291837).  
Poly(2-oxazoline)s (POx). The conjugation of the FDA-approved dopamine agonist, rotigotine (high affinity for the 
subclass of dopamine receptors in the brain that mediate dopamine signaling), to a poly(2-ethyl-2-oxazoline) 
(PEtOx) backbone (SER-214) resulted in a stimulant, which displayed an impressive efficacy in vivo.[278] The 
continuous dopaminergic stimulation profile provided by SER-214 represents a powerful tool in the treatment of 
the Parkinson’s disease. In October 2015, Serina Therapeutics started to recruit participants for a clinical phase I 
study (NCT02579473). Serina Therapeutics is furthermore offering a versatile POx-platform (POZTM) for multiple 
applications in drug delivery.[279] 
Poly(vinyl ether) (PVE). Arrowhead Pharmaceuticals follows a concept 
of covalent attachment of the genetic material to the polymer 
backbone with triggered intracellular release. This platform is named 
Dynamic PolyConjugate (DPC). DPCs are composed of an amphipathic 
butyl- and amine PVE (PBAVE, Figure 4) that has shown the best 
transfection performance in trial and error experiments.[280] To this 
backbone, GalNAc as hepatic targeting ligand and PEG are attached as 
 
Figure 4. Schematic representation of the 
chemical structure of the amphipathic butyl- and 
amine poly(vinyl ether) (PBAVE). 
 
Figure 3. Schematic representation of the chemical 
structure of the camptothecin(CPT)-conjugate of the 
copolymer PNU-166148. 
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well as a siRNA that is linked via a disulfide bond.[281] Once taken up by a cell, PEG and GalNAc are split off and the 
membrane-disrupting PBAVE is exposed to promote the endosomal escape (Figure 5). The siRNA is then released in 
the cytosol under the existing reducing conditions. ARC-520, ARC-521 and ARC-AAT are the formulations in clinical 
trials for the treatment of liver related diseases that are based on the DPC platform. 
 
 
 
Figure 5. The proposed mechanism of siRNA delivery. A) Schematic representation of the siRNA Dynamic PolyConjugate (DPC), its cellular 
uptake, disassembly in the low pH environment of the endosome, and release of the siRNA into the cytoplasm of the target cell 
(CDM = Carboxylated dimethyl maleic acid); B) mechanism of pH-sensitive CDM chemistry and the structures of the CDM derivatives used in this 
study. Depicted is the reaction of CDM with free tertiary amines on the polymer, which is reversible under acidic conditions. Reprinted from [281] 
with permission of National Academy of Sciences, Copyright (2017). 
 
Table 6. Synthetic polymer-drug conjugates in clinical trials (PEG-alternatives). 
TRADE NAME POLYMER SYSTEM DRUG INDICATION/USE MANUFACTURER STATUS 
Zinostatin Stimalmer® 
(SMANCS) 
Poly(styrene-co-
maleic anhydride) NeoCardioStatin 
Hepatocellular 
carcinoma Astellas Pharma Market 
PK1, FCE28068 PHPMA DOX Lung and breast cancers Pfizer  
Phase II  
(NCT00003165, Disc.) 
PK2, FCE28069 PHPMA DOX-Galactosamine 
Hepatocellular 
carcinoma Pfizer  
Phase I[264] 
(Disc.) 
AP5280  
 
AP5286 
PHPMA Carboplatin platinate 
Various cancers 
 
Various cancers 
Abeona Therapeutics 
 
Abeona Therapeutics 
Phase I/II[282] 
 
Phase I[236] 
ProLindac™, AP5346 PHPMA DACHplatin Ovarian, melanoma & colorectal cancers Abeona Therapeutics 
Phase II 
(NCT00415298) 
PNU-166945 PHPMA TXL Various cancers (Breast cancer) Pfizer 
Phase I[271] 
(Disc.) 
PNU-166148 PHPMA CPT (MAG) Various cancers Pfizer Phase I (NCT00004076, Disc.) 
OPAXIO™, CT-2103, 
Paclitaxel poliglumex, 
(formerly Xyotax™) 
PGluA TXL 
Lung, ovarian, 
colorectal, breast & 
esophageal cancers 
CTI BioPharma Market 
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CT-2106 PGluA CPT Colorectal, lung & ovarian cancers CTI BioPharma 
Phase II 
(NCT00291837) 
SER-214 POx Rotigotine Parkinson's Disease Serina Therapeutics Phase I (NCT02579473) 
ARC-AAT PBAVE siRNA 
Liver disease 
associated with 
alpha-1 antitrypsin 
deficiency 
Arrowhead 
Pharmaceuticals 
Phase II  
(NCT02900183) 
ARC-520 PBAVE siRNA Hepatitis B Arrowhead Pharmaceuticals 
Phase II  
(e.g. NCT02065336, 
NCT02738008)  
ARC-521 PBAVE siRNA Hepatitis B Arrowhead Pharmaceuticals 
Phase I  
(NCT02797522) 
DOX: doxorubicin, DACH: diaminocyclohexane, TXL: paclitaxel, MAG: (20-O-(N-methacryloyl-glycyl-aminohexanoyl-glycyl)), CPT: camptothecin. 
 
3.2 Micro- and nanoparticulate drug carriers 
Polymeric micro- and nanoparticulate drug carriers for active pharmaceutical ingredients (APIs) have been in the 
focus of intense research since the mid 90’s. In the best case, the API is protected during the delivery and released 
in a controlled way at the targeted site, which reduces the required frequency of administration, the therapeutic 
dose, and the possibility of adverse side effects, reducing issues related to patients’ compliance.[283] The term 
‘microparticle’ by definition refers to particles with dimensions between 100 nm and 100 µm, while particles are 
called ‘nanoparticles’ if their size ranges from 1 to 100 nm.[284] However, several materials are considered as 
nanoparticles in literature although they slightly exceed the defined limit, but still exhibit similar properties. 
Therefore, we do not strictly comply with the given definition, but subdivide the materials according to their 
properties or the route of administration, respectively. Nevertheless, the size of all mentioned nanoparticles does 
not exceed 500 nm, which is still accepted.[284] 
In the context of this review, the terms polymeric micro- and nanoparticles summarize stable solid dispersions 
(prepared by emulsion polymerization of monomers or direct dispersion of premade polymers), which also include 
polymeric micelles (including cross-linked micelles) or vesicles (often called polymersomes) as well as modified 
liposomes, and polymer-based micro- and nanogels, but also polyplexes. The latter are formed by electrostatic 
interactions between genetic materials (DNA, siRNA, mRNA) and cationically charged hydrophilic polymers in 
solution. The different sizes of nano- and microparticles obviously influence their properties as for example 
nanoparticles have a reduced tendency to aggregate in comparison to microparticles. Concerning drug delivery 
applications, the size influences key parameters like the distribution within the body, the ability to cross biological 
barriers, or the uptake into cells. Larger microparticles, for example, need to be delivered directly to the site of 
action, but they also remain at this location and act as a depot releasing their payload over weeks, e.g. by slow 
degradation of the microparticles. On the contrary, nanoparticles distribute in the body and cross barriers, but they 
are also able to penetrate into leaky vascular tissue usually observed in tumors and inflamed sites.[285] 
Moreover, they are small enough to enter cells via pinocytosis, which is the “cell drinking” of any cell type, while 
microparticles are only taken up by phagocytosis. As a consequence of these variations in the properties, the 
question of the right size of the drug delivery vehicle strongly depends on the application and the route of 
administration. The most common way of administration is certainly the oral uptake. The main challenges for 
particulate carriers are the protection of the drug during the harsh conditions in the gastrointestinal (GI) tract and 
the transport through the GI epithelium including a mucus layer as additional barrier.[286] For the direct targeting of 
the GI barrier layers itself, particles of about 2 µm reveal the best adsorption after oral application.[283] 
Smaller nanoparticles are found to cross these barriers, but for a more detailed understanding the area of oral 
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administration of nanosized materials still requires significant basic research.[287] In pulmonary administrations, 
particles around 5 µm penetrate deeply in the smaller airways of the lung, which is well-suitable for topical 
treatment.[288] In contrast, 1 to 2 µm particles are able to deposit in the capillary-rich alveoli, where systemic drug 
delivery is targeted. Nanoparticles can be exhaled if they are not immobilized by aggregation or in suspension as 
droplets. In the case of an intravitreal, subcutaneous or intramuscular administration, microspheres are preferably 
in the order of 10 to 250 μm to avoid uptake by macrophages while minimizing inflammatory reactions. 
For local administration in the brain, the microspheres should not be larger than 100 μm to preserve the structure 
of the brain. Considering intravenous nanotherapies, particles should preferably have a size below 200 nm to 
increase the circulation time in the blood stream and avoid filtration by the spleen or clearance by renal 
excretion.[289] The probably most difficult route of administration is the transport through the skin, which 
represents a natural barrier against particle penetration if not damaged.[290] Common nano- and microparticles 
(above 10 nm) are not able to cross the stratum corneum, but may accumulate in the hair follicles (300 to 600 nm 
sized particles).[291] An overview of these different routes of administration and the suitable size range is given in 
Figure 6. 
 
  
Figure 6. Overview of different routes of administration of micro- and nanoparticulate drug carriers; GI: gastrointestinal tract. 
 
3.2.1 Solid colloidal dispersions 
Microparticle dispersions. For the local and continuous delivery of APIs, injections of degradable microparticles 
certainly are the most commonly chosen route of administration. The particles are usually produced by emulsion 
techniques, i.e. the polymer and the drug are dissolved in a suitable organic solvent and the mixture is suspended 
in water, while the solvent is evaporated by continuous stirring. 
Additional surfactants such as PVA might be added to stabilize the 
resulting particles. Besides the classic procedure more 
sophisticated double (multiple) emulsion techniques were 
developed for example to encapsulate water soluble compounds, 
but also other methods like spray drying or precipitation 
 
Figure 7. Schematic representation of the chemical 
structure of poly(lactic-co-glycolic acid) (PLGA). 
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techniques are applied.[292] As polymers poly(lactide acid) and the copolymer poly(lactic-co-glycolic acid) (PLGA, 
Figure 7) are the most accepted and also approved materials for microparticle formation. The tunable 
biodegradability of the polymer (by varying molar mass, structure (end-group) and composition 
(lactic acid/glycolide ratio)) and morphology of the particles enables PLA/PLGA to be easily engineered regarding 
their aimed distribution and release profiles. Marketed products of PLGA microparticles include long-acting dosage 
forms with in vivo life-times ranging from 2 to 80 weeks if administered as a gluteal intramuscular or abdominal 
subcutaneous depot for peptides, proteins but also small molar mass drugs.[293] Table 7 provides an overview of 
marketed PLGA microparticle products (no other polymers are used in marketed microparticle formulations) 
treating various diseases such as cancer and psychological disorders. They are also used in dentistry as local 
antibiotics and in animal husbandry for deworming. 
An innovative route of administration is the in situ formation of biodegradable matrices after the liquid carrier 
(e.g. DMSO) has diffused quickly from the polymeric solution towards surrounding tissue. Risperidone ISM® 
represents a PLGA microparticle releasing risperidone for the treatment of schizophrenia. Clinical phase II trials 
have been successfully performed (NCT02086786).[294] 
 
Table 7. List of marketed controlled release parenteral microspheres based on PLGA. 
TRADE NAME DRUG INDICATION/USE MANUFACTURER[a] 
Risperdal Consta®  Risperidone Schizophrenia Janssen 
Zoladex® LHRH agonists Prostate cancer AstraZeneca 
Lupron Depot®,  
Eligard®, 
Enantone®/Trenantone® 
Leuprolide Prostate cancer 
AbbVie, 
TOLMAR Pharmaceuticals, 
Takeda 
Decapeptyl®,  
Trelstar®, 
Pamorelin® 
Triptorelin Prostate cancer 
Ferring Pharmaceuticals, 
AllerganTM, 
Ipsen Pharma 
Profact Depot®,  
Suprefact Depot® Buserelin Prostate cancer, endometriosis  Sanofi 
Bydureon® Exenatide Diabetis AstraZeneca 
Sandostatin® LAR,  
Somatuline® LA Octreotide Acromegaly, diarrhea Novartis 
Nutropin Depot® Somatropin Growth hormone deficiency Genentech/Alkermes® (disc.) 
Vivitrol® Naltrexone Opioid- & alcohol dependence Alkermes® 
Arestin® Minocycline HCl Peridontal disease Valeant® (disc.) 
Longrange® Eprinomectine Parasitic disease Merial (Sanofi) 
[a] Selection thereof. 
 
The versatility and unique properties of PLGA and PLA certainly promote the domination of the market of these 
materials considering microparticles for drug delivery. As a consequence, it is no surprise that further 
developments, which are currently in clinical trials, are also based almost exclusively on these polymers. To the 
best of our knowledge, only two alternatives have at least entered the stage of clinical testing. The first one is a 
microparticulate formulation consisting of paclitaxel and a biodegradable polyphosphoester (NCT00005046). 
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The polymer is a copolymer of short PLA oligomers and ethyl phosphate (P(DAPG-EOP)) (Figure 8).[295] 
The microparticles (Paclimer®) were injected into the peritoneal cavity for treatment of recurrent ovarian 
cancer.[296] The study (phase I) verified the beneficial properties of the 
material ensuring a controlled and continuous release over more than 
eight weeks. However, the presence of polymer filaments after several 
months indicated a slow degradation and caused a marked 
inflammatory response. The second one is the microsphere Retin-A 
Mikro® (Valeant®), which is based on the Microsponge® technology 
comprising styrene, divinylbenzene and methyl methacrylate and the 
starting material ethylene glycol dimethacrylate in its polymer 
backbone.[297] Tretinoin is encapsulated in the polymer in the 
application form of a skin cream that slowly releases the active medication to treat acne vulgaris. 
Amphiphilic block copolymer micelles. Polymeric micelles are created by dispersion of a block copolymer 
consisting of a hydrophobic and a hydrophilic domain. The block-like and amphiphilic structure is essential for 
polymeric micelles and their self-assembly behavior.[284] In contrast to small molecule surfactants, polymeric 
micelles often seem to be not dynamic, which means that there is almost no exchange of polymer molecules 
between the aggregates, and the polymeric micelles are kinetically frozen.[298] However, in most cases these 
exchange dynamics are simply not investigated as the experiments require long acquisition times (up to several 
days or weeks) to provide a detectable signal. According to its definition, polymeric micelles are still in an 
equilibrium with its dissolved polymer chain.[284] Consequently, the formation and stability of the micelles depend 
on the concentration. However, with increasing size of the hydrophobic block this equilibrium can be shifted 
towards the formation of micelles, and the 
critical micelle concentration (CMC) might be 
below the detection limit.[299] Nevertheless, a 
common concept to overcome any stability 
issues related to polymeric micelles is the cross-
linking of the micellar core, which ideally can be 
used to covalently entrap the API.[300] The 
research and development of polymeric micelles 
has a very strong focus on cancer therapy. The 
toxic and undesirable side effects of 
chemotherapeutic agents are supposed to be 
diminished by using these nanoparticulate carrier 
systems.[301] The low lymphatic drainage of 
tumors and the highly vasculature tumor tissue results in an enhanced penetration and retention (EPR) effect of 
the micelles, which consequently yields a passive targeting of tumor tissue. Even more efficient is the use of 
micelles bearing targeting moieties, which allow selective recognition of specific receptors that are overexpressed 
in cancer cells. Recently published review articles cover the outcomes of clinical research and also show the results 
of preclinical studies in terms of polymeric nanoparticles in cancer therapy.[301-302] However until now, none of 
these formulations reached FDA approval for cancer therapy. Only one micellar delivery system is on the South 
Korean market (Table 8).[303] Genexol® PM is a paclitaxel encapsulating polymeric micelle consisting of a block 
copolymer of methoxy-PEG and poly(D,L-lactic acid) (Figure 9A).[304]  
Nevertheless, a considerable number of micellar systems are currently undergoing clinical trials in various stages. In 
the following, we provide an overview of the various materials, which are clinically tested, and exemplarily describe 
the applications where these materials are in latest stage of clinical trials. In general, most of these micellar 
 
Figure 9. Schematic representation of the chemical structures of the block 
copolymers of A) methoxy-PEG and poly(D,L-lactic acid) (Genexol® PM); B) 
PEG and esterified PAs (4-phenyl-1-butanol) (NK105); C) PEG and PPG (also 
called Pluronic®, SP1049C). 
 
Figure 8. Schematic representation of the 
chemical structure of the copolymer consisting 
of short PLA oligomers and ethyl phosphate 
(P(DAPG-EOP)). 
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formulations are also in preclinical/clinical trials for treatment of other cancerous diseases, which shows the 
potential of polymeric nanoparticles in cancer therapy in future. A good example is the block copolymer PEG-b-PLA 
which is identical to the material used in Genexol® PM. This polymer is further used for the formulation of 
docetaxel encapsulating PEG-b-PLA polymeric micelles with similar sizes (20 to 50 nm) named Nanoxel®-PM, which 
is in clinical phase I.[305] Other materials also take advantage of the generally accepted use of PEG for the 
hydrophilic block. In contrast, a variety of different polymers is used for the hydrophobic block. NK105 uses a block 
copolymer of PEG and partially hydrophobized poly(aspartate) (PAs) (esterification of the carboxylic groups with 
4-phenyl-1-butanol, Figure 9B) for the delivery and release of docetaxel.[306] SP1049C is a mixture of non-ionic 
PEG-block-PPG-block-PEG copolymers (Pluronic® L61, Pluronic® F127, Figure 9C) that form a micelle to encapsulate 
doxorubicin.[307] SP1049C has the state as an orphan drug for gastric cancer as approved by the FDA.  
With the effort to improve the specifity of nanoparticles, targeted strategies were developed and already entered 
clinical trials. BIND-014 is the outcome of a combinatorial library of nanoparticles based on PEG-b-PLA and 
PEG-b-PLGA that encapsulate docetaxel and bear a prostate-specific membrane antigen (PSMA) on the micelle 
surface. PSMA is a tumor antigen preferentially expressed on prostate cancer cells and vasculature of non-prostate 
solid tumors.[308] The PSMA substrate analog inhibitor S,S-2-(3-(5-amino-1-carboxypentyl)-ureido)-pentanedioic acid 
(ACUPA) is covalently attached to a PEG-b-PLA. A mixture of PEG-b-PLA and PEG-b-PLA-ACUPA is finally used for the 
micelle formation in a microfluidic supported emulsion/solvent evaporation process. BIND-014 was the best 
performing candidate in terms of particle size, drug loading, targeting ligand density, PEG/PLA ratio and so on. The 
same technology (Accurins® technology) was recently used to deliver a selective Aurora B kinase inhibitor, 
AZD2811, that induces apoptosis in tumor cells.[309] Increased encapsulation efficiency and reduced drug leakage 
could be achieved by simple ion pairing of AZD2811 and are currently tested in phase 1 studies. Preclinical studies 
using the same Accurins® portfolio involve BIND-510 (encapsulated drug: Vincristine, PEG-b-PLA with PSMA 
targeting) and others as proposed by BIND Therapeutics.[310] A critical point is that the physical entrapment of drugs 
can be associated with drug leakage before reaching the side of action.  
Therefore, the covalent attachment via labile linkers to the polymer backbone can be advantageous. A popular 
system is a block copolymer of PEG and polyglutamate. The polyaminoacid is able to complex different platinum 
complexes, which renders the polymer amphiphilic. NC-6004 is delivering cis-platin and already entered clinical 
phase III. The same concept is applied for NC-4016 in phase I, using 1,2-diaminocyclohexane platinum (DACHplatin) 
to modify PEG-b-PGlu block copolymers. Also other anti-cancer drugs were covalently attached to the PGlu block: 
NK012 is functionalized with SN-38, a camptothecin derivative, and completed clinical phase II for the treatment of 
breast and lung cancer. A similar system using poly(amino acid) is NK911, with DOX covalently linked to the carboxy 
groups of the copolymers of PEG and PAs. NK911 revealed less stability and more drug release but also higher 
accumulation at other cell regions compared to liposomal doxorubicin (Doxil®).[311] Clinical phase I finished in 2004 
and did not recruit for phase II until now. There are only few examples of materials in clinical trials that are not 
aiming at the treatment of cancer. SEL-068 is a PEG-b-PLGA-based micelle loaded with peptides for the treatment 
of nicotine addiction.[312] This nicotine vaccine creates nicotine specific antibodies that bind free nicotine and 
prevent it from crossing the BBB. The same particle platform (Synthetic Vaccine Particle (SVPTM)) is used for the 
design of SEL-110 in antigen-specific immunotherapy. SEL-110 is loaded with specific protein- or peptide antigens 
and rapamycin and aims to prevent unwanted anti-drug-antibodies from forming.[313] 
 
Table 8. List of active clinical trials using amphiphilic block copolymer micelles. 
TRADE NAME POLYMER SYSTEM  DRUG INDICATION/USE MANUFACTURER STATUS 
Genexol® PM 
(US: CynviloqTM, IG-001)  PEG-b-PLA Docetaxel 
Breast, lung, ovarian 
cancer 
Samyang 
Biopharm 
Market  
(South Korea) 
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Nanoxel®-PM 
(Docetaxel-PNP) PEG-b-PLA Docetaxel Solid tumors 
Samyang 
Biopharm 
Phase I 
(NCT02274610) 
NK105 PEG-b-PAs Docetaxel Gastric, breast cancer NanoCarrier® Phase III  (NCT01644890) 
SP1049C PEG-b-PPG-b-PEG (Pluronic® L61, F127[a]) DOX Adenocarcinoma Supratek Pharm Phase II
[307] 
BIND-014  
(Accurins® technology)  
PEG-b-PLGA,  
PEG-b-PLA Docetaxel  Solid tumors 
BIND 
Therapeutics/ 
Pfizer 
Phase II  
(e.g. NCT01812746, 
NCT01792479,) 
AZD2811 
(Accurins® technology) PEG-b-PLA AZD2811  Solid tumors AstraZeneca 
Phase I  
(NCT02579226) 
NC-6004 PEG-b-PGlu Cisplatin Solid tumors NanoCarrier® Phase III  (NCT02043288 ) 
NC-4016 PEG-b-PGlu DACHplatin Solid tumors NanoCarrier® Phase I[314] 
NK012 PEG-b-PGlu SN-38 Breast, lung, colorectal cancer Nippon Kayaku 
Phase II  
(e.g. NCT00951613, 
NCT00951054) 
NK911 PEG-b-PAs DOX Pancreatic, colorectal cancer n.a. Phase I
[311] (disc.) 
SEL-068 PEG-b-PLGA TLR agonist and T cell helper peptide Nicotine addiction 
Selecta 
Biosciences 
Phase I 
(NCT01478893 ) 
SEL-110 PEG-b-PLGA Rapamycin, peptide antigen 
Production of anti-
drug antibodies, 
unwanted immune 
response 
Selecta 
Biosciences 
Phase I  
(NCT02648269 ) 
DOX: doxorubicin, DACH: diaminocyclohexane; [a] L = liquid, F = flake/solid, the first one or two digits (in a three-digit number) in the code, 
multiplied by 300, indicates the approximate molar mass of the PPG block and the last digit of this code × 10 provides the percentage PEG 
content; n.a.: not applicable. 
 
Nanoparticle dispersions. Besides the large number of micellar structures made from amphiphilic block copolymers 
only few systems have entered clinical studies, which are solid nanoparticle dispersions prepared by 
nanoprecipitation or emulsion polymerization (Table 9). CRLX101 is a nanoparticle formulation consisting of a 
statistical copolymer based on β-cyclodextrin and PEG, that is hydrophobized by conjugation of CPT to the 
cyclodextrin ring via an acid labile glycine linker.[315] The current studies are recruiting participants for several 
clinical studies in cancer therapy, which shows the potential of this formulation as novel nanomedical device. 
CRLX301 has recently started phase IIa and uses the same polymer platform as CRLX101 but with docetaxel as 
active agent.[316] While the previously mentioned system is still stabilized by the amphiphilic character of the 
polymer, DOX-Transdrug is a solid nanoparticle dispersion that is produced by emulsion polymerization of isohexyl 
cyanoacrylate in the presence of DOX. DOX-Transdrug is used for the treatment of liver cancer by local injection via 
the hepatic artery and has recently entered clinical phase III. This system was also successfully applied to pass the 
BBB for the therapy of glioblastomas as observed in rats.[317] Another acrylate-based nanocarrier is prepared in a 
comparable way resulting in mitoxantrone (dihydroxyanthracenedione, DHAD) encapsulating poly(isobutyl 
cyanoacrylate) nanoparticles (DHAD-PBCA-NP). The formulation shows good efficacy in treating liver cancer and, 
thus, enhances the survival period.[318] DHAD-PBCA-NP reached clinical phase II but did not continue since 2009. 
 
Table 9. List of active clinical trials using nanoparticle dispersions. 
TRADE NAME POLYMER SYSTEM DRUG INDICATION/USE MANUFACTURER STATUS 
CLRX101  
(IT-101)  P(EG-co-cyclodextrin) CPT 
Lung cancer, renal cell 
carcinoma Cerulean
TM 
Phase II  
(e.g. NCT02010567, 
NCT02769962) 
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CRLX301 P(EG-co-cyclodextrin) Docetaxel Solid tumors CeruleanTM Phase I/IIa (NCT02380677) 
Livatag®  
(DOX-Transdrug) 
Poly(isohexyl cyanoacrylate) 
coated with Tween 80  DOX Liver cancer Onxeo 
Phase III  
(NCT01655693) 
DHAD-PBCA-NP Poly(isobutyl cyanoacrylate) Mitoxantrone Liver cancer n.a. Phase II[318] (Disc.) 
CPT: campthothecin, DOX: doxorubicin; n.a.: not applicable. 
 
Modified liposomes. Liposomes are structurally slightly different species also using polymers in a nanoparticular 
device. They are composed of phospholipids, which self-assemble into lipid bilayers (able to incorporate lipophilic 
molecules) surrounding an aqueous core (able to incorporate hydrophilic molecules).[319] For improving the desired 
properties, the phospholipids can be covalently modified with polymers or targeting functions resulting in surface 
modified liposomes. For example, PEG is generally used to improve the circulation and drug retention. In addition 
to the stealth effect, PEG is acting as spacer molecule between lipid structures and targeting functions. Besides 
Doxil® being the most prominent example of a PEG-containing liposome on the market[320] there are also 
Lipodox®,[321] Oncodox® PEG[322] and LipoplatinTM[323] showing good performances in cancer treatment with DOX 
and cisplatin, respectively, as APIs (Table 10). The heat-responsive liposomal formulation ThermoDox® is now 
recruiting patients for a phase III study of PEGylated liposomal DOX. 
 
Table 10. List of PEG-modified liposomes on the market or in active clinical trials in phase III. 
TRADE NAME DRUG INDICATION/USE MANUFACTURER STATUS 
Doxil® 
(Caelyx®) DOX 
Ovarian cancer,  
AIDS-related Kaposi's sarcoma, multiple myeloma Janssen Market 
Lipodox® DOX Metastatic carcinoma of the ovary, metastatic breast cancer, AIDS related Kaposi’s Sarcoma Sun Pharma Market 
Oncodox® PEG DOX Ovarian cancer, breast cancer, AIDS related Kaposi’s Sarcoma Ciplamed Market 
LipoplatinTM Cisplatin Pancreatic cancer, head and neck cancer, mesothelioma, breast cancer, non-cell lung cancer Regulon Phase III
[324] 
ThermoDox® DOX Primary liver cancer, breast cancer Celsion Phase III (NCT02112656) 
DOX: doxorubicin. 
 
3.2.2 Polyplexes 
The delivery of small molecules either encapsulated or conjugated to yield apoptosis in cancer cells is only one 
strategy in cancer therapy. The pharmaceutical industry also holds promise on gene therapy. However, to transport 
genetic material such as plasmid DNA (pDNA), short interfering RNA (siRNA) and messenger RNA (mRNA) into body 
cells these structures must be protected against degradation and shielded to avoid clearance. A common way is the 
complexation of the negatively charged genetic material with cationically charged polymers via electrostatic 
interactions. The result is a so-called polyplex, which ideally should mimic the nature of viruses and result in 
efficient gene delivery and transfection without showing an immune response. Poly(ethylene imine) (PEI) and its 
variations are among the most studied materials for this purpose. In contrast to other cationic polymers, linear and 
branched PEI are capable of mediating endosomal escape, which is essential for transfection.[325] Other prominent 
examples are poly(L-lysine) or poly(2-(dimethylamino)ethyl methacrylate) (PDMAEMA).[326] In general, it can be said 
that only pDNA and RNA therapeutics passed preclinical studies so far for clinical trials.[325, 327]  
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Different PEI formulations and modifications that all resolved general toxicity issues of PEI in vitro and in vivo reveal 
encouraging results in clinical phases (Table 11). SNS01-T is a jetPEI® formulation, i.e. a linear PEI dissolved in a 
special buffer system. Although the precise composition is undisclosed, it is expected to have a molar mass (Mn) of 
about 22,000 g mol-1. The polyplex contains both a B-cell-specific expression pDNA and a siRNA, which suppresses 
hypusinated eIF5A. A reduction of eIF5A levels was found to sensitize myeloma cells to apoptosis.[328] CYL-02 is also 
based on jetPEI® as transfection agent and in clinical phase II for pDNA delivery. It strongly inhibits tumor 
progression and dissemination of pancreatic cancer after intratumoral administration using endoscopic 
ultrasound.[329] A promising intravenously administered system is a polyplex of the pDNA BC-819 with PEI. 
BC-819/PEI targets cancer cells that generally express the H19 gene, which activates Diphtheria Toxin A (DTA) and 
leads to cell death, whereas healthy cells that are also exposed to the pDNA are not affected. In 2016, BC-819 was 
announced to commence phase III.[330] In addition, BioCancell developed a dual-DTA expression system named 
BC-821, which is a pDNA that is again transfected with PEI and switches the distinct promoters H19 and IGF2-P4.[331] 
The dual expression system may have the benefit of enhanced cancer cell toxicity and a higher chance that at least 
one of the promoters will be active in any tumor. A further pDNA PEI-based formulation in clinical trials is EGEN-
001. It contains a cholesterol modified low molar mass branched PEI that is also PEGylated.[332] EGEN-001 is 
designed for direct injection into cancerous tissue where it increases the local concentration of interleukin 12 
(IL-12) in the tumor microenvironment. IL-12 has several functions, amongst them it is known to potentiate 
antitumoral functions of the host immune system.[333] The delivery of a RNA sequence is also in the focus of Celsion 
by using the TheraSilence™ technology platform.[334] In general, the intrinsic cytotoxicity of PEI is a serious problem 
in the transfer to a FDA approved PEI-based product. 
The benefit of non-viral siRNA delivery is to selectively silence gene expression in vivo. The first targeted (siRNA) 
nanoparticle formulation in clinical trials is denoted as CALAA-01.[335] The polymer matrix is a cationic cyclodextrin 
containing polymer prepared by polycondensation of a diamine-functionalized cyclodextrin and dimethyl 
suberimidate leading to a polyamidine. Adamantyl functionalized PEG with and without human transferrin ligands 
is complexed with the cyclodextrin moieties for steric stabilization and also for the targeting ability of the 
polyplexes. CALAA-01 completed phase I in 2012 but did not proceed further. However, this study was the first 
evidence that systemically administered siRNA induces RNA interferences in humans.[336] 
In the early days of gene therapy, the discovery of interferon caused much excitement. Various forms of interferon 
are produced by virally infected cells and interfere with further viral growth and, thus, show promise in antitumor 
and antiviral therapy. The synthetic double-stranded RNA (dsRNA), an interferon that consists of a pair of 
polyinosinic and polycytidylic acids, is condensed with poly(L-lysine) and supplemented with 
carboxymethylcellulose to form Hiltonol®.[337] Probably the first clinical study using this system was already 
conducted in 1978.[338] Nowadays, there are many clinical trials of Poly-ICLC for various types of cancer. 
However, Poly-ICLC is also in clinical trials to test its efficacy as adjuvant (to boost the immune response) in 
HIV-infected patients. A further polylysine-based polyplex is a PEGylated version that demonstrated an effect for 
cystic fibrosis patients after administration of the complexed pDNA carrying the cystic fibrosis transmembrane 
regulator-encoding gene to the nasal mucosa in an early phase I study.[339] 
Although cancer is certainly the most prominent disease to be treated by polyplex-based gene delivery, the 
treatment of other human diseases can also benefit of the approach if applied at the right site or by using targeting 
functions. The DermaVir patch is a topical application of a pDNA, encoding the entire HIV genome minus the 
integrase gene that is formulated with mannosylated jet-PEI® in a glucose solution.[340] For this purpose, the 
stratum corneum needs to be interrupted to deliver the polyplex to the Langerhans cells to be transported to the 
lymph nodes in order to express the HIV antigens. The DermaVir therapeutic vaccination completed phase II but did 
not proceed further maybe due to infection risks of the skin. A different pDNA vaccination that already started 
phase III trials is ASP0113. It is designed to suppress the activation of the cytomegalovirus (CMV) in transplant 
recipients. It basically consists of two plasmids encoding CMV glycoprotein B and phosphoprotein 65, respectively, 
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formulated with poloxamer, a triblock PEG-b-PPG-b-PEG (CRL1005), and a mixture of alkyl-
benzyldimethylammonium chlorides (BAK, alkyl chains: C12, C14, C16, C18).[341] The hydrophobic cationic 
surfactant BAK and the hydrophilic CRL1005 self-assemble with the pDNA into nanoparticles.  
 
Table 11. List of active clinical trials using polyplexes. 
TRADE NAME POLYMER SYSTEM DRUG INDICATION/USE MANUFACTURER STATUS 
SNS01-T LPEI (jetPEI®) pDNA,  siRNA Multiple myeloma Sevion Therapeutics 
Phase II  
(NCT01435720) 
CYL-02 LPEI (jetPEI®) pDNA Pancreatic adenocarcinoma InvivoGen Phase II  (NCT02806687) 
BC-819/PEI  
(DTA-H19) BPEI DNA 
Bladder cancer, ovarian 
cancer, 
pancreatic adenocarcinoma 
BioCancell Phase II  (NCT00595088) 
EGEN-001  
(GEN-1) 
Cholesterol and  
PEG-modified PEI DNA 
Ovarian, tubal, colorectal 
peritoneal cancer GOG® Foundation 
Phase II  
(NCT01118052) 
CALAA-01 Cationic cyclodextrin, adamantane modified PEG  siRNA  Solid tumors 
Calando 
Pharmaceuticals 
Phase I  
(NCT00689065) (disc.) 
Hiltonol®  
(Poly-ICLC)  
Polylysine,  
carboxymethyl cellulose dsRNA 
Brain tumor, non-small cell 
lung cancer, skin cancer, 
breast cancer 
 
 
HIV 
Oncovir 
Phase II  
(e.g. NCT01984892, 
NCT02423863) 
 
Phase I/II 
(NCT02071095) 
DermaVir 
(LC002) 
Mannosylated LPEI 
(jetPEI®) DNA HIV vaccine Genetic Immunity 
Phase II  
(NCT00711230) 
ASP0113  
(VCL-CB01,  
formerly TransVax®) 
PEG-b-PPG-b-PEG, 
(CRL1005) DNA CMV vaccine Vical 
Phase III  
(NCT01877655) 
pDNA: plasmid deoxyribonucleic acid, siRNA: small interfering ribonucleic acid, dsRNA: double-stranded ribonucleic acid, CMV: cytomegalovirus. 
 
3.2.3  Micro-/Nanogels 
 
Microgels. ‚Microgels‘ (IUPAC name) are defined as hydrogel microparticles (also mentioned as ‘microhydrogels’ or 
‘hydrogel microspheres’) formed by water soluble polymers which are physically or chemically cross-linked. In 
physical gels, the cross-linking points of the network are formed by non-covalent or supramolecular interactions, 
such as hydrogen bonds, ionic or hydrophobic interactions, respectively. On the other side covalent bonds form the 
links of the network in chemical gels, i.e. cross-linking of ready polymers on functional groups or polymerization of 
multivalent monomers. These three-dimensional networks fill the size gap between dendrimers/polymers 
(10 to 20 nm) and macroscopic hydrogels (see Chapter 3.3.1) comprising sizes from 100 nm to 100 μm according to 
the definition of microparticles.[342] Microgel systems possess high capacity for drug loading, are mostly 
biocompatible, and can be modified for biodegradability, which represent the key points to design an effective drug 
delivery system. Their structure features some key advantages in comparison to dendritic systems including their 
superior swelling behavior, the opportunity to introduce responsive modalities, and the presence of suitable gaps 
for encapsulation of other compounds (without the need of a chemical attachment). Besides their application as 
drug delivery systems, they have shown promising potential for use in adjacent fields such as diagnostics, antiviral 
compounds, and embolic therapies.[343] Microgel-based formulations for drug delivery have shown significant 
enhancements in effectiveness and safety considering certain anti-cancer drugs or other pharmaceutically active 
compounds, which was confirmed by numerous in vivo studies. Despite this progress, only very few microgels have 
been explored in clinical studies and several safety issues have to be overcome. The challenges in terms of cargo 
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delivery and their efficient clearance once they have accomplished their mission in vivo demand careful 
engineering of the microgels. This remains challenging due to the complexity of the systems and the unique 
structural features. To date, there are only three microgel systems based on synthetic polymers that are approved 
for use as drug delivery system. They are all used in the treatment of hepatocellular carcinoma (Table 12). 
DC Bead® is an embolic hydrogel microsphere product that is capable of being 
loaded with anthracycline drugs just before administration in a transarterial 
chemoembolization (TACE) procedure. TACE is a minimally invasive 
(non-surgical) procedure performed by an interventional radiologist. In this 
process, the microgel is not just delivering the drug, but also occludes the 
arteries supplying the tumor. DC Bead® is composed of a biocompatible PVA 
hydrogel, which has been modified with the ionic monomer sodium 
2-acrylamido-2-methylpropanesulfonate (AMPS, Figure 10). The latter enables 
the electrostatic loading and delivery of chemotherapeutic drugs. The beads 
are produced by an inverse emulsion polymerization and are available in sizes 
from 100 to 900 μm.[344] Injected into the local artery, the formulation occludes the blood flow to the target tissue 
and delivers a local and sustained dose of the drug directly to the tumor. DC Bead® is approved as anti-tumor 
formulation with doxorubicin (DEBDOX™)[345] and irinotecan (DEBIRI™).[346] Current research is focusing on an 
increase of the drug doses of administered drug.[347] In addition, the microbeads can be loaded with idarubicin 
(IDASPHERE II) by the interaction of the positively charged protonated amine group of idarubicin hydrochloride 
with the sulphonate of the DC Beads®.[348] They are currently in randomized phase II studies. Special radiopaque 
beads (RO Beads), which are also based on the DC Bead® platform, have been investigated to not only be 
pharmacologically active, but allow the imaging of the active site in a rabbit VX2 liver tumor model by X-ray scans. 
These RO Beads were covalently modified with a triiodobenzyl group to allow a better traceability in comparison to 
DC beads® which were loaded with a soluble contrast agent.[349] The first commercially available RO bead, LC Bead 
LUMI™, was cleared by the FDA for the chemoembolization of hypervascular tumors and arteriovenous 
malformations.[350]  
Other commercialized microgels include the Tandem® microspheres, which are spherical, biocompatible, non-
resorbable hydrogel cores based on cross-linked poly(methacrylic acid) (PMAA).[351] They are subdivided into two 
classes of microspheres, Oncozene® and Embozene®, which are both available in a size range from 40 to 100 μm. 
The latter features an additional outer layer of CeloNova’s proprietary Polyzene®-F, a 
poly(bis(trifluoroethoxy)phosphazene) (Figure 11), which is introduced to enhance biocompatibility and reduce 
inflammation. These materials have been optimized for loading with a variety of drugs (Table 12). Current studies 
focus on the use of DOX (NCT02141906) or idarubicin,[352] loaded in the Oncozene® microspheres. HepasphereTM 
represents another hydrogel microsphere, which is approved for clinical use and commercially available (in the 
range from 30 to 200 μm). In general, DOX is loaded into a polymer network of poly(vinyl alcohol-co-acrylic 
acid).[353] The microsphere binds drugs with the same mechanism as 
DC Bead®, using carboxylate instead of sulfonate groups. Recent 
developments in the treatment of hepatocellular carcinoma with 
HepasphereTM were summarized by Malagari et al..[354] LifePearl® is a 
PEG-based embolization hydrogel that can be loaded with 
chemotherapeutic agents to treat primary hyper vascular tumors or 
liver metastasis. The microspheres are biocompatible, hydrophilic, 
and precisely calibrated.[355]  
A new injectable formulation for the delivery of IFN-α 2b is Locteron®, which is one of the few systems for 
continuous release of proteins that reached late-stage clinical trials. It is a microparticulate formulation 
encapsulating a protein which is suspended in an injection vehicle prior to subcutaneous administration. 
 
Figure 11. Schematic representation of the chemical 
structure of poly(bis(trifluoroethoxy)phosphazene) 
(Polyzene®-F). 
 
Figure 10. Schematic representation of 
the chemical structure of P(VA-co-2-
acrylamido-2-methylpropane sulfonate). 
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The technology is based on PolyActive® – a variety of biodegradable poly(ether ester) segmented copolymers based 
on PEG and PBT. The polymers absorb water up to 65% of their weight resulting in a hydrogel network. 
Biolex Therapeutics announced that its remaining asset (phase III) for the treatment of hepatitis C virus (HCV) and 
hepatitis B virus (HBV) is finally commercialized.[356] 
 
Nanogels. When the size of microgels is in submicron range 
(1 to 100 nm), they are usually specified as nanogels 
(‘nanohydrogels’, ‘hydrogel nanospheres’).[357] Although 
significant effort has been dedicated into their research,[358] 
there is only a limited number of nanogel systems under 
clinical investigations that are based on synthetic polymers. 
A new gel-based approach with the ability to form a depot 
(Medusa®) has been developed by Flamel Technologies 
(today: Avadel Pharmaceuticals). It enables a controlled 
drug release within an adjustable time ranging from one day up to one week without the often observed initial 
burst effect or a decreasing activity. The formulation will be administered as a subcutaneous injection. The polymer 
platform is based on poly(α-glutamate) (hydrophilic), where vitamin E is grafted onto (Figure 12). The resulting 
amphiphilic polymer spontaneously forms stable nanogels (20 to 50 nm) when dissolved in water due to the 
hydrophobic domains of vitamin E.[359] Different cargos (e.g. peptide, protein, small molecule) can be loaded into 
the nanogel simply by mixing the two components, and the uptake into the nanogel is solely based on non-
covalent, hydrophobic and electrostatic interactions. The formulations with several therapeutic proteins (e.g. IL-2, 
IFN-α 2b and IFN-β 1a) revealed a release period of one week in animal models.[360] Clinical phase I trials were 
performed on the application of the interferon IFN-α 2b, which was administered to patients with genotype 1 
hepatitis C virus (HVC), and the outcomes were compared to the established treatment with the respective 
PEGylated interferon PegIntron® (Table 3). The study demonstrated a favorable antiviral activity and safety profile 
using the Medusa® technology.[361] A phase II study followed (over a period of 12 weeks) in order to compare this 
formulation to PegIntron®, which was combined with ribavirin.[362] Currently, Avadel Pharmaceuticals explores the 
product Medusa® exenatide, which is called a once-a-week formulation. After successful preclinical studies on the 
administration to minipigs (June 2014), the company reported the completion of phase 1b trials for type 2 diabetes 
mellitus.[363] 
 
Table 12. Micro- and nanogels based on synthetic polymers on the market or in clinical trials. 
TRADE NAME SUBNAME POLYMER SYSTEM DRUG INDICATION/USE MANUFACTURER STATUS 
Microgel 
DC Bead®  
(US: LC Bead®) 
DEBDOX™ P(VA-co-AMPS) DOX 
Malignant 
hypervascular 
tumor 
BTG Market 
DEBIRI™ P(VA-co-AMPS) Irinotecan Metastatic colorectal cancer BTG Market 
IDASPHERE II P(VA-co-AMPS) Idarubicin Liver cancer 
Federation Franco-
phone de Cancer-
ologie Digestive 
Phase II 
(NCT02185768) 
Tandem® 
Oncozene® PMAA DOX, epirubicin,  
idarubicin,  
irinotecan 
Neurovascular 
arteriovenous 
malformations, 
hypervascular 
tumors 
CeloNova 
BioSciences 
Market 
Embozene®  PMAA + Polyzene®-F Market 
Figure 12. Schematic representation of the chemical structure 
of vitamin E-grafted poly(α-glutamate) (α-PGlu). 
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HepaSphereTM 
(US: QuadraSphere®)  Poly(VA-co-AA) DOX 
Hepatocellular 
carcinoma Merit Medical® Market 
LifePearl®  PEG DOX, irinotecan 
Hyper vascular 
tumor, 
liver metastasis 
Terumo Market 
PolyActive® Locteron® (OctoPlus) 
PEG-b-PBT 
(Multiblocks) IFN-α 2b Hepatitis C virus Biolex Therapeutics 
Phase III 
(NCT00863239) 
Nanogel 
Medusa® 
 
 α-PGlu grafted with  vitamin E 
IL-2,  
IFN-α 2b, 
IFN-β 1a, 
exenatide 
Various cancers, 
viral infections 
Avadel 
Pharmaceuticals Phase I/II
[363] 
DOX: doxorubicin. 
 
3.3 Macroscopic drug carriers 
3.3.1 Hydrogels 
Hydrogels. Hydrogels represent macroscopic, hydrophilic polymer networks, which are able to absorb water or 
aqueous biological fluids in amounts ranging up to multiple times of their own mass. In analogy to microgels, they 
can be subdivided by their type of cross-linking, i.e. chemical or physical cross-linking. Hydrogels are able to imitate 
natural living tissue more than any other class of synthetic biomaterials due to their high water content, soft 
consistency and porosity. Undoubtedly, their most advanced application field is their usage as contact lenses, in 
particular in form of soft lenses. However, the relatively low drug loading capacity and the burst release upon 
ocular administration is a challenge that has to be overcome. To date, no drug loaded contact lens is on the market. 
An advanced alternative to frequent application of eye drops for steroid therapy is the hydrogel punctum plug 
DextenzaTM. The dexamethasone loaded depot for ophthalmic drug delivery is based on branched PEG and 
represents the first sustained release ophthalmic product that entered phase III trials (Table 13).[364] As cross-linker, 
a molecule with four arms is used bearing complimentary 
reactive sites on each end which are not further described in 
literature. Very recently, Ocular TherapeutixTM announced 
positive results from this clinical trial for the treatment of post-
surgical ocular inflammation and pain.[365] It is placed through the 
punctum (natural opening in the eye lid) into the lacrimal 
canaliculus and allows a controlled delivery of corticosteroid to 
the eye (Figure 13). After an application period of four weeks, the 
hydrogel degrades and liquefies through bulk hydrolysis[366] and 
naturally exits the nasolacrimal system. Besides the treatment of 
post-operative inflammation, as well as allergic conjunctivitis 
(phase III), the system is studied in phase II trials to treat the 
inflammatory dry eye disease.  
Besides ocular applications, hydrogels represent a promising platform for injection into the human body which 
facilitates the well-controlled administration of drugs at the desired rate and site. An overview of recent patent 
applications has been given by Calo and Khutoryanskiy.[367] A successful example for a hydrogel-based (non-ocular) 
drug delivery system is the vaginal insert Propess® (US: Cervidil®) used to induce cervical ripening, which is on the 
market since 1995. The network consists of polyurethane (PU) obtained from the cross-linking of PEG-diol and 
diisocyanates units (Figure 14) and releases the previously loaded drug dinoprostone continuously over a period of 
12 h. This release is induced by the swelling of the hydrogel when it is placed in the moist vaginal environment.[368] 
 
Figure 13. The hydrogel plug DextenzaTM (loaded with 
dexamethasone to treat inflammatory dry eye disease) is 
placed through the punctum (natural opening in the eye 
lid) into the lacrimal canaliculus and allows a controlled 
delivery of corticosteroid too the eye. 
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Based on a similar polymer system, Moraxen® represents a hydrogel 
that features a slow, controlled release of morphine sulfate over a 
whole day and is mainly used to relieve pain related to end-stage 
cancer.[369] It is used for rectal delivery, but it is not considered a 
classic suppository. The hydrogel is rather a reservoir type device 
which has to be removed and replaced if needed due to the lack of 
biodegradability. In 2008, Marillion Pharmaceuticals and 
Cytokine PharmaSciences announced that they signed a license 
agreement concerning the delivery system Pilobuc™, which is a buccal insert containing pilocarpine for the 
treatment of symptoms associated with primary and secondary Sjögren’s syndrome, e.g. xerostomia.[370] 
Pilobuc™ is based on a PU hydrogel system, which is an adaption of the marketed products Propess® and 
Moraxen®.[371] It is placed between the buccal mucosa and gingiva at the back of the mouth.[371] In 2015, the phase 
II trial for the treatment of xerostomia has been discontinued.[372] A second controlled release system for vaginal 
delivery is Mysodelle®/Myspess® (US: Misodel®), which is based on a similar cross-linked system, synthesized from 
PEG, 1,2,6-hexanetriol and dicyclohexylmethane-4,4’-diisocyanate. The drug misoprostol, which is applied for the 
induction of labor, is released from a reservoir over a period of 24 h. The product is equipped with a withdrawal 
tape that enables rapid removal when active labor begins.[373] The product Supprelin® LA is a hydrogel system that 
is used as subcutaneous insert. The system acts as a reservoir and releases histrelin acetate 
(gonadotropin-releasing hormone agonist) for the treatment of children with central precocious puberty. The drug 
decreases the luteinizing hormone levels and the serum concentration of sex steroids. The formulation is composed 
of 2-hydroxyethyl methacrylate (HEMA), 2-hydroxypropyl methacrylate, trimethylolpropane trimethacrylate, 
benzoin methyl ether, di(4-tert-butylcyclohexyl) peroxydicarbonate (Perkadox-16) and Triton X-100 (non-ionic 
surfactant).[374] Histrelin acetate is continuously delivered over a period of 12 months until the implant has to be 
removed as it is nonbiodegradable.[375] Another subcutaneous insert based on a similar polymer reservoir release 
system of histrelin acetate is Vantas®,[376] which is indicated to treat the symptoms of advanced prostate cancer. 
Aquamere® and Aquatrix® II are types of hydrogel-based devices, which are produced by Hydromer®. 
The trademark Aquamere® comprises several hydrogels based on poly(vinyl pyrrolidone) (PVP) containing 
PU segments acting as cross-linker.[377] The materials are mainly used for topical applications, but some are applied 
in oral drug delivery systems. The product line includes four different polymer types (H-, A-, C- and S-series) which 
contain various comonomers to adjust the properties of the final hydrogel. The H-series products are solutions of 
PVP and hydrophilic PU that facilitate high viscosity, superb film formation properties and excellent compatibility. 
Based on the same polymer system as the H-series, the A-series exhibits polymers that are dispersed in ethanol for 
quick drying. The C-series products of cationic grafted PDMAEMA/PVP copolymers and hydrophilic PU have 
excellent adhesion and greater substantivity to skin and hair than H-series while maintaining excellent film forming 
properties. The S-series contains unique silicone-based copolymers of dimethiconylacrylate/PVP and hydrophilic 
PU, exhibiting a low viscosity and silky feel without oily residue. As a consequence, they are used for applications 
where sheen or tack reduction is required. The products under the trademark Aquatrix® II are sold as two separate 
aqueous solutions, forming a hydrogel upon mixing and result in superior cohesive and elastic properties. One part 
is a solution of PVP in water and the other one contains either chitosan or PEI depending on the specific 
product.[378] The resulting network can be loaded with active cosmetic and pharmaceutical ingredients by addition 
to the aqueous solution prior to the gel formation. Another hydrogel system, Hypan® is based on a segmented 
copolymer structure consisting of hard blocks (PAN sequences, good mechanical properties) and soft blocks 
(hydrophilic derivatives of acrylic acid obtained by controlled partial hydrolysis of PAN, good water binding 
capability) whereby more than one block of each kind is present per chain.[379] Hypan® hydrogels are used for the 
treatment of colon diseases and various cancers. The materials can be processed by extrusion and injection 
molding, which represent rather unusual methods considering hydrogels. Hypan® is produced and sold by 
 
Figure 14. Schematic representation of the 
chemical structure of polyurethane (orange: 
urethane unit) obtained by a diol (i.e. PEG-diol) and 
a diisocyanate (R1 = aliphatic, aromatic moiety). 
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Hymedix.[380] SQZ GelTM is a hydrogel system for oral medication composed of chitosan and PEG, which allows a 
pH-sensitive release of diltiazem hydrochloride to treat hypertension.[369, 381] In the basic environment of the gut, 
the swollen network shrinks and releases the drug. 
Smart HydrogelTM is a blend of the polymers PAA and PEG-b-PPG-b-PEG (Pluronic®) that forms a gel when it is 
warmed to body temperature. Once injected at the desired body surface, it gels and enables a constant dosing of 
drugs in situ for hours.[382] Increasing temperatures result in the aggregation of the hydrophobic ends of adjacent 
Pluronic®-PAA molecules and, therefore, the formation of micelles. In this conformation, the hydrophilic ends 
connect with each other to form a network that provides rigidity and structure to the mixture.[383] An intensely 
investigated thermo-gelling hydrogel is the OncogelTM system, which is a network loaded with paclitaxel (TXL). It is 
currently investigated for its application in the treatment of different cancer types.[384] As an example, it has been 
proven to be effective in the treatment of malignant gliomas in rat models.[385] The physically cross-linked hydrogel 
by itself is known under the trade name ReGel® and consists of an amphiphilic triblock copolymer 
(PLGA-b-PEG-b-PLGA).[386] The system is soluble at low temperatures (< 15 °C), but upon injection into the body, 
ReGel® forms a gelled depot. The temperature increase towards the critical gelation temperature results in 
hydrophobic interactions of the PLGA segments and a strong micellar aggregation.[387] As a consequence, the 
entrapped active compounds are released for systemic/local delivery over several weeks. OncoGelTM has been 
evaluated in clinical studies on solid tumors[388] and in combination with radiotherapy on esophageal cancer.[389] 
A recent phase IIb study failed as it showed no impact on the tumor in patients with esophageal cancer. Based on 
these results, BTG has discontinued its clinical studies and its search for new partners to further develop 
OncoGelTM.[390] Nevertheless, they will continue studies on ReGel® as a drug delivery technology. 
 
Table 13. Hydrogels based on synthetic polymers on the market or in clinical trials. 
TRADE NAME POLYMER SYSTEM DRUG INDICATION/USE MANUFACTURER STATUS 
DEXTENZA™ PEG Dexamethasone 
Post-operative 
inflammation, 
allergic conjunctivitis 
 
Ocular 
TherapeutixTM 
 
Phase III[364] 
 
Inflammatory dry eye 
disease 
Ocular 
TherapeutixTM Phase II
[364] 
Propess® 
(US: Cervidil®) PU (PEG-diol) 
Dinoprostone, 10 mg 
(prostaglandin E2/PGE2)  Induction of labor 
Ferring 
Pharmaceuticals Market 
Moraxen® PU (PEG-diol) Morphine sulfate End-stage cancer pain BTG, PAION Market 
PilobucTM PU (PEG-diol) Pilocarpine Sjögren’s syndrome (Xerostomia) 
Ferring 
Pharmaceuticals 
Phase II[372] 
(Disc.) 
Mysodelle®, 
Myspess® 
(US: Misodel®)  
PU (PEG-diol) Misoprostol, 200 µg (prostaglandin E1/PGE1) Induction of labor 
Ferring 
Pharmaceuticals Market 
Supprelin® LA 
2-Hydroxyethyl/propyl 
methacrylate, 
trimethylolpropane 
trimethacrylate 
Histrelin acetate Treatment of children with central precocious puberty Endo® Market 
Vantas® 
2-Hydroxyethyl/propyl 
methacrylate, 
trimethylolpropane 
trimethacrylate 
Histrelin acetate Advanced prostate cancer Endo® Market 
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Aquamere® 
PVP and PVP-grafted 
copolymers  
(cl[a]: PU segments) 
(H-, A-, C-, S-series) 
Broad range of cosmetic 
& drug ingredients 
Topical and oral drug 
delivery Hydromer® Market 
Aquatrix® II PVP (cl: Chitosan), PVP (cl: PEI) 
Broad range of cosmetic 
& drug ingredients 
Drug delivery matrices  
(i.e. transdermal) Hydromer® Market 
Hypan® Multiblocks of  PAN-b-PAA 
[b] Colon diseases, various 
cancers Hymedix Market 
SQZ Gel™ PEG, Chitosan (blend) Diltiazem Hypertension BTG, Macromed Market 
Hycore-V™, 
Hycore-R™ Not discclosed Metronidazole 
Vaginal and rectal 
infections BTG , PAION Market 
Smart Hydrogel™ PAA, Pluronic® (blend) Broad range of drug ingredients Drug delivery matrices MedLogic Global Market 
OncoGelTM PLGA-b-PEG-b-PLGA (ReGel®) TXL 
Esophageal cancer 
 
 
Recurrent glioma 
BTG 
Phase IIb[390] 
(disc.) 
 
Phase I/II 
(NCT00479765) 
TXL: paclitaxel; [a] cl = cross-linker; [b] Hymedix has developed a line of seven products for the chronic wound care market. Which of them are 
used for drug delivery applications has not been described in publicly available resources.[380] 
 
3.3.2 Solid implants and inserts 
Solid drug delivery devices, which are implanted or simply inserted into natural orifices, possess several advantages 
over parenteral or oral dosage forms. Besides the site specific drug administration and, hence, significantly lower 
doses of the applied drugs, implantable or insertable devices usually allow a sustained and continuous release of 
the therapeutic agents. Furthermore, the medication by implantable devices guarantees a better patient 
compliance and acceptance than frequent injections or the taking of several pills a day. In this chapter, we focus on 
passive delivery devices that provide continuous release over time periods ranging from weeks to several years 
without the need for replenishment. These systems are particularly applied for the delivery of highly potent drugs, 
which work at low doses such as hormones. Numerous commercial systems are available for applications ranging 
from the prevention of HIV and the treatment of glaucoma to various methods for contraception. 
Vaginal inserts. Currently, five different vaginal rings are commercially available (Table 14). For decades, silicone 
elastomers (PDMS-based) are used for their fabrication due to the low weight, high flexibility and excellent 
biocompatibility of these materials. Estring® and Femring® are used for 
hormone replacement therapy, whereas Progering® represents a 
contraceptive. Fertiring® combines both applications. The only commercialized 
vaginal ring that is based on poly(ethylene-co-vinyl acetate) (PEVA, Figure 15) is 
NuvaRing® for contraception. Numerous vaginal rings based on PDMS are 
currently under clinical investigations, which are not only used for 
contraception but also as prevention for sexually transmitted diseases. 
MilprosaTM and NES/EE already went through clinical phase III and are close to 
commercialization. The most advanced microbicide ring, dapivirine (DPV) Ring-004, was designed for HIV 
prevention and is in phase III trials.[391] Different rings for the controlled and simultaneous delivery of preventives 
for HIV (maraviroc, levonorgestrel) have recently entered clinical phase I. UPA-CVR, a vaginal ring releasing 
ulipristal acetate, is already investigated in clinical phase II studies.[392] The trend goes towards multifunctional 
applicable drug reservoirs. The dual protection vaginal ring of CONRAD is currently in phase I trials. It consists of 
two segments, which are based on different aliphatic polyether-based PUs from the Tecoflex® family (variable in 
 
Figure 15. Schematic representation of 
the chemical structure of 
poly(ethylene-co-vinyl acetate) (PEVA). 
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hardness and hydrophilicity based on varying contents of PEG and poly(tetramethylene ether glycol) (PTMEG)). 
The system is optimized to deliver a high flux of tenofovir (HIV/herpes prevention) from one segment and a low flux 
of levonorgestrel (contraception) from the other.[393] Another polyurethane-based ring entering clinical trials is 
VR101, which releases glycerin to counteract vaginal dryness. Currently, the Population Council is developing a 
PEVA ring for simultaneous delivery of medivir-150 (targets HIV), carrageenan (targets human papilloma virus (HPV) 
and herpes simplex virus-2 (HSV-2)), zinc acetate (targets HIV and HSV-2) and levonorgestrel (targets unintended 
pregnancy).[394] 
Another option for reliable contraception is the insertion of an intrauterine device (IUD, Figure 16). The hormonal 
IUD’s are usually made of PDMS (Table 14). The levonorgestrel-releasing 
system Mirena® was approved by the FDA in 2000, after it had been used in 
Europe since 1991. A new version of Mirena®, called Skyla® (U.K.: Jaydess®), 
which is based on the same mechanism of action, was introduced to the US 
market in 2013. It features a smaller size and a reduced dose of the released 
hormone levonorgestrel. The latest IUD entering the market (Liletta®) was 
approved by the FDA in 2015 and exhibits similar characteristics (shape and 
dose of released levonorgestrel) compared to Mirena®. Intrauterine copper 
contraceptives (e.g. Paragard®) are not described herein, although their 
monofilament threads and T-frames are usually made of polyethylene (PE). 
 
Table 14. Vaginal inserts on the market and selected inserts in clinical trials. 
TRADE NAME POLYMER SYSTEM DRUG INDICATION/USE MANUFACTURER STATUS 
VAGINAL RING 
Estring® PDMS 17β-Estradiol Hormone replacement (menopause) Pfizer Market 
Femring®  PDMS 17β-Estradiol-3-acetate 
Hormone replacement 
(menopause) Allergan Market 
Progering®  PDMS Progesterone Contraception Population Council, Grünenthal 
Market  
(South America) 
Fertiring®  PDMS Progesterone 
Contraception & 
hormone replacement 
(menopause)  
Population Council, 
Grünenthal Market 
NuvaRing® PEVA Etonogestrel & ethinyl estradiol Contraception Merck & Co. Market 
MilprosaTM PDMS Progesterone Contraception Ferring Pharmaceuticals Phase III[395] 
NES/EE PDMS Nestorone® (NES) & ethinyl estradiol Contraception Population Council 
Phase III finished 
(NCT00455156) 
NES/E2 PDMS Estradiol & nestorone® (NES) Contraception Population Council 
Phase II 
(NCT02626208) 
DPV-Ring PDMS 
Dapivirine (DPV),  
(DPV Ring-004) 
 
DPV/ 
levonorgestrel 
DPV/maraviroc 
HIV prevention IPM 
 
Phase III finished[396] 
 
Phase I  
(NCT02855346) 
Phase I 
(NCT01363037) 
 
Figure 16. Schematic representation of an 
intrauterine device (IUD). 
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UPA-CVR PDMS Ulipristal acetate Contraception 
HRA Pharma,  
Population Council Phase II
[392] 
Dual protection 
PU, PEG & PTMEG 
(TecoflexTM, Lubrizol 
Corp.) 
Levonorgestrel, 
tenofovir 
Contraception & 
HIV/herpes prevention CONRAD 
Phase I 
(NCT02235662) 
VR101 PU Glycerin Vaginal dryness 
J3 Bioscience 
(formerly ViroPan) 
Phase 0 
(NCT02029053) 
INTRAUTERINE DEVICE 
Mirena® PDMS Levonorgestrel Contraception 
Bayer,  
Population Council 
Market  
(as Levosert® in GB) 
Skyla® PDMS Levonorgestrel Contraception Bayer 
Market 
(as Jaydess® in GB) 
Liletta® 
(LNG20) PDMS Levonorgestrel Contraception 
Allergan, 
Odyssea Pharma Market 
 
Subcutaneous implants. An effective contraception can further be accomplished by subcutaneous implants which 
are implanted at the inside of the upper arm (Figure 17) and continuously release hormones into the blood. 
After discontinuing the production of Norplant® (silicone capsules 
containing levonorgestrel),[397] Norplant® II (Jadelle®) was 
developed, which consists of small rods based on PDMS (Table 15). 
Once inserted, Norplant® II lasts up to 5 years. Utilizing the same 
mechanism of action, Sino-Implant II (two thin, flexible silicone 
rods) represents one of the most effective birth control products 
with annual pregnancy rates below 1%.[398] The product is 
considered for four years of use, so far.[399] Another type of 
subdermal implant is Nexplanon®, which is based on a PEVA 
copolymer. Nexplanon® reveals two main advantages compared to 
its predecessor Implanon®, which is replaced gradually: 
I) The easier insertion that avoids placing the implant too deep 
under the skin; II) the rod allows localization via X-ray since it is radiopaque due to the addition of 15 mg barium 
sulphate.[400] Despite showing great promise for being another contraceptive alternative, the development of 
PCL-based Capronor releasing levonorgestrel was abandoned in the 1990s due to skin irritation and stability in 
storage issues. Furthermore, there were concerns about removal of the device and a long release tail.[401] 
However, the single, tubular implant was able to achieve up to one year of ovulation suppression. [402] Very 
recently, the FDA approved another implant based on PEVA, called Probuphine®, which is the first device for the 
continuous release of buprenorphine. It is used for the maintenance treatment of opioid dependence as part of a 
complete treatment program including counseling and psychosocial support. Probuphine® consists of four rods that 
are implanted under the skin on the inside of the upper arm and provides treatment for six months.[403] VC-01TM is a 
subcutaneous implant currently under clinical investigation (phase I/II) to treat diabetes type I. It is composed of 
ViaCyte’s Encaptra® drug delivery technology (made of undisclosed polymers[404]) and is used to deliver human 
embryonic stem cells (pancreatic PEC-01TM cells).  
 
 
 
Figure 17. Schematic representation of the 
implantation of a subcutaneous implant. Reprinted 
from Acta Cir. Bras. 2009, 24, 7-12. with permission of 
Creative Commons Corporation (2009). 
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Table 15. Subcutaneous implants on the market and in clinical trials. 
TRADE NAME POLYMER SYSTEM DRUG INDICATION/USE MANUFACTURER STATUS 
Jadelle® 
(Norplant® II) PDMS Levonorgestrel Contraception 
Bayer,  
Population Council Market (not in US) 
Sino-Implant II PDMS Levonorgestrel Contraception 
Shanghai Dahua 
Pharmaceuticals 
Market 
(as Zarin®, Fem-plant®, 
Trust®, Simplant® etc. 
registered in 24 countries) 
Nexplanon® PEVA Etonogestrel Contraception Merck & Co. Market 
Capronor PCL Levonorgestrel Contraception RTI International Phase II[401] (disc.) 
Probuphine® PEVA Buprenorphine HCl Opioid dependence Titan & Braeburn
TM 
Pharmaceuticals Market 
VC-01TM undisclosed (Encaptra®) PEC-01
TM cells[a] Diabetes type 1 ViaCyte Phase I/II (NCT02239354)  
[a] Embryonic stem cell–derived precursors of insulin-producing beta cells. 
 
Ocular implants and inserts. Implantable or insertable devices are 
well-established for the local treatment of eye diseases. Ocusert® Pilo was one 
of the first ocular delivery devices and represents an ocular insert, which is 
placed in the lower cul-de-sac of the eye to be used for the treatment of 
glaucoma (Table 16).[405] It contains a core reservoir consisting of pilocarpine and 
alginic acid and a framework of hydrophobic poly(ethylene-co-vinyl acetate) 
(PEVA) membrane that regulates diffusion of pilocarpine. However, the product 
has been withdrawn from the market, which is mainly related to the difficulties 
(in particular for elderly people) replacing the insert.[406] The first intravitreal 
implant was Vitrasert®. This ganciclovir pellet was used for the treatment of 
cytomegalovirus retinitis. The antiviral medication is coated by nondegradable 
layer of impermeable PEVA, which is sandwiched in between two permeable layers of PVA. This design enables a 
well-controlled rate of release of the drug by the diffusion only through the areas where no impermeable material 
is present. As a consequence, reimplantation is necessary after 5 to 8 months.[407] Due to market forces, Vitrasert® 
has not been produced since 2014, and all remaining implants have passed their expiration dates.[408] 
Retisert® followed as the second generation of reservoir-based implants, which are used for treatment of chronic 
noninfectious uveitis (Figure 18).[409] This implant for sustained release consists of a silicon laminate and PVA 
coating, which control the release of fluocinolone acetonide (FA). Further studies have proven the potential of this 
device in the treatment of edema (caused by diabetes) and central retinal vein occlusions.[410] Another implant for 
the delivery of FA and the treatment of diabetic macular edema is Iluvien®. 
This rod-like device is based on polyimide tubes (Figure 19) with a PVA 
membrane at the caps. Due to its small size, it can remain in the cavity even 
after the whole drug has been released. A similar, small rod-like device, which is 
injected into the white of the eye, is Ozurdex®. This system is designed to 
deliver the corticosteroide dexamethasone also applied for the treatment of 
macular edema. In contrast to previous devices, the use of degradable PLGA 
allows the dissolution of the implant and, therefore, eliminates the need of 
surgically removal. Another biodegradable PLGA-based implant is Surodex®, which is a rod-shaped device inserted 
into the anterior chamber after a cataract surgery in order to control postoperative inflammation.[407] 
 
Figure 18. Schematic representation 
of the reservoir-based Retisert® 
implant. 
 
Figure 19. Schematic representation 
of the chemical structure of 
polyimides. 
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Further ophthalmic inserts (e.g. I-vationTM or HeliosTM), which are currently under clinical investigations, have been 
nicely reviewed elsewhere.[407, 411] 
 
Table 16. Ocular implants and inserts on the market and in clinical trials. 
TRADE NAME POLYMER SYSTEM DRUG INDICATION/USE MANUFACTURER STATUS 
Ocusert® Pilo PEVA Pilocarpine Treatment of glaucoma 
Johnson & Johnson, 
Alza Cooperation 
Market 
(withdrawn) 
Vitrasert® PVA, PEVA (VersaTM platform) Ganciclovir 
Cytomegalovirus 
retinitis Auritec Pharmaceuticals 
Market 
(withdrawn) 
Retisert® PVA, PDMS (VersaTM platform) 
Fluocinolone 
acetonide 
Chronic non-
infectious uveitis 
Valeant® (Bausch & Lomb), 
Auritec Pharmaceuticals Market 
Iluvien® Polyimide, PVA Fluocinolone acetonide 
Diabetic macular 
edema AlimeraSciences Market 
Ozurdex® PLGA (Novadur®) Dexamethasone 
Diabetic macular 
edema Allergan Market 
Surodex® PLGA, hydroxypropyl methylcellulose Dexamethasone 
Postcataract surgery 
inflammation Oculex Pharmaceuticals 
Market (China, 
Singapore, etc.) 
I-vationTM PMMA, PEVA Triamcinolone acetonide 
Diabetic macular 
edema SurModics 
Phase II finished 
(NCT00692614) 
HeliosTM PDMS Bimatoprost Intraocular pressure (IOP)-lowering ForSight
TM VISION5 Phase II (NCT02537015) 
* PLGA Brimonidine tartrate 
Retinitis pigmentosa Allergan Phase II (NCT00661479) 
Age-related macular 
degeneration Allergan 
Phase II 
(NCT00658619) 
* No trade name listed. 
 
Implants for deeper tissue. While the majority of implantable devices comprises subcutaneous or ocular systems, 
which do not require major surgery to be applied, replaced or removed, a few devices were developed to be 
implanted into deeper tissue in the body (Table 17). Based on a biodegradable polymer (a copolymer of 
bis-(p-carboxyphenoxy)propane and sebacic acid called 
Polifeprosan 20) the Gliadel® wafer is approved for the 
treatment of malignant glioma.[412] It is inserted into cavities 
resulting after the surgical removal of the tumor in the brain 
(Figure 20) and will be degraded by the body to release the 
cytostatic drug carmustine. Another commercialized implant 
for the application in deeper tissue is Propel® based on the 
biodegradable polymer PLGA.[413] This steroid-eluting device is 
implanted after surgery into the nose to assist in the treatment 
of chronic sinusitis. 
The presented implant systems reflect only a selection of currently commercially available systems. Besides, a large 
pipeline of polymer-based implant delivery technologies has been studied in promising clinical trials. 
The biodegradable implant siG12D-LODER™ (PLGA-based) is inserted into the tumor and releases a siRNA drug 
against KRASG12D over four months. In combination with chemotherapy it is used as targeted therapy for locally 
advanced pancreatic cancer (phase IIb).[414] RestoraTM represents a transmucosal PU steroid-eluting device[415] for 
thirty day treatment of sinusitis (phase II/III).[416] In contrast, LiRIS® is a pretzel-shaped silicone tube that could be 
inserted into the bladder, releasing lidocaine over two weeks in females with interstitial cystitis (phase II).[417] 
 
Figure 20. Schematic representation of the inserted 
Gliadel® wafer (polymer system) in the brain. 
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Table 17. Implants for deeper tissue on the market and in clinical trials. 
TRADE NAME POLYMER SYSTEM DRUG INDICATION/USE MANUFACTURER STATUS 
Gliadel® Wafer Polifeprosan 20[a] Carmustine Malignant glioma Arbor Pharmaceuticals Market  
Propel® PLGA, PEG Mometasone furoate Chronic sinusitis Intersect® ENT Market 
siG12D-LODER™ PLGA (LoderTM) siRNA therapeutic (KRASG12D) Pancreatic tumor Silenseed 
Phase IIb 
(NCT01676259) 
RestoraTM PU Steroid Sinusitis SinuSysTM 
Phase II/III 
(NCT02627794)  
LiRIS® PDMS Lidocaine 
Interstitial cystitis/ 
bladder pain 
syndrome 
Allergan 
Phase II 
(e.g. NCT01475253, 
NCT01824303) 
 
[a] Polifeprosan 20 (poly[bis (p-carboxy-phenoxy)] propane and sebacic acid). 
Several companies are working continuously on new technologies (e.g. MedidurTM, DebioStarTM, Duros®, 
MedLaunchTM), which can be used as polymer platform for different drugs. Implanted drug-eluting stents are 
described in Chapter 3.4.2 as the polymers are used as coatings in that case. Implanted devices built up from 
hydrogel networks, e.g. Supprelin® LA and Vantas®, are described in Chapter 3.3.1. 
 
3.4 Coatings 
3.4.1 Solid oral dosage forms 
Despite the complexity of the related uptake mechanism, oral administration of pharmaceutical compounds is the 
preferred route for the drug delivery applications due to the ease of ingestion, the avoidance of painful procedures, 
its versatility, the high patient compliance, reduced sterility constraints, and flexibility of dosage form design 
(e.g. solids: Powder, granules, capsules).[418] In addition, the oral uptake allows patients to conveniently 
self-administer drugs without the need of any health care professionals.[419] But the oral delivery of 
pharmaceuticals remains challenging for several reasons: I) The typical transit time in the gut (from mouth to anus) 
is about 30 hours, which limits the use of drugs that aim at longer dosing times;[420] II) the physiological parameters 
and the biological environment of the gastrointestinal (GI) tract can vary quite significantly from one stage to the 
next. For example, the pH value of the saliva in the mouth is usually in the range of 5.8 and 7.4. Inside the stomach 
the pH value decreases dramatically to 1 (extremely acidic) and increases back to 7 (neutral) in the bowels; 
III) the food and beverage intake causes dynamic changes in the concentration of bile salts, lipids, carbohydrates 
and digestive enzymes throughout the GI tract that can interact with the drug;[421] IV) finally, before reaching the 
bloodstream, the drug has to overcome some anatomical obstacles including the degradative environment in the 
lumen and traversing the mucosa and epithelial cells. However, one of the main concerns remains the patient 
compliance considering the oral uptake of pharmaceuticals, in case the drugs have disagreeable taste and require 
frequent dosing. As a result of these limitations, various functional coatings based on polymers have been designed 
to improve the efficacy of the oral route of administration. These polymer coatings are mainly applied to solid 
dosage forms, i.e. tablets, granulates and capsules, with the aim to achieve selective delivery of active ingredients 
to a particular gastrointestinal (GI) tract, such as the small intestine or the large bowel, or to improve the patient 
compliance by improving the odor or masking the taste. Since the established systems comprise proven and 
versatile materials, there doesn’t exist an immediate need for new polymer systems.  
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Polymer coatings for site specific delivery. The release of a drug at a specific site in the GI guarantees an optimized 
uptake into the blood stream or activity of the delivered active ingredient at the desired side, but avoids 
complications with other parts of the tract. Several polymer-based coatings have been developed to target various 
sites of the GI. An enteric polymer coating prevents the release of the drug in the gastric environment and 
facilitates the release in the small intestine or in the colon. This enables: I) The protection of the stomach from 
some drugs, which may cause stomach ulcers, such as aspirin, diclofenac 
and naproxen; II) the protection of special pharmaceutical compounds 
such as proton pump inhibitors (PPIs) (e.g. omeprazole or pantoprazole) 
against the acidic environment in the stomach, and, III) the targeting of 
the small intestine or colon.[422] Enteric coatings contain carboxylic acid 
groups, which remain in an unionized (protonated) form at low pH values 
and, therefore, are insoluble in the acidic aqueous environment of the 
stomach.[169] However, as the pH value increases in the small intestine, the 
carboxylic acids become deprotonated (negatively charged), which results in the dissolution of the polymers in the 
intestinal fluid.[423] Table 18 summarizes marketed poly(meth)acrylate copolymers, which are used for enteric 
coatings, including their chemical composition, product form and the pH value at which they become soluble. 
The critical pH value for dissolution of the polymers mainly depends on the content of the carboxylic acid and 
esterified groups. The different dissolution properties of enteric coatings enable targeting specific areas of the 
intestine. For example, EUDRAGIT® L100-55 and EUDRAGIT® L100 dissolve above pH value of 5.5 and 6.0, 
respectively, and are used for targeting the small intestine, whereas EUDRAGIT® S100 and EUDRAGIT® FS 30D 
(Figure 21) dissolve above pH value of 7.0 and are used for colon targeting.[424] In addition, the release of the 
encapsulated drugs can further be controlled by the thickness of the coating material or simply by blending the 
different enteric polymers in different ratios.[422] 
 
Table 18. Marketed poly(meth)acrylates as enteric coatings. 
TRADE NAME PRODUCT FORM POLYMER SYSTEM DISSOLUTION pH MANUFACTURER 
EUDRAGIT® L 100-55 Powder 
Poly(MAA-co-ethyl acrylate) 1:1 
Soluble > pH 5.5 Evonik 
EUDRAGIT® L 30D-55 Aqueous dispersion 30% 
Kollicoat® MAE 30 DP Aqueous dispersion 30% 
Soluble > pH 5.5 BASF 
Kollicoat® MAE 100 P Powder 
EUDRAGIT® L 100 Powder 
Poly(MAA-co-MMA) 1:1 Soluble > pH 6.0 Evonik 
EUDRAGIT® L 12.5 Organic solution 12.5% 
EUDRAGIT® S 100 Powder 
Poly(MAA-co-MMA) 1:2 Soluble > pH 7.0 Evonik 
EUDRAGIT® S 12.5 Organic solution 12.5% 
EUDRAGIT® FS 30D Aqueous dispersion 30% Poly(MAA-co-methyl acrylate-co-MMA) 7:3:1 Soluble > pH 7.0 Evonik 
 
Apart from enteric coatings, sustained release coating polymers releasing the drug over time can also be used for 
modified/controlled release applications. These polymers lack ionizable groups and they are not soluble in the 
entire GI tract. However, they can swell with exposure to the gastrointestinal fluids and, consequently, release the 
active ingredients by a diffusion-controlled mechanism. These polymer coatings are mainly used in prolonged-
action dosage forms. EUDRAGIT® RL and RS, which contain 10% or 5% quaternary ammonium groups, respectively, 
 
Figure 21. Schematic representation of the 
chemical structure for the copolymer 
poly(MAA-co-methyl acrylate-co-MMA), 
named EUDRAGIT® FS 30D. 
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as well as the neutral EUDRAGIT® NE and NM, which are the copolymers of ethyl acrylate and methyl methacrylate, 
are preferred coating materials for a sustained release. Table 19 includes marketed poly(meth)acrylate based 
copolymers which are used for sustained release coatings and their chemical composition as well as dissolution 
properties. 
 
Table 19. Various marketed poly(meth)acrylates for sustained release. 
TRADE NAME PRODUCT FORM POLYMER SYSTEM  PROPERTIES ADVANTAGES 
EUDRAGIT® RL 30 D Aqueous dispersion 30% 
Poly(ethyl acrylate-co-MMA-co-
TMAEMA) 1:2:0.2 
Insoluble, 
high permeability, 
pH-independent swelling Customized release profiles by 
combination of RL 
and RS grades in 
different ratios, 
suitable for matrix 
structures 
EUDRAGIT® RL PO Powder 
EUDRAGIT® RL 100 Granules 
EUDRAGIT® RL 12.5 Organic solution 12.5% 
EUDRAGIT® RS 30 D Aqueous dispersion 30% 
Poly(ethyl acrylate-co-MMA-co-
TMAEMA) 1:2:0.1 
Insoluble, low permeability, 
pH-independent swelling 
EUDRAGIT® RS PO Powder 
EUDRAGIT® RS 100 Granules 
EUDRAGIT® RS 12.5 Organic solution 12.5% 
EUDRAGIT® NE 30 D Aqueous dispersion 30% 
Poly(ethyl acrylate-co-MMA-co-
TMAEMA) 2:1:0 
Insoluble, low permeability, 
pH-independent swelling 
No plasticizer 
required, highly 
flexible, suitable for 
matrix structures 
EUDRAGIT® NE 40 D Aqueous dispersion 40% 
EUDRAGIT® NM 30 D Aqueous dispersion 30% 
TMAEMA = trimethylammonioethyl methacrylate chloride. 
 
Polymer coatings for odor or taste masking. Polymer coatings are also applied to protect the sensitive ingredients 
from environmental influences such as light and moisture or to mask the unpleasant taste of the formulations.[169, 
425] Methacrylates containing tertiary amino groups are commonly applied for masking the taste and moisture 
protection (Table 20). These pH-responsive polymer coatings take advantage of the differences in pH values 
between the oral cavity (pH 5.8 to 7.4) and the stomach (pH 1 to 3.5).[426] The polymers are insoluble in water at the 
neutral pH value of the saliva. Therefore, they suppress the release of the drug, which usually exhibit an unpleasant 
taste, and the diffusion of water molecules to the core of the system protecting any moisture sensitive ingredients. 
However, they become protonated and water-soluble at acidic conditions resulting in the release of the content in 
the stomach or in the small intestine. 
 
Table 20. Marketed pH-responsive poly(meth)acrylates as protective coatings. 
TRADE NAME PRODUCT FORM POLYMER SYSTEM  DISSOLUTION pH MANUFACTURER 
EUDRAGIT® E 100 Granules 
Poly(BMA-co-DMAEMA-co-MMA) 1:2:1 Soluble ˂ pH 5.0 Evonik EUDRAGIT® E 12.5 Organic solution 12.5% 
EUDRAGIT® E PO Powder 
Kollicoat® Smartseal 30D Aqueous dispersion Poly(MMA-co-DEAEMA[a]) 7:3 Soluble ˂ pH 5.0; Stable in saliva BASF 
[a] DEAEMA= diethylaminoethyl methacrylate. 
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Apart from these pH-responsive methacrylates, some other water soluble synthetic polymers, including vinyl 
polymers and hydrophilic copolymers, are also applied for masking unpleasant tastes or protecting against 
moisture (Table 21). These polymers do not contain any ionic groups, which decreases the risk of chemical 
interactions with any other ingredient of the formulation.[425] 
 
Table 21. Marketed water soluble synthetic polymers as protective coatings. 
TRADE NAME PRODUCT FORM POLYMER SYSTEM MANUFACTURER 
Kollidon® Powder PVP BASF 
Kollicoat® IR Powder PVA-PEG-graft copolymer BASF 
Kollicoat® Protect Powder PVA-PEG-graft copolymer (Kollicoat® IR), PVA BASF 
Opadry® AMB Powder PVA Colorcon® 
Moreover, the previously mentioned enteric polymers (see Table 18) and coatings for sustained release 
(see Table 19) can also be used for taste masking and moisture protection if they provide a sufficient suppression of 
the drug release in the mouth and prevent moisture to pass into the formulation. However, to realize the desired 
fast drug release after swallowing, relatively thin coatings are applied.[425] Table 22 represents selected examples of 
commercialized drug formulations which are coated with EUDRAGIT® polymers. 
 
Table 22. Examples for marketed dosage forms coated with EUDRAGIT® polymers. 
TRADE NAME POLYMER SYSTEM DRUG INDICATION/USE MANUFACTURER 
Clipper® EUDRAGIT® L 100-55 Beclometasone dipropionate Inflammatory bowel disease Chiesi 
Colo-Pleon® EUDRAGIT® L 100-55 Sulfasalazine Inflammatory bowel disease Sanofi-Aventis 
Entocort® EUDRAGIT® L 100-55 Budesonide Inflammatory bowel disease Prometheus Lab. 
Salofalk® EUDRAGIT® L 100 Mesalazine Inflammatory bowel disease Dr. Falk Pharma 
Ipocol® EUDRAGIT® S 100 Mesalazine Inflammatory bowel disease Sandoz 
Budenofalk® EUDRAGIT® S 100 & EUDRAGIT® L 100 Budesonide Inflammatory bowel disease Dr. Falk Pharma 
Premique® EUDRAGIT® NE 30 D 
Conjug. estrogens & 
medroxyprogesterone 
acetate (MPA) 
Hormone replacement therapy for 
estrogen deficiency symptoms in 
postmenopausal women within an intact 
uterus 
Pfizer 
Nutrizym 22 EUDRAGIT® L 30 D Pancreatin BP 
Symptomatic relief of pancreatic exocrine 
insufficiency such as in fibrocycstic 
disease of the pancreas & chronic 
pancreatitis 
Merck Serono 
Convulex® CR EUDRAGIT® RL 30 D Sodium valproate Epilepsy and bipolar disorder G. L. Pharma GmbH 
Amisulpride film-
coated tablets EUDRAGIT® E 100 Amisulpride Acute & chronic schizophrenic disorders 
Lek Pharmaceuticals D. D., 
Salutas Pharma GmbH 
Adanif® XL EUDRAGIT® E Nifedipine Hypertension, prophylaxis of chronic stable angina pectoris Focus Pharmaceuticals 
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3.4.2 Drug-eluting stents 
Coronary artery disease (CAD) is a heart disease, which 
is considered to be one of the leading causes of death 
worldwide.[427] The lining of the coronary arteries, 
which guarantee the blood supply to heart muscle, 
becomes harder and stiffer, and, finally, the artery’s 
diameter is narrowed due to the accumulation of 
plaque on their inner walls (atherosclerosis). The 
percutaneous transluminal coronary angioplasty 
(PTCA) is a well-established method to counteract the 
symptoms of the CAD. However, this treatment is not 
sufficient as the risks of early abrupt closure, intimal 
hyperplasia and late restenosis are considerably high, if it is not accompanied by further therapies.[428] An early 
approach to overcome these limitations resulted in the development of bare metal stents (BMS).[429] BMS are 
devices, which are first inserted in the narrowed coronary artery by an inflatable catheter. At the side of action, the 
BMS gets expanded by the attached balloon and acts as a mechanical scaffold to recover the original dimensions of 
the vessel (Figure 22).[430] Despite an initial improvement, the implantation of the BMS commonly results in an in-
stent restenosis (ISR) due to the migration of vascular smooth cells within the stents.[431] The first attempts to 
prevent this restenosis by systematic drug delivery systems failed. As a consequence, focus was set on the 
development of drug-eluting stents (DES). These systems carry an antiproliferative drug, which is incorporated into 
a polymer coating of the BMS. The drugs are directly released at the injured sites to prevent the ISR by the 
suppression of the neointimal growth.[432] The first generation of DES comprises the sirolimus-eluting stent 
(Cypher®) and the paclitaxel-eluting stent (Taxus®), which are made of a stainless steel (SS) scaffold coated with the 
polymers poly(n-butyl methacrylate) (PBMA) and poly(ethylene-co-vinyl acetate) (PEVA) or poly(styene-b-
isobutyelene-b-styrene) (PSIBS), respectively. The application of these modified stents resulted in a remarkable 
reduction of the usually occurring restenosis. However, safety concerns have been raised regarding the possibility 
of late stent thrombosis in case of a long term use.[433] In recent years, a second generation of DES has been 
developed with the aim to improve the efficacy and the long term 
safety of the stents. For this purpose, stent frames with thinner 
struts were introduced, and novel, more effective drugs were 
incorporated compared to the first generation DES. Similar to the 
first generation, these DES still use synthetic, nonbiodegradable 
polymers such as PBMA, PEVA, PSIBS, poly(hexafluoropropylene) 
(PHFP), and poly(vinylidene fluoride) (PVDF), sometimes in 
combination with a phosphorylcholine polymer (PCh) 
(Figure 23),[434] as coating materials of a metal surface. Table 23 
summarizes all DES approved by the FDA that use polymer 
coatings.[428-429, 431, 435] Keeping in mind that the above mentioned 
polymers are nonbiodegradable, these coatings remain on the 
stent even after the drug is fully released, which may induce local 
hypersensitivity, inflammation and delayed vascular healing 
resulting in the development of late stent thrombosis.[436]  
 
 
Figure 22. General mechanism of the insertion of a stent. A) Insertion 
of the stent by an inflatable catheter; B) expansion of the stent by the 
attached ballon; C) removal of the ballon. 
 
Figure 23. Schematic representation of the chemical 
structure of an exemplary phosphorylcholine 
polymer (PCh, PC technologyTM). 
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Table 23. Drug-eluting stents (DES) with nonbiodegradable polymers as coating materials on the market or in clinical trials. 
TRADE NAME STENT PLATFORM[a] POLYMER SYSTEM DRUG DRUG RELEASE (DAYS) MANUFACTURER APPROVAL 
Cypher® SS PEVA, PBMA, PCh Sirolimus  
40% (5);  
85% (30);  
100% (90) 
Cordis Corporation FDA[b] 
Taxus® SS Poly(styrene-b-isobutylene-b-styrene) TXL <10% (28) Boston Scientific FDA 
Promus 
PREMIERTM Pt-Cr 
PBMA, 
poly(vinylidene-co-
hexafluoropropylene) 
Everolimus  71% (28);  100% (120) Boston Scientific FDA 
Xience V® Co-Cr 
PBMA, 
poly(vinylidene-co-
hexafluoropropylene) 
Everolimus  80% (28);  
100% (120) Abbot Vascular 
FDA 
Endeavor® Co-Cr PCh Zotarolimus  
75% (2);  
95% (15);  
100% (28) 
Metronic FDA 
Endeavor® 
Resolute Co-Cr 
Blend of PVP, poly(hexyl 
methacrylate)-co-PVP-
co-PVAc and PBMA-co-
PVAc (BioLinx) 
Zotarolimus  
50% (7);  
70% (28);  
100% (31) 
Metronic FDA 
Firebird2®  Co-Cr Poly(styrene-butylenes-styrene)  Sirolimus 
50% (7);  
90% (30) 
Essen Technology 
(Beijing) 
Phase IV 
(NCT01257373) 
TXL: paclitaxel; [a] Pt-Cr: platinum chromium, SS: stainless steel, Co-Cr: cobalt chromium; [b] FDA approved stents also have CE approvals. 
 
These issues have promoted the recent development of stents coated with fully biodegradable polymers such as 
PLGA and PLA. A successful example is the everolimus-eluting stent, which consist of a platinum chromium (Pt-Cr) 
platform coated with a biodegradable PLGA copolymer. A summary of FDA and CE approved DES based on 
biodegradable polymers are listed in Table 24.[429, 437] 
 
Table 24. Drug-eluting stents (DES) with biodegradable polymers as coating materials. 
TRADE NAME STENT PLATFORM[a] POLYMER SYSTEM DRUG 
DRUG RELEASE 
(DAYS) MANUFACTURER STATUS 
SynergyTM Pt-Cr PLGA Everolimus  50% (60);  100% (90) Boston Scientific FDA
[b] 
AxxessTM Nitinol PLA Biolimus A9  45% (30) Biosensors CE 
BioMatrix FlexTM SS PLA Biolimus A9  45% (30) Biosensors CE 
Nobori® SS PLA Biolimus A9  45% (30) Terumo CE 
Supralimus® SS PLLA-PLGA-PCL-PVP Sirolimus  100% (48) SMT CE 
Orsiro Co-Cr PLLA + silicon carbide Sirolimus  50% (30);  80% (90) Biotronik CE 
BioMimeTM Co-Cr PLLA + PLGA Sirolimus  100% (30) Meril CE 
Inspiron® Co-Cr PLLA, PDLLGA Sirolimus  60% (10);  100% (45) Scitech Medical 
Phase IV 
(NCT01856088) 
Firehawk® Co-Cr PDLLA Sirolimus  90% (90) MicroPort Medical CE 
DESyne® BD Co-Cr PLA NovolimusTM  90% (90) Elixir® CE 
MiStent SES® Co-Cr PLGA Sirolimus 
100% (270) 
(sustained 
release) 
Micell Technologies CE 
Tivoli® Co-Cr PLGA Sirolimus  50% (7);  80% (28) 
Essen Technology 
(Beijing) 
Phase III 
(NCT02448524) 
[a] Pt-Cr: platinum chromium, SS: stainless steel, Co-Cr: cobalt chromium; [b] FDA approved stents also have CE approvals.  
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Although the above mentioned efforts have increased the efficacy and lifetime of stents, it has to be kept in mind 
that even after the degradation of the polymer coatings the metal scaffold (BMS) remains in the artery, which still 
might cause restenosis.[438] As a consequence, the development of fully biodegradable stents has gained 
considerable attention. Several fully degradable DES have been investigated clinically or are still in clinical trials, but 
so far only the evorolimus-eluting stent AbsorbTM is FDA approved and the NovolimusTM-eluting DESolve® is CE 
approved for commercial use in coronary patients (Table 25).[429, 439] In addition to these fully degradable systems, 
dual drug-eluting stents (DDES) are tested to deliver both anti-proliferative and pro-healing agents reducing the 
occurrence of stent thrombosis. Although some of the DDES have shown promising results in clinical trials, the 
Combo stent (OrbusNeich) is the only marketed DDES, which has CE approval. Combo stent uses stainless steel as 
stent platform and elutes the sirolimus and CD-34 antibody as drugs from a biodegradable polymer matrix that 
achieves the complete release within 30 days. Unfortunately, the chemical formulation of the used polymer matrix 
is not specified. Moreover, since the DDES in clinical trials are either polymer free or use no synthetic polymers, 
readers are referred to literature for more information.[429] 
 
Table 25. Drug-eluting stents (DES) with fully biodegradable scaffolds and coatings. 
TRADE NAME STENT PLATFORM 
POLYMER 
SYSTEM DRUG DRUG RELEASE (DAYS) MANUFACTURER STATUS 
AbsorbTM PLLA PDLLA Evorolimus  80% (28) Abbot Vascular FDA approval 
DESolve® PLLA PLLA NovolimusTM 100% (180 to 270) Elixir® CE approval 
Dreams I Mg[a] PLGA TXL 100% (90) Biotronik Phase 0 (NCT01168830) 
Dreams II Mg PLLA Sirolimus n.a. Biotronik Phase 0 (NCT01960504) 
ReZolve2 PTD-PC[b] n.a. Sirolimus Majority of drug (90) REVA Clinical study
[c] 
(NCT01845311) 
[a] Mg, magnesium; [b] PTD-PC, poly-tyrosine-derived polycarbonate; [c] status not clear; n.a.: not applicable. 
 
3.5 Polymers as matrix excipients  
Besides the previously described application forms, several synthetic polymers are added to pharmaceutical dosage 
forms. By definition they have to be inactive ingredients (all materials other than the API) in final drug products to 
belong to the so-called excipients.[440] The FDA provides an online database comprising all inactive ingredients 
approved for certain formulations for their particular route of administration, amount and concentration (also the 
polymers used for coatings, e.g., several Eudragit® products, can be found here, see Chapter 3.4.1).[441] 
Excipients have undergone a paradigm shift from being “inert ingredients” to “functional ingredients”. For instance, 
polymers on one hand act as binders in tablets, capsules and granules, as solubilizing, lyophilizing, wetting or taste 
masking agents[442] but also as mucoadhesives.[443] They are referred to provide sustained release of drugs, to 
solubilize and protect them from degradation or to enhance their bioavailability. They ensure mucus permeability 
of the formulation and enhance the probability for the drug to permeate epithelial barriers (intestinal, nasal, 
pulmonary).[444] Thus, in fact they are used to modulate the overall efficacy of a drug and are, therefore, major 
components in so-called modified release (MR) drug delivery systems. Based on the solubility and permeability of 
an API, a Biopharmaceutical Classification System (BCI) has been introduced grouping the APIs into 4 classes 
(I to IV).[445] According to FDA, an API is for instance highly soluble when its highest clinical dose strength is soluble 
in 250 mL of aqueous media over a pH range of 1 to 7.5 at 37.5 °C, and it is considered to be highly permeable if the 
absorption of an orally administered dose in humans is > 90% when determined using mass balance or in 
comparison to an intravenous reference dose.[446] Such API is referred to as a class I API and can be more easily 
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delivered via e.g. an oral dosage form. For class II drugs (low solubility and high permeability) different formulation 
strategies have to be applied to deliver them orally, e.g. as polymeric amorphous solid dispersion.[447] Related to 
this, polymer matrix excipients can be classified as hydrophilic or hydrophobic matrices. The class of hydrophilic 
matrices is dominated by different celluloses (most often hydroxypropyl methylcellulose, HPMC) and polysorbates 
(both not subject of this review), but also PVP and PEG as synthetic polymers are used.  
Due to the vast number of products on the market containing synthetic polymers as matrix excipients, herein only 
an impression of the most superficial functions of each polymer class is provided followed by an arbitrary selection 
of commercially available dosage forms. Often polymers can be included into formulations to fulfill several tasks 
depending on the formulation technology. Therefore, assignment of a certain polymer or polymer class to a 
particular function, dosage form or manufacturing process is difficult since it can perform different functions in 
different dosage forms (Table 26). 
Eudragit®. Different poly(methacrylate)s (Eudragits®) are most frequently applied as synthetic hydrophobic 
matrices.[448] For instance, Eudragit® NE 30 D can serve as a coating material or can be processed into a tablet 
formulation acting as matrix (with up to 20 wt%), e.g. by wet granulation or direct compression of powders. 
The drug and other excipients are partially impregnated with the polymer. Subsequent compression results in 
embedment of the drug in a sponge-like network of thin polymer layers. The polymer network controls the 
penetration of digestive fluid into the tablet as well as the diffusion of the dissolved drug through the pores. In this 
way, a time controlled release and pH value independent formulation for sustained-release formulation can be 
realized. Eudragit® E PO (EE) is a cationic copolymer based on dimethylaminoethyl methacrylate, butyl 
methacrylate, and methyl methacrylate (for exact composition, see Table 20). It is soluble in gastric fluid up to pH 5, 
thus the drug release can be controlled to occur only in acidic environment. It is frequently used as a coating agent 
due to its film forming capability, but also finds application as a binder in tablets prepared by direct compression in 
10% to 50% concentration. The coating of solid oral dosage forms is highlighted separately in Chapter 3.4.1. 
Carbomer. “Carbomers” (Carbopol™) are high molar mass poly(acrylic acid)s (PAA), sometimes cross-linked with 
small amounts of allyl ethers of polyalcohols. The different numbers in the labels of carbomers (934, 934p, 
940, 941) denote their different molecular sizes as well as the use of benzene during the manufacturing process. 
If benzene is not used during the manufacture, carbomers of type a, b or c are distinguished according to the 
viscosity of their solutions in water. They are most commonly used in cosmetic industry but also in tablet 
formulations, in particular for oral mucoadhesive controlled drug delivery systems.[449] Carbomers can absorb large 
amounts of water, thus increasing in volume up to 1,000 times to form gels and thick solutions that are stable and 
resistant to spoilage. Usually, carbomers are provided as a dried, white powder. Carbomers are considered to be 
generally regarded as safe by the FDA, although high concentrations may lead to eye and skin irritation. 
Polycarbophil. Poly(acrylic acid) cross-linked with divinyl glycol is named polycarbophil. It is a bulk-forming laxative 
that increases the amount of water in stools to make them softer and easier to pass. Polycarbophil is used to treat 
constipation and to help to maintain regular bowel movements. It has been developed as pharmaceutical polymer 
with superior bioadhesive properties used in the field of controlled drug delivery systems. It could be used as a 
highly efficient thickener, bioadhesive agent, suspending aid and emulsion stabilizer when dispersed in water or 
other polar solvents.[450] Polycarbophil can also be used as a controlled release polymer in oral solid dose 
applications (e.g. Striant®). Typical usage levels for achieving controlled release characteristics in tablets 
manufactured by aqueous granulation are 5 wt% to 10 wt%, depending on the drug properties, co-excipients and 
processing parameters. 
Dimethicone. Poly(dimethylsiloxane) (PDMS) is widely used under the name “dimethicone”’ as lubricant and 
conditioning agent, but is also present in tablet capsules (e.g. Keflex®). An orally administered dosage form is the 
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over-the-counter drug “simethicone” (mixture of 90% to 99% of PDMS with siliciumdioxide, see Chapter 3.6). 
It is also used as excipient in tablets and capsules (e.g. Antara®). The presence of PDMS was found in many 
registered drugs, including familiar ones such as AugmentinTM, Maalox®, and VapoSteamTM, just to name a few 
examples. 
Poly(ethylene glycol) (PEG). PEG is frequently used as stealth polymer covalently coupled to drugs (Chapter 3.1) or 
in micro- and nanoparticulate drug delivery systems (Chapter 3.2),[15] but also as matrix excipients in oral and 
parenteral dosage forms and more.[451] PEG is mainly added to solubilize poorly water soluble drugs to enhance 
their bioavailability and to reduce inter-subject variability of plasma concentrations. In particular, clear liquid PEG 
with low molar masses (Mn) of 300 to 600 g mol-1 is frequently used to solubilize poorly water soluble drugs in soft 
gelatin or HPMC capsules for oral application (e.g. Cetirizine capsules) and for almost all parenteral formulations 
(e.g. Robaxin®, Ativan®). PEG with molar masses (Mn) exceeding 4,000 g mol-1 is found in hard shell capsules, which 
is related to the administered drugs and the required stability of the capsules during passage.[452] Another reason is 
that the solubility of most drugs in PEG drops significantly upon dilution with water (leading to re-precipitation of 
the drug). Therefore, also surfactants are often added, which reduce the risk of precipitation of the drug from the 
PEG solution (e.g. phosphadidylcholine or polysorbat 80). Other solubility enhancers are further added to increase 
the solubility of drugs in PEG. These are commonly used ionizing agents; for acidic compounds (e.g. ibuprofen or 
naproxen) bases are added and for basic compounds (e.g. thioridazin or ranitidine) acids. Furthermore, hydrophilic 
polymers (e.g. povidone or cellulose derivatives) are added for the same reason. Administration of capsules results 
in increased rates of absorption and faster achievement of maximum plasma concentration, as shown for instance 
for the Ibuprofen containing soft gel capsules Spalt-Liqua® compared to a standard tablet formulation.[453] 
PEG (i.e. PEG 1000 and PEG 540) serves as a formulation base for some suppositories to dissolve the active 
substance in order to allow enhanced bioavailability by facilitating effective and complete release of the active 
substance in the body. Rather high molar mass PEGs are used to coat suppositories, providing elasticity and 
lubricity. 
Poloxamer. Poloxamers represent another important group in the field of polymer excipients, which are triblock 
amphiphilic copolymers of the structure PEG-b-PPG-b-PEG (also known as Pluronic® from BASF). They are used for 
drug delivery as formulation excipients. They act as surfactants, emulsifying agents, solubilizing agents, dispersing 
agents, and as in vivo absorbance enhancers. They are also used in topical dosage forms, rectal suppositories, for 
the modification of the surface of hydrophobic drugs,[454] for drug delivery,[455] as micelles and micellar drug 
formulations for gene delivery,[456] and as components in formulations for transdermal drug delivery.[457] Because of 
the different customized block-lengths in the copolymers various poloxamers exist. Due to their inertness, a few 
poloxamers are on the rather tight list of excipients that were officially approved by the European Pharmacopoeia 
as well as the U.S. Pharmacopoeia even for human parenteral administration acting as dispersing, emulsifying and 
coemulsifying excipient, as tablet lubricant or wetting agent. 
Poly(vinyl pyrrolidone) (PVP). PVP, also known as “povidone”, is used in the pharmaceutical industry as a synthetic 
polymer vehicle for dispersing and suspending drugs. It has multiple uses, including as a binder for tablets and 
capsules, a film former for ophthalmic solutions, to aid in flavoring liquids and chewable tablets, and as an adhesive 
for transdermal systems. In oral dosage forms it is also added as a wicking agent to facilitate the entry of water to 
the inner surface of the core of the tablet by the formation of channels. A wide range of vinyl pyrrolidone 
homopolymers (povidone k12 to k90) with different molar masses are also available from BASF under the name 
Kollidon®. The k number refers to the mean molar mass of the PVP. The polymers with higher k-values (i.e. k90) are 
not usually administered by injection since their high molar masses prevent excretion by the kidneys and lead to 
accumulation in the body. The best-known example of PVP formulations is povidone-iodine, an important 
disinfectant. “Crospovidones” (polyplasdones, polyvinylpolypyrrolidone) are synthetic, insoluble, cross-linked 
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homopolymers of N-vinyl-2-pyrrolidone. They are insoluble in water, though they still absorb water and swell very 
rapidly generating a swelling force. As a consequence, they are used as disintegrants and dissolution agents for 
solid oral dosage forms and are even effective for poorly soluble dosage forms. Such orally disintegrating tablets 
have emerged as one of the novel solid oral dosage forms with the potential to deliver a wide range of drug 
candidates.[458] PolyplasdoneTM XL crospovidone (Ashland) is a commonly used polyplasdone. 
Poly(vinyl alcohol). Poly(vinyl alcohol) (PVA) as a water-soluble synthetic polymer is used to increase viscosity in 
pharmaceuticals but also as a lubricant and protectant in ophthalmic preparations (known as “artificial tears”).[459] 
PVA is often found in over-the-counter eye redness and eye lubricant drops (Liquifilm Tears). PVA is the lubricant, 
and works by providing moisture to the eye, which helps to relieve dryness and protects the eye from becoming 
more irritated sometimes in combination with, for instant, phenylephrine. 
 
Table 26. Selected examples of synthetic polymers as matrix excipients. 
TRADE NAME POLYMER SYSTEM PREDOMINANT DOSAGE FORMS USED IN … 
FUNCTION IN DOSAGE FORMS AS  
MATRIX EXCIPIENT 
Eudragit® P(MAA-co-MMA) Oral Film former, tablet binder, tablet diluent 
Carbomer/CarbopolTM PAA Ophthalmic Mucoadhesive , viscosity enhancer, thickening agent 
Polycarbophil Poly(acrylic acid) cross-linked with divinyl glycol Oral, vaginal gels Mucoadhesive 
Dimethicone PDMS Oral Antifoaming agent, emollient 
Poly(ethylene glycol) PEG Oral, parenteral, rectal 
Ointment base, plasticizer, solvent, suppository 
base, tablet and capsule lubricant, mucoadhesive, 
tablet binder, thickening agent 
Poloxamer/Pluronic® PEG-b-PPG-b-PEG Parenteral 
Dispersing agent, emulsifying and coemulsifying 
agent, solubilizing agent, tablet lubricant, wetting 
agent, non-ionic surfactant 
Povidone PVP Oral, ophthalmic Disintegrant, dissolution aid, suspending agent, tablet binder 
Crosspovidone Polyvinylpolypyrrolidone  (highly cross-linked povidone) Oral Tablet disintegrant 
Copolyvidone P(VP-co-VAc) Oral Film-former, granulating agent, tablet binder 
Poly(vinyl alcohol) PVA Ophthalmic Viscosity enhancer, lubricant & protectant 
 
3.5.1 Oral dosage forms 
Oral drug delivery combines several advantages and is, as already described, the most frequently used route for 
introducing drugs into the body.[460] The drug absorption depends on different factors making this process a 
complex one. One important issue is the solubility of the API’s in the GI fluids to enable oral absorption (see coating 
of solid oral dosage forms, Chapter 3.4.1). Indeed, more than 50% of potential new drug candidates are expected to 
be lipophilic and have poor aqueous solubility.[461] In recent years, polymeric excipients have been widely used to 
overcome low solubility and formulation difficulties. Furthermore, various new solid formulations have been 
developed using technologies that involve polymer excipients. Selected examples of commercial oral drug 
formulations containing different synthetic polymers as matrix excipients are summarized in Table 27. Further oral 
products containing PEGs are nicely summarized by Gullapalli et al..[451a] 
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Table 27. Selected examples of oral drug formulations on the market containing different synthetic polymers as matrix excipients. 
NAME DRUG[a] POLYMER SYSTEM INDICATION/ USE MANUFACTURER 
Diethylpropion Diethylpropion hydrochloride Carbomer homopolymer type a Treatment of obesity (anorexiant) Lannett 
Metformin Metformin hydrochloride Carbopol® 974P NF Blood sugar control in people with type 2 diabetes 
Aurobindo 
Pharma Limited 
Alfuzosin Alfuzosin hydrochloride Carbomer homopolymer type b Benign prostatic hyperplasia 
Aurobindo 
Pharma Limited 
Macrobid® Nitrofurantoin Carbomer 934[b] Urinary tract infection Norwich Pharmaceuticals 
Striant® Testosterone Polycarbophil Treatment of hypogonadism Columbia Laboratories 
Keflex® Cephalexin Dimethicone 
Bacterial infection, skin or soft tissue 
infection, bladder infection, upper 
respiratory tract infection 
Advancis 
Pharmaceutical 
Antara® Fenofibrate Simethicone Lowering high cholesterol &  triglyceride levels in the blood Lupin 
Zarontin® Ethosuximide PEG 400[c] Prevention and control of a certain type of seizure Pfizer 
Advil® Ibuprofen PEG 600 Pain relief for headaches, migraines & minor arthritis Pfizer 
Lybrel® Ethinyl estradiol/ levonorgestrel PEG 400, PEG 1450 
Abnormal uterine bleeding, birth 
control, ovarian cysts, endometriosis, 
polycystic ovary syndrome 
Wyeth 
AugmentinTM Amoxicillin/clavulanic acid PEG 4000, PEG 6000,  dimethicone 
Antibiotic (beta-lactamase inhibitors) 
for short term treatment of a wide 
range of infections caused by bacteria 
GlaxoSmithKline 
Lipofen® Fenofibrate PEG 8000, PEG 20000 
Primary hypercholesterolemia,  
mixed dyslipidemia, severe 
hypertriglyceridemia 
CipherTM 
Maalox® Aluminium & magnesium hydroxide/calcium carbonate Simethicone 
Acid indigestion, heartburn & 
sour stomach Novartis 
VapoSteamTM Camphor PDMS, poloxamer 124[d] Cold symptoms Vick 
Alprazolam Alprazolam Poloxamer 188  (Pluronic F 68) 
Anxiety, panic disorder, depression, 
tinnitus, dysautonomia TEVA 
AccretropinTM 
Somatropin  
(recombinant human growth 
hormone (r-hGH)) 
Poloxamer 188 
(Pluronic F 68) 
Pediatric growth hormone deficiency, 
Turner syndrome 
Cangene 
Corporation 
Famciclovir Famciclovir (guanosine analogue antiviral drug) 
Poloxamer 407  
(Pluronic F 127 NF) Herpes zoster, herpes simplex Apotex 
Endocet® Acetaminophen/oxycodone Povidone Chronic pain Endo® 
Naproxen Naproxen Povidone Back pain, ankylosing spondylitis, sciatica, bursitis, tendonitis TEVA 
Cetirizine Cetirizine hydrochloride Povidone k29/32 Allergic rhinitis, urticaria Northstar Rx LLC 
Tinidazole Tinidazole Povidone k12 Bacterial vaginitis, trichomoniasis, giardiasis, amebiasis 
Roxane 
Laboratories 
Adenovirus 
vaccine  Plasdone C (PVP) Adenovirus type 4 & type 7 vaccination Barr Labs 
Isoptin® SR Verapamil hydrochloride PEG, Povidone 
Cluster headaches, migraine 
prevention, arrhythmia, high blood 
pressure 
Ranbaxy 
Pharmaceuticals 
Opana® ER Oxymorphone PVA, PEG Narcotic analgesic Endo® 
BuPROPion Bupropion hydrochloride PVA, copovidone, povidone 
SSRI induced sexual dysfunction, major 
depressive disorder, anxiety Actavis 
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[a] All mentioned drugs are used in various drug formulations. However, in most cases they do not comprise a polymeric matrix excipient; 
[b] carbomer codes (e.g. 934) are an indication of molar mass and the specific components of the polymer; [c] PEG # (e.g. PEG 400) indicates the 
average molar mass of the specific PEG (i.e. 400 g mol-1); [d] the first two digits code the molar mass of the PPG core, and the last digit codes the 
PEG content. 
 
3.5.2 Parenteral dosage forms 
Parenteral dosage forms describe all forms of administration avoiding any part of the gastrointestinal tract. 
The advantages of parenteral injection through the skin or other external boundary tissue are immediate systemic 
drug availability and rapid onset of action, as well as a long-term drug delivery by the formation of a depot or 
reservoir at the injection site. The sustained release of the drugs results from its long-acting property and its 
residence in the blood stream or the bone. However, the use of excipients for injectable drugs is more limited than 
for oral administration.[462] The application of novel excipients or the increase of their established concentration 
requires additional safety studies, which impedes the continuous progress of novel matrix excipients. 
Therefore, the well-established PEG is still the method of choice for polymeric excipients (Table 28).[451a] 
In comparison to compounds that are soluble and stable in a PEG vehicle (formulation as solution), insufficient 
solubility requires the formulation as suspension. Therefore, higher molar mass PEGs are used as suspending 
agents (viscosifying) to prevent setting of the dispersed material and to maintain homogeneity. 
 
Table 28. Selected examples of parenteral drug formulations on the market containing PEG as matrix excipients. 
TRADE NAME DRUG POLYMER SYSTEM INDICATION/ USE MANUFACTURER 
Solutions 
VePesid® Etoposide PEG 300[a] Antineoplastic Bristol-Myers Squib 
Robaxin® Methacarbamol PEG 300 CNS depressant,  musculoskeletal relaxant Wyeth 
Busulfex®  
(Myleran®) Busulfan PEG 400 
Preparatory regimen prior to 
allogeneic hematopoietic progenitor 
stem cell transplantation 
Otsuka Pharmaceutical 
Ativan® Lorazepam PEG 400 Antianxiety, anticonvulsant Biovail Laboratories 
Persantine® Dipyridamole PEG 600 Coronary vasodilator Boehringer Ingelheim (disc.) 
Extended-release suspensions 
BioclateTM Antihemophilic  factor VIII PEG 3350 
Prevention of bleeding episodes in 
persons with hemophilia A, control 
the bleeding related to surgery or 
dentistry in a person with hemophilia 
Baxter Healthcare, 
Genetics Institute 
Depo-Provera® Medroxyprogesterone acetate PEG 3350 Contraception Pfizer 
Depo-Medrol Lidocaine® Methylprednisolone acetate, lidocaine PEG 3350 
Osteoarthritis, rheumatoid arthritis, 
acute & subacute bursitis Pfizer 
Aristocort® Forte Triamcinolone PEG 3350 Asthma, atopic dermatitis, drug hypersensitivity reactions Sandoz 
Invega Sustenna® Paliperidone palmitate PEG 4000 Schizophrenia Janssen 
[a] PEG # (e.g. PEG 300) indicates the average molar mass of the specific PEG (i.e. Mn = 300 g mol-1). 
 
3.5.3 Rectal, vaginal and urethral dosage forms 
Suppositories. Suppositories are one type of solid dosage forms and can be administered rectal,[463] vaginal,[464] and 
to a much lesser extent, urethral. Although there are different suppository types, the systemic absorption is limited 
63 
 
to the rectal absorption, while the other two forms are mainly intended for local action. The rectal route is the 
method of choice if the oral dosage is not possible because of nausea, incapability of swallowing, or if the patient is 
unconscious. Different advantages and disadvantages of rectal administration have been nicely summarized by 
Vora and AliChisty.[463] The suppositories should melt or dissolve in the respective fluids in order to release the 
drug. Depending on the drug and the site of action different “suppository bases” are used, mainly fatty and 
oleaginous bases as well as water soluble and water miscible bases. Whereas the former ones are mostly derived 
from cocoa butter (also cottonseed oil, vegetable oils) the latter ones contain reasonable amounts of various PEGs 
of different molar masses (Table 29).[463] Certain PEG polymers may be used singly as suppository bases, but more 
commonly, formulas call for compounds of two or more molar masses mixed in various proportions as needed to 
yield a finished product of satisfactory hardness and dissolution time. Since the water miscible suppositories 
dissolve in body fluids and need not be formulated to melt at body temperature, they can be formulated with much 
higher melting points and thus may be safely stored at room temperature. 
 
Table 29. Selected examples of suppositories on the market containing PEG as matrix excipients. 
TRADE NAME DRUG POLYMER SYSTEM INDICATION/ USE MANUFACTURER 
Rectal 
THE MAGIC BULLETTM Bisacodyl PEG Relief of occasional constipation Concepts in Confidence, USA 
AcephenTM Acetaminophen PEG 100 stearate[a] Reduction of fever, relieve minor aches, pains & headache G & W Laboratories 
Indocin® Indomethacin PEG 3350,PEG 8000 Severe rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, gouty arthritis G & W Laboratories 
Numorphan® Oxymorphone PEG 1000, PEG 3350 Relief of moderate to severe pain Endo® 
Vaginal 
AVC Sulfanilamide PEG 400, PEG 3350 Treatment of Candida albicans infections Monarch 
Encare® Nonoxynol-9 PEG Contraception Thompson Medical 
Endometrin® Progesterone PVP Help to become & stay pregnant Ferring 
Urethral 
MUSE® Alprostadil PEG 1450, PEG 400 Treatment of erectile dysfunction (male) Meda Pharmaceuticals 
[a] PEG # (e.g. PEG 100) indicates the average molar mass of the specific PEG (i.e. Mn = 100 g mol-1). 
 
Gels. Gels have been established as useful dosage form for vaginal applications of different drugs endowed with 
moisturizing and lubrication effect, physiological pH restoring effect, as contraceptive, and as labor inducer.[465] 
They represent semi-solid systems comprising small amounts of solid, dispersed in a large volume of liquid. 
Gels show several advantages over other vaginal drug delivery systems such as higher bioavailability, safety, 
versatility, and economical savings.[466] Among the common natural derivatives (cellulose, chitosan etc.), 
PAA derivatives are mainly used as synthetic polymeric excipients (Table 30). Thanks to the high content in water, 
gels based on mucoadhesive polymers, without addition of drugs, are proposed for moisturization of the vagina in 
cases of vaginal dryness. Such Vaginal gels contain polycarbophil that forms the basis of well-consolidated 
marketed products (e.g. Replens®, Miphil®).[467] 
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Table 30. Selected examples of vaginal gels on the market containing different synthetic polymers as matrix excipients. 
TRADE NAME DRUG POLYMER SYSTEM INDICATION/ USE MANUFACTURER 
Zidoval® Metronidazole Carbomer 974P[a] Bacterial vaginosis Meda Pharmaceuticals 
Metrogel® Metronidazole Carbomer 934P Inflammatory papules & pustules of rosacea Galderma 
Replens®  Polycarbophil Vaginal dryness Church & Dwight 
RepHresh® 
(Miphil®)  Polycarbophil Vaginal dryness, bacterial vaginosis Sanol 
Advantage S Nonoxynol-9 Carbomer 934P, polycarbophil Contraception Columbia Laboratories 
Crinone® Progesterone Carbomer 934P, polycarbophil Infertile women with progesterone deficiency, secondary amenorrhea Watson 
Conceptrol® Nonoxynol-9 Povidone Contraception Revive 
[a] Carbomer codes (e.g. 974P) are an indication of molar mass and the specific components of the polymer. 
 
3.5.4 Ophthalmic dosage forms 
Typically, gels with high water content but with certain viscosity are applied in ophthalmic drug formulations. 
To impart a high viscosity and a water content > 90%, in particular carbomers/carbopolsTM[468] and poloxamers[469] 
are used (Table 31). The polymers have to prolong the contact time on the ocular surface and to slow down the 
drug elimination. Eye drops represent an alternative dosage form to achieve therapeutic concentrations of drugs in 
ocular tissues. Thereby, the topical administration is effective for molecules with poor ocular uptake or poor 
efficacy-to-safety ratio when given systematically. The poor bioavailability and therapeutic response exhibited by 
conventional ophthalmic solutions due to pre-corneal elimination of the drug may be overcome by the use of in situ 
gel forming systems. In situ gelling systems increase the viscosity by changing the pH value or temperature in the 
pre-corneal region and lead to an increase of drug bioavailability by slowing drainage. Poloxamers possess thermal 
gelling properties and are frequently included in ophthalmic formulations to improve the ocular bioavailability of 
drugs by increasing the viscosity.[470] Future prospects are the delivery of peptides and proteins with the help of 
stimuli-responsive polymers.[471] 
 
Table 31. Selected examples of ophthalmic drug formulations on the market containing different synthetic polymers as matrix excipients. 
TRADE NAME DRUG POLYMER SYSTEM DOSAGE FORM INDICATION/ USE MANUFACTURER 
Pilopine HS® Pilocarpine hydrochloride Carbopol 940 Gel 
Control intraocular 
pressure 
Alcon 
Laboratories 
Zirgan® Ganciclovir Carbomer Gel Acute herpetic keratitis (dendritic ulcers) Bausch & Lomb 
RESTASIS® Cyclosporine Carbomer copolymer type A Emulsion Chronic dry eye Allergan 
AzaSite® Azithromycin Poloxamer 407/ polycarbophil (DuraSite®) Solution Bacterial conjunctivitis Akorn 
ALREX® loteprednol etabonate Povidone Suspension 
Seasonal allergic 
conjunctivitis Bausch & Lomb 
Refresh Redness 
Relief® 
Phenylephrine 
hydrochloride PVA Solution Eye redness & dryness Allergan 
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3.6 Polymeric drugs 
 
Polymers that act as pharmaceutically active ingredients are relatively rare. Besides several attempts already in the 
1960s, poly(ethylene sulfonate) and poly(maleic anhydride-co-divinylether) (DIVEMA) were studied for their 
effects, e.g. as anti-tumor agents, but failed due to toxicity issues. The pharmaceutical industry remarked strong 
doubts that a polymer can be a therapeutic agent in diseases where small molecules failed.[472] Major concerns 
were the presumably high dispersity (Ð) and the structural heterogeneity, in particular with regard to regulatory 
issues. However, in the last years a new market grew up with polymeric drugs that are approved and have defined 
and well-characterized structural features. The polymer characteristics but also the administration routes strongly 
influence the therapeutic effect of the polymeric drugs. 
 
Polymeric sequestrants. One field of application is the removal of detrimental species from the gastrointestinal (GI) 
tract in a selective manner. Such polymeric sequestrants work as therapeutic agents and are able to bind and 
subsequently eliminate harmful species that were either ingested or produced by the human body itself. These 
polymers are usually ion exchange resins in the form of hydrogels that are not adsorbed by the GI tract. For the 
treatment of hyperkalemia (i.e. high levels of potassium ions in the serum, which can cause abnormal heart 
rhythms and other health problems), a sodium polystyrene sulfonate (Kayexalate®) is used as cation-exchange resin 
since decades (Table 32).[473] However, the high levels on resulting sodium may cause other critical effects.[474] 
Recently, Valtessa® was approved as a new medication to treat hyperkalemia.[475] This cross-linked polymer based 
on calcium 2-fluoroprop-2-enoate, divinylbenzene and octa-1,7-diene (also named patiromer) with a calcium-
sorbitol counterion is established as a formulation of 100 µm beads.  
Patients suffering from chronic or end-stage renal diseases often have elevated serum phosphate concentrations 
(hyperphosphatemia) that can be treated with sevelamer hydrochloride marketed under the brand name Renagel®, 
which is a poly(allylamine) cross-linked with epichlorohydrin (Figure 24).[476] Comparing to this, Renvela®, 
a sevelamer carbonate, shows fewer side effects. Bile acid sequestrants are one strategy in the treatment of 
elevated cholesterol levels. Cholestyramine (quarternized ammonium groups attached to poly(styrene-co-
divinylbenzene)) and colestipol (copolymer of diethylenetriamine and epichlorohydrin) are polymeric therapeutics 
that bind bile acid, which is necessary for the production of cholesterol 
in the liver, but both therapeutics lack on low clinical efficiency.[477] 
Besides diverse other amine containing cross-linked polymers that 
entered clinical trials, Colestilan (poly(2-methylimidazol-co-
(chlormethyl)oxiran) and Colesevelam hydrochloride (poly(allylamine) 
with 1-chloro-2,3-epoxypropane, (6-(allylamino)-
hexyl)trimethylammonium chloride and N-allyldecylamine) are already 
on the market and show better performances as bile acid sequestrants 
for the treatment of hypercholesterolemia.[478] Micronized 
crospovidone can be used in the treatment of diarrhea based on its 
ability to form complexes with toxins.[164b] 
For binding and removing toxins, originating e.g. from bacteria, such 
ion exchange resins are not efficient enough. More specific binding sides are necessary to reach multivalency. 
Tolevamer®, a high molar mass poly(styrene sulfonic acid), is such a toxin binder that is used to treat diarrhea.[479] 
However, this alternative to antibiotics failed in final clinical trials. The concept of multivalency is also used in 
research for the treatment of viruses, but none of them did reach the market yet. For example, specific peptides, 
that are conjugated to different polymer backbones, are able to protect cells from the anthrax toxin action.[480] 
A linear poly(acrylamide) bearing the C-glycoside of sialic acid shows antiviral activity against the influenza virus.[481] 
As preventional medicine for HIV infections, a naphthalene sulfonate polymer (PRO-2000®) was developed but also 
 
Figure 24. Schematic representation of the 
chemical structure for sevelamer, a 
poly(allylamine) cross-linked with epichlorohydrin 
(hydrochloride: Renagel®, carbonate: Renvela®). 
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failed in clinical phase studies.[482] The development of fat binding hydrogel-like polymers for the treatment of 
human obesity is also a growing area of research. Such polymers should inhibit fat hydrolysis and absorb 
unhydrolyzed fat droplets. They are based on e.g. poly(acrylamide)s, poly(meth)acrylates and other polymers that 
contain both cationic and hydrophobic moieties.[483] An even higher efficiency is aimed by additional conjugation of 
a lipase inhibitor to the polymer backbone (GT 389-255).[484] 
Dimethicone (PDMS) and Espumisan® (dimethicone compounded with 4 to 7% silicone dioxide) are used as active 
pharmaceutical ingredients (API) in medicinal products such as chewable tablets, granulations, tablets, capsules, 
suspensions and drops.[485] These polymers are used in gastroenterology to relieve flatulence, tension in stomach, 
bowel colic and gastric ulceration due to their anti-foaming and anti-flatulent properties.[486] 
Moreover, simethicone can be used prior to upper GI endoscopy to reduce the amount of air bubbles and foam.[487] 
This increases the visibility during the procedure and provides the possibility of more accurate evaluation of the 
mucosa and consequently decreases the endoscopy duration. 
 
Synthetic analogues of antigens. There are basically only very few polymeric drugs that are not related to 
sequestration of small molecules. They act as synthetic analogues of specific disease-associated antigens for 
systemic therapy. The first developed drug as such is glatiramer acetate (also known and marketed as Copaxone®). 
Glatiramer acetate is a copolymer of four L-amino acids (alanine, lysine, glutamic acid, and tyrosine in a molar ratio 
of 4.2 : 3.4 : 1.4 : 1.0) that are randomly copolymerized in a ring-opening polymerization of the corresponding 
amino acid anhydrides.[488] Glatiramer acetate acts via immunomodulation of pathways involved in the 
pathogenesis of multiple sclerosis. However, the complete mode of action is not yet fully understood. 
Patients suffering from multiple sclerosis demonstrate a significant decrease in the number of relapses and rate of 
progression when treated with glatiramer acetate. A recent study also shows a reduction of symptoms in patients 
with the Rett syndrome.[489] There was also a clinical trial where age-related macular degeneration could 
successfully be treated with glatiramer acetate.[490] The most recent research goes to other poly(amino acid) 
combinations that might also show a high potential as drugs for modulating immune responses.[491] 
 
Miscellaneous polymeric drugs. Another polymeric drug is the commonly used highly purified non-ionic surfactant 
poloxamer 188, a block copolymer consisting of PEG-b-PPG-b-PEG (Pluronic® F-68). It is used in treating sickle cell 
disease to reduce inflammation and pain.[492] Clinical trials showed rheologic, cytoprotective, anti-adhesive and 
antithrombotic effects that help to reduce the overall duration of painful episodes of patients suffering from the 
sickle cell disease. The trials passed phase III (NCT00004408) but the drug (Flocor®) did not come to the market yet. 
An innovative approach is the PolyHealTM technology, using negatively charged microspheres (~ 5 µm). They consist 
of nonbiodegradable, medical grade polystyrene (PS) in a suspension of serum-free nutrient medium. Cells and 
macromolecules are able to attach to the surface of the microspheres and to participate in the wound healing 
process. Further polymer-based wound healing dressings have been nicely summarized by Ghadi et al..[493] 
 
Table 32. Selected examples of polymeric drugs on the market. 
TRADE NAME POLYMER SYSTEM INDICATION/USE MANUFACTURER 
Kayexalate® Cross-linked sodium poly(styrene sulfonate) Hyperkalemia Sanofi 
Valtessa® 
Cross-linked calcium 2-fluoroprop-2-
enoate, divinylbenzene, octa-1,7-diene 
(patiromer) 
Hyperkalemia Relypsa 
Renagel® Cross-linked poly(allylamine) (sevelamer hydrochloride)  Hyperphosphatemia Sanofi (Genzyme) 
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Renvela® Cross-linked poly(allylamine) (sevelamer carbonate) Hyperphosphatemia Sanofi (Genzyme) 
BindRen® 
(Colestilan) 
Cross-linked poly(2-methylimidazol-co-
(chlormethyl)oxiran) Hypercholesterolemia Mitsubishi Tanabe Pharma 
Welchol®, Cholestagel® 
(Colesevelam)  Cross-linked poly(allylamine) Hypercholesterolemia Sanofi (Genzyme) 
Espumisan® PDMS (simethicone) Flatulence Berlin-Chemie 
Copaxone® Glatiramer acetate Multiple sclerosis TEVA 
PolyHealTM PS Wound healing TEVA 
 
4. Future prospects and concluding remarks 
Besides the previously described systems on the market or in clinical trials, a large variety of polymer-based 
materials are currently under preclinical investigations, and these materials show immense potential concerning 
drug delivery applications. In the following chapter, we highlight a few exemplarily chosen systems used for 
pharmaceutical applications, which in our opinion hold an enormous potential and will certainly be in forthcoming 
clinical studies.  
Polymer-drug conjugates. Although polymer-drug conjugates are under investigation for several decades now, the 
research interest in this field is still unabated. PEGylation has certainly dominated the area so far, but increasing 
concerns about its immunogenicity have promoted the development of new polymers and their conjugates. Some 
of these materials already reached the stage of clinical testing (conjugates of poly(N-(2-
hydroxypropyl)methacrylamide (PHPMA), poly(2-oxazoline) (POx), see Chapter 3.1.2), and based on their 
performance more conjugates are currently in preclinical studies. The latest investigations, however, focused on 
the development of biodegradable polymers such as polyphosphoesters to substitute the nondegradable PEG. In 
the following some of the most promising systems are described. 
Nondegradable polymers for drug conjugates. Among the vinyl based materials prepared by radical 
polymerizations PHPMA had certainly the highest impact on the area of polymer-drug conjugates. Due to the good 
compatibility and shielding capacity it is no surprise that more studies are ongoing. Besides the previously 
described drug conjugations, PHPMA has, e.g., successfully been conjugated to NPC1161 (8-[(4-amino-1-
methylbutyl) amino]-5-[3,4-dichlorophenoxy]-6-methoxy-4-methylquinoline), an 8-aminoquinoline analog with 
anti-leishmanial activity, and already passed successfully preclinical studies (in vivo).[494] In combination with 
N-acetylmannosamine (ManN) in the side chains, this polymer conjugate represents a promising candidate for 
clinical studies with reduced toxicity and increased efficiency of anti-leishmanial drugs for the treatment of visceral 
leishmaniasis. Mannose-grafted systems allow a selective delivery of anti-leishmanial drugs and a maximization of 
the potential of the drug to destroy the parasite at the site where it resides by mimicking the invasion process 
(mannose-dependent receptor-mediated endocytosis). 
Further candidates based on vinyl polymers, which are close to be tested in clinical studies, rely on established 
systems, such as the Dynamic PolyConjugate (DPC) products: ARC-F12 (thrombosis, angioedema, inhibits the 
production of factor 12), ARC-LPA (cardiovascular diseases, reduces the production of apolipoprotein A), and 
ARC-HIF2 (clear cell renal cell carcinoma, first candidate to target tissue outside of the liver).[495]  
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During the last two decades, the class of POx has gained increasing attention for biomedical and drug delivery 
applications. Besides the already mentioned first POx conjugate (SER-214) under clinical investigations, several 
studies deal with the conjugation to drugs or proteins. The first report on a protein coupled to POx was published in 
1990 by Miyamata et al..[496] Preparing POx with a carboxylic acid as end-group allowed to attach the polymer to 
amine groups of the protein (lysine groups) using DCC/NHS chemistry. Other publications also show the increasing 
thermal stability,[497] as well as a decreasing rate of aggregation[498] using POx ligated proteins. The coupling of 
carboxy functionalized POx using NHS chemistry is the most common reaction for protein conjugation,[499] 
alongside using pyromelitic anhydride,[500] CuAAc,[501] reductive amination,[499b] native chemical ligation,[502] or the 
direct reaction of a protein with the living chain end of the polymerization.[503] Luxenhofer et al. recently 
summarized poly(2-oxazoline) drug and protein conjugates in different stages of their preclinical investigations.[113b] 
An interesting feature of POx is the versatility of the various types of oxazolines allowing to alter the properties and 
functionalities of the resulting polymers. For example, it was demonstrated that the cellular uptake can be 
influenced by the choice of the oxazoline monomer and architecture[499a, 503] and in vivo investigations showed a 
low immune response, as well as an increased circulation of 
POxylated proteins.[504] Besides these protein conjugates, POx 
was also conjugated to small molecule drugs in order to alter 
their pharmacokinetics. The anticancer drug Ara-C[498] as well 
as the antibiotic ciprofloxacin[505] showed similar behavior 
when conjugated to PEtOx as comparable PEG conjugates. In 
summary, it seems that in terms of biocompatibility and 
pharmacokinetic POxylation and PEGylation have very similar 
effects,[506] however, from a synthetic point of view the 
properties of POx can be altered with relative ease compared 
to PEG, just by changing the type of monomer used rendering 
POx a highly versatile tool. 
A further alternative are zwitterionic polymers, that are 
mainly represented by polycarboxybetaine, polysulfobetaine 
and poly(methacryloyloxyethyl phosphorylcholine) 
(Figure 25). They are postulated to partially substitute the 
current benchmark polymer for protein conjugates, PEG, and 
to take a key role in the future of protein therapeutics.[507] 
These polymers are able to maintain the stability of proteins 
without diminishing their binding affinity, which represents a major improvement over the current PEGylation 
technique. An interesting example for this class of polymers is the hyperbranched copolymer poly(3-ethyl-3-
(hydroxymethyl)oxetane)-co-(carboxybetaine) which is used as a biomimetic material in drug delivery carriers.[508] 
Another promising candidate is poly(carboxybetaine methacrylate) that was modified with the charged drug 
DOX.[509] The resulting conjugate features a low cytotoxicity, prolonged circulation time and a controlled release of 
DOX under mild acid conditions. Studies on tumor-bearing mice showed a tumor-inhibition rate of 55% without 
resulting in any body weight loss which usually accompanies this treatment. As previously mentioned, zwitterionic 
polymers are very promising materials to maintain the bioactivity of proteins. In this context, Chen and co-workers 
synthesized a zwitterionic block copolymer poly(methyl acrylic acid-b-sulfobetaine methacrylate) to modify a 
protein drug (uricase).[510] They demonstrated that the stability of the enzyme is improved without causing any 
destructive effects on its bioactivity by the conjugation of a zwitterionic copolymer with a short poly(methyl acrylic 
acid) block. 
 
Figure 25. Schematic representation of the chemical 
structures of zwitterionic polymers: A) Poly(carboxybetaine) 
(R5 = COO-) and poly(sulfobetaine) (R5 SO3-); B) 
poly(methacryloyloxyethyl phosphorylcholine). 
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Degradable polymers for drug conjugates. Undoubtedly, the degradability in biological relevant environment or 
at least the possibility for excretion of the applied polymers is a key aspect for their application in drug delivery. 
As a consequence, the nondegradable nature of many polymer conjugates using PEG or PHPMA has certainly 
hindered their progression towards market approval, although many of them have progressed into clinical 
development. Despite the efficiency of these materials, the safety of their administration is of utmost importance, 
and therefore it would not be surprising, if biodegradable polymer conjugates will have a much higher probability 
of clinical success. 
Polyphosphoesters (PPE) represent a promising class of polymers which is not only biocompatible, but also 
degradable under physiological conditions. These alternatives have already been proposed as PEG substitutes in 
polymeric prodrugs.[130, 132d, 511] The simple and versatile adjustment of the hydrophobicity and polyvalence by 
attachment of different pendant ester groups of the variation of the backbone in PPEs allows the formation of fully 
biodegradable polymer-drug or -protein conjugates (“PPEylation”[512]) as well as the encapsulation of different 
drugs (e.g. low-molar-mass drugs, proteins, DNA, and plasmids) depending on the functionalities of the polymers. 
Recently, Zhang et al. presented a novel drug system containing ultra-high levels of drug loading via covalent 
attachment.[513] In this case, PEG-b-PPE-based paclitaxel (TXL) drug conjugates were synthesized by organocatalyst-
promoted ring-opening polymerization (ROP) followed by click-reaction-based conjugation of PTX to the PPE block 
of the copolymer. The resulting amphiphilic polymer forms micelles with a loading capacity of 65 wt% of PTX and 
demonstrated to be effective against several cancer cell lines. In another study, dual pH-sensitive nanoparticles 
(PPC-Hyd-DOX-DA) have been designed, which are able to reverse their surface charges when exposed to tumor 
tissue to facilitate cell uptake.[514]  
Polymers based on repeating ester units are another potential biodegradable class of polymers which is intensively 
investigated for polymer-drug conjugate approaches and also possesses a wide range of functionalities and 
properties.[515] Among them, polycarbonates have recently received 
much attention for protein/peptide conjugation.[516] Hedrick and co-
workers demonstrated the synthesis of functional polycarbonates by 
ROP starting from the monomer pentafluorophenyl 5-methyl-2-oxo-
1,3-dioxane-5-carboxylate (MTC-OC6F5, Figure 26). The active 
pentafluorophenyl esters enable a substitution with suitable 
nucleophiles such as alcohols and amines and, thus, the 
functionalization with other active groups.[517] The versatility of this 
approach was demonstrated by the preparation of numerous 
functional polycarbonates, which are of particular relevance to 
polymer-drug conjugates, including polycarbonates with PEG,[516] 
hydroxyl-containing[518] and zwitterionic side-chains.[519] Recently, Cheng et al. reported an in vivo efficacy for the 
first example of a polymeric therapeutic based on polycarbonates for the treatment of systemic methicillin-
resistant Staphylococcus aureus (MRSA) infection. Other novel functional nanocarriers for biomedical applications 
have been extensively reviewed by numerous research groups, highlighting these polycarbonate-based degradable 
alternatives to PEG with minimal toxicity.[518, 520] 
Micro- and nanoparticulate drug carriers. Although polymer-drug conjugates have certainly made a huge impact in 
the research area of synthetic pharmapolymers, great promises have been expected from particulate drug carrier 
systems. The versatility and diversity of potential materials used for their preparation allows a flexible design with 
tailor made properties, which has certainly resulted in the success of various systems in clinical trials or on the 
market. However, several issues still have to be addressed and the potential of these systems has by far not been 
fully exploited. The transfer of degradability to nondegradable polymers often represents a missing link between 
the design of advanced materials and their use in biomedical applications. To fulfill the criteria of degradability 
 
Figure 26. Schematic representation of the chemical 
structure of pentafluorophenyl 5-methyl-2-oxo-1,3-
dioxane-5-carboxylate (MTC-OC6F5). 
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appropriate units have to be integrated into the main chain during the synthesis. Another big issue in the 
application of particles, in particular microparticles, for drug delivery is the initial burst release.[521] This problem 
can be overcome by choosing the optimal conditions for the formulation processing or by changing the properties 
of the drug or the polymer itself to prevent polymer-drug separation. Doubtless, the main challenge is the targeted 
delivery that is necessary for cancer and some other diseases to perform better than conventional medications. 
An analysis of over 100 cancer studies has shown that in the average only 0.7% of injected particles reach their 
targets.[522] And what is more surprising, this number did not change within the last 10 years. Reasons for this are 
the increased immunogenicity and plasma protein adsorption in vivo, which masks the targeting molecules and also 
results in decreased blood circulation times.[301] Consequently, targeted nanoparticles behave with the same or less 
efficacy than untargeted particles. Even the often studied EPR effect only yielded poor delivery efficiency and 
shows the lack of ‘proof-of-concept’ studies to be translated to patient care.[522] A better understanding of the in 
vivo nanoparticle transport is necessary and can be accomplished by quantitative analysis with subsequent 
collection of all the information in databases including organization and interpretation of the data also with the 
help of computational tools. Such open excess databases are already established and supported by several 
programs (e.g. DaNa2.0[523] and Cancer Nanomedicine Repository[524]). Only a translation from research to the 
patient might stimulate the application of nanotechnology for treating human diseases as promised. 
Solid colloidal dispersions. One strategy is the use of copolymers of PLGA and PEG making the particles more 
hydrophilic and in consequence more suitable for protein delivery.[525] The hydrophilic domains facilitate a slow and 
controlled release by diffusion. Further improvements on the release profiles and an additional increase in the 
loading capacity could be achieved by a triblock copolymer system consisting of PLGA, PEG and poly(allyl glycidyl 
ether); the latter can also be used to conjugate targeting ligands.[526] Several other systems based on these classic 
release mechanisms of drugs (diffusion through water filled pores, diffusion through the polymer matrix, osmotic 
pumping, and erosion) encapsulated in polymeric nano- and microparticles are currently still under intensive 
investigation in in vitro, in vivo and preclinical studies.[527] However, besides these systems rapid progress has been 
made in the development of stimuli-responsive nano- and microparticles as smart alternatives within the last 
years.[528] In this case, the release can be triggered by internal (coming from the cells/tissue itself) or external 
(coming from outside) stimuli. Such triggers can for example be temperature, light, ultrasound, pH-value, redox 
environment, or specific biomolecules and enzymes.[528] The development of more efficient targeting structures 
may further improve the efficiency of nano-/microparticles. For example, particles carrying siRNA and targeting 
molecules are able to simultaneously attack numerous pathways.[529] The given examples display only a small 
fraction of the numerous systems in development. The wide field of polymeric materials with countless variations 
in constitution, conformation, configuration, and molar mass will definitely yield nano- and microparticles that have 
the potential to show efficacy beyond the current products in clinical stages and on the market. However, a 
translation from bench to bedside is more cost- and time efficient if the polymeric material is already used in 
pharmaceutical products.[308] An interesting study shows the beneficial properties of doxorubicin (DOX) loaded 
PLGA microparticles that could be used in transarterial chemoembolization (TACE) instead of recently developed 
PLGA based microgels.[530] Such PLGA microparticles allow a re-entry into the tumor feeding arteries after an initial 
TACE trial combined with higher drug release rates. A further important step is the development of a robust and 
scalable process for the fabrication of micro-/nanoparticles with reproducible quality and the subsequent GMP 
(good manufacturing practice) production in kilogram quantities. 
An interesting alternative to PLGA is poly(caprolactone) (PCL), which has a slower degradation rate than PLGA 
(up to one year), a high permeability for the diffusion of small molecules and does not generate an acidic 
environment after degradation often causing the destabilization of proteins.[531] Up to now, PCL is most commonly 
used in tissue engineering. Its use as therapeutic molecule delivery system is still limited since PCL carriers reveal in 
many cases low encapsulation efficiency, burst release and low bioactivity. In contrast, besides its beneficial slow 
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degradation rate, PCL is a rubbery at room temperature, which allows high permeability for many drugs. In recent 
years, PCL-materials have been intensively investigated in in vitro and in vivo biocompatibility and efficiency studies 
in order to deliver drugs, genetic materials and proteins. They have been nicely reviewed by Venkatraman and 
co-workers.[532] One example is the encapsulation of chloramphenicol in PCL-Pluronic® composite nanoparticles 
(CAM-PCL-NP). These systems exhibited significantly enhanced anti-MRSA (methicillin-resistant Staphylococcus 
aureus) activity against ten clinical isolates of MRSA strains. Compared to free-chloramphenicol treatment, the 
in vivo study of CAM-PCL-NPs in MRSA-infected burn-wound mice models revealed quicker efficiency in MRSA 
clearance and an improved survival rate.[533] Preclinical studies of a further formulation named NC-6300 show 
promising results in mice and are now under way for clinical studies in Japan.[534] In NC-6300, epirubicin is attached 
via an acide-labile hydrazone bond to PEG-PAs, which can be beneficial due to a better controlled release kinetic. 
Further attempts are also in the development of targeted drug delivery systems, which was already shown, 
e.g. by attaching several anti-TF antibodies resulting in an enhanced antitumor activity against TF-high expressing 
human pancreatic cancer cells, a subunit toolbox with insensibly large possible combinatorial combinations of 
desired bio-functionality and evolutionary optimization techniques.[535] 
Polyplexes. Cationic polymers have already been bloomed over years as non-viral vectors in gene therapy. 
They show tremendous potential in treating different types of cancer and genetic disorders without using 
conventional drugs. One approach is to develop alternative gene delivery platforms by creating higher ordered 
macromolecular structures such as multi-component supramolecules or 2D and 3D scaffolds.[536] Another approach 
is to enhance existing vector platforms (e.g. by functionalization). For instant, the successful clinical application of 
the gold standard poly(ethylene imine) (PEI) for gene delivery depends mainly on three factors: I) The enhancement 
of the transfection efficiency; II) the reduction of toxicity, 
and, III) the ability of the vectors to overcome numerous 
biological barriers after systemic or local administration. 
Current research is focusing on the design of 
biodegradable[537] and more biocompatible derivatives[538] by 
modifying the PEI backbone. Very recently, our group 
introduced a new generation of linear PEI (3rd generation, 
Figure 27) bearing multiple functional groups comprising 
cationic functionalities, cell viability increasing functional 
groups as well as a third group of functionalities which can be 
used, e.g., for targeting molecules.[38] One promising opportunity is the conjugation of glutathione moieties to the 
cationic backbone which enables the transport of genetic materials and, simultaneously, the passage through an 
hCMEC/D3 endothelial cell layer mimicking the highly selective blood-brain barrier (BBB) within a microfluidically 
perfused biochip.[539] Cationic methacrylate copolymers are another upcoming polymer platform able to interact 
with genetic material. Poly(2-dimethylaminoethyl methacrylate) (PDMAEMA) has shown promising gene 
transfection activity due to its cationic character.[540] Jiang and co-workers synthesized PEGylated PDMAEMA/DNA 
polyplexes for efficient brain-targeted gene delivery in mice. As mentioned for phosphates, inorganic safe materials 
will add an important basis for composites with synergistic functions.[541] 
Microgels. The importance of degradability has also been recognized for the design of carrier gels and, in 
particular, micro- and nanosized structures. One quite established example is a PEG microgel, which contains 
degradable PLGA sequences. Injecting them into the cavity of sheep shoulder joint, the new PEG-hydrogel 
microspheres were compared to nondegradable microgels with regard to location, degradation and 
inflammation.[542] The degradable microgel offers several advantages over the nondegradable material considering 
drug delivery in synovial tissue as it reduces the intensity of inflammatory reactions triggered in synovium. 
An interesting strategy for the continuous in vivo expression of a protein is the direct delivery of an ex vivo modified 
 
Figure 27. Schematic representation of the general chemical 
structure for the 3rd generation LPEI which describes the 
presence of multiple functional units comprising cationic 
functionalities (blue), cell viability increasing functional 
groups (black) as well as further functionalities (orange, 
e.g. targeting molecules). 
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cell encapsulated in a gel structure to shield it from the immune system. Sonnet et al. have developed a 
PEG-diacrylate (PEGDA) microgel with allogeneic carrier cells transduced with an adenovirus expressing BMP2 for 
bone regeneration.[543] The PEGylated microsphere system shields the cell and, thus, suppresses the destructive 
inflammatory processes. Within 3 weeks, a 5 mm long femur defect in a rat model was healed completely through 
secretion of 100-fold lower levels of protein compared to similar studies using recombinant protein. For the future, 
this class of injectables opens the macroscopic functional embodiment space staying close to a minimal invasive 
paradigm replacing larger drug eluting devices. 
Nanogels. Besides the already discussed Medusa® technology (Chapter 3.2.3), the only nanogel examples that 
have been evaluated under clinical trials are based on a polysaccharide structure, e.g. cholesterol-bearing 
pullulan (CHP) network,[544] which are described elsewhere.[545] However, researchers still consider tailored nanogel 
systems as a very promising platform for drug delivery applications.[546] Recent successful studies prove the 
efficiency of nanogels by targeting multiple immune cell subsets in the draining lymph nodes.[547] In contrast to 
other gel materials, these systems are fabricated by the synthesis of mesoporous silica (MS) particles (200 nm) as 
templates and subsequent infiltration with pyridine dithioethylamine (PDA) modified poly(methacrylic acid) 
(PMAA-PDA). The infiltration of cysteamine (SH) modified PMAA (PMAASH) leads to a cross-linking by disulfide 
exchange followed by template removal. Further PEGylation of these PMAA nanogels did not affect their cellular 
association in vitro, but improved their lymphatic drainage in vivo (mice). 
Similar to other nanoparticulate systems, the integration of stimuli responsive polymers promises access to carriers 
with local control of the cargo release. Recently, a new type of dual-responsive nanogel with tunable volume phase 
transition temperature and redox-labile properties was investigated.[548] The nanogel system is constructed from a 
copolymer based on vinylcaprolactam (VCL) and HPMA cross-linked with N,N′-bis(acryloyl)cystamine (P(VCL-s-s-
HPMA)). The hydrophilicity of the nanogel allows a stable blood circulation at 37 °C. A higher temperature of the 
tumor tissue forces the nanogel to turn into a hydrophobic state which enhances its cell uptake. Upon the entrance 
into the tumor cells, a redox-triggered degradation of the nanogel (due to the presence of disulfide bonds) leads to 
a burst drug release. In vivo studies (A549 tumor-bearing mice) revealed that these nanogels can significantly limit 
the tumor growth with no side effects to normal tissues. These results underline the immense potential of the dual-
responsive biodegradable nanogels for cancer therapy. Many other nanogel systems have been investigated in vivo 
based on polymers such as PMAA (drugs: DOX/TXL[549]), PEG (siRNA[550]), PEI (AZT 5′-triphosphate[551]), PEG-b-PGluA 
(17-AAG/DOX[552]; cisplatin/TXL[553]) and PMEO3MA-b-PPFPMA (siRNA[554]). Considering the ongoing effort for the 
development of such carrier systems, we are certain that first nanogel materials will soon enter clinical trials. 
 
Macroscopic drug carriers. They probably represent the most versatile application forms of pharmapolymers 
comprising the wide range of hydrogels and solid implants and inserts. The general trend is towards the creation of 
multiple functional systems. In our opinion, in particular the application of hydrogel systems will change 
significantly. Sensor and conditional release/activity can be established and are already shown for vaccination on 
animal trial stage.[555] 
 
Hydrogels. The most common application form for hydrogels is certainly their use in contact lenses, but 
surprisingly they are not used as drug delivery vehicles so far, which is probably related to the loss of lens quality 
accompanied with the release. The recent development of new techniques to design contact lenses enables an 
extended drug release over a few weeks without any significant impact on the lens properties. Compared to 
alternative eye drops, these contact lenses revealed safety, efficacy and increased bioavailability in in vivo 
studies.[556] Corresponding contact lenses, placed on the cornea, release drugs into the post-lens (between lens and 
cornea) and reveal a prolonged contact time with the cornea.[557] The increased efficiency (35× higher than delivery 
with drops[558]) allows the delivery of drugs over extended time periods (which eliminates the need for multiple 
73 
 
dosing) while decreasing side effects since less drug amount is needed. Further ocular applications are the 
development of hydrogels based on poly(2-hydroxyethyl methacrylate) (PHEMA)[559] or poly(dimethyl siloxane) 
(PDMS),[560] which may serve as drug delivery agents for the anterior segment of the eye. The latter is also used for 
punctual plugs releasing cyclosporine A for a period of 3 months.[561] In the last years, immense effort has been put 
into the development of devices for ocular drug delivery,[562] and we are convinced that suitable systems will enter 
the market soon. 
A real innovation is the non-hormonal contraceptive “Reversible inhibition of sperm under guidance” (RISUG®, 
Figure 28) for men developed by Guha and co-workers based on poly(styrene-co-maleic anhydride).[563] 
It represents a long acting and reversible alternative to a 
vasectomy as the polymer can be flushed with another 
injection of a dissolver.[564] It has been patented in several 
countries including India, China and the United States. While 
clinical phase III is already ongoing in India,[565] the Parsemus 
Foundation began to develop a similar polymer contraceptive 
inspired by RISUG® for the rest of the world in 2010 
(VasalgelTM).[566] After one year of successful in vivo studies, 
they recently announced the start of first clinical trials in the 
second half of 2017 and a commercial launch in 2018.[567] 
Besides the classic hydrogels, the development of so-called 
interpenetrating polymer networks (IPN) has expended 
enormously in the field of controlled release and targeted drug delivery in the last decades.[568] Introduced in 1960 
by Miller,[569] IPN’s are defined as “polymers comprising two or more networks which are at least partially 
interlaced on a molecular scale but not covalently bonded to each other and cannot be separated unless chemical 
bonds are broken” (IUPAC[570]). They represent a subgroup of physical gels. The blending of natural and/or synthetic 
polymers opens the field for the design of new controlled release systems for a variety of drugs and broadens the 
range of their properties.[571] IPNs reveal several advantages like an excellent swelling behavior, improved 
responsiveness and mechanical strength, which play an important role in drug delivery systems and differentiate 
them from single networks (such as hydrogels). Even if in vitro and in vivo data have been extensively studied and 
reviewed,[568, 571-572] and the number of patents on this technology is increasing frequently, IPN drug-loaded systems 
have not found their way into clinical studies up to now, and, hence, commercialization, so far. Their complexity 
due to the combination of various different properties has hindered a major breakthrough in pharmaceutical 
applications so far. The current research is still at the academic level, but in our opinion, IPNs are expected to 
receive much more attention in the future. 
Coatings. Colon specific drug delivery has gained considerable attention not only considering colon associated 
diseases but also for the safe delivery of therapeutic peptides and proteins to the blood stream as the activity of 
proteolytic enzymes is far lower compared to the upper GI tract.[573] The marketed dosage forms that aim the site 
specific delivery of the drugs usually depend on the pH variations in the GI tract. However, the pH value difference 
between the small intestine and the colon is not high enough. This limits the efficient colon targeting in particular 
when the distal colon is targeted. Therefore, to achieve an efficient colon targeting, variations in the environment 
comparing the small and the large intestine are exploited in several in vivo studies, which include changes in the 
pH value, the different microbial enzymatic activity, the fluctuating intraluminal pressure or the transit time. 
Dosage forms which are coated with innovative colon targeting polymers have been extensively reviewed 
elsewhere.[574] However, it should be noted that novel polymers with unknown safety data always require 
additional safety assessment. Therefore, most of these studies use polymers with well-established safety profiles 
 
Figure 28. The work principle of “Reversible inhibition of 
sperm under guidance” (RISUG®): A) The hydrogel is 
injected into the vas deferens connected to each testicle; 
B) it coats the wall of the vas deferens. When sperm gets 
into contact with the wall it becomes unable to swim. 
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for coatings. Hence, we do not envisage new marketed dosage forms with novel complex polymeric coatings in 
near future. 
 
5. Concluding remark 
The presented review attempted to provide a comprehensive overview of the current state of synthetic polymers 
used for drug delivery applications, so-called ‘pharmapolymers’. Within the last decades, the impact of synthetic 
polymers has resulted in tremendous advances in chemical synthesis and analysis. The contribution highlights the 
current market situation and clinical status of respective polymers while paying attention to underlying chemical 
structures. In addition, we highlight upcoming trends in the development of new pharmapolymers, which in our 
opinion will have a tremendous impact on the market situation soon. However, we also summarize the obstacles 
these materials still have to overcome to the market for drug delivery applications. Our review comprises a detailed 
description of the most important polymer classes and their fields of application. Application forms like 
polymer-drug conjugates, drug carrier systems in scales ranging from nano- to macroscopic size, polymers as 
coatings and matrix excipients as well as polymeric drugs are described. We hope that providing a link between the 
properties and structures of these systems and their area of application helps scientists from different research 
fields where the systems are often just known by their trade names or abbreviations. 
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ABSTRACT: (Bio)degradable poly(ethylene imine-co-
glycine)s (P(EI-co-Gly)) were synthesized through eﬃcient
and controlled oxidation of linear poly(ethylene imine)
(LPEI) using hydrogen peroxide in a methanol/water mixture.
Temperature, peroxide concentration, and reaction time were
varied to adjust the degree of oxidation (DO). At low
temperatures, the oxidation process was found to be well-
controlled with almost 85% of ethylene imine units converted
to the corresponding amide. Importantly, oxidation of more
than 10% of the LPEI rendered the polymers water-soluble.
The oxidation reaction and molecular structure of P(EI-co-Gly)s were studied in detail by various nuclear magnetic resonance
(NMR) methods, infrared (IR) spectroscopy, and size exclusion chromatography (SEC). The introduction of backbone amide
groups to the P(EI-co-Gly)s facilitated its (bio)degradation under acidic conditions or by proteases. Moreover, the P(EI-co-Gly)s
exhibited negligible cytotoxicity, particularly relative to LPEI. The interaction of the copolymers with serum-containing medium
was investigated showing no indication of coagulation. Preliminary studies indicate that P(EI-co-Gly) is a promising
biodegradable polymer with negligible toxicity in human cell lines.
■ INTRODUCTION
Poly(ethylene imine) (PEI) is one of the most successfully and
widely studied vectors in nonviral gene delivery and is
considered the gold standard for gene transfection.1,2 The
repeating ethylene amine structure of PEI can electrostatically
interact with the DNA/RNA phosphate groups and form so-
called polyplexes.3−5 The polymer exists in branched or linear
architecture, which inﬂuences the transfection behavior.6,7
However, PEI suﬀers from several drawbacks such as
cytotoxicity,8−10 low hemocompatibility,11 and nonbiodegrad-
ability,12,13 which limits its clinical applications.
In the past decade, the chemical modiﬁcation of PEI has
garnered tremendous interest, with the primary objective of
reducing cytotoxicity, increasing transfection eﬃciency and cell
selectivity.2,14−16 Most biological studies have focused on
partially modiﬁed PEI conjugates.17−19 Procedures have
involved chemical transformation of the amine groups of PEI
via alkylation, ring-opening of epoxides, and Michael addition,
among others.2
Previously, MacDonald and co-workers reported the
oxidation of branched PEI by hydrogen peroxide.20 The
authors demonstrated that the modiﬁcation of the PEI
backbone proceeds via the following intermediate species:
hydroxylamine (2),21 nitrone (3),22,23 and oxaziridine (4)23−25
(Scheme 1). The ring-opening of the oxaziridine, as postulated
by MacDonald, leads to a Beckmann-type rearrangement
product26 and, subsequently, to the formation of the
thermodynamic product, a stable amide group (5). The
resulting structure resembles the repeating unit of poly(glycine)
(PGly), which renders the polymers potentially biocompatible
and degradable. However, this report claimed the oxidation to
be accompanied by partial chain degradation, mainly referring
to the appearance of carboxylic acid and aldehyde signals.
These signals can, among others, occur from the oxidation (and
subsequent hydrolysis) of primary amines present in branched
PEI.20 To this end, we utilize linear PEI for the presented study
to prevent the inﬂuence of primary amines. Furthermore, the
use of a linear polymer precursor simpliﬁes the characterization
due to the absence of primary and tertiary amines. Using
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modern characterization techniques and careful kinetic studies,
we show that polymer degradation is minimal.
Surprisingly, since the initial report of the PEI oxidation, few
(if any) similar reports have appeared in the past 40 years. The
controlled oxidation of PEI represents a highly useful method
for the modiﬁcation of PEI and oﬀers a unique opportunity to
facilitate biocompatibility and degradability of an otherwise
toxic PEI. Such an improvement would enable, for the ﬁrst
time, in vivo studies especially for applicability in gene delivery.
Recently, Hauser and co-workers demonstrated that the
oxidation of an already formed PEI/DNA polyplex would
decrease the amount of cationic charges.27 However, this
contribution focused on the biological performance of these
altered polyplexes and lacked details on the chemical nature of
the modiﬁcation.
The goal of the present work was to understand the
oxidation of PEI, to identify the optimal reagents/conditions to
gain control over the oxidation process, and to evaluate the
structure of the resulting polymers in detail. Therefore, we
investigated the inﬂuence of several parameters, including time,
temperature, and concentration, as well as the nature of the
oxidizing agent in order to identify optimized conditions. A
series of four P(EI-co-Gly) copolymers were synthesized and
extensively analyzed. The degradation of the polymers was
examined using HCl or trypsin and underlined the potential of
the presented macromolecular system. Furthermore, serum
stability and cytotoxicity were evaluated and found to be
superior as compared to unmodiﬁed PEI.
■ RESULTS AND DISCUSSION
Oxidation of Linear Poly(ethylene imine). The ﬁrst
parameter investigated in the oxidation process of LPEI28 was
the oxidizing agent. Initial experiments focused on evaluating
the suitability of various oxidizing agents (Table 1), where the
degree of oxidation (DO) was assessed by 1H NMR
spectroscopy. Interestingly, the use of common oxidizing
agents such as oxone, m-chloroperoxybenzoic acid (mCPBA),
or the White catalyst (a palladium coordination complex) led to
no measurable DO and, in some cases, degradation of the
polymer. The oxidation of LPEI with hydrogen peroxide,
however, led to oxidized species with a DO of up to 80%. The
modiﬁed polymers exhibited an extraordinarily high water
solubility for DOs > 10%. The simplicity of the oxidation
reaction together with the ease of puriﬁcation (precipitation in
diethyl ether followed by freeze-drying) makes this procedure
straightforward. For these reasons, hydrogen peroxide oxidation
was the method used for all following investigations.
In the mechanism described above (Scheme 1), the oxidation
of LPEI converts the latter into a partially oxidized poly-
(ethylene imine-co-glycine) (P(EI-co-Gly)) (Scheme 2), which
consists of unaﬀected ethylene imine (EI) and newly formed
glycine (Gly) units. Because of incomplete hydrolysis during its
industrial synthesis process, the starting LPEI contains up to
5% 2-ethyl-2-oxazoline units.31 These groups remain unaﬀected
during the oxidation, which is shown by oxidation experiments
of poly(2-ethyl-2-oxazoline) homopolymer (Supporting In-
formation, Figure S1). Furthermore, the unaﬀected 2-ethyl-2-
oxazoline (EtOx) repeating units were also used to quantify the
DO. Since the signals of EI and Gly repeating units,
respectively, are not entirely baseline separated, the error of
the quantiﬁcation of the DO is estimated as ±5%. The sharp
signal at ∼8.30 ppm could be attributed to degraded species or
Scheme 1. Schematic Representation of the Oxidation Mechanism of a Secondary Amine (1) via Hydroxylamine (2), Nitrone
(3), and Oxaziridine (4) Intermediates To Form the Final Amide Group (5), As Proposed by MacDonald et al.20
Table 1. Diﬀerent Approaches for the Oxidation of Linear Poly(ethylene imine)
Scheme 2. Schematic Representation of the Oxidation of
Commercial LPEI to P(EI-co-Gly) by Hydrogen Peroxide
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solvent impurities. However, the integral of the peak is lower
than 2% as compared to the polymer signals.
The successful oxidation is exempliﬁed by 1H NMR analysis
in Figure 1, which shows an overlay of LPEI and P(EI-co-
Gly67%) spectra. As veriﬁed by HSQC NMR measurements
(Figure S2), the newly formed signal F can be primarily
ascribed to the CH2 group of the glycine backbone. Signal E
indicates the formation of an amide group showing no coupling
to polymer associated carbon signals (see Figure S2).32 Its
appearance is rather surprising and cannot be used for
quantiﬁcation of the degree of oxidation (DO) due to proton
exchange processes in D2O. The
13C NMR signal at ∼170 ppm
corresponds to the amide carbonyl group (no coupling was
observed by heteronuclear NMR, HSQC). The DO was
calculated from the integration of the 1H NMR signals of the
copolymer backbones via eq 1 (Experimental Section).
Kinetic Investigations. Synthetic control over the
oxidation process is critical, so the oxidation reaction was
investigated as a function of the concentration of peroxide, the
temperature, and reaction time. First, the oxidation was
performed with varying concentrations of hydrogen peroxide
(0−1 equiv of H2O2 per EI repeating unit) for 20 h at 18 °C,
the optimized time/temperature to observe a maximum DO
(Figure S3). The increase in peroxide concentration resulted in
a nearly linear increase of the DOs and represents a simple and
eﬀective method to control the DO. Moreover, with 0.9 equiv
of H2O2 per EI unit, the DO reaches a maximum of 60%,
whereas an excess of H2O2 (4 equiv) enables the oxidation of
almost 85% of EI units. For this reason, excess of H2O2 was
used for the following kinetic studies.
Starting from identical mixtures of LPEI, methanol, and
H2O2, the oxidation reaction was performed at various
temperatures and reaction times. The determined DOs from
temperature- and time-dependent investigations (by 1H NMR)
resulted in the kinetic curves depicted in Figure 2. Increasing
temperature led to faster oxidation and, hence, higher DOs.
The short recording times of the curve associated with the
reaction conducted at 0 °C is due to technical limitations, as it
was diﬃcult to maintain this temperature for longer time
periods. Higher temperatures were also explored; a similar
experiment at 55 °C resulted in a multitude of sharp signals in
the 1H NMR spectrum of the products, which are not typical
for polymers with broad molar mass distributions, suggesting
degradation to low molar mass species (Figure S4). We
therefore concluded that ambient temperature (18 °C in our
case) was suﬃcient for attaining high DOs of up to 85%
without causing polymer degradation. In summary, adjusting
the H2O2 concentration, time, and temperature represents a
simple and eﬀective method to control the DO.
P(EI-co-Gly) with Varying DOs. The ability to adjust the
DO via temperature and time enabled the synthesis of a series
of P(EI-co-Gly)s with varying amounts of glycine units (Table
2, 1−4). To avoid the investigation of potential degradation
products, centrifugal concentration was performed for all P(EI-
co-Gly) samples using disposable Vivaspin 20 ultraﬁltration
devices with a molar mass cutoﬀ (MWCO) of 3000 g mol−1.
Larger H2O2 concentrations and higher temperatures
resulted in a faster and less controllable oxidation. Therefore,
to achieve polymers with lower DOs (e.g., 1 and 2), the
reaction was performed at 0 °C. Higher oxidation degrees (3
and 4) were obtained at 18 °C followed by puriﬁcation through
precipitation and freeze-drying.
An overlay of the 1H NMR spectra of 1−4 can be found in
Figure 3. A downﬁeld shift of the LPEI backbone signal D to
signal F as well as the appearance of the amide signal around
7.90 ppm (E) indicates a successful oxidation.
Diﬀusion-ordered NMR spectroscopy (DOSY NMR)
conﬁrms the presence of a single (polymeric) species, as
indicated by the diﬀusion coeﬃcient and, hence, the absence of
degradation (Figure S5). Diﬀusion coeﬃcients are speciﬁed in
Table 2. Missing Mark−Houwink values, α and K, for the
copolymers hinder the calculation of the molar weights via the
Mark−Houwink equation. For LPEI, the molar mass (Mn) was
determined as 4200 g mol−1 by viscosity measurements using
literature values.33 The viscosity of methanol (determined by
viscosity measurements using a capillary/ball combination) and
the diﬀusion coeﬃcients were used to calculate the hydro-
dynamic radii R0 of the (co)polymers via the Einstein−
Smoluchowski relation (Table 2). Because of equipment
dependent data, the diﬀusion coeﬃcient from the residual
water peak was used to “standardize” R0 values of the
(co)polymers by simple correction to literature reported
value of DH2O.
Figure 1. Comparison of 1H NMR spectra of LPEI and P(EI-co-Gly)
(including unaﬀected EtOx units, <5%) with a degree of oxidation of
about 67% (D2O, 400 MHz).
Figure 2. Kinetic studies of the oxidation of LPEI at diﬀerent
temperatures with a 4-fold excess of H2O2. Degrees of oxidation were
calculated from 1H NMR spectra (D2O, 400 MHz).
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A diﬀerence in R0 of LPEI and P(EI-co-Gly)s can be
explained by two factors: ﬁrst, hydrogen bonding, which occurs
due to the presence of the newly formed amide groups, and
second, decreasing charges owing to the disappearance of
secondary amines. This allows an entanglement of the polymer
chains, and as a result, smaller hydrodynamic radii are observed
for the oxidized species. However, the larger R0 of LPEI could
also be attributed to the formation of aggregates as the polymer
is known to form hydrogen bonds in aqueous solution.34
Unfortunately, asymmetric ﬂow ﬁeld ﬂow fractionation (AF4,
RC membrane with MWCO of 10 000 g mol−1), a well-
established method for the detailed characterization of cationic
polymers,35 was not successful due to the low molar masses of
the starting LPEI and the corresponding oxidized copolymers
(<10 000 g mol−1).
The IR spectra (in the wavenumber region between 1200
and 2000 cm−1) of LPEI and 1−4 are shown in Figure 4.
Numerous investigations regarding IR spectroscopy of
polyglycine are known from the literature.39−41 The vibration
at 1660 cm−1 results from the carbonyl stretching vibration of
the secondary amide group in P(EI-co-Gly).20,42 This signiﬁes a
successful oxidation. Signals attributable to carboxylic acid
derivatives, as possible degradation products, are expected to
appear at higher wavenumbers (>1700 cm−1);43 however, they
are not observed. Starting from LPEI (no carbonyl vibration),
increased DOs lead to more intense carbonyl bands. The signal
at 1600 cm−1 is likewise assigned to amide mode. The
vibrations between 1400 and 1340 cm−1 can be assigned to the
CH2 bending and wagging mode of the formed glycine,
respectively. The 1480 cm−1 band of the LPEI-CH2 backbone
gradually decreases in wavenumber (to 1435 cm−1) with an
increase of DO.
Poor solubility in common solvents and expected inter-
actions of the cationic polymer with the column material in the
case of aqueous SEC setups prohibit successful determination
of molar masses of the P(EI-co-Gly) by size exclusion
measurements. However, LPEI and copolymers 1−4 could be
dissolved in N,N-dimethylacetamide (DMAc) at low concen-
trations. The appearance of the LPEI signal at higher elution
volumes, and hence at lower molar masses, compared to the
P(EI-co-Gly)s is another indication for the absence of
quantitative degradation during oxidation (Figure S6).
Unfortunately, a calibration for cationic polymers is not
available, which complicates the determination of accurate
molar masses by SEC.
Degradation Studies. One potential advantage of P(EI-co-
Gly) compared to unmodiﬁed LPEI is the possibility of
biodegradation due to the incorporation of amide bonds in the
Table 2. Parameters for P(EI-co-Gly)s 1−4 and Starting LPEI at 25 °C: Degree of Oxidation (DO), Number-Averaged Molar
Mass Mn (NMR, SEC), Diﬀusion Coeﬃcient D (DOSY), Intrinsic Viscosity μint, and Hydrodynamic Radius R0 According to the
Einstein−Smoluchowski Relation
Mn [g mol
−1]
no. composition DOa [%] NMRb SEC (DMAc)c,g Dd [10−10 m2 s−1] μint
e [mL g−1] R0
f [nm]
LPEI 650036 1100 2.8 28.6 3.07
1 P(EI80-co-Gly20) 20 6900 1500 6.3 6.9 1.37
2 P(EI60-co-Gly40) 40 7300 1400 8.9 8.0 0.97
3 P(EI33-co-Gly67) 67 7900 1700 6.8 8.6 1.27
4 P(EI15-co-Gly85) 85 8200 1600 7.9 8.3 1.09
aPercentage of formed GLY units determined by 1H NMR spectroscopy. bDetermined by 1H NMR (calculated from LPEI: 6500 g mol−1,36 ratio of
PEI and GLY). cDetermined by SEC (eluent: DMAc + 0.21% LiCl, calibration against polystyrene standard). dDetermined by diﬀusion-ordered
NMR spectroscopy (DOSY, D2O, 400 MHz, 25 °C, see Figure S4).
eDetermined by viscosity measurements (MeOH, 25 °C). fCalculated by
Einstein−Smoluchowski relation by means of η0,MeOH = 0.61 × 10
−3 kg m−1 s−1 (Experimental Section, eq 2).37 The diﬀusion coeﬃcient from
residual water peak (DH2O = 5.60 × 10
−9 m2 s−1 (25 °C)) was used to “standardize” R0 values by simple correction to literature reported value of
DH2O,Lit = 2.30 × 10
−9 m2 s−1 (25 °C).38 gAll samples are hardly soluble in the SEC eluent DMAc. Unfortunately, there is no calibration standard
available for cationic polymers like LPEI and derivatives.
Figure 3. 1H NMR spectra of LPEI and P(EI-co-Gly)s 1−4 (D2O, 400
MHz).
Figure 4. IR spectra of P(EI-co-Gly)s 1−4 and LPEI in the
wavenumber range from 1200 to 2000 cm−1.
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polymer backbone. To investigate the decomposition behavior,
P(EI-co-Gly67%) (3) was chosen as a model polymer and
subjected to acidic (6 mol L−1 HCl) and enzymatic (trypsin)
conditions. While the pure LPEI showed no changes under
these conditions, the 1H NMR spectra of the oxidized species
revealed sharp and undeﬁned signals (comparable to the
oxidation reactions at high temperatures), usually atypical for
polymers with broad molar mass distributions and chain
lengths of around 150 units (Figure 5). Further evidence of a
successful degradation is given by the splitting of the signals of
the EtOx side chain and the reduction in the peak intensity of
the amide bond at 7.9 ppm, which completely disappeared
upon the treatment with HCl. Simultaneously, the intensity of
the sharp signal at 8.45 ppm increases, validating the earlier
assumption of this signal being attributed to degradation
products. Furthermore, successful degradation was conﬁrmed
utilizing DOSY NMR (Figure 5). Polymer degradation results
in increased diﬀusion coeﬃcients as well as a fractionation of
the signals. The signal of water was used for calibration.
Size exclusion chromatography in DMAc conﬁrmed the
successful degradation (Figure S7). The improved solubility
and the shift to lower molar masses further support our claim.
Cytotoxicity and Serum Stability. Another important
parameter for a candidate polymer for biomedical applications
is its biocompatibility. Pure PEI, although known as a gold
standard for nonviral gene delivery,1,2 possesses a high
cytotoxicity due to its high cationic charge density. Since
oxidation of LPEI results in repeating units similar to natural
occurring peptides, we hypothesized that the cytocompatibility
of oxidized LPEI (i.e., P(EI-co-Gly)) should exceed that of PEI.
Such an improvement would enable in vivo studies especially
for gene delivery applications. In order to evaluate this
parameter, cytotoxicity was investigated by 3-[4,5-dimenthyl-
thiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay
using human embryonic kidney 293 cell line (HEK 293)
(Figure 6A).
While LPEI induces a toxic eﬀect already at very low
concentrations (<6.25 mg L−1), all copolymers investigated are
cytocompatible up to a concentration of 25 mg L−1.
Furthermore, a noticeable eﬀect of the DO on the cell viability
can be observed. For example, while cell viability values drop
below 60% after incubation with P(EI-co-Gly20%) (1) at 50 mg
L−1 for 48 h, P(EI-co-Gly85%) (4) still does not induce harmful
eﬀects, with ∼80% cell viability even at relatively high
concentrations (200 mg L−1).
A second important parameter, the interactions of polymers
with serum proteins, was assessed by DLS measurements of
P(EI-co-Gly)s after treatment with fetal bovine serum (FBS)
(Figure 6B). All investigated copolymers resulted in Z-average
values that were indistinguishable from the untreated control
sample (pure FBS), indicating no further aggregation and,
hence, polymer stability in the presence of serum proteins over
48 h. LPEI itself could not be investigated since its addition to
serum resulted in an immediate precipitation of protein
components. It should be noted that this investigation does
only demonstrate the absence of serum coagulation, while an
interaction of protein and polymer is still possible. In
conclusion, it can be stated that even a low DO is able to
shield the copolymer from interacting with cell membrane/
proteins and therefore signiﬁcantly reduces harmful eﬀects on
cells, as shown by the cytotoxicity investigations.
■ EXPERIMENTAL SECTION
Materials. Reagents were used as received unless otherwise noted.
LPEI (MW 25 000 g mol−1) was obtained from Polysciences. Aqueous
hydrogen peroxide solution (30% w/w) and methanol were purchased
from Sigma-Aldrich (USA). Poly(2-ethyl-2-oxazoline) with a degree of
polymerization of 95 was synthesized according to the literature
starting from 2-ethyl-2-oxazoline (Sigma-Aldrich).44 Hydrochloric acid
and trypsin were purchased from Sigma-Aldrich. Centrifugal
Figure 5. DOSY NMR of 3 before (blue) and after treatment with 6
mol L−1 aqueous hydrogen chloride (orange) and peptidase (trypsin)
(green) (D2O, 400 MHz, 25 °C).
Figure 6. (A) Cytotoxicity of LPEI as well as P(EI-co-Gly)s 1−4 by MTT assay on HEK 293 cells. (B) Serum stability by time-dependent DLS
measurements of FBS in the presence of P(EI-co-Gly)s 1−4.
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concentration was performed using disposable Vivaspin 20 ultra-
ﬁltration devices with a molar mass cutoﬀ (MWCO) of 3000 g mol−1.
General Methods and Instrumentation. Proton (1H) nuclear
magnetic resonance (NMR) and carbon (13C) NMR spectra were
acquired in D2O, at room temperature using a Bruker AC 400 MHz or
a Bruker AC 300 MHz (100 MHz 13C); chemical shifts (δ) are
expressed in parts per million relative to TMS. 1H NMR measure-
ments were carried out with an acquisition time of 3.2 s, a pulse
repetition time of 2.0 s, a 30° pulse width, 5208 Hz spectral width, and
32K data points.
The degree of oxidation (DO) was calculated from the integrals of
the 1H NMR signals of the copolymer backbones (see Figure 1 and
Figure S2) using eq 1
=
−
− +
( )
( )
F A
F A D
DO
2
2
4
3
4
3 (1)
where F is the integral of NH−CO−CH2, A is the integral of CH2−
CH3 (provided that A≪ F), and D is the integral of NH−CH2−CH2.
Diﬀusion-ordered NMR spectroscopy (DOSY) was performed on a
Bruker 400 MHz Avance I NMR system equipped with a BBO z-
gradient probehead. 2D spectra were recorded using a pulse programm
(Bruker: “ledbpgp2s”) with bipolar gradient pulses and two spoil
gradients.45 Experimental parameters were optimized once using a 1D
version of the aforementioned pulse sequence and then kept constant
for all samples: 32 number of scans, recycle delay of 2 s, acquisition
time of 1.7 s, diﬀusion time (d20) of 75 ms, a gradient pulse length
(p30) of 2.5 ms, and a linear gradient amplitude ramp ranging from 5
to 95% (with respect to the maximum strength of 53.5 G/cm) with 64
increments. Sample temperature was set to 25 °C. Standard DOSY
processing algorithms provides by TopSpin were utilized to obtain the
ﬁnal DOSY spectra and to extract the diﬀusion coeﬃcients.
Size exclusion chromatographies (SEC) were performed on an
Agilent Technologies 1200 Series gel permeation chromatography
system equipped with a G1329A autosampler, a G131A isocratic
pump, a G1362A refractive index detector, and both a PSS Gram 30
and a PSS Gram 1000 column placed in series. As eluent, a 0.21% LiCl
solution in N,N-dimethylacetamide (DMAc) was used at 1 mL min−1
ﬂow rate and a column oven temperature of 40 °C. Molar masses were
calculated using poly(styrene) standard.
Fourier transform infrared (FT-IR) spectra were recorded on a
Thermo Nicolet Nexus 670 FT-IR spectrometer, using the attenuated
total reﬂectance (ATR) method.
Viscosity measurements were conducted using an AMVn
viscometer (Anton Paar, Graz, Austria), with the capillary/ball
combination of the measuring system. The respective ﬂow times for
the solvent (methanol) and polymer solutions, τ0 and t, were measured
at 25 °C, with relative viscosities ηr = t/τ0 in the range of 1.1−1.8,
which corresponds to dilute solutions.
The hydrodynamic radius R0 was calculated from diﬀusion
coeﬃcients D (DOSY) and liquids viscosity η0 by eq 2, the
Einstein−Smoluchowski relation.
πη
=R
k T
D6
0
B
0 (2)
where kB is the Boltzmann constant, T is the temperature, η0 is the
liquid’s viscosity, and D is the diﬀusion coeﬃcient.
Oxidation of Linear Poly(ethylene imine). The synthesis is
exempliﬁed by the P(EI-co-Gly67%) with a degree of oxidation (DO)
about 67%. LPEI (0.025 g) was dissolved in methanol (V = 0.63 mL).
After stirring for 5 min, aqueous hydrogen peroxide solution (4 equiv
per EI unit, 0.125 mL, 30% w/w) was added dropwise into the stirring
polymer mixture at room temperature (water bath, 18 °C). After 2 h,
the mixture was precipitated two times into 15 mL of ice-cold diethyl
ether. The oxidized polymer was ﬁltered oﬀ and washed with 5 mL of
diethyl ether. The residue was dissolved in 3 mL distilled water and
freeze-dried overnight (yield: 95%).
LPEI. 1H NMR (400 MHz, D2O): δ 3.46−3.28 (NH−CH2−CH2),
3.00−2.60 (NH−CH2), 2.35 (CH2 EtOx), 0.99 (CH3 EtOx) ppm.
13C
NMR (100 MHz, D2O): δ 148.5 (CO−CH2−CH3), 47.1 (NH−CH2−
CH2), 25.1 (CH2−CH3), 9.8 (CH2−CH3) ppm. FT-IR: v ̃ 3180 (OH,
NH), 2870 (CH asym/sym str), 1480 (C−H def), 1280, 1125 (C−N
str), 1045 (C−N) cm−1.
P(EI-co-GLY67%). DO = 67%, μInt = 8.6 mL g
−1. 1H NMR (400
MHz, D2O): δ 8.30, 8.05−7.75 (NH−CO−CH2), 3.75−3.18 (NH−
CO−CH2), 3.14−2.41 (NH−CH2−CH2), 2.30 (CH2−CH3), 1.94
(CH2−CH3) ppm.
13C NMR (100 MHz, D2O): δ 171.1 (NH−CO−
CH2), 166.5, 140.5 (CO−CH2−CH3), 47.0−34.7 (NH−CH2−CH2,
NH−CO−CH2), 25.2 (CH2−CH3), 8.5 (CH2−CH3) ppm. FT-IR: v ̃
3260 (OH, NH), 2870 (CH asym/sym str), 1658 (CO), 1600 (NH
bending), 1435 (C−H def), 1395, 1340 (CH2,Gly asym/sym str), 1155
(C−N str), 1065 (C−N) cm−1.
Kinetic Investigations. The peroxide concentration dependent
oxidation of linear poly(ethylene imine) was performed according to
the general procedure described above. For further kinetic
investigations, the H2O2 concentration was set constant to 4 equiv
per EI unit to reach a maximum level of oxidation. To investigate the
inﬂuence of temperature, ﬁve analogue stock solutions of LPEI,
ethanol, and H2O2 were prepared and stirred at selected temperatures
(ranging from −20 to 55 °C). After deﬁned time ranges (ranging from
0.5 to 20 h) aliquots were taken and puriﬁed by precipitation. After
washing with diethyl ether the samples were freeze-dried. The degree
of oxidation was determined by proton nuclear magnetic resonance
measurements (1H NMR).
P(EI-co-Gly) with Varying DOs. The oxidation of linear
poly(ethylene imine) was performed in larger scales according to
the general procedure described above. Since larger amounts of H2O2
lead to higher generation of heat and, hence, to a faster and more
uncontrollable oxidation, the reaction for lower oxidation samples 1
and 2 was performed at 0 °C. Higher oxidation degrees (3 and 4) were
obtained at room temperature (18 °C).
Degradation Studies. Polymer 1 (DO 67%, 20 mg) was dissolved
in 6 mol L−1 HCl (2 mL) and stirred for 20 h at 70 °C. Subsequently,
the mixture was neutralized with sodium hydroxide and freeze-dried. A
second approach was the addition of the protease Trypsin (0.5 mL) to
an aqueous solution of 1 (5 mg in 1 mL of H2O). After stirring for 20
h at 37 °C, the mixture was freeze-dried. Both products were analyzed
by 1H and DOSY NMR and SEC.
Cytotoxicity. HEK 293 cells were cultured in RPMI-1640 supplied
with 10% fetal bovine serum (FBS) and 1% penicillin−streptomycin.
HEK 293 cells were seeded onto 96-well plates at a density of 10 000
cells/well. The cells were incubated at 37 °C, 5% CO2. After 24 h, the
medium was replaced with fresh medium containing polymer at
various concentrations. After incubation for 48 h, 100 μL of fresh
medium and 20 μL of 5 mg/mL MTT solution were used to replace
the sample medium. After 4 h of incubation, the medium was
removed, and DMSO (150 μL) was added to each well to dissolve the
formazan crystals. The absorbance of each well was measured with a
microplate reader (Power-Wave X, Biotek Instruments, USA) at 690
nm as reference and subtracted from the absorbance of the same well
at 550 nm. The results were presented as a percentage of absorbance
of the blank control.
Serum Stability. Polymers were dissolved in PBS containing 10%
FBS. The particle sizes within the polymer solutions were analyzed
using a Zetasizer 3000 HAS (Malvern Instrument Ltd., Malvern, UK)
equipped with a He−Ne laser beam at 658 nm (scattering angle: 90°)
over 48 h. The concentration of the polymers was 500 mg/L. Each
sample was measured three times, and an average particle size was
obtained.
■ CONCLUSION
A method for the tailored oxidation of commercially available
linear poly(ethylene imine) (LPEI) was developed. The 1972
report by MacDonald et al. on the oxidation of branched
poly(ethylene imine) was revisited by means of extensive
kinetic studies and characterizations of the modiﬁed LPEIs
(NMR, DOSY, IR, SEC, viscometry). Concentration as well as
temperature proved eﬃcient parameters to control the degree
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of oxidation of poly(ethylene imine-co-glycine)s (P(EI-co-Gly))
copolymers. At low temperatures, the oxidation process was
found to be well-controlled, and a maximum of 85% oxidized EI
units could be reached. Notably, oxidation of only 10% of the
LPEI led to water-soluble polymers. The formed amide groups
render the copolymers (bio)degradable, as shown by the
decomposition experiments using aqueous hydrogen chloride
and trypsin. Finally, the biocompatibility improvement of P(EI-
co-Gly)s compared to LPEI was demonstrated by cytotoxicity
investigations and serum stability measurements.
The controlled oxidation of LPEI, as shown in this
contribution, enables the speciﬁc improvement of the (bio)-
properties, such as biodegradation and biocompatibility, and
hence helps to overcome the main drawbacks of the initial
material. It can be assumed that there is an optimal
composition of copolymers to reach high transfection
eﬃciencies (EI content) while showing good cytocompatibility
(Gly content). However, the investigation of the transfection
abilities will be the focus of further studies.
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Facile carbohydrate-mimetic modiﬁcations of
poly(ethylene imine) carriers for gene delivery
applications†
Christoph Englert,a,b,c Mareva Fevre,a Rudy J. Wojtecki,a Wei Cheng,d Qingxing Xu,d
Chuan Yang,d Xiyu Ke,d Matthias Hartlieb,‡b,c Kristian Kempe,‡b,c
Jeannette M. García,a Robert J. Ono,a Ulrich S. Schubert,*b,c Yi Yan Yang*d and
James L. Hedrick*a
Commercially-available linear and branched PEIs (LPEI and BPEI) were chemically-modiﬁed with carbo-
hydrates and carbohydrate-mimetics to improve biocompatibility. Hydroxyl moieties were installed in a
close proximity via reaction of PEI’s amines with paraformaldehyde (pF) or glycidol. Mixing PEI with pF led
to the formation of hemiaminal moieties as well as N-methylation of the backbone through an
Eschweiler–Clarke-type rearrangement. The amount of attached hydroxyl groups depended on the initial
amount of pF and the results were in agreement with NMR studies on model reactions with primary and
secondary amines. The primary amines of BPEI triggered the ring-opening of glycidol and sugar-contain-
ing epoxides, in methanol and at room temperature. PEI chains modiﬁed with pF displayed the same cyto-
toxicity as the parent polymer, unless a suﬃcient amount of pF was added to trigger N-methylation of the
backbone. In contrast, glycidol and sugar-functionalized BPEIs exhibited lower toxicity but similar (if not
higher) transfection eﬃciency as compared to unmodiﬁed BPEI.
Introduction
Nucleic acid-based gene therapy holds great promise in treat-
ing human diseases by replacement of defective genes or
repression of redundant gene expression to normal levels by
the use of RNA interference.1 Gene delivery vectors are com-
monly classified as viral or non-viral. Although viral vectors
have superior transduction capabilities, their clinical appli-
cations have been limited owing to their immunogenic and
oncogenic potentials.2,3 To circumvent this problem, a
number of non-viral gene delivery systems have been reported,
which include (1) complexes of nucleic acids with various cat-
ionic molecules including lipids,4 polymers5 and peptides6
and (2) conjugates of nucleic acids with natural ligands such
as cholesterol,7 as well as cell-penetrating peptides.8
The successful clinical application of gene delivery vectors
depends mainly on three factors: (1) high gene transfection
eﬃciency, (2) low toxicity and (3) the ability of the vectors to
overcome numerous biological barriers after systemic or local
administration. Among the various types of non-viral vectors,
poly(ethylene imine) (PEI) has been used as the gold stan-
dard.9 Indeed, linear PEI (LPEI) and branched PEI (BPEI)
possess one of the highest cationic charge density potential of
all organic macromolecules.10 Every third atom is an amine, of
which every sixth nitrogen atom is protonated under
physiological conditions.10 In this way, PEI is able to interact
with the phosphate groups of deoxyribonucleic acid (DNA), as
well as ribonucleic acid (RNA) to form toroidal complexes
that are readily endocytosed by cells.11,12 Therefore,
PEI demonstrates an extremely high gene transfection
eﬃciency in vitro.10,13–16 However, the net positive charge of
PEI/polyplexes led to major drawbacks associated with toxicity,
aggregation and undesired non-specific interactions with
cellular and non-cellular components, particularly in vivo.17
Notably, since LPEI shows various advantages over BPEI,
both from a synthetic (more defined products, easier to
characterize)13 and from a biological/clinical side (increased
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biocompatibility),18 it has been the focus of multiple clinical
trials for years.19–23
The most common method for the synthesis of LPEI is the
acidic24–26 or basic27,28 hydrolysis of poly(2-alkyl-2-oxazoline)s
(POx). In contrast, branched poly(ethylene imine) can be syn-
thesized by the ring-opening polymerization of unsubstituted
aziridines leading to branched chains with primary, secondary,
and tertiary amino groups.29 Current research focuses on the
design of biodegradable30–34 and more biocompatible deriva-
tives35,36 by modifying the PEI backbone and/or side chains.
Various chemical transformations of the amino groups of PEI
have been reviewed,13 and can be categorized as follows: reduc-
tive N-methylation,37,38 nucleophilic substitution with alkyl-
halogenids,39 ring-opening of epoxides and carbonates,40–43
conjugate addition31,44 and acylation resulting in carbamates45
or pseudo-poly(2-oxazoline)s.43,46,47 Synthetic post-polymeri-
zation functionalization methods for enhanced biocompati-
bility of BPEI are summarized in Table 1.
Considerable eﬀorts have focused on the attachment of
carbohydrate-containing moieties, owing to the non-toxicity of
such molecules, as well as the potential to target cells exhibit-
ing carbohydrate-receptors. For instance, saccharides such as
oligo-maltose,53 chitosan,54 galactose55 and mannose56 have
been grafted onto PEI. Recently, we reported on the modifi-
cation of the primary amines of BPEI using a single ring-
opening step of mannose-functionalized cyclic carbonates.52
This transformation mitigated PEI cytotoxicity and non-
specific interactions, as well as enhanced the gene transfection
eﬃciency. However, most of these modifications required
multi-step syntheses or harsh experimental conditions, often
resulting in poor control over the final polymer composition.
Herein, in an eﬀort to devise a facile and economical syn-
thetic strategy to carbohydrate-like modification of PEI, we
focused on the installation of hydroxyl moieties in close
proximity to the PEI backbone, in an eﬀort to mimic the
vicinal diols of sugars. Towards this goal, PEI was functiona-
lized by a single-step transformation with hemiaminal moi-
eties using paraformaldehyde and by ring-opening of glycidol
or galactose- and mannose-functionalized epoxides. All
reagents were either commercially available or easily syn-
thesized. Detailed nuclear magnetic resonance (NMR) investi-
gations allowed for the accurate characterization of the
structure of the modified PEI. The relevance of these modifi-
cations for the use of PEI as a gene delivery vector was vali-
dated by cytotoxicity and gene transfection eﬃciency assays.
Results and discussion
Functionalization with formaldehyde
Hydroxyl functional groups were installed on both LPEI and
BPEI by modification of the polymer with paraformaldehyde
(pF). In the case of BPEI, both the primary and secondary
amines could be successfully reacted to obtain a polymer with
Table 1 Synthetic post-polymerization modiﬁcation methods for enhanced biocompatibility of branched PEI
Reagent(s)
Functionalized
Product(s) Transfection Ref.–NH2 –NH–
mPEG–NCO ✓ n.d.a 45
✓ pDNA 44 and 48
siRNA
✓ ✓ pDNA 49 and 50
pDNA
✓ ✓ pDNA 40, 41 and 43
siRNA
n.d.
✓ ✓ pDNA 50
✓ ✓ siRNA 48 and 43
n.d.
✓ ✓ siRNA 48 and 43
n.d.
✓ pDNA 42, 51 and 52
pDNA
pDNA
a n.d. – not determined.
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a high degree of functionalization. BPEI is a hyperbranched
polymer that contains primary (pKa ∼ 9.6, measured in 0.5 M
NaCl/H2O), secondary (pKa ∼ 8.6) and tertiary (pKa ∼ 7.5)
amine groups in a theoretical ratio of 1 : 2 : 1.57 However, the
experimental ratio was found to be 1 : 1 : 1 for commercially-
available BPEI,58 with only about 20% of the amine moieties
protonated under physiological conditions.59 Therefore, when
the primary and secondary amine moieties are functionalized
quantitatively, tertiary amines are available for protonation in
the endosome to facilitate endosomal escape through the
“proton sponge eﬀect”.10,60–62 Moreover, the decoration of the
amine groups also mitigates the toxicity of PEI, enabling
higher dosing and nitrogen/phosphorus ratios.
We recently reported that hemiaminal and bis-hemiaminals
were intermediates in the reaction of amino-functionalized
poly(ethylene glycol) with pF63 and that transient species were
kinetically captured when stoichiometric or an excess of pF
was used with respect to the amine groups.64,65 Preliminary
experiments with BPEI and super-stoichiometric amounts of
pF (10 equiv. per amine functionality, including primary, sec-
ondary and tertiary amine groups) resulted in the formation of
an insoluble gel after <1 min stirring at 90 °C, attesting of the
crosslinking of the BPEI chains. Model 1H NMR studies on
small molecule primary amines showed that variable species
were produced depending on the electronics and solubility of
the model compound in D2O. Moreover, as already established
while reacting diamino-functionalized PEG and pF in organic
solvents,64,65 transient species are kinetically-quenched to
form gels, owing to the polymeric nature of the amine. Both
these observations precluded accurate identification of the
crosslinks with PEI in aqueous conditions, which was most
likely a mixture of aminals and hemiaminal ethers as pre-
viously reported for melamine/formaldehyde resins66,67 and
possibly a small quantity of hexahydrotriazine crosslinks.63,64
NMR experiments on the reaction of LPEI with >0.5 equiv.
pF showed the appearance of a new signal in the 1H NMR spec-
trum of the product at ∼2.1 ppm. This signal was identified by
DEPT 135/90 to correspond to a N-methyl group, attributed to
the methylation of the PEI backbone, likely according to an
Eschweiler–Clarke-type rearrangement (see Scheme S1†),37,68
where iminium intermediate forms as secondary amines are
reduced to the corresponding tertiary amines. This side reaction
with excess formaldehyde therefore limited the amount of
hemiaminal moieties that could be attached to the PEI back-
bone. However, the N-methylation of PEI was shown to reduce
the cytotoxicity by lowering the net positive charge of the PEI/
polyplexes under physiological conditions, but also to decrease
the transfection eﬃciency.69
Therefore, the concentration of pF was decreased and
varied from 0.05 to 1.20 equivalents (per amine functionality,
see Table 2), to mitigate the occurrence of crosslinking of BPEI
(B1 to B4) and N-methylation of the backbone of LPEI (L1 to
L5) (see Scheme 1). The reactions were carried out for 15 h at
90 °C to accommodate for the diminished reactivity of steri-
cally-encumbered amino groups of BPEI. In the case of BPEI, a
viscosity increase was observed with increasing formaldehyde
concentration and, eventually, the reaction mixture turned
into a completely insoluble gel for initial formaldehyde load-
ings greater than 0.5 equiv.
Fig. 1 depicts the 1H NMR spectra of linear and branched
PEI modified with increasing pF concentration. The integration
values of signal C, attributed to network formation (C′, for
BPEI) and hemiaminal species, increased with formaldehyde
concentration for both polymer architectures. With 0.50 equiv.
of pF (L3, B4) or higher (L4, L5), methylation of the PEI back-
bone was also observed.37 These data are in agreement with
model reactions performed using n-propylamine (to model
primary amine reactivity) and dipropylamine (to model second-
ary amines) with 0.50 equiv. pF in d6-DMSO (see Fig. S2†).
Diﬀusion-ordered NMR (DOSY) spectra of LPEI and BPEI
reacted with 0.50 (L3) and 0.05 equiv. pF (B1), respectively, are
displayed in Fig. 2 (the signal of methanol was used as an
internal standard). A single diﬀusion coeﬃcient was observed
for both functionalized species. The diﬀusion coeﬃcients of
L3 and B1 were larger than the unmodified counterparts, indi-
cating that the functionalization of PEI with formaldehyde led
to a decrease of the hydrodynamic radius of the polymer in
solution. The absence of sharp signals on the 1H NMR spectra
of L3 and B1, as well as the detection of a single diﬀusion
Table 2 Overview of modiﬁed poly(ethylene imine)s obtained by
varying the paraformaldehyde (pF) content
Polymer structure
Functional.
agent Polymer
Equiv.
pFa
Linear poly(ethylene imine) L1 0.15
L2 0.30
L3 0.50
L4 0.75
L5 1.20
Branched
poly(ethylene imine)
B1 0.05
B2 0.15
B3 0.30
B4 0.50
a Per amine functionality, including primary, secondary and tertiary
amine groups.
Scheme 1 Schematic representation of the functionalization of (A)
linear poly(ethylene imine) (L1 to L5) and (B) branched poly(ethylene
imine) (B1 to B4) with paraformaldehyde; wavy lines represent network’s
formation (R represents possible crosslinking groups, ratio not
determined).
Paper Polymer Chemistry
5864 | Polym. Chem., 2016, 7, 5862–5872 This journal is © The Royal Society of Chemistry 2016
Pu
bl
ish
ed
 o
n 
08
 S
ep
te
m
be
r 2
01
6.
 D
ow
nl
oa
de
d 
by
 T
hu
er
in
ge
r U
ni
ve
rs
ita
ts 
La
nd
es
bi
bl
io
th
ek
 Je
na
 o
n 
26
/0
1/
20
17
 0
8:
27
:2
2.
 
View Article Online
coeﬃcient ruled out any backbone degradation. However, the
functionalization of amino moieties of PEI using paraformalde-
hyde leads to (i) a decrease of charged species per chain owing
to increased N-substitution, and (ii) the introduction of hydroxyl
groups that can create intramolecular H-bonding. Both
phenomena could cause the formation of more compact par-
ticles in solution and could explain the observed smaller hydro-
dynamic radii exhibited by the functionalized PEI chains.
Modification with epoxides
Glycidol, as well as, mannose- and galactose-functionalized
epoxides were used to modify PEI through a straightforward
ring-opening reaction under mild and catalyst-free conditions
(see Table 3).
Glycidol was employed as a control carbohydrate-mimetic
to facilitate comparison with the hemiaminal modification
(Scheme 2, L6 to L10 and B5 to B9). Noteworthy, hemiaminal
moieties exhibited poor stability under acidic conditions,
while ring-opened glycidol moieties are stable in biological
environments.43 Eﬃcient polymer functionalization was veri-
fied by 1H NMR (see Fig. S3†) and DOSY NMR experiments of
L8 and B7 (see Fig. S4†). Mannose and galactose have already
been used as eﬃcient modifiers to decrease the toxicity of PEI
while allowing for targeting of cells exhibiting either
mannose52,56 or galactose55 receptors. However, as already
mentioned, the sugar-functionalization of PEI usually involves
tedious synthetic work.70
Epoxides bearing pendant sugars were prepared by a one-
step nucleophilic substitution of commercially-available pro-
tected sugars with epichlorohydrin in THF. To modify the poly-
mers, ring-opening reactions were carried out in MeOH at
room temperature (see Scheme 2B), followed by hydrolysis of
the acetal protecting groups for the sugar-containing polymers
(Galactose: B10, Mannose: B11). Eﬃcient polymer functionali-
zation was verified by 1H NMR experiments (see Fig. S5† for
galactose, Fig. S6† for mannose functionalization). Due to the
overlapping of the 1H NMR signals in the 2.5 to 4.0 ppm
region for the deprotected sugar-functionalized BPEI, compo-
Fig. 1 1H NMR spectra of (A) linear (L1 to L5) and (B) branched (B1 to B4) poly(ethylene imine)s modiﬁed with varying contents of pF; wavy lines rep-
resent network’s formation (D2O, 400 MHz).
Fig. 2 Diﬀusion ordered NMR spectra (MeOD, 400 MHz, 25 °C) of (A) LPEI and corresponding hemiaminal-functionalized L3 (0.5 equiv. pF vs.
–NH), and, (B) BPEI and corresponding hemiaminal-functionalized B1 (0.05 equiv. pF per amine functionality, including primary, secondary and ter-
tiary amine groups).
Polymer Chemistry Paper
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sition of these polymers was calculated on dialyzed samples
prior to hydrolysis.
Biocompatibility and transfection experiments
As previously mentioned, one of the major disadvantages of
PEI is its inherent cytotoxicity. In vitro studies were performed
on hemiaminal, glycidol and sugar-functionalized PEIs to
evaluate their biocompatibility and gene transfection eﬃciency
in a model mammalian cell line HEK293.
The modification of LPEI and BPEI with pF did not allow
for any improvement of the toxicity, except when LPEI was
modified with higher amounts of pF (see Fig. S8†). Mixing
more than 0.5 equiv. pF (vs. –NH) with LPEI induced
N-methylation of the backbone, which is thought to reduce the
toxicity of PEI through a decrease of the extent of positive
charges per chain.69 In addition, the hemiaminal moieties
proved unstable in acidic pH values, releasing formaldehyde
under endosomal conditions.71 This eﬀect could account for
the similar toxicity of pF-modified samples compared to pure
PEI (see Fig. S7† for cytotoxicity assays of pF-modified PEI).
For this reason, pF-functionalized samples were not used in
transfection studies and the biological assessment was
focused on epoxide-modified PEI.
The positive charges of glycidol and sugar-functionalized
BPEIs were used to condense anionic DNA in order to prepare
PEI/DNA nanocomplexes. The size, charge, cytotoxicity and
ability to bind as well as transfect a luciferase-reporter gene
in vitro of the DNA polyplexes of B6 (0.15 equiv. glycidol), B9
(0.75 equiv. glycidol), B10 (0.09 equiv. galactose), and B11
(0.09 equiv. mannose) were analysed. All polymers were able to
bind DNA eﬀectively at N/P 5 and above, where complete retar-
dation of DNA mobility was achieved as demonstrated in gel
electrophoresis assays (Fig. S8†). The DNA molecules were fully
complexed with B6, and retardation of DNA mobility achieved
at N/P 1 and above. Increasing the number of glycidol
decreased polymer/DNA interaction (B6 vs. B9) as the number
of primary amine groups, which were responsible for DNA
binding, was reduced. B6 had higher DNA binding ability than
unmodified BPEI. Although the number of galactose and
mannose attached onto PEI was slightly lower than that of gly-
cidol (B10 and B11 vs. B6), B6/DNA interaction was still stron-
ger than B10 or B11/DNA interaction, most probably owing to
steric hindrance provided by mannose and galactose moieties.
Nanoparticle sizes below 200 nm are commonly desirable
for eﬀective cellular uptake.72 As depicted in Fig. 3A, the size
of the polymer/DNA complexes inversely correlated with N/P
ratio, suggesting more compact complexes formed via strong
electrostatic interaction between functionalized BPEIs and
anionic DNA at higher N/P ratios. The size of the complexes
dropped from over 200 nm at N/P 10 to 89, 96, 90 and 129 nm
at N/P 50 for B6, B9, B10 and B11, respectively. Moreover, the
size distributions of B6/DNA, B9/DNA, B10/DNA and B11/DNA
complexes were narrow with polydispersity indices (PDI) of
0.10, 0.11, 0.16 and 0.15, respectively. DNA complexes formed
with unmodified BPEI at N/P 10 displayed a similar size
(∼84 nm) and PDI (0.12). These results suggest that except for
B9 the lower charge density of the modified BPEI did not sig-
nificantly aﬀect its ability to complex DNA as compared to
unmodified BPEI.
The surface charge of polymer/DNA complexes plays a key
role in determining toxicity and gene transfection eﬃciency.73
It has been reported that positively charged particles are prone
to undesired interactions with plasma proteins and erythro-
cytes, a process called opsonization, which triggers a rapid
clearance by the reticuloendothelial system (RES), limiting
in vivo applications.74 The high positive charge of PEI is also
thought to induce side eﬀects such as liver necrosis, and
Scheme 2 Schematic representation of the functionalization of (A)
linear poly(ethylene imine) with glycidol (L6 to L10) and (B) branched
poly(ethylene imine) with glycidol (B5 to B9), galactose (B10) and
mannose (B11) sugar moieties.
Table 3 Overview of modiﬁed poly(ethylene imine)s obtained by
varying the glycidol, mannose and galactose contents
Polymer structure Functional agent Polymer
Equiv.
epoxidea
Linear
poly(ethylene imine)
L6 0.15
L7 0.30
L8 0.50
L9 0.75
L10 1.20
Branched
poly(ethylene imine)
B5 0.05
B6 0.15
B7 0.30
B8 0.50
B9 0.75
Branched
poly(ethylene imine)
B10 0.09
Branched
poly(ethylene imine)
B11 0.09
a Per amine functionality, including primary, secondary and tertiary
amine groups.
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shock after systemic injection of high doses.17,74 Therefore, a
reduction of the zeta potential of PEI/DNA complexes would
be beneficial for gene delivery applications. B6, B10, and B11/
DNA complexes exhibited reduced cationic charge density on
the surface at N/P 10 to 50 as compared to BPEI/DNA com-
plexes at N/P 10 (Zeta potential: ∼11 to 15 mV for B6, B10 and
B11/DNA complexes and ∼16 mV for BPEI/DNA complexes,
Fig. 3A). B9/DNA complexes presented a significantly lower cat-
ionic charge density on the surface than other complexes at
N/P 10 to 50 (zeta potential: ∼−4 to 9 mV). Indeed, a higher
degree of functionalization provided more hydroxyl groups
eﬀectively shielding the surface charge of the polymer/DNA
nanocomplexes, as well as, lowered the amount of cationic
charges owing to the pKa decrease of amines with substitution.
The cytotoxicity of modified BPEI/DNA and control BPEI/
DNA complexes was evaluated by MTT assay using HEK293
cells. BPEI is thought to aggregate on cell surfaces and initiate
hole formation in the cell membrane, leading to leakage of
vital cellular contents and cell death, limiting potential in vivo
applications.75 As shown in Fig. 3C, the high cytotoxicity
associated with BPEI caused less than 10% cell viability for
N/P higher than 20. In a sharp contrast, all the glycidol- and
sugar-functionalized PEI/DNA complexes were much less cyto-
toxic at all N/P ratios tested. For instance, at N/P ratio of 20,
more than 75% and 60% cells were viable upon 4 h treatment
with glycidol-modified B6 and B9/DNA and sugar-modified
B10 and B11/DNA complexes, respectively (vs. only 5%
viable cells in the BPEI/DNA complexes-treated group). Even at
N/P ratio 50, B10 and B11/DNA complexes demonstrated more
than 30% cell viability, and more than 63% cells survived
upon B9/DNA treatment. Therefore, cytotoxicity was eﬃciently
mitigated by the installation of hydroxyl groups on BPEI by
ring opening of glycidol- or sugar-functionalized epoxides,
owing to both higher substitution degrees of amines and
shielding of BPEI positive charges from hydroxyl moieties.
To assess the suitability of these polymers as gene delivery
vectors, in vitro luciferase gene transfection assays were per-
formed on HEK293 cells. BPEI achieved high gene transfection
eﬃciency of 1.3 × 108 RFU mg−1 protein at N/P 10 with cell via-
bility of ∼60% (Fig. 3D). Increasing N/P ratio to 20 led to
significant cytotoxicity, as evidenced by cell viability <45%. At
N/P 30, both B10 and B11 achieved high transfection eﬃciency
(1.16 × 108 CFU mg−1 protein and 2.2 × 108 CFU mg−1 protein,
respectively, comparable to that induced by unmodified BPEI),
while exhibiting lower cytotoxicity (cell viability was ∼65%), in
contrast to BPEI/DNA complexes. At N/P 20, B6 exhibited a
10-time higher luciferase transfection eﬃciency than unmodi-
fied BPEI (1.5 × 109 RFU mg−1 protein vs. 2.6 × 108 RFU mg−1
protein, respectively) and tremendously lower cytotoxicity
(∼76% cell viability vs. 5% for unmodified BPEI). B9 displayed
a lower transfection eﬃciency than B6, evidencing that the
incorporation of a higher number of hydroxyl groups led to
Fig. 3 (A) Particle size and (B) zeta potential of polymer/DNA complexes at various N/P ratios. (C) Viability of HEK293 cells after incubation for 4 h
with polymer/DNA complexes at various N/P ratios in comparison to BPEI/DNA complexes. Results represent mean ± standard deviation of 6 repli-
cates. Polymer concentrations in the order of N/P ratios speciﬁed: B6 – 3.1, 6.3, 9.4, 12.5, 18.8, 25.1, and 31.4 mg L−1. B9 – 3.8, 7.6, 11.4, 15.2, 22.9,
30.5, and 38.1 mg L−1. B10 – 4.3, 8.7, 13.0, 17.4, 26.0, 34.7, and 43.4 mg L−1. B11 – 4.3, 8.5, 12.8, 17.0, 25.5, 34.0, and 42.5 mg L−1. BPEI – 2.9, 5.7,
8.6, 11.5, 17.2, 22.9, and 28.6 mg L−1. (D) In vitro luciferase expression levels in HEK293 cells, mediated by polymers at various N/P ratios. Results rep-
resent mean ± standard deviation of triplicates. Polymer concentrations in the order of N/P ratios speciﬁed: B6 – 0, 3.1, 6.3, 9.4, 12.5, 18.8, 25.1, and
31.4 mg L−1. B9 – 0, 3.8, 7.6, 11.4, 15.2, 22.9, 30.5, and 38.1 mg L−1. B10 – 0, 4.3, 8.7, 13.0, 17.4, 26.0, 34.7, and 43.4 mg L−1. B11 – 0, 4.3, 8.5, 12.8,
17.0, 25.5, 34.0, and 42.5 mg L−1. BPEI – 0, 2.9, 5.7, 8.6, 11.5, 17.2, 22.9, and 28.6 mg L−1.
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lower surface charge (Fig. 3B) and transfection eﬃciency of
polymer/DNA complexes. Overall, owing to the lower cyto-
toxicity of modified BPEIs, higher N/P ratios could be used,
leading, in the case of B6, to a 10-fold increase in gene trans-
fection eﬃciency, as compared to non-functionalized BPEI.
Conclusion
Poly(ethylene imine) (PEI) is one of the most widely used poly-
meric transfection vectors. Although PEI allows for an extre-
mely high transfection eﬃciency, its cytotoxicity is still a major
issue in the context of biomedical applications. Here, commer-
cially-available poly(ethylene imine) was modified by the
attachment of hydroxyl groups through hemiaminal chemistry
or via ring opening of glycidol or of sugar-containing epoxides.
The initial stoichiometry of paraformaldehyde (pF) vs. PEI had
a tremendous impact on the composition of the product: at
low pF concentrations, hemiaminal decorated-PEI was formed,
while partially N-methylated polymers due to an Eschweiler–
Clarke-type rearrangement, and/or crosslinked materials were
obtained when using higher amounts of pF. Primary amines
present in BPEI were found to readily ring-open glycidol and
epoxides modified through a one-step procedure with
mannose and galactose, allowing for the easy decoration of
PEI with vicinal diols and sugar moieties. Hemiaminal functio-
nalized PEI exhibited limited stability in acidic conditions,
leading to toxicity similar to the parent PEI unless
N-methylation of the backbone was induced. In contrast,
attachment of glycidol or sugar groups allowed mitigating toxi-
city with minimal loss in eﬃcacy, with only 9% amine
functionalization in the case of sugars. The most promising
candidate for gene delivery applications was obtained by react-
ing 0.15 equiv. of glycidol with BPEI, which led to a 10-fold
increase in luciferase expression level as compared to unmodi-
fied BPEI, while maintaining a cell survival higher than 65%.
Experimental
Materials
Paraformaldehyde, n-propylamine, dipropylamine, glycidol,
epichlorohydrin, 2,3:5,6-di-O-isopropylidene-α-D-mannofura-
nose, 1,2:3,4-di-O-isopropylidene-α-D-galactopyra-nose, and
sodium hydride were purchased from Sigma Aldrich. d6-DMSO
was obtained from Cambridge Isotope Labs (CIO). LPEI (MW
25 000 g mol−1) was obtained from Polysciences and BPEI
(MW 10 000 g mol−1) was purchased from Sigma Aldrich
(USA). All reagents were used as received unless otherwise
noted.
General methods and instrumentation
Proton (1H) nuclear magnetic resonance (NMR) and carbon
(13C) NMR spectra were acquired at room temperature using a
Bruker AC 400 MHz or a Bruker AC 300 MHz spectrometer
(100 MHz 13C); chemical shifts (δ) are expressed in parts per
million relative to TMS. 1H NMR measurements were carried
out with an acquisition time of 3.2 s, a pulse repetition time of
2.0 s, a 30° pulse width, 5208 Hz spectral width, and 32k data
points.
Model reactions
The model reactions were performed in a 3 mol% solution of
n-propylamine (20.0 µL) or dipropylamine (20.0 µL) with 0.5
equiv. paraformaldehyde (3.6 mg and 2.2 mg respectively, pF)
in d6-DMSO (0.7 mL) at 90 °C for 2 h. The reaction mixtures
were then analyzed by 1H NMR (see Fig. S2†).
pF-Propylamine. 0.5 equiv. formaldehyde, 1H NMR
(400 MHz, d6-DMSO): δ 3.80–2.70 (–NH2 (precursor), –NR2–CH2–
NR2–, pF fragments), 2.48 (–CH2–NH2), 2.30 (–CH2–NR2), 1.35
(CH3–CH2), 0.85 (CH3–CH2) ppm.
pF-Dipropylamine. 0.5 equiv. formaldehyde, 1H NMR
(400 MHz, d6-DMSO): δ 3.60–3.10 (CH2–NH–CH2, pF frag-
ments), 2.95 (–NR2–CH2–OH), 2.43 (–CH2–NHR), 2.38
(CH2–NR–CH2OH), 1.38 (CH3–CH2), 0.84 (CH3–CH2) ppm.
Modification of linear poly(ethylene imine) with formaldehyde
(L1 to L5)
Commercial LPEI (1.00 g, 25 kDa, PolySciences) was reacted
with varying equivalents of paraformaldehyde (from 0.094 g to
0.742 g, 0.50 to 1.20 equivalents) in deionized water (Vtotal =
30 mL, 3.3 wt%). The reaction mixture was heated to 90 °C in
an oil bath. After 15 hours, the water was removed under
reduced pressure and the residue dissolved in methanol (ca.
10.0 mL). Subsequently, the mixture was precipitated two
times into 250 mL ice-cold diethyl ether. The functionalized
LPEI was filtered oﬀ and washed with 50.0 mL diethyl ether.
The residue was dissolved in 10 mL water and freeze-dried
(yield: 70 to 85%).
LPEI: 1H NMR (400 MHz, D2O): δ 3.46–3.28 (NH–CH2–CH2),
3.00–2.60 (NH–CH2), 2.35 (CH2 EtOx), 0.99 (CH3 EtOx) ppm;
13C NMR (100 MHz, D2O): δ 148.5 (CO–CH2–CH3), 47.1 (NH–
CH2–CH2), 25.1 (CH2–CH3), 9.8 (CH2–CH3) ppm.
L2: 0.3 equiv. formaldehyde, 1H NMR (400 MHz, D2O): δ
8.32, 7.92, 3.33 (Hem: NR2–CH2–OH), 2.72 (RNHem–CH2–CH2),
2.67, 2.57 (RNH–CH2–CH2), 2.32 (CH2 EtOx), 0.95 (CH3 EtOx)
ppm; 13C NMR (100 MHz, D2O): δ 75.4 (Hem: NR2–CH2–OH),
53.7–52.9 (RNH–CH2–CH2), 51.7 (RNHem–CH2–CH2), 47.1–46.6
(RNH–CH2–CH2), 26.1 (CH2–CH3), 9.0 (CH2–CH3) ppm.
L4: 0.75 equiv. formaldehyde, 1H NMR (400 MHz, D2O): δ
4.74, 3.33 (Hem: NR2–CH2–OH), 2.71 (RNHem–CH2–CH2), 2.57
(RNH–CH2–CH2), 2.46 (RN(CH3)–CH2–CH2), 2.30 (CH2 EtOx),
2.15, 2.12 (NR2–CH3), 0.95 (CH3 EtOx) ppm;
13C NMR
(100 MHz, D2O): δ 75.3 (Hem: NR2–CH2–OH), 53.7 (RN(CH3)–
CH2–CH2), 53.2 (RNH–CH2–CH2), 51.8 (RNHem–CH2–CH2), 41.6
(NR2–CH3), 26.1 (CH2–CH3), 9.1 (CH2–CH3) ppm.
Modification of branched poly(ethylene imine) with
formaldehyde (B1 to B4)
The formaldehyde functionalization of commercial BPEI was
performed analog to LPEI functionalization. Therefore, BPEI
(1.50 g, 10 kDa, Sigma Aldrich) was reacted with varying
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equivalents of paraformaldehyde (from 0.570 g to 0.843 g, 0.05
to 0.50 equiv.) in deionized water (Vtotal = 30 mL, 5 wt%). The
reaction mixture was heated to 90 °C in an oil bath. After
15 hours, the water was removed under reduced pressure and
the residue dissolved in methanol (ca. 10 mL). Subsequently,
the mixture was precipitated two times into 250 mL ice-cold
diethyl ether. The functionalized BPEI was filtered oﬀ and
washed with 50 mL diethyl ether. The residue was dissolved in
10 mL warm water and freeze-dried. For higher functionali-
zation degrees, gelation occurred. For these samples, the
swollen gel was washed with 50 mL water, and, subsequently,
freeze-dried (yield: 75 to 90%).
BPEI: 1H NMR (400 MHz, MeOD): δ 2.81–2.54 (BPEI back-
bone) ppm, 13C NMR (100 MHz, MeOD): δ 56.1, 53.1, 51.0,
50.7, 47.6, 45.5, 39.8, 37.7 (BPEI backbone) ppm.
B2: 0.15 equiv. formaldehyde, 1H NMR (400 MHz, MeOD): δ
3.41–3.27 (NR2–CH2–OH, NR2–CH2–NR2), 2.84, 2.70 (RNHem–
CH2–CH2), 2.80–2.30 (BPEI backbone) ppm;
13C NMR
(100 MHz, MeOD): δ 76.2 (NR2–CH2–NR2), 69.5 (NR2–CH2–
OH), 51.8 (NR2–CH2–CH2, RNHem–CH2–CH2), 43.8 (NR2–CH2–
CH2, RNHem–CH2–CH2), 56.0, 53.0, 51.1, 48.1, 46.9, 40.2, 38.92
(BPEI backbone) ppm.
B4: 0.5 equiv. formaldehyde, 1H NMR (400 MHz, MeOD): δ
3.77–3.39 (NR2–CH2–OH; NR2–CH2–NR2), 3.10–2.90 (RNHem–
CH2–CH2), 2.86–2.63 (BPEI backbone), 2.59 (RN(CH3)–CH2–
CH2), 2.35 (NR2–CH3), 1.33 ppm;
13C NMR (100 MHz, MeOD):
δ 76.1 (NR2–CH2–NR2), 69.4 (NR2–CH2–OH), 55.6 (RN(CH3)–
CH2–CH2), 51.7 (NR2–CH2–CH2, RNHem–CH2–CH2), 44.2 (NR2–
CH3), 43.6 (NR2–CH2–CH2, RNHem–CH2–CH2), 55.4, 52.7, 52.2,
51.7, 46.3 (BPEI backbone) ppm.
Modification of linear poly(ethylene imine) with glycidol
(L6 to L10)
Commercial LPEI (1.0 g, 25k Da, PolySciences) was reacted
with varying equivalents of glycidol (from 240 µL to 1.89 mL)
in methanol (Vtotal = 20.0 mL, 5 wt%) according to literature.
43
The reaction mixture was stirred at room temperature for
20 hours. Subsequently, the mixture was concentrated under
reduced pressure (to 10.0 mL) and precipitated two times into
250 mL of ice-cold diethyl ether. The functionalized LPEI was
filtered oﬀ and washed with 50.0 mL diethyl ether. The
residue was dissolved in 10 mL water and freeze-dried (yield:
80–90%).
LPEI: 1H NMR (400 MHz, MeOD): δ 3.57–3.40, 2.97–2.71
(NH–CH2–CH2), 2.48 (CH2 EtOx), 1.15 (CH3 EtOx) ppm;
13C
NMR (100 MHz, MeOD): δ 48.2, 46.8 (NH–CH2–CH2), 25.7
(CH2–CH3), 8.7 (CH2–CH3) ppm.
L8: 0.5 equiv. glycidol, 1H NMR (400 MHz, MeOD):
δ 3.97–3.71 (RCH2–CHOH–CH2–OH), 3.64–3.42 (RCH2–CHOH–
CH2–OH), 2.96–2.65 (RNH–CH2–CH2), 2.65–2.50 (RNGly–CH2–
CH2), 2.47 (CH2 EtOx), 1.15 (CH3 EtOx) ppm;
13C NMR
(100 MHz, MeOD): δ 73.8, 72.6 (RCH2–CHOH–CH2–OH), 70.9,
69.9 (CH2–CHOH–CH2), 64.4, 63.0 (RCH2–CHOH–CH2–OH),
57.4, 53.9, 52.7 (RNGly–CH2–CH2), 48.5–46.3 (RNH–CH2–CH2),
25.8 (CH2–CH3), 8.8 (CH2–CH3) ppm.
Modification of branched poly(ethylene imine) with glycidol
(B5 to B9)
The glycidol functionalization of commercial BPEI was per-
formed analog to LPEI functionalization. Therefore, BPEI
(1.00 g, 10 kDa, Sigma Aldrich) was reacted with varying
equivalents of glycidol (from 90.0 µL to 1.25 mL) in methanol
(Vtotal = 20.0 mL, 5 wt%) according to literature.
43 The reaction
mixture was stirred at room temperature for 20 hours.
Subsequently, the mixture was concentrated under reduced
pressure (to 10 mL) and precipitated two times into 250 mL
ice-cold diethyl ether. The functionalized BPEI was filtered oﬀ
and washed with 50 mL diethyl ether. The residue was dis-
solved in 10.0 mL water and freeze-dried (yield: 70–90%).
BPEI: 1H NMR (400 MHz, MeOD): δ 2.81–2.54 (BPEI back-
bone) ppm, 13C NMR (100 MHz, D2O): δ 56.1, 53.1, 51.0, 50.7,
47.6, 45.5, 39.8, 37.7 (BPEI backbone) ppm.
B7: 0.3 equiv. glycidol, 1H NMR (400 MHz, MeOD):
δ 3.96–3.70 (CH2–CHOH–CH2–OH), 3.63–3.44 (RCH2–CHOH–
CH2–OH), 2.88–2.44 (BPEI backbone, RNGly–CH2–CH2) ppm;
13C NMR (100 MHz, MeOD): δ 73.9, 72.6 (RCH2–CHOH–CH2–
OH), 71.4–68.4 (CH2–CHOH–CH2), 64.6, 63.1 (RCH2–CHOH–
CH2–OH), 54.7–51.2, 49.1–46.3, 40.5, 38.8 (BPEI backbone,
RNGly–CH2–CH2) ppm.
Modification of branched poly(ethylene imine) with
sugar-functionalized epoxides (B10, B11)
1,2:3,4-Di-O-isopropylidene-α-D-galactopyranose glycidyl
ether. 6.14 g 1,2:3,4-Di-O-isopropylidene-α-D-galactopyranose
(23.59 mmol) and 1.88 mL epichlorohydrin (24.1 mmol, 1.02
equiv.) were dissolved in 60 mL dry THF in a 250 mL round
bottom flask. 1.13 g NaH (60 wt% dispersion in mineral oil,
28.3 mmol, 1.20 equiv.) was next added at 0 °C. The mixture
was stirred at room temperature for 1 h and refluxed overnight.
The reaction was cooled down and quenched with excess
MeOH and H2O. The solvent was evaporated and the crude
product redissolved in EtOAc (150 mL) and washed with water
(100 mL) twice. Purification by column chromatography
(silica, 4 : 1 CH2Cl2/EtOAc) provided the desired product as a
colorless oil (yield: 43%).
1H NMR (400 MHz, CDCl3): δ 5.47 (m, 1H, CHringGal), 4.54
(m, 1H, CHringGal), 4.25 (m, 1H, CHringGal), 4.19 (t, 1H,
CHringGal), 3.92 (t, 1H, CHringGal), 3.82–3.32 (m, 4H, –CH2–O–
CH2–), 3.11 (m, 1H, CHepoxide), 2.73 (t, 1H, CH2epoxide), 2.55 (m,
1H, CH2epoxide), 1.48 (s, 3H, CH3), 1.38 (s, 3H, CH3), 1.26 (s, 6H,
CH3) ppm.
isoB10: 1,2:3,4-Di-O-isopropylidene-α-D-galactopyranose gly-
cidyl ether (0.30 g, 0.94 mmol, 25 equiv.) and BPEI (0.38 g,
10 kDa, Sigma Aldrich) were stirred in MeOH (3 mL) at room
temperature for three days. A 0.2 mL aliquot was dialyzed vs.
MeOH for quantification of the attached amount of sugar
(three MeOH changes, MWCO: 1000 g mol−1) by 1H NMR (see
Fig. S5,† 20 galactose moieties attached). To the rest of the
reaction mixture were added 9 mL H2O, 7 mL MeOH and 1 mL
37% HCl (final HCl concentration: 0.5 M). Hydrolysis of the
isopropylidene groups was carried out for 2 h at reflux. The
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reaction mixture was cooled down to room temperature and
dialyzed vs. H2O (three H2O changes, MWCO: 1000 g mol
−1)
and finally lyophilized (see Fig. S5† for 1H NMR spectrum
attesting of the full hydrolysis).
1H NMR (400 MHz, CDCl3): δ 5.60–3.35 (isoGalBPEI),
3.35–2.10 (isoGalBPEI), 1.60–1.29 (isoGalBPEI) ppm.
2,3:5,6-Di-O-isopropylidene-α-D-mannofuranose glycidyl
ether. 2,3:5,6-Di-O-isopropylidene-α-D-mannofuranose glycidyl
ether was prepared using a similar procedure.
1H NMR (400 MHz, CDCl3): δ 5.05 (d, 1H, CHMan), 4.81 (t,
1H, CHMan), 4.66 (t, 1H, CHMan), 4.42 (m, 1H, CHMan), 4.13 (m,
1H, CHMan), 4.06 (m, 1H, CHMan), 3.99 (m, 1H, CHMan),
3.88–3.37 (m, 2H, –CH2–O–), 3.16 (br, 1H, CHepoxide), 2.83 (t,
1H, CH2epoxide), 2.65–2.60 (m, 1H, CH2epoxide), 1.47 (s, 3H,
CH3), 1.40 (s, 3H, CH3), 1.34 (s, 6H, CH3) ppm.
isoB11: Mannose-functionalized BPEI was prepared using a
similar procedure (see Fig. S6† for 1H NMR spectrum attesting
of the full hydrolysis).
0.09 equiv. mannose, 1H NMR (400 MHz, CDCl3):
δ 5.06–3.31 (isoManBPEI), 3.26–2.12 (isoManBPEI), 1.55–1.21
(isoManBPEI) ppm.
Preparation and characterization of polymer/DNA complexes
The polymer was dissolved in DNase/RNase-free water
(Fermentas, Singapore). Subsequently, an equivolume solution
of DNA (pCMV-luciferase, Carl Wheeler, Vival, San Diego, CA,
USA) was dripped into the polymer solution to achieve the
intended N/P ratios (molar ratio of nitrogen content in the
polymer to the phosphorus content of the nucleic acids) under
gentle vortexing for about 5 s. The resulting mixture solution
was equilibrated for 30 min at room temperature to allow com-
plete electrostatic interaction between the polymer and DNA.
The particle sizes and zeta potentials of the polymer/DNA
complexes were measured by Zetasizer (Malvern Instrument
Ltd, Worcestershire, UK). Immediately prior to the measure-
ment, the polymer/DNA complexes were diluted 10 times in
PBS to mimic the dilution in the physiological environment
after i.v. administration. Particle size and zeta potential
measurements were repeated for three runs per sample and
reported as the mean ± standard deviation of three readings.
Gel retardation assay
Polymer/DNA complexes were prepared as described above
with N/P ratios ranging from 1 to 50. 20 μL of the post equili-
brated complexes were used for electroporation on ethidium
bromide stained 1% agarose gel in 1× TBE buﬀer (Biopolis
Shared Facilities, A*STAR, Singapore) at 110 V for 50 min. The
gel was then viewed under a UV illuminator (Chemi Genius,
Evolve, Singapore), and the N/P ratio where complete binding
and retardation of the free DNA plasmid occurred were noted.
Cell culture
HEK293 cells (ATCC, USA) were cultured in Dulbecco’s
Modified Eagle Medium (DMEM, Invitrogen, Singapore). The
media were supplemented with 10% (v/v) fetal bovine serum
(FBS, Invitrogen, Singapore), streptomycin at 100 µg mL−1,
penicillin at 100 U mL−1, L-glutamine at 2 mM, and 1 mM
sodium pyruvate (Sigma-Aldrich, Singapore). Cells were cul-
tured at 37 °C, under an atmosphere of 5% CO2 and 95%
humidified air. Cells were split using Trypsin/EDTA medium
(Invitrogen, Singapore) when reached 90% confluence.
In vitro gene transfection eﬃciency
The in vitro gene transfection eﬃciency of the polymer/DNA
complexes was investigated using HEK293 cells. Cells were
seeded onto 24-well plates (Nunc, Thermo Fisher Scientific,
Singapore) at a density of 1 × 105 cells per 500 μL per well for
luciferase gene delivery. After 24 h, the plating media were
replaced with fresh growth media, followed by the drop-wise
addition of 50 μL of complex solution (containing 2.5 μg luci-
ferase plasmid DNA) at various N/P ratios. Following 4 h of
incubation, free complexes were removed by replacing the
medium in each well with fresh medium. After a further 68 h
of incubation, the cell culture medium in each well was
removed and the cells were rinsed once with 0.5 mL of phos-
phate-buﬀered saline (PBS, pH 7.4). Reporter lysis buﬀer
(0.2 mL) was added to each well. The cell lysate collected after
two cycles of freezing (−80 °C, 30 min) and thawing (room
temperature, 30 min) was cleared by centrifugation at 14 000
rpm for 5 min. After that, 20 μL of supernatant was mixed with
100 μL of luciferase substrate for the determination of relative
light units (RLU) using a luminometer (Lumat LB9507,
Berthold, Germany). The RLU readings were normalized
against the protein concentration of the supernatant deter-
mined using the Pierce™ BCA Protein Assay Kit (Thermo
Fisher Scientific, Singapore) to give the overall luciferase
expression eﬃciency. In all in vitro gene expression experi-
ments, naked DNA was used as a negative control. Data were
expressed as mean ± standard deviations of three replicates.
Cell viability
The cytotoxicity of the polymer/DNA complexes was studied
using the standard MTT assay protocol. Briefly, HEK293 cells
were seeded onto 96-well plates at a density of 10 000 cells per
well, and allowed to grow to 60 to 70% confluence before treat-
ment. After 24 h, the medium was replaced with fresh
medium. The cells in each well were subsequently incubated
with growth medium comprising of 10 μL of polymer/DNA
complexes and 100 μL of fresh medium for 4 h at 37 °C.
Following incubation, the medium was replaced with fresh
growth medium and incubated further for 68 h. Subsequently,
100 μL of growth medium and 20 μL of MTT solution (5 mg
mL−1 in PBS, Merck, Singapore) were added to each well and
the cells were incubated for 4 h at 37 °C. Formazan crystals
formed in each well were solubilized using 150 μL of DMSO
upon removal of growth media. A 100 μL aliquot from each
well was then transferred to a new 96-well plate for determi-
nation of absorbance using a microplate spectrophotometer at
wavelengths of 550 nm and 690 nm. Relative cell viability was
expressed as [(A550 − A690)sample/(A550 − A690)control] × 100%.
Data were expressed as mean ± standard deviations of eight
replicates per N/P ratio.
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methylation of LPEI (D2O, 400 MHz). 
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2Scheme S1. Mechanism for Eschweiler-Clarke rearrangement leading to the methylation of secondary amines.37,69
Figure S2. 1H NMR spectra (d6-DMSO, 400 MHz) of the reaction mixture of A) n-propylamine and 0.5 equiv. 
paraformaldehyde in d6-DMSO (0.7 mL) after stirring at 90 °C for 2 h, and, B) dipropylamine and 0.5 equiv. 
paraformaldehyde in d6-DMSO (0.7 mL) after stirring at 90 °C for 2 h.
3Figure S3. 1H NMR spectra of (A) linear (L6-L10) and (B) branched PEI, modified with varying contents of 
glycidol (B5-B9) (D2O, 400 MHz).
4Figure S4. Diffusion ordered NMR spectra (MeOD, 400 MHz, 25 °C) of (A) LPEI and corresponding glycidol-
functionalized L8 (0.5 equiv. glycidol vs. -NH), and, (B) BPEI and corresponding glycidol-functionalized species B7 
(0.3 equiv. glycidol per amine functionality, including primary, secondary and tertiary amine groups).
Figure S5. 1H NMR spectra of A) a dialyzed aliquot of isoB10 (CDCl3, 400 MHz), and, B) the dialyzed aliquot of 
B10 after hydrolysis (D2O, 400 MHz).
5Figure S6. 1H NMR spectra of A) a dialyzed aliquot of isoB11 (CDCl3, 400 MHz), and, B) the dialyzed aliquot of 
B11 after hydrolysis (D2O, 400 MHz).
6Figure S7. Cytotoxicity of formaldehyde functionalized A) LPEI (L1-L5) and B) BPEI (B1-B3) by MTT assay on 
HEK 293 cells.
7B6 (0.15 equiv. glycidol)
B9 (0.75 equiv. glycidol)
B10 (0.09 equiv. galactose)
DNA ladder     0              1             2              5             8              10          20            30           40           50
DNA ladder     0              1             2              5             8            10         20          30           40           50
8B11 (0.09 equiv. mannose)
BPEI
DNA ladder     0              1             2              5               8              10           20             30             40            50
DNA ladder     0              1             2              5               8            10           20           30            40           50
9Figure S8. Electrophoretic mobility of DNA in polymer/DNA complexes.
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Microwave-Assisted Polymer Modiﬁcations
Christoph Englert, Almut M. Schwenke, Stephanie Hoeppener,
Christine Weber, and Ulrich S. Schubert
Abstract Modern microwave synthesizers allow a detailed adjustment and control
of temperature and power, such that many polymer modiﬁcation reactions are
performed nowadays using established synthesis protocols. This chapter provides
a broad overview of post-polymerization modiﬁcation reactions where these advan-
tages are exploited for functionalization of synthetic and natural polymers. Selected
examples are discussed in detail to demonstrate the versatility of the technique but
also to address the challenges of screening approaches often applied to identify the
optimum reaction conditions. While microwave synthesizers are regarded as efﬁ-
cient heating devices in the ﬁeld of synthetic chemistry, selective heating of,
for example, conjugated polymers has opened non-standard opportunities for the
development of novel nanomaterials.
Keywords Carbon nanomaterials • Microwave-assisted synthesis • Poly(ethylene
imine) • Polymer modiﬁcation • Polysaccharide • Post-polymerization modiﬁcation
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1 Introduction
Nature provides a vast and cheap amount of resources for polymer science. Natu-
rally occurring polymers, i.e., biopolymers such as cellulose are readily available in
large quantities and represent raw materials for many applications, in packaging,
paper, or textile industry. However, the properties of these natural precursors often
have to be tailored to make them suitable for specialized applications. Polymer
modiﬁcation reactions are ideally suited for this purpose. A major part of this
chapter covers the microwave-assisted functionalization of polysaccharides. Func-
tional moieties in synthetic polymers are often introduced by polymerization with
functional monomers, initiators, or direct end-capping reagents. For such
microwave-assisted polymerizations, the reader is referred to the respective chap-
ters in this book [1–5]. Besides, microwave-assisted approaches also have been
used for post-polymerization modiﬁcation of synthetic polymers, which is the focus
in this chapter.
From the perspective of material sciences, microwave irradiation is used for two
kinds of polymer modiﬁcations. On the one hand, the morphology of solid polymers
and their blends can be affected, as has been reported for both natural [6–8] and
synthetic [9–13] polymers. Furthermore, polymer solutions and solid polymer
structures can be treated with microwave irradiation, to obtain solid carbon mate-
rials. The latter is discussed at the beginning of this chapter. Subsequently, the
chemical functionalization of natural and synthetic polymers via microwave-
assisted approaches is summarized.
2 Microwave-Assisted Formation of Carbon Materials
from Polymeric Precursors
The microwave-assisted heating of solutions containing a polymer can not only be
used to introduce functionalities but can also induce reactions that result in the
formation of carbon materials. Such processes are often accompanied by a color
change to yellowish-brown as a result of the formation of carbon nanoparticles. The
so-called carbon dots (C-dots), which often possess ﬂuorescent properties, are
highly useful for applications, for example as optical-imaging agents for life-
science applications. Various carbonaceous precursors are reported to yield such
C-dots in straightforward and rapid one-step synthesis protocols. For example a
triblock copolymer composed of a poly(propylene oxide) central block and two
poly(ethylene oxide) blocks (PEO-PPO-PEO) was irradiated in the presence of
phosphoric acid for only 4 min, resulting in carbon particles with diameters of
5–20 nm [14]. By applying a microwave-assisted hydrothermal process (180 C for
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20 min), aqueous solutions of natural resources such as ﬂour yielded C-dots with
diameters ranging from 1 to 4 nm [15]. Although the detailed mechanism remains
unclear to date, the proposed pathway of the formation of C-dots from
carbohydrate-based materials includes the decomposition of the precursor via
hydrolysis and dehydration. The soluble compounds obtained are believed to
polymerize via polycondensation reactions to yield different soluble polymeric
products. Finally, the C-dots would be formed by subsequent aromatization and
carbonization [16].
The synthesis of C-dots doped with hetero atoms can be accomplished by
utilization of nitrogen or phosphorus-containing precursors. Therefore, precursor
polymers were synthesized from a mixture of glucose and amino acids in a
microwave-assisted synthesis via the Maillard reaction. Subsequently, an open
vessel microwave treatment for 5 min at 275 C resulted in the formation of
nitrogen-doped C-dots with tunable multicolor luminescence (Fig. 1) [17]. The
irradiation of a tannin–melamine–hexamine polymer in the presence of
polyphosphoric acid yielded nitrogen and phosphorus co-doped mesoporous car-
bon. Spherical structures were obtained after 10–30 min of irradiation [18].
Chains of graphitic carbon particles in the range from 340 to 620 nm were
obtained from poly(ethylene glycol) by microwave-assisted heating in a hydrother-
mal setup (mixture of ethanol, water, and sodium hydroxide) [19]. After a
prolonged irradiation (2 h at 220 C), as well ﬁbrous carbon structures were
obtained.
When polymer structures are heated by microwave irradiation in the solid state,
even the transformation of the polymer backbone into a more or less pure carbon
material can be achieved. Because microwave radiation provides direct heating of
the reactants and strongly interacts with speciﬁc types of materials, carbonization
can occur within a short irradiation period of just a few minutes [20]. In particular,
exceptional fast heating is observed when conductive polymer structures are irradi-
ated, which efﬁciently absorb the microwave irradiation. Zhang and co-workers
[21, 22] prepared nanostructured chlorine-doped polypyrrole precursors of different
shapes including ﬁbers, tubes, and spherical particles (Fig. 2). The structures were
Fig. 1 Synthesis scheme and TEM image of nitrogen-doped C-dots with tunable emission color
[17]. Reprinted with permission of Macmillan Publishers Ltd: Scientiﬁc Reports 2014, 4, 3564,
copyright 2014
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carbonized within 3–5 min when subjected to microwave radiation. Thereby, a
weight loss of 50% occurred, and the carbon content of the material was increased
from 56% to more than 90%. Despite being performed under non-inert conditions,
no oxidation of the backbone took place, which is most likely prevented because of
the very rapid heating and carbonization process. The morphology of the
nanostructures was retained even though a slight shrinkage occurred.
Structures composed of non-conducting polymers can be as well carbonized by
microwave irradiation although longer heating times are required. For example,
poly(acrylonitrile) ﬁbers were graphitized by a microwave plasma process in an
argon atmosphere [23]. Biowaste materials such as cotton, wood, or ﬁlter paper
could also be graphitized when polypyrrole was added as ﬁller material to increase
the heating efﬁciency. The morphology and porosity of the biowaste precursors was
retained, but the materials exhibited a graphitic structure after the microwave-
assisted treatment [24].
Additionally, graphitic materials with high crystallinity were prepared by
microwave-supported heating and can be exfoliated into graphene in a two-step
microwave protocol [25]. First, metal phthalocyanine was synthesized, which was
carbonized at 450 C in a second step. Direct quenching with a mixture of water and
ice or with liquid nitrogen resulted in the exfoliation to graphene with typically one
to eight layers [25].
Fig. 2 Microwave-assisted synthesis of nanostructured carbon from doped polypyrrole structures.
SEM and TEM images before (a–c) and after (a’–c’) heating. Scale: 100 nm. Reproduced from
[22] with permission of The Royal Society of Chemistry
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3 Microwave-Assisted Modiﬁcation of Polysaccharides
The manifold functional biopolymer moieties that nature has been developing over
millions of years represent a rich pool of which synthetic chemists can take
advantage. Microwave irradiation has been exploited for the functionalization of
these raw materials since the 1980s. However, some of these functional moieties
and their stereochemistry are exactly the reason that make natural polymers often
difﬁcult to dissolve in common solvents because of the presence of strong inter- or
intramolecular hydrogen bonds. Because solubility represents a prerequisite for
homogeneous functionalization reactions, the development of optimum reaction
conditions is often challenging and requires harsh conditions or very aggressive
solvents such as concentrated acids. The main advantages of the application of
microwave irradiation in this respect are the high temperatures that can be applied
(along with the opportunity to heat above the boiling point of the solvent in closed
reaction vessels) and the very efﬁcient heating of special solvents such as ionic
liquids. However, the dissolution of barely soluble materials under rather drastic
conditions can still be accompanied by a degradation of the polymeric materials, a
fact that has been exploited for the tailored synthesis of polysaccharides with lower
degrees of polymerization.
3.1 Dissolution and Degradation
Starch consists of mainly two polysaccharide fractions. Although amylose is a
linear polymer where the α-D-glucose monomers are linked 1,4-glycosidically,
additional 1,6-glycosidic linkages result in a branched structure and higher molar
mass of the second component amylopectin (Scheme 1). Because starch is a natural
product, its composition is prone to variation depending on the resource from which
it was isolated. A large amount of different starches could be dissolved in dimethyl-
sulfoxide (DMSO) without degradation using microwave irradiation [26]. At a
constant power of 900 W, a few seconds of heating time were sufﬁcient to dissolve
the entire starch samples without noticeable degradation in most cases (35 s,
maximum temperature 143 C). On the other hand, microwave reactors can be
used to tailor the degradation of starch during acidic hydrolysis. In a semi-dry
process, the molar mass of granular starch was efﬁciently reduced in less than 2 min
[27]. In particular, the amylopectin fraction was affected, and the ﬁnal degree of
polymerization (DP) could be tuned by the reaction temperature (60–85 C) and the
amount of hydrochloric acid catalyst. Higher reaction temperatures (up to 100 C)
resulted in the formation of dextrins, i.e., poly(α-D-glucose)s with much lower
molar masses.
Because cellulose consists of β-D-glucose repeating units linked
1,4-glycosidically, strong hydrogen bonds are present that ultimately lead to its
ﬁbrous structure but make its dissolution extremely difﬁcult. Applying ionic liquids
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in a screening approach using varying microwave settings proved suitable to
dissolve up to 10 wt% of cellulose. Thereby, the DP was decreased by roughly a
third in some cases [28]. Because the N-acetyl-β-D-glucopyramin repeating units of
chitin are linked in a similar fashion, its solubilization is also challenging [29]. As
for cellulose, the combination of ionic liquids and microwave-assisted heating is
helpful to overcome the tight hydrogen bonds of this polysaccharide. Hence, it is
possible to prepare 20 wt% solutions [30]. Chitosan, i.e., partially deacetylated
chitin, represents one of the few cationic polymers directly available from natural
resources [31]. However, its solubility in water (which is often required for appli-
cations or further functionalization under mild conditions) is limited to polymers
with a low DP [32]. Such oligomeric chitosans are obtained via degradation of high
molar mass polymers using different methods. A mild treatment with hydrogen
peroxide under microwave irradiation is highly reproducible and prevents the
occurrence of undesired side reactions [33]. Appropriate adjustment of the reaction
conditions even enables the tailoring of the DP of the oligomers [34].
Similarly, microwave-supported treatment has been reported for the preparation
of sulfonated polysaccharides based on galactose with deﬁned molar masses.
Factors such as pH value, adjustment of microwave power, or heating time were
varied to obtain both λ- and κ-carrageenan oligomers [35, 36].
3.2 Modification of Polysaccharide Hydroxyl Groups
All polysaccharides possess multiple hydroxyl functionalities, which can be used to
modify the polymers’ nature. Scheme 2 outlines the synthetic possibilities that have
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Scheme 1 Schematic representation of the structure of selected polysaccharides. The dashed
blue lines represent the hydrogen bonds that complicate the dissolution of polymers based on
β-D-glucopyranose
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been exploited using microwave-assisted synthetic approaches, which are summa-
rized in the following section.
Among these, the most well-known strategy is the esteriﬁcation of the –OH
moieties. Similar to protocols utilizing traditional heating, common microwave-
assisted approaches include enzymatically catalyzed esteriﬁcation using simple
carboxylic acids, acid chlorides, and the use of anhydrides with or without addi-
tional catalyst. Table 1 provides an overview of selected microwave-assisted
Scheme 2 Schematic representation of microwave-assisted modiﬁcations of polysaccharides by
utilization of hydroxyl functionalities. It should be noted that the polysaccharide structure is
exemplary and varies as described in the text
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synthesis conditions and the degrees of substitution (DS) that could be achieved,
although a direct comparison is difﬁcult because of the various types of microwave
synthesizers that were applied in different modes. Despite the versatility modern
(automatized) microwave synthesizers offer and the unique possibilities to design
experiments design of experiments [40] with respect to the optimization of reaction
Table 1 Esteriﬁcation of polysaccharides using microwave-assisted chemistry
Poly-
saccharide Method Product Conditions DS References
Starch Carboxylic
acid/lipase
Acetate DMF/DMSO 0.03–
0.51
[37]
Laurate 80/160 mW g1a
Stearate 60/120 min
Starch Carboxylic
acid/lipase
Acetate DMF/DMSO 0.01–
0.43
[37]
Laurate 25/80C
Stearate 120/300 min
Starch Anhydride Acetate NaOH/NaOAc 0.37 [38]
Succinate 260–1,300 W
1–5 min
Starch Anhydride
Carboxylic
acid
Acetate Max. 650 W 0.19–
0.78
[39]
150C, 4–7 min
Variable deﬁned tempera-
ture programs
Starch Anhydride
Carboxylic
acid
Acetate I2 catalysis 0.02–
1.27
[40]
100 W, 100C
2–10 min
Konjac Anhydride Succinate 600 W 0.17–
0.24
[38]
100 s
Cellulose Anhydride Acetate Ionic liquid 1.5–
2.9
[41]
Propanoate 30 W
Butyrate 80C
Pentanoate 8–12 h
Hexanoate
Cellulose Anhydride Acetate 0.01–0.15 equiv. I2 0.48–
2.8
[42]
300–800 W, 80–130C,
5–45 min
Pectin Anhydride Linolate 0.1 equiv. K2CO3 N/A [43]
Oleate 900 W
Palmitate 3–6 min
Carboxy-
methyl
Anhydride Octenyl-
succinate
DMSO, 0.1 equiv. pTosOH 0.05–
0.55
[44]
1–5 min, 140 W
starch 90–160C
Hemi-
cellulose
Acid Propionate DMF, 0.05 equiv. NBS 0.67–
1.28
[45]
chloride Octanoate 300 W, 78C,
Laurate 5 min
Oleate
Hemi-
cellulose
Acid Laurate DMF, LiCl, TEA,
various catalysts
0.77–
1.64
[46]
chloride
300 W, 78C, 1–8 min
aWith reference to the amount of sample
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conditions, these opportunities should not replace critical thinking. It must be noted
that the applied reaction conditions sometimes impose a strong inﬂuence on the
materials obtained. Short reaction times are often reported at the expenses of high
DS. Nevertheless, the efﬁciency of a careful adjustment of the reaction conditions
in the microwave synthesizer was demonstrated by Possidonio et al., who could
achieve very high and tailored DS values by reacting cellulose with a range of
anhydrides in ionic liquids under microwave irradiation with negligible degradation
of the polysaccharide [41].
Because of the manifold esters that can be obtained (ranging from acetates to
fatty acid esters), this method offers access to polymers from renewable resources
featuring a variety of properties. Besides the adjustment of hydrophobicity and the
resulting variation of mechanical properties [47], the introduction of further func-
tional moieties such as double bonds derived from fatty acids [43] or carboxylic
acids has also been reported. The latter is easily possible in a one-step reaction by
conversion of the polysaccharide hydroxyl groups with a cyclic anhydride such as
succinic [38] or maleic [48] anhydride. Using appropriately designed anhydrides,
the combination of both has been reported simultaneously in a one-step synthesis
[44]. On the other hand, the selective esteriﬁcation of the hydroxyl moieties of
pectin, a polysaccharide which already contains carboxylic acid functionalities, has
also been reported [43].
Carboxymethylation represents a common method to introduce carboxylic acid
functionalities to polysaccharides using chloracetic acid under alkaline conditions.
This reaction has been performed under microwave irradiation with several natural
polysaccharides, such as konjac [38], agarose [49], and hemicellulose [50]. In
comparison to conventional heating, similar DS values could be achieved, although
shorter reaction times were sufﬁcient during microwave-assisted syntheses.
The utilization of analogous reactants (Scheme 2) makes it possible to introduce
amine functionalities to polysaccharides via the hydroxyl groups already present.
For starch, microwave irradiation proved superior to conventional heating in both
reaction time and DS [38]. However, when the fraction of amines in chitosan was
increased, conventional heating resulted in much higher DS because of the evap-
oration of the solvent in the microwave reactor [38]. This problem would probably
be avoided by application of modern synthesizers which enable the use of closed
reaction vessels nowadays.
An alternative approach towards amino-functional agarose involves the conver-
sion of the agarose hydroxyl functionalities with phthalimide and subsequent
hydrazinolysis [51]. During both steps of the Gabriel-like synthesis, optimized
microwave-assisted procedures gave rise to DS of around 0.9. Activation of inulin
using bis(4-nitrophenyl) carbonate via microwave-assisted chemistry represents
another possibility to include amine moieties to a polysaccharide the basis of
which functional groups are alcohols [52].
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3.3 Modification of Chitosan Amine Moieties
The nucleophilicity of the primary amine functionalities of chitosan offers several
ways for polymer modiﬁcation (Scheme 3). However, in the case of unselective
reactants, the polysaccharide hydroxyl groups are prone to reaction as well. One
example is the application of phthalic anhydride, which was well investigated in
terms of microwave-assisted as well as conventional heating [53]. Optimized
reaction conditions in the microwave synthesizer (DMF, 500 W, 3 min) resulted
in a DS value of 1.4, almost without degradation of the chitosan. To achieve a
similar DS value by conventional heating, a reaction time of 5 h was necessary,
which caused signiﬁcant polymer degradation.
In contrast, the formation of Schiff’s bases is a possibility to functionalize
selectively the primary amine moieties of chitosan. If a reducing agent such as
sodium boron hydride is added in situ, the selective alkylation is possible via the
so-called reductive amination approach. This reaction has been studied by Petit
et al., who compared the alkylation yields achievable via microwave-assisted
synthesis in detail to conventional heating using octanal as an exemplary aldehyde
reactant [54]. As depicted in Fig. 3, the microwave setup proved superior in terms
Scheme 3 Schematic representation of the main strategies for microwave-assisted modiﬁcations
of chitosan amine moieties
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of alkylation yield, in particular when short reaction times were used. The rheo-
logical and surface active properties of the alkylated chitosan derivatives were
similar to those of materials prepared by conventional methods.
To obtain scavenger materials for lead and mercury ions, the Schiff’s base route
was applied to prepare crosslinked chitosan using a double aldehyde functional
crown ether via microwave irradiation (800W, 10 min) [55]. On the other hand, this
type of chemistry was reported useful to protect the amine functionalities of
chitosan prior to crosslinking with epichlorohydrin [56]. Subsequent deprotection
of the Schiff’s bases from benzaldehyde under acidic conditions yielded the amino
functionalities, which were then functionalized with EDTA via the anhydride
method. Microwave-assisted chemistry was exploited in all of these ﬁve synthetic
steps. A much simpler method to prepare crosslinked copper complexes from
chitosan involves the direct complexation of chitosan amine functions followed
by Schiff’s base formation using glutaraldehyde to include covalent junctions in the
network [57]. Both steps comprised the use of microwave synthesizers.
3.4 Modification of Carboxylic Acid Functional
Polysaccharides
Alginic acid represents a polysaccharide based on α-L-guluronic acid and
β-D-mannuronic acid that naturally contains carboxylic acid functionalities which
have been exploited for further modiﬁcation of the biopolymer. The deprotonated
alginate can be crosslinked by addition of calcium ions, a reaction which can also be
Fig. 3 Comparison of yields obtained for the synthesis of alkylchitosan using conventional
heating and microwave irradiation. Reprinted from Carbohydrate Polymers 116, C. Petit et al.,
Amphiphilic derivatives of chitosan using microwave irradiation: towards an eco-friendly process
to chitosan derivatives, 26–33, Copyright 2015, with permission from Elsevier [54]
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used for co-precipitation of proteins. The selectivity of this so-called afﬁnity
precipitation can be enhanced by pre-treatment of the native alginic acid [58]. In
addition, sodium alginate was successfully applied as a stabilizing agent during the
microwave-assisted synthesis of copper nanoparticles [59]. Besides the mere use of
the carboxylic acid moieties for the formation of salts, their existence provides the
opportunity for further chemical modiﬁcation by amidation using amines. Without
further activation of the carboxylic acid groups, DS between 0.5 and 1.0 could be
achieved after reaction with an excess of varying diamines at 100 C for 10 min
using 300 W microwave irradiation, even in aqueous media [60]. The resulting
amino-functional alginates were subsequently crosslinked using the natural ﬂuo-
rescent dye genipin. In a similar approach, the modiﬁed biopolymer
carboxymethylated cellulose (see above) was reacted with ethylene diamine and
subsequently crosslinked with alginic acid using the same reaction conditions
[61]. Interestingly, microwave irradiation (800 W, 1 min) alone has been reported
to be sufﬁcient to crosslink carboxymethylated starch via formation of anhydrides
because of dehydration during the heating process [62].
In an alternative approach, carboxymethylated cellulose was applied for
transesteriﬁcation of methyl esters derived from rapeseed oil via microwave-
assisted heating [63]. Although the DS values achievable were moderate
(DS< 0.1), the environmentally benign synthetic approach using a mixture of
water and DMF required only reaction times of a few minutes to produce efﬁcient
emulsiﬁers from almost entirely natural resources.
3.5 Grafted Polysaccharides
Singh and Sanghi have reviewed the microwave-assisted grafting of polysaccha-
rides in 2012 based on a distinction between the different types of polysaccharides
[64]. Hence, this topic is only brieﬂy discussed here from a viewpoint that distin-
guishes the type of grafting mechanism based on the functional groups present in
the polysaccharides and monomers used for the grafting (Scheme 4).
Because alcohols represent initiators for various ring-opening polymerizations
(ROP) of lactones to yield polyesters, polysaccharides with their multiple hydroxyl
groups seem to be ideal starting materials for grafting-from approaches. Microwave
irradiation is especially favorable because the standard catalyst for this type of
ROP, tin octoate, requires high reaction temperatures to promote the polymeriza-
tion of, for example, the quite robust monomer ε-caprolactone (CL). However, the
large difference in hydrophilicity between unmodiﬁed polysaccharides and the
hydrophobic CL and PCL gives rise to complications because of miscibility in
bulk polymerizations. Only when unmodiﬁed starch was swollen in water
microwave-induced polymerization of the monomer could be observed [38]. The
grafting of PCL from the more hydrophobic acetylated konjac was reported to be
more successful. In any case, water can initiate the ROP of CL as well, leading to
the formation of PCL homopolymers, which requires exhaustive puriﬁcation of the
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graft copolymers [65]. In addition, the exact determination of the composition of
the isolated products by spectroscopic means is difﬁcult, although the microwave-
assisted bulk synthesis and puriﬁcation of PCL grafted cellulose [65] and chitin [66]
whiskers was achieved successfully in general. The grafting of PCL from chitosan
is further complicated by the presence of amine functionalities, which have to be
protected prior to the ROP [67]. Phthalic anhydride has been used for this purpose,
although the subsequent deprotection via hydrazine can easily induce a degradation
of the grafted PCL chains.
The grafting of polymers from vinylic monomers onto or from polysaccharides
via microwave-assisted synthesis protocols is mainly performed using various
initiator systems able to generate radicals on the polysaccharide. In particular,
redox initiators and persulfates are utilized frequently. Hence, this represents a
free radical polymerization (FRP), further complicated by the fact that the radical
initiator systems are not only capable of creating active radical species on the
polysaccharides but can also simply initiate polymerization of the vinylic mono-
mers on their own [68]. This can be compensated to some extent by an addition of
monomer subsequent to an “activation step” in which only the polysaccharide and
the initiator are heated. It should be clearly stated that the combination of both FRP
and unselective initiation results in the formation of considerable amounts of
non-grafted synthetic polymer chains, which can be difﬁcult to remove from the
graft copolymer. However, optimization of microwave-assisted synthesis was suit-
able to reach high monomer conversions of acrylonitrile in very short reaction times
of a few minutes [69]. On the other hand, longer reaction times (2 h) were reported
to be more favorable as soon as the graft copolymers are puriﬁed and characterized
thoroughly, as shown for alginate-g-poly(vinylpyrrolidone) [70].
The homopolymer removal plays a minor role when the surfaces of polysaccha-
ride ﬁbers [71, 72] or other solid materials based on cellulose (pine needles) [73] are
Scheme 4 Schematic representation of microwave-assisted grafting modiﬁcations of polysaccha-
rides using ε-caprolactone (bottom) and FRP of vinylic monomers (top). It should be noted that the
polysaccharide structure is exemplary and varies as described in the text
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directly modiﬁed via such methods, because the separation of ungrafted polymer
chains can easily be accomplished in this case. Bifunctional vinylic monomers are
often added as crosslinkers, which results in the formation of hydrogels, i.e.,
insoluble materials that are again easy to purify [74–77].
4 Microwave-Assisted Modiﬁcation of Synthetic Polymers
Microwave-assisted approaches for the modiﬁcation of synthetic polymers com-
prise a wide ﬁeld, ranging from recycling of commodity polymers over the intro-
duction of functional moieties, which can be pendant or at the chain end groups, to
the functionalization of resins or surfaces. Hence, we ﬁrst provide an overview
about the general possibilities and approaches that can be and have been applied.
Subsequently, selected examples are discussed in more detail, in particular those
where extensive investigations on the microwave-assisted syntheses were made and
resulted in the establishment of optimized synthesis protocols.
4.1 General Approaches for the Microwave-Assisted
Modification of Synthetic Polymers
A wide range of reaction types have been performed under microwave irradiation,
ranging from “simple” modiﬁcations of commodity polymers to the precise adjust-
ment of functionalities in speciality polymers (see Table 2). One of the ﬁrst
modiﬁcations reported is the rapid surface oxidation of polyethylene (PE) with
potassium permanganate, which leads to the formation of vinyl and hydroxyl
moieties [78]. This method represents an environmentally friendly technique with-
out affecting the thermal properties of the PE and without the formation of
hydroperoxy groups.
An additional application of microwave irradiation is the conversion of
expanded polystyrene (PS) waste into polymeric ﬂocculants by a sulfonation
reaction using sulfuric acid in the presence of the catalyst silver sulfate [79]. The
product revealed similar properties to the modiﬁed PS obtained after conventional
heating and the reaction time could be signiﬁcantly reduced (from 1 h to 15 min).
The phosphonation of branched poly(ethylene imine) (PEI) via microwave-assisted
synthesis using formaldehyde and phosphorous acid also provides similar products
as conventional heating [80]. Although the DS could be well tailored in both
methods, microwave-assisted heating proved faster and easier once more.
Taking advantage of the high temperatures that can be achieved, even in
low-boiling solvents in closed reactions vessels, microwave-assisted approaches
are especially useful for hetero-Diels–Alder reactions. The deprotection of furan–
maleimide adducts pendant to PEO-based copolymers was only possible after
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subjecting the protected polymers to microwave-supported heating in a
chloroform–acetonitrile mixture, and attempts to use conventional heating failed
[81]. Within 1 h, the complete removal of the furan protecting groups was achieved,
and the copolymer itself remained intact.
4.2 Polymer Functionalization Using Nucleophilic Reagents
Nucleophiles such as amines, phenolates, or thiolates represent valuable reagents to
introduce further functionalities or to simply modify the properties of a precursor
polymer. In the following, suitable precursor polymer types are discussed, struc-
tured according to the underlying chemical reaction mechanisms. Table 3 provides
an overview of the respective microwave-assisted polymer modiﬁcations, along
with a general description of the utilized reaction conditions.
The nucleophilic ring opening of cyclic ethers represents an early example
where microwave irradiation was studied as synthetic tool for further modiﬁcation
of polymers. In the easiest case, suitable polymers for this purpose can simply be
epoxidized liquid natural rubber, as reported by Huy et al., who used α-naphthyl
acetic acid as nucleophilic reagent to open the three-membered ring [82]. As for
many other reactions discussed above, microwave-assisted approaches resulted in
higher conversions at shorter reaction time compared to conventional heating. The
ring opening of oxetanes as the analogous four-membered rings with amines was
successfully employed in a similar fashion to functionalize various polymers based
on bisphenols [83]. Microwave-assisted synthesis approaches alone already gave
rise to higher conversions. The addition of zinc chloride as catalyst enhanced this
effect even further, presumably because its polarity made it an efﬁcient microwave
absorber [84].
The microwave-assisted amidation and esteriﬁcation of various carboxylic acid-
functional polymers has been thoroughly studied by Ritter and co-workers. A poly
(acrylic acid) (PAA) homopolymer could be functionalized with various adamantyl
moieties simply by mixing with the respective adamantyl-functional amine and
subsequent use of microwave irradiation [85]. Without the requirement of solvents
or coupling agents, copolymers with 5 mol% of adamantyl units were obtained,
whose sodium salts were used to form hydrogels produced by the intermolecular
association of the hydrophobic side chains. Utilizing p-toluenesulfonic acid (pTos–
OH) as catalyst, poly[ethylene-co-(acrylic acid)] (PE-co-PAA) could be modiﬁed
with phenol derivatives under solvent-free conditions [86]. In a direct comparison
with conventional oil bath heating, the microwave irradiation was shown to pro-
mote effectively the esteriﬁcation of the copolymer. A reaction within a few
minutes resulted in a high level of reproducibility and conversion. An analogous
approach proved suitable for the amidation of PE-co-PAA with (2-aminoethoxy)
ethanol in a single step to obtain a polyinitiator for the ROP of CL [87]. Subse-
quently, the results were transferred to poly(ether sulfone)s as alternative polymer
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type, which could be successfully functionalized with 1-naphthol as well as
4-aminobenzoic acid, even in an apolar solvent such as xylene [88].
DMF can act as an excellent source for dimethylamine and carbon monoxide
under microwave irradiation [89]. The in situ generation of these gases is especially
advantageous for small-scale reactions where the direct use is impractical, as shown
by the modiﬁcation of poly(vinylimidazolium) salts. The proposed ﬁnal copolymer
structure contains mainly units of 1-vinylimidazole and some units of amines,
formamides, and alkenes.
Microwave-assisted modiﬁcations of synthetic polymers are not limited to
speciality polymers but have also proved to be useful for the functionalization of
commodity polymers such as poly(vinyl chloride) [90]. A series of copolymers was
obtained by nucleophilic substitution with 1,2,4-triazol-5-yl-sulfanyl groups. Using
microwave irradiation as heating source, the reaction could be performed with the
highest level of conversion, a signiﬁcant decrease in reaction times and without the
occurrence of secondary reactions. In a similar fashion, a copolymer of styrene and
chloromethyl styrene was quaternized with tributyl amine to serve as phase transfer
catalyst [91].
When a polymeric nucleophile such as poly(vinylalcohol) is used, hydrogels can
be prepared directly from suitable precursor polymers such as PAA or poly(methyl
vinyl ether-alt-maleic anhydride), taking advantage of the excellent microwave
absorption of water [92]. Irradiation of appropriate combinations of polymers in
aqueous solutions directly resulted in sterile hydrogels with high swelling ratios,
which did not require further puriﬁcation steps because the use of monomers could
be omitted during the synthetic approach.
4.3 Hydrolysis of Poly(2-Oxazoline)s
PEI represents the “gold standard” for non-viral gene transfection and, thus, is of
major importance in pharmaceutical research [93, 94]. However, the direct poly-
merization of its monomer aziridin results in the formation of branched polymers.
Thus, linear PEIs (LPEIs) with deﬁned molar masses are usually prepared by
hydrolysis of its N-acyl derivatives, i.e., poly(2-oxazoline)s (POx). Although the
required time for acidic hydrolysis ranges from a few hours to several days under
conventional heating (depending on the substituent of the POx), the alkaline
hydrolysis is even slower. Because drastic reaction conditions are frequently
applied, intensive investigations have been carried out regarding the use of
microwave-assisted synthetic approaches under several hydrolysis conditions to
accelerate this type of reaction (Table 4).
The ﬁrst reports relied on the use of the hydrophilic POx, i.e., poly(2-methyl-2-
oxazoline) (PMeOx) and poly(2-ethyl-2-oxazoline) (PEtOx) [95]. Thereby, kinetic
investigations during the microwave-assisted acidic hydrolysis revealed that 2 h
were sufﬁcient to reach conversions above 90%, even for the slightly more hydro-
phobic PEtOx. Subsequent optimization of the hydrolysis and puriﬁcation
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procedure proved that even a reaction time of 1 h is sufﬁcient if the reaction is
performed at 130 C [96]. An effective way to accelerate further the hydrolysis of
PEtOx is to increase the reaction temperature while using comparatively low acid
concentrations [97]. Detailed kinetic investigations, along with the determination of
the Arrhenius parameters, revealed the best results at 180 C with a
low-concentrated aqueous solution of HCl. Further increase of the temperature
resulted in main chain degradation.
The fact that the hydrolysis rate of hydrophilic POx is signiﬁcantly enhanced
compared to hydrophobic POx has been exploited to prepare gradient and block
copolymers, where preferentially the hydrophilic block is transformed to PEI
[98]. The preferential cleavage of the PMeOx block in block copolymers with
poly(2-phenyl-2-oxazoline) (PPhOx) enabled the synthesis of novel PEI-PPhOx
copolymers which exhibit thermoresponsive micellization behavior, and, in some
cases, pH responsive micellization. Utilizing an ethanol–water mixture, the selec-
tivity of the hydrolysis could be further enhanced, even allowing a certain differ-
entiation of the hydrophilic PMeOx and PEtOx [99]. Similarly, the hydrolysis rate
of PEtOx is higher than that of the hydrophobic poly(2-n-nonyl-2-oxazoline) under
the same conditions, presumably because the n-nonyl chains collapse around the
Table 4 Overview of microwave-assisted hydrolysis of poly(2-oxazoline)s
∗
N
N
H
∗
O R
b c
∗
N
∗
O R
a
Starting (co-)
polymer R1 R2
a
(units)
Ox1:Ox2:
EI (%)a Hydrolysis conditions References
Homo CH3 – 5–200 1:99 HCl (16 wt%), 100
C [95]
C2H5
Homo C2H5 – 10–200 1:99 HCl (16 wt%), 130
C [96]
Homo C2H5 – 30, 500 5:95 HCl (3 wt%), 180
C [97]
Statistical CH3 C6H5 a1¼ 60 0:2:98 HCl (16 wt%), 100
C [98]
a2¼ 40 20:21:59 NaOH
Block 0:16:84 HCl (16 wt%), 100 C
23:36:42 NaOH
Homo CH3 – 100 5:95 HCl (12 wt%), 100
C,
EtOH:H2O 4:1
[99]
C2H5 68:22
C6H5 87:13
Block CH3 C2H5 a1¼ 50 15:37:48
a2¼ 50
C6H5 a1¼ 60 4:18:78
a2¼ 15
Homo C2H5 – 100 5:95 HCl (16 wt%), 160
C [100]
n-
C9H19
13:87
aThe maximum degree of hydrolysis can be determined only within the limits of the 1H NMR
accuracy
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polymer backbone in aqueous HCl [100]. Nevertheless, the degree of hydrolysis of
both POx could be well controlled by adjustment of the reaction time. Hence, a
range of copolymers with antimicrobial activity was obtained.
4.4 Modification of Polymer End Groups
The fact that many polymers with deﬁned end groups are accessible from living and
controlled polymerizations has brought these “tiny” parts of the polymer chains into
the focus of research. Although a range of polymers from microwave-assisted
polymerizations can be end-functionalized in situ [101, 102], we only discuss
end-group modiﬁcations here, where microwave-assisted synthesis approaches
have actually been applied for the end-group modiﬁcation (Table 5).
As a prominent polymer for life science applications, PEO and its copolymer
with propylene oxide, PEO-b-PPO, have long been commercially available with
hydroxyl end groups and with various architectures. Hence, these precursors are
often applied to introduce further functionalities. In a two-step microwave-assisted
approach, PEO-OH was functionalized with piperazinyl and diazepanyl moieties to
serve as support for further preparation of guanidium derivatives [103].
PEO-diol and star-shaped PEO were also easily and quickly functionalized with
methacrylate moieties on both end groups. The very simple and well described
microwave-assisted procedure can also be adapted for functionalization of the N-
termini of peptides [104]. The attachment of glucose to the end groups of PEO-b-
PPO-b-PEO via microwave-assisted ring-opening of the sugar’s lactone represents
another example where microwave synthesizers were applied successfully for a
reaction that typically requires high temperatures [105].
Bromo end groups derived from atom transfer radical polymerization (ATRP) or
from the synthesis of polythiophenes represent another type of end functionality
that has been further functionalized using microwave-assisted approaches. Thus,
telechelic PS and poly(methyl methacrylate) functionalized with C60 were prepared
with an increased degree of functionalization in comparison to conventional
heating, both polymer types remaining intact [106]. The coupling of highly
regioregular poly(thiophene)-based multiblock copolymers can also be achieved
and improved under microwave conditions taking advantage of active nickel
complexes present as end groups of the individual blocks [107].
The azide-alkyne 1,3-dipolar cycloaddition has become a valuable tool in
synthetic polymer chemistry. Microwave-assisted approaches make use of its
versatility for step-growth polymerizations [110, 111], for dendrimer synthesis
[112, 113], and for monomer preparation [114]. In terms of modiﬁcation of polymer
end groups, alkyne functional PCL has been utilized to synthesize star-shaped PCL
with a β-cyclodextrin core via microwave-assisted “click” chemistry in a core-ﬁrst
approach [108]. The same PCL was also coupled to 3,6-di(pyridine-2-yl)pyridazine
via a Diels–Alder reaction with inverse-electron-demand to give access to [2 2]
grid-like metal complexes.
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Microwave-assisted “click” chemistry on polymer end groups is not limited to
reactions in solution. Relying on the azide-alkyne 1,3-dipolar cycloaddition,
propargyl-end functional PEtOx was coupled to surfaces functionalized with
azide-carrying monolayers in a microwave setup modiﬁed to ﬁt silicon substrates
inside the common reaction vessels [109]. Vice versa, silica surfaces with an
immobilized polymer, i.e., poly(PEO-methacrylate) tethered with both azide and
alkyne moieties obtained from surface-initiated ATRP, were subjected to this type
of reaction with small molecules as counterparts to functionalize the surfaces
further [115].
4.5 Modification of Polymeric Resins
Merriﬁeld resins represent very common substrates for a wide range of reactions on
solid polymeric supports and are well known, for instance, in the ﬁeld of solid phase
peptide synthesis. Consisting of crosslinked PS with varying fractions of incorpo-
rated chloromethyl styrene, the benzyl chloride groups provide the reactive posi-
tions prone to attack by nucleophiles.
Microwave-assisted heating proved superior in comparison to conventional
heating during the conversion of the resin’s chloride functionalities with PEO
under alkaline conditions [116]. Even in 2 min, higher DS values of the resin
were achieved than after 35 min during conventional heating, although the thermal
degradation of the PEO was signiﬁcantly reduced. Amines are the more common
nucleophiles used with Merriﬁeld resins, but thiols and imidazoles were also
immobilized via microwave-assisted approaches [117]. Careful investigations of
the obtained products from immobilization of N-methyl-D-glucanamine revealed
that chemistry using microwave synthesizers is not superior to conventional
methods in any case, a fact which is often disregarded upon selling novel synthetic
approaches [118]. However, the direct volumetric heating and the possibility to
work at higher temperatures than the boiling points of the solvents certainly are
advantages which can help to improve reaction times and homogeneity. As such,
microwave-assisted synthesis protocols can be very effective during the synthesis
of peptides if the reaction conditions are thoroughly adjusted [119]. This also
enables the custom-made synthesis of specially designed glycopeptides in a much
faster fashion than under conventional heating [120, 121].
5 Summary, Conclusions, and Outlook
Since microwave synthesizers have found their way into synthetic chemical labo-
ratories, a wide range of natural and synthetic polymers have been subjected to
microwave-assisted modiﬁcation reactions. However, the way these heating
sources are applied has signiﬁcantly changed since the 1990s. The pioneers had
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to rely on household microwave ovens or self-built equipment and merely com-
pared the properties of modiﬁed polymers derived from microwave-supported
heating to those obtained by established synthesis protocols. In contrast, the modern
microwave synthesizers allow a detailed adjustment and control of temperature and
power, so that many microwave-assisted polymer modiﬁcation reactions are
performed nowadays using optimized synthesis protocols that could be established.
In those ﬁelds, microwave synthesizers are recognized as common synthetic tools
because of advantages such as fast and homogenous heating, the possibility to
perform reactions at high temperatures and under pressure, and their ease of
handling.
Other ﬁelds of research still struggle with the identiﬁcation of optimum reaction
conditions and questions of special microwave effects beyond more effective
heating. Unfortunately, some of these investigations tend to lack critical judgment
of the chemistry performed and merely highlight the systematic workﬂows applied.
However, also in these ﬁelds detailed structural investigations of the products
obtained will lead to reasonable synthetic approaches so that microwave synthe-
sizers will become standard equipment for more synthetic polymer chemists in the
future.
On the other hand, selective heating of, for example, conjugated polymers by
microwave irradiation has opened non-classical opportunities in materials science.
Hence, more developments of novel nanomaterials prepared from polymers via
microwave-assisted approaches are to be discovered in this still vital ﬁeld of
research.
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3rd generation poly(ethylene imine)s for gene
delivery†
Tanja Bus,‡ab Christoph Englert,‡ab Martin Reifarth,abcd Philipp Borchers,ab
Matthias Hartlieb,§ab Antje Vollrath,ab Stephanie Hoeppener,ab Anja Traeger*ab and
Ulrich S. Schubert*ab
Cationic polymers play a crucial role within the field of gene delivery offering the possibility to
circumvent (biological) barriers in an elegant way. However, polymers are accompanied either by a high
cytotoxicity or low efficiency. In this study, a series of high molar mass poly(2-oxazoline)-based
copolymers was synthesized introducing 2-ethyl-2-oxazoline, ethylene imine, and primary amine bearing
monomer units representing a new generation of poly(ethylene imine) (PEI). The potential of these
modified PEIs as non-viral gene delivery agents was assessed and compared to linear PEI by studying the
cytotoxicity, the polyplex characteristics, the transfection efficiency, and the cellular uptake using plasmid
DNA (pDNA) as well as small interfering RNA (siRNA). High transfection efficiencies, even in serum
containing media, were achieved using pDNA without revealing any cytotoxic effects on the cell viability at
concentrations up to 1 mg mL1. The delivery potential for siRNA was further investigated showing the
importance of polymer composition for different genetic materials. To elucidate the origins for this superior
performance, super-resolution and electron microscopy of transfected cells were used, identifying the
endosomal release of the polymers as well as a reduced protein interaction as the main difference to
PEI-based transfection processes. In this respect, the investigated copolymers represent remarkable
alternatives as non-viral gene delivery agents.
Introduction
Within the last decades synthetic polymers emerged as versatile
tools in the field of gene delivery.1 They represent promising
alternatives to viral vectors or lipid-based, non-viral transfection
agents, since they combine the advantages of large scale produc-
tion, simple storage conditions, and the availability of a variety
of architectures with tailored properties, e.g. defined molar
masses, end groups, and functionalities.2 The most prominent
representative of synthetic, cationic polymers utilized for nucleic
acid delivery is the gold standard poly(ethylene imine) (PEI).3,4
Subdivided into a linear (lPEI) and a branched (bPEI) topology,
it reveals one of the highest cationic-charge-densities of all
organic macromolecules.5 Under physiological conditions,
every sixth nitrogen (N) is protonated6 and able to interact with
the phosphate groups (P) of deoxyribonucleic acid (DNA) as well
as ribonucleic acid (RNA) to form nanoscale interelectrolyte
complexes, so-called polyplexes.7–9
lPEI offers the benefit to be synthesized by hydrolysis of
poly(2-alkyl-2-oxazoline)s (POx) using a living polymerization
process resulting in well-defined structures.10 However, these
advantages are accompanied by a severe cytotoxicity and undesired
non-specific interactions with cellular and non-cellular components,
both in vitro and in vivo.11–13 Various attempts have been made to
optimize PEI by focusing on the design of biodegradable14–16 and
biocompatible17,18 derivatives, which represent the 2nd generation
of PEI-based polymers. Carbohydrates, e.g. dextran19 or hydroxyethyl
starch (HES),20 as well as stealth polymers like poly(ethylene glycol)
(PEG)21,22 are extensively studied.23 Approaches as the introduc-
tion of biodegradable linkers, such as disulfide bonds,24–26 the
combination with liposomes27,28 or the utilization of micelles
or nanoparticles in combination with PEI29,30 are further con-
cepts partially fulfilling the complex requirements. Besides the
post-modification of the PEI backbone, the partial hydrolysis
of POx, resulting in P(Ox-stat-EI) copolymers, represents a
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promising approach.31,32 The ‘‘stealth behavior’’ of POx, compar-
able to PEG, facilitates a reduction of cytotoxicity.32,33 Although
the cytotoxicity problem might be solved, the modifications
often result in inefficient gene delivery presumably due to weak
DNA complexation and decreased cell interaction.34 Hence, the
design criteria for a perfect polymeric vector are still unknown and
other polymer characteristics, i.e. the degree of hydrophobicity
or synergistic effects of different polycationic species within
one polymeric vector, have to be considered.17,35
The present contribution focusses on the synthesis of high
molar mass copolymers of lPEI and POx. A combination of
primary and secondary amines as well as non-charged 2-ethyl-2-
oxazoline (EtOx) units was aspired. While different amine
species were used to support the polyplex formation, biocom-
patibility is achieved via the integration of EtOx. To realize the
synthesis of the targeted polymer structure, a post-polymerization
functionalization of partially hydrolyzed high molar mass poly(2-
ethyl-2-oxazoline) (PEtOx) was used. The insertion of alkenes is
followed by the functionalization via thiol–ene click chemistry.
This extraordinary combination of modification techniques offers
a new platform of copolymers which marks the beginning of a
new generation – the 3rd generation of PEI (see Fig. 1).
The designed copolymers were investigated concerning their
in vitro transfection potential including polyplex characterization,
competitor/serum interaction and the cellular uptake mechanism
using plasmid DNA as well as siRNA. For a detailed understanding
of themechanism during the gene delivery process super-resolution
fluorescence as well as electron microscopy were utilized.
Materials and methods
Materials
2-Ethyl-2-oxazoline (EtOx) and methyl tosylate were obtained
from Acros Organics, distilled to dryness (over barium oxide
in the case of EtOx), and stored under argon atmosphere.
Pyridine, methanol, dichloromethane, 4-N,N-dimethylamino-
pyridine (DMAP), 2-(boc-amino)ethanethiol, 2,2-dimethoxy-2-phenyl-
acetophenone (DMPA), trifluoroacetic acid and Amberlysts A21
(free base) were obtained from Sigma Aldrich (Steinhausen,
Germany) and are of analytical grade and were used without
further purification. Acetonitrile was purified on aMBraun solvent
purification system (MB SPS-800). The dye Cy5 was purchased
from Lumiprobe GmbH (Hannover, Germany). N-Succinimidyl-4-
pentenate was prepared according to literature procedures.36 The
commercially available poly(ethylene imine)s, both the branched
(bPEI) as well as the linear (lPEI) type, were purchased from
Polysciences (USA). Poly(methacrylic acid) (PMAA, DP = 200) was
synthesized according to literature procedures.37 The transfection
reagent jetPRIME, used as positive control for siRNA delivery,
was obtained from Polyplus (Polyplus transfection SA, USA).
5-(N-Ethyl-N-isopropyl)amiloride (EIPA) was purchased from
Sigma-Aldrich (Merck, Darmstadt). Ethidium bromide solution
(1%, 10 mg mL1) was purchased from Carl Roth (Karlsruhe,
Germany). AlamarBlue, YOYO-1 iodide, Hoechst 33342 trihydro-
chloride as well as all other indicated CLSM dyes were obtained
from Life Technologies (Thermo Fisher Scientific, Germany). If not
stated otherwise, cell culture media and solutions (L-glutamine,
antibiotics) were obtained from Biochrom (Berlin, Germany).
Plasmid pEGFP-N1 (4.7 kb, Clontech, USA) encoding green
fluorescent protein (EGFP) was isolated with the Giga Plasmid
Kit provided by Qiagen (Hilden, Germany). The siRNA negative
controls (scrambled siRNA, 21 nucleotides, double-stranded) and
the siRNA against egfp (sense 50-GCAAGCTGACCCTGAAGTTCAT-30,
antisense 50-ATGAACTTCAGGGTCAGCTTGC-30) were purchased
from Eurogentech (Seraing, Belgium).
General methods and instrumentation
An Initiator Sixty single-mode microwave synthesizer from Biotage,
equipped with a noninvasive IR sensor (accuracy: 2%), was used for
polymerizations and hydrolyses under microwave irradiation.
Proton (1H) nuclear magnetic resonance (NMR) spectra were
acquired in deuterated methanol, at room temperature using
a Bruker AC 300 MHz spectrometer; chemical shifts (d) are
expressed in parts per million relative to TMS.
Size exclusion chromatography (SEC) was performed using an
Agilent Technologies 1200 Series gel permeation chromatography
system equipped with a G1329A auto sampler, a G131A isocratic
pump, a G1362A refractive index detector, and both a PSS Gram
30 and a PSS Gram 1000 column placed in series. As eluent a
0.21% LiCl solution in N,N-dimethylacetamide (DMAc) was used
at 1 mL min1 flow rate and a column oven temperature of 40 1C.
Molar masses were calculated using a poly(styrene) calibration.
Fig. 1 Overview of different generations of linear poly(ethylene imine) (lPEI). Compared to the original lPEI (1st generation), which has been established
over the last decades, the 2nd generation lPEI contains functional monomer units (black or orange) besides the present ethylene imine units (blue). The
3rd generation lPEI describes the presence of multiple functional units comprising cationic functionalities (blue), functional groups to increase cell
viability (black) as well as a third group of functionalities (orange, e.g. primary amine functionalities or targeting molecules).
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Asymmetric flow field-flow fractionation (AF4) was performed on
an AF2000 MT System (Postnova Analytics, Landsberg, Germany)
coupled to an UV (PN3211, 260 nm (Postnova)), RI (PN3150), multi-
angle light scattering (MALLS, PN3070, 633 nm (Postnova)) and DLS
(ZetaSizer Nano ZS; Malvern) detector. The eluent was delivered by
three different pumps (tip, focus, cross-flow) and the sample was
injected by an autosampler (PN5300) into the channel. The channel
has a trapezoidal geometry and an overall area of 31.6 cm2. The
nominal height of the spacer was 500 mm. A regenerated cellulose
membrane with a molar mass cut-off of 10 kDa served as
accumulation wall. All experiments were carried out at 25 1C with
pure water as eluent. A sample of 10 mL (1 mg mL1) was injected
with an injection flow rate of 0.2 mL min1 and a cross-flow rate
of 1.2 mL min1 for 7 min (detector flow rate 0.5 ml min1, focus
flow rate 1.5 mL min1). After the focusing step, the cross-flow
rate was reduced under an exponential gradient (0.4) within 10 min
to 0 mL min1. The cross-flow was kept constant at 0 mL min1
for 40 min to ensure complete elution. All measurements were
in triplicate.
For the acid/base titration the copolymers P1 to P3 (mB 20mg)
were dissolved in 4 mL deionized water, and 20 mL conc. hydro-
chloric acid were added (0.06 M). The titration was performed
against 0.1 M aqueous sodium hydroxide solution using a 765
Dosimat fromMetrohm, a digital pH/mV-thermometer GMH 3530
from Greisinger electronic, and the EBS9 M Recorder software.
Synthesis of poly(2-ethyl-2-oxazoline) (PEtOx)
The monomer 2-ethyl-2-oxazoline (3.965 g) and the initiator
methyl tosylate (12.42 mg, 0.067 mmol) were dissolved in dry
acetonitrile (6.0 mL) in a microwave vial within a glovebox
under nitrogen atmosphere. After stirring for 2 minutes the
vessel was transferred to a microwave synthesizer and heated for
128min at 140 1C. After cooling to room temperature, a sample was
taken to determine the chain length by 1H NMR. The polymeriza-
tion mixture was diluted with 5 mL of dichloromethane, followed
by precipitation in 250 mL ice-cold diethyl ether. The precipitate
was filtered off, dissolved in deionized water and lyophilized
(yield: 3.720 g, 94%).
PEtOx. DP = 575. 1H NMR (300 MHz, D2O): d 3.70–3.20
(–NR–CH2–CH2), 2.41–2.08 (CH2–CH3), 1.09–0.79 (CH2–CH3)
ppm. SEC (DMAc, LiCl): Mn = 69 000 g mol
1, Ð = 1.3. AF4:
Mn = 57 000 g mol
1, Ð = 1.23.
Synthesis of poly(2-ethyl-2-oxazoline-stat-ethylene imine)
(P(EtOx-stat-EI))
To obtain a specific degree of hydrolysis of P(EtOx-stat-EI),
kinetic studies were performed previously according to litera-
ture procedures.38 The results were used to synthesize PEtOx
with defined degree of hydrolysis in larger scale. Accordingly,
PEtOx (3.510 g, 0.062 mmol) was dissolved in 6 M hydrochloric
acid (36 mL). The reaction mixture was heated in a microwave
synthesizer at 100 1C for 100 min. Subsequently, the excess of
HCl and the resulting propionic acid were distilled off and the
residue was dissolved in 15 mL water. The obtained solution
was neutralized with 3 M aqueous NaOH to a pH value48, and
the remaining solvent was removed under reduced pressure. The
residue was dissolved in DMF and the filtered polymer solution
was precipitated two times in 500 mL cold diethyl ether. The
obtained product was dried at 85 1C under reduced pressure.
1H NMR spectroscopy was used to determine the conversion
of the PEtOx to lPEI. Therefore, the signals from the released
lPEI backbone and the signals from the remaining CH3 group in
the side chain of PEtOx were used (yield: 2.350 g, 91%).
P(EtOx-stat-EI). EtOx : EI [%] = 54 : 46. 1H NMR (300 MHz,
MeOD): d 3.69–3.41 (NR–CH2–CH2), 2.93–2.63 (NH–CH2–CH2),
2.55–2.31 (CH2–CH3), 1.19–1.03 (CH2–CH3) ppm. SEC (DMAc,
LiCl): Mn = 48 000 g mol
1, Ð = 1.28. AF4: Mn = 31 300 g mol
1,
Ð = 1.03.
Synthesis of P(EtOx-stat-EI-stat-ButEnOx) (preP1 to preP3)
The partially hydrolyzed PEtOx, P(EtOx-stat-EI) (1: 659 mg, 2:
654 mg, 3: 647 mg), and the catalyst 4-N,N-dimethylamino-
pyridine (DMAP, 100 mg, 0.82 mmol) were dissolved in a
microwave vial in pyridine (V = 8 mL) at 80 1C. In a second
vial, a defined quantity of N-succinimidyl-4-pentenate (645 mg,
483 mg, 318 mg) was dissolved in the same solvent (4 mL) and
heated up to 80 1C. The two solutions were combined and solvent
was added (3 mL) to yield a 4 wt%mixture of P(EtOx-stat-EI). The
reaction mixture was stirred for 20 h at 80 1C. After cooling to
room temperature the sample was filtered and precipitated into
400 mL ice-cold diethyl ether. The copolymer was filtered off
and washed with 40 mL of diethyl ether. Due to the negligible
effect of the side product N-hydroxysuccinimide on subsequent
reaction steps, no further purification steps were required. The
residue was dried under reduced pressure to constant weight
(yield: 1: 619 mg, 68%, 2: 650 mg, 75%, 3: 625 mg, 77%).
preP1. EtOx : EI : ButEnOx = 54 : 12 : 34%. 1H NMR (300 MHz,
MeOD): d 6.00–5.77 (HCQCH2), 5.18–4.95 (HCQCH2), 3.81–3.40
(NR–CH2–CH2), 3.00–2.74 (NH–CH2–CH2), 2.67 (NHS), 2.60–2.20
(CH2–CH3, CH2–CH2–C2H3), 1.20–0.97 (CH2–CH3) ppm. SEC (DMAc,
LiCl): Mn = 36 000 g mol
1, Ð = 2.12. AF4: Mn = 25 500 g mol
1,
Ð = 1.41.
preP2. EtOx : EI : ButEnOx = 54 : 17 : 29%. 1H NMR (300 MHz,
MeOD): d 6.00–5.78 (HCQCH2), 5.17–4.95 (HCQCH2), 3.81–3.40
(NR–CH2–CH2), 2.95–2.68 (NH–CH2–CH2), 2.59 (NHS), 2.57–2.21
(CH2–CH3, CH2–CH2–C2H3), 1.21–1.00 (CH2–CH3) ppm. SEC (DMAc,
LiCl): Mn = 34 500 g mol
1, Ð = 1.63. AF4: Mn = 30 900 g mol
1,
Ð = 1.33.
preP3. EtOx : EI : ButEnOx = 54 : 23 : 23%. 1H NMR (300 MHz,
MeOD): d 5.99–5.76 (HCQCH2), 5.19–4.96 (HCQCH2), 3.81–3.40
(NR–CH2–CH2), 2.94–2.66 (NH–CH2–CH2), 2.57 (NHS), 2.55–2.25
(CH2–CH3, CH2–CH2–C2H3), 1.22–0.99 (CH2–CH3) ppm. SEC (DMAc,
LiCl): Mn = 36 000 g mol
1, Ð = 1.55. AF4: Mn = 30 400 g mol
1,
Ð = 1.33.
Synthesis of P(EtOx-stat-EI-stat-bocAmButOx) via thiol–ene
functionalization (bocP1 to bocP3)
In a microwave vial, P(EtOx-stat-EI-stat-ButEnOx) (preP1: 253 mg,
preP2: 351 mg, preP3: 360 mg) was dissolved in methanol (2 mL).
In a second vial, the photoinitiator 2,2-dimethoxy-2-phenylaceto-
phenone (DMPA, 49 0.5mg, 0.19 mmol) and a 1.3-fold excess per
double bond of 2-(boc-amino)ethanethiol (193 mL, 239 mL, 205 mL)
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were dissolved in methanol (2 mL), likewise. The combined
solutions (10 wt%) were degassed with nitrogen for 20 min and
the clear solution was stirred in a UV chamber (l = 365 nm)
overnight. Subsequently, the copolymer was precipitated in
200 mL ice-cold diethyl ether. After filtration, the copolymer was
dried under reduced pressure for two days (yield: bocP1: 361 mg,
89%, bocP2: 493 mg, 92%, bocP3: 476 mg, 92%).
bocP1. EtOx :EI :bocAmButOx = 54 :12 :34%. 1HNMR (300MHz,
MeOD): d 3.81–3.40 (NR–CH2–CH2), 3.27–3.16 (S–CH2–CH2),
3.00–2.74 (NH–CH2–CH2), 2.64 (NHS), 2.63–2.55 (S–CH2–CH2),
2.54–2.27 (CH2–CH3, CH2–C2H4–CH2), 1.82–1.57 (CH2–C2H4–CH2),
1.55–1.39 (C(CH3)3), 1.21–1.00 (CH2–CH3) ppm.
bocP2. EtOx :EI :bocAmButOx = 54 :17 :29%. 1HNMR (300MHz,
MeOD): d 3.81–3.41 (NR–CH2–CH2), 3.28–3.16 (S–CH2–CH2),
2.92–2.72 (NH–CH2–CH2), 2.69–2.59 (S–CH2–CH2), 2.58 (NHS),
2.54–2.29 (CH2–CH3, CH2–C2H4–CH2), 1.82–1.56 (CH2–C2H4–CH2),
1.55–1.39 (C(CH3)3), 1.21–1.03 (CH2–CH3) ppm.
bocP3. EtOx : EI : bocAmButOx = 54 : 23 : 23%. 1H NMR
(300 MHz, MeOD): d 3.79–3.41 (NR–CH2–CH2), 3.27–3.17
(S–CH2–CH2), 2.91–2.71 (NH–CH2–CH2), 2.67–2.59 (S–CH2–CH2),
2.58 (NHS), 2.54–2.29 (CH2–CH3, CH2–C2H4–CH2), 1.80–1.56
(CH2–C2H4–CH2), 1.55–1.39 (C(CH3)3), 1.20–1.02 (CH2–CH3) ppm.
Synthesis of P(EtOx-stat-EI-stat-AmButOx) via deprotection
(P1 to P3)
The copolymer P(EtOx-stat-EI-stat-bocAmButOx) (bocP1: 321 mg,
bocP2: 402 mg, bocP3: 420 mg) was dissolved in dichloromethane
(3 mL). Trifluoroacetic acid was added (5 mL) and the reaction
mixture was stirred overnight at room temperature. The copolymer
was precipitated in 400 mL ice-cold diethyl ether. The precipitate
was filtered, washed with 40 mL diethyl ether, dissolved in
methanol and shaken overnight with Amberlyst A21 (free base)
(B0.5 g). The solvent was removed and the copolymer lyophilized
(yield: P1: 240 mg, 95%, P2: 293 mg, 91%, P3: 330 mg, 95%).
P1. EtOx :EI : bocAmButOx = 54 : 12 : 34%. 1H NMR (300 MHz,
MeOD): d 3.76–3.29 (NR–CH2–CH2), 3.11–2.98 (S–CH2–CH2),
2.84–2.65 (NH–CH2–CH2), 2.58 (NHS), 2.57–2.46 (S–CH2–CH2),
2.45–2.16 (CH2–CH3, CH2–C2H4–CH2), 1.83–1.44 (CH2–C2H4–CH2),
1.10–0.89 (CH2–CH3) ppm. SEC (DMAc, LiCl):Mn = 30500 g mol
1,
Ð = 1.60. AF4: Mn = 35300 g mol
1, Ð = 1.74.
P2. EtOx : EI : bocAmButOx = 54 : 17 : 29%. 1H NMR (300 MHz,
MeOD): d 3.68–3.21 (NR–CH2–CH2), 3.01–2.87 (S–CH2–CH2),
2.72–2.56 (NH–CH2–CH2), 2.50 (NHS), 2.48–2.37 (S–CH2–CH2),
2.37–2.08 (CH2–CH3, CH2–C2H4–CH2), 1.70–1.36 (CH2–C2H4–CH2),
1.03–0.82 (CH2–CH3) ppm. SEC (DMAc, LiCl):Mn = 39000 g mol
1,
Ð = 1.58. AF4: Mn = 43700 g mol
1, Ð = 1.72.
P3. EtOx : EI : bocAmButOx = 54 : 23 : 23%. 1H NMR (300 MHz,
MeOD): d 3.87–3.40 (NR–CH2–CH2), 3.23–3.03 (S–CH2–CH2),
2.97–2.75 (NH–CH2–CH2), 2.74–2.57 (S–CH2–CH2), 2.56–2.28
(CH2–CH3, CH2–C2H4–CH2), 1.88–1.56 (CH2–C2H4–CH2), 1.22–0.98
(CH2–CH3) ppm. SEC (DMAc, LiCl): Mn = 31500 g mol
1, Ð = 1.45.
AF4: Mn = 30500 g mol
1, Ð = 1.62.
Copolymer labeling with Cy5
Copolymer P3 (40 mg) and triethylamine (150 mL) were dissolved
in DMF (10 mL). After addition of the cyanine-5-NHS-ester
(0.4 mg) the reaction was stirred at room temperature over-
night. The labeled copolymer was precipitated in 500 mL ice-
cold diethyl ether, filtered and re-dissolved in H2O (15 mL).
Further purification was performed by dialysis against water
using a Spectra/Por 3 dialysis membrane (3500 g mol1 cut-off).
Finally, the product was lyophilized and obtained as a blue
powder. The calculated labeling efficiency (via UV-Vis) for
conjugation was 65% for P3–Cy5 (yield: 27 mg, 67%). lPEI
was treated likewise but dialyzed against a water/methanol
mixture and dried under reduced pressure, subsequently (yield:
2.6 mg, 26%; labeling efficiency: 2%).
Synthesis of linear poly(ethylene imine) (lPEI)
The synthesized copolymer P(EtOx-stat-EI) (DP = 575, 100 mg)
was treated with an excess of 6 M aqueous hydrochloric acid
(1.5 mL) for 2 hours at 100 1C in a microwave synthesizer
to yield a hydrolyzed linear poly(ethylene imine) (DP = 575).
Neutralization and purification via precipitation were per-
formed analogous to the described synthesis of P(EtOx-stat-EI)
(see above). The product lPEI was dried at 85 1C under high
vacuum for 2 days and the degree of hydrolysis was determined
by 1H NMR by correlating the integrals of the PEI backbone and
the remaining methyl group of the PEtOx side chain (yield:
51 mg, 87%).
lPEI. EtOx :EI [%] = 5 :95. 1HNMR (300MHz,MeOD): d 3.58–3.41
(NR–CH2–CH2), 2.91–2.61 (NH–CH2–CH2), 2.56–2.36 (CH2–CH3),
1.18–1.06 (CH2–CH3) ppm.
Polyplex preparation
Polyplexes of pDNA and polymers were prepared by mixing
stock solutions of 15 mg mL1 pDNA and different amounts of
polymers (1 mg mL1) to obtain various N/P ratios (nitrogen
of polymer to phosphate of pDNA) in HBG buffer (20 mM
4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES) and
5% (w/v) glucose, pH 7.2). The solutions were vortexed for 10 s
at maximal speed and incubated at room temperature for
20 min to ensure complex formation. For the preparation of
polyplexes with siRNA, 1 mM siRNA (final concentration) was
used as described above.
Ethidium bromide quenching assay
The formation of polyplexes with pDNA as well as siRNA was
examined by quenching of the ethidium bromide fluorescence.
Briefly, pDNA (15 mg mL1) or siRNA (1 mM) in a total volume
of 100 mL HBG buffer were incubated with ethidium bromide
(0.4 mg mL1) for 10 min at room temperature. Subsequently,
polyplexes with different amounts of polymer (various N/P ratios)
were prepared in black 96-well plates (Nunc Thermo Fisher).
The samples were incubated at room temperature for 15 min.
The fluorescence of the samples was measured at an excitation
wavelength of 525 nm and an emission wavelength of 605 nm
using a microplate reader (TECAN Infinite M200 Pro, Crailsheim,
Germany). A sample containing only pDNA and ethidium
bromide was used to calibrate the device to 100% fluorescence
against a background of 0.4 mg mL1 of ethidium bromide in
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HBG solution. The percentage of dye displaced upon polyplex
formation was calculated using eqn (1):
RFU½% ¼
Fsample  F0
FpDNA  F0
 100 (1)
Here, RFU is the relative fluorescence and Fsample, F0, and FpDNA
are the fluorescence intensities of a given sample, the ethidium
bromide in HBG alone, and the ethidium bromide intercalated
into pDNA alone.
Heparin dissociation assay
To investigate the release of pDNA from polyplexes, the heparin
dissociation assay was performed. Polyplexes with an N/P ratio
of 30 were prepared as described above in a total volume of
100 mL HBG buffer containing ethidium bromide (0.4 mg mL1).
After incubation in the dark at room temperature for 15 min,
the polyplexes were transferred into a black 96-well plate, and
heparin of indicated concentrations was added. The solution
was mixed and incubated for further 30 min at 37 1C in the
dark. The fluorescence of ethidium bromide was measured
at Ex 525 nm/Em 605 nm with a Tecan microplate reader. The
percentage of intercalated ethidium bromide was calculated as
described before.
Dynamic and electrophoretic light scattering
Dynamic light scattering (DLS) was performed on a Zetasizer
Nano ZS (Malvern Instruments, Herrenberg) with a He–Ne laser
operating at a wavelength of l = 633 nm. All measurements
(30 runs, triplicate) were carried out at 25 1C after an equili-
bration time of 120 s. The counts were detected at an angle of
1731. The mean particle size was approximated as the effective
(z-average) diameter and the width of the distribution as the
polydispersity index of the particles (PDI) obtained by the
cumulants method assuming a spherical shape. Electrophoretic
light scattering (ELS) was used to measure the zeta potential (z).
The measurement was performed on a Zetasizer Nano ZS
(Malvern Instruments, Herrenberg, Germany) by applying laser
Doppler velocimetry. For each measurement, 20 runs were
carried out using the slow-field reversal and the fast-field
reversal mode at 150 V. Each experiment was performed in
triplicate a 25 1C. The zeta potential was calculated from the
electrophoretic mobility (m) according to the Henry equation.
Henry coefficient f (ka) was calculated according to Oshima.
Determination of the cytotoxicity
Cytotoxicity studies were performed with the mouse fibroblast
cell line L929 (CCL-1, ATCC), as recommended by ISO10993-5.
The cells were routinely cultured in Dulbecco’s modified eagle’s
medium (DMEM, Lonza, Basel) supplemented with 10% fetal calf
serum (FCS), 100 UmL1 penicillin and 100 mgmL1 streptomycin
at 37 1C in a humidified 5% (v/v) CO2 atmosphere.
In detail, cells were seeded at 104 cells per well in a 96-well
plate and incubated for 24 h, whereas no cells were seeded in the
outer wells. Subsequently, the testing substances (polymers) at
indicated concentrations (from 0.25 mg mL1 to 1 mgmL1) were
added to the cells and the plates were incubated for further 24 h.
Control cells were incubated with fresh culture medium.
Subsequently, the medium was replaced by a mixture of fresh
culture medium and Alamar-Blue solution (Life technologies,
Darmstadt, Germany), prepared according to the manufacturer’s
instructions. After a further incubation of 4 h at 37 1C, the
fluorescence wasmeasured at Ex 570/Em 610 nm, with untreated
cells on the same well plate serving as negative controls. The
negative control was standardized as 0% of metabolism inhibi-
tion and referred as 100% viability. Cell viability below 70%
was considered indicative of cytotoxicity. Data are expressed as
mean  SD of three determinations.
Hemolysis assay
The interaction of polymers with cellular membranes was investi-
gated by analyzing the release of hemoglobin from erythrocytes.
Blood from sheep, collected in heparinized tubes, was provided by
the Institute of Laboratory Animal Science and Animal Welfare,
Friedrich-Schiller University Jena. The blood was centrifuged at
4500  g for 5 min, and the pellet was washed three times with
cold 1.5 mM phosphate buffered saline (PBS, pH 7.4). After
dilution with PBS in a ratio of 1 : 7, aliquots of erythrocyte suspen-
sion were mixed 1 : 1 with the polymer solution and incubated in a
water bath at 37 1C for 60 min. After centrifugation at 2400  g
for 5 min, the hemoglobin release into the supernatant was
determined spectrophotometrically using a microplate reader
(TECAN Infinite M200 Pro, Crailsheim, Germany) at a wave-
length of 544 nm. Complete hemolysis (100%) was achieved
using 1% Triton X-100 serving as positive control. Pure PBS
was used as negative control (0% hemolysis). The haemolytic
activity of the polycations was calculated as follow (2):
% Hemolysis ¼ 100
ASample  ANegative control
 
APositive control
(2)
A value less than 2% hemolysis rate were classified as non-
hemolytic, 2 to 5% as slightly haemolytic and values 45%
as hemolytic. Experiments were run in triplicates and were
performed with three different batches of donor blood.
Erythrocyte aggregation
Erythrocytes were isolated as described above. The erythrocyte
suspension were mixed 1 : 1 with the polymer solutions (100 mL
total volume) in a clear flat bottomed 96-well plate. The cells
were incubated at 37 1C for 2 h, and the absorbance was
measured at 645 nm in a microplate reader. Cells, which were
treated with PBS served as negative control and 25 kDa bPEI
(50 mgmL1, Polysciences) was used as positive control. Absorbance
values of the test solutions lower than the negative control were
regarded as aggregation. Experiments were run in triplicates and
were performed with three different batches of donor blood.
Polyplex uptake
HEK-293 cells (CRL-1573, ATCC) were cultured in RPMI 1640
medium (Lonza, Basel) supplemented with 10% FCS, 100 mg mL1
streptomycin, 100 U mL1 penicillin and 2 mM L-glutamine at
37 1C in a humidified 5% CO2 (v/v) atmosphere.
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For uptake studies, cells were seeded at a density of 105 cells
per mL in 24-well plates and cultured for 24 h. One hour prior
to the addition of the polyplexes, the medium was changed to
OptiMEM (Life Technologies, Darmstadt, Germany). The poly-
plexes were prepared as described above and at least 50 mL
polyplexes in solution were added to the cells. The plates were
incubated for 4 h at 37 1C, 5% CO2.
For kinetic studies of the polyplex uptake within 4 h, pDNA
was labeled with YOYO-1 iodide prior to the polyplex prepara-
tion. For labeling of 1 mg pDNA, 0.026 mL of 1 M YOYO-1
solution was mixed with pDNA and incubated for 20 min at 4 1C
protected from light. Afterwards, HBG buffer and polymers
were added at the indicated N/P ratio and the polyplexes were
formed as described previously. The cells were harvested 0.5, 1,
2 and 4 h after polyplex addition and 10% trypan blue was
added to quench the outer fluorescence of the cells. For energy-
dependent uptake studies, cells were equilibrated in OptiMEM
at 4 1C 1 h prior polyplex addition. The plates were incubated at
4 1C for 4 h. To determine the relative uptake of the polyplexes,
104 cells were measured by flow cytometry using a Cytomics FC
500 (Beckman Coulter) and the amount of viable cells showing
YOYO-1 signal were gated. Dead cells were identified via counter-
staining with propidium iodide (PI). The experiments were
performed at least three times independently.
For inhibition experiments, cells were treated with 100 mM
5-(N-ethyl-N-isopropyl)amiloride (EIPA) in standard culture media
30 min prior to polyplex addition. Subsequently, P3 and lPEI
polyplexes were added to the cells and incubated for further
4 h. Afterwards, the cells were harvested and analyzed as
described above via flow cytometry or were further prepared
for STEM imaging.
Transfection of adherent cells
For transfection of adherent HEK-293 cells, the cells were
seeded at a density of 105 cells per mL in 24-well plates and
incubated for 24 h at 37 1C, 5% CO2. One hour prior to
transfection, the cells were washed with PBS and supplemented
with 0.5 mL OptiMEM or fresh serum containing growth
medium (RPMI 1640). The polyplexes were prepared as
described above, and were added to the cells (50 mL per well).
After an incubation time of 4 h at 37 1C, the supernatant was
replaced by fresh growth medium and the cells were incubated
for further 20 h. For analysis via flow cytometry (Cytomics FC
500, Beckman Coulter), cells were harvested by trypsinization.
For determination of the viability during flow cytometry, dead
cells were identified via counterstaining with propidium iodide.
For determination of the transfection efficiency, 104 viable cells
expressing EGFP were gated. The experiments were performed
three times independently. Regarding the Bafilomycin experi-
ments, 175 nM Bafilomycin was added to the cells in OptiMEM
and incubated for 20 min, prior to the polyplex addition. The
knockdown studies were performed with stable EGFP expressing
CHO cells (CCL-61, ATCC, stable transfected with pEGFP-N1) and
the corresponding siRNA (against egfp, riboxx, Germany). The
polyplexes were incubated in OptiMEM for 6 h and measured
after 72 h via flow cytometry.
Electron microscopy
Scanning transmission electron microscopy with high-angle
annular dark-field detection (STEM-HAADF) was carried out using
a Technai G2 system (FEI), with 120 kV or 200 kV acceleration
voltage on ultrathin slices of resin-embedded cell samples.
For cell preparation, HEK-293 cells (105 cells mL1) were
seeded on 6-well plates and incubated for 4 h at 37 1C with the
respective polyplex samples (N/P 30). The cells were harvested,
washed with PBS and fixed for 2 h with glutaraldehyde (2% in
PBS, prepared from 8% EM grade stock solution) on ice.
Subsequent to aldehyde fixation, the cells were washed with
PBS prior to the fixation with OsO4 for 1 h (1% in PBS, prepared
from 4% EM grade stock solution, both purchased from EMS,
Hatfield). After this, the cells were washed with MilliQ water
and staining with uranyl acetate solution was carried out for
1 h and protected from light (1% in solution in MilliQ water
prepared from depleted uranyl acetate dihydrate purchased
from EMS, Hatfield). Subsequently, the sample was washed
with pure water prior to dehydration by an ethanol/water series
(50%, 70%, 90%, 2  100% dry EtOH, purified with a Solvent
Purification System and stored over molecular sieves). Thereafter,
the cells were transferred into BEEM capsules (Plano, Wetzlar),
in which the cell suspension was immersed in mixtures of
Embed 812 (EMS, Hatfield) and ethanol (Embed/EtOH = 1 : 1 v/v
for 1 hour, 2 : 1 v/v for 12 h, pure Embed 812 for 4 h).
Subsequent to a further exchange of the embedding medium,
the resin was allowed to harden at 70 1C for 24 h. From the
resin block, ultrathin sections with a thickness of 80 nm were
cut with an ultramicrotome (PT-XL PowerTome, RMC, Tucson)
using a diamond knife (RMC, Tucson). The ultrathin resin
sections were applied on a carbon supported copper grid
(400 mesh, Quantifoil, Jena).
Confocal microscopy and structured illumination microscopy
Live cell imaging was performed for uptake studies. In detail,
HEK cells (105 cells mL1) were seeded on glass-bottomed dishes
(ibidi, Germany, thickness 170  5 mm for high-resolution fluores-
cence microscopy) and cultivated for 24 h in a humidified atmo-
sphere. One hour prior to the polymer addition, the cells were
rinsed with phosphate buffered saline (PBS) and the medium
was changed to OptiMEM. The polyplexes were formed with
Cy5-labeled P3 and YOYO-labeled pDNA or Cy3-labeled siRNA,
added to the cells and incubated for further 4 h. Subsequently,
medium was replaced by fresh culture medium or PBS supple-
mented with Hoechst 33342 for nucleus staining, LysoTracker
Red DND-99 or LysoTracker Green DND-26 (all from Thermo
Fisher Scientific) for lysosome staining.
Imaging was performed with LSM880, Elyra PS.1 system (Zeiss,
Oberkochen, Germany) applying a 63 1.4 NA plan apochromat
oil objective. For SIM imaging, cells were grown on high precision
cover glasses (Marienfeld-Superior, 18  18 mm, 170  5 mm
certified thickness) at a density of 5  104 cells mL1, fixed with
paraformaldehyde (2% in PBS) and embedded in prolong
gold antifading reagent (Thermo Fisher Scientific). Regarding
the SIM performance, excitation wavelengths of 405 nm
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(exc. grating 28.0 mm), 488 nm (exc. grating 34.0 mm), 561 nm
(exc. grating 42.0 mm) and 642 nm (exc. grating 42.0 mm resp.
51.0 mm) were used. The following four color channels were
used for both microscopy techniques: Nucleus (Hoechst 33342
staining, excitation wavelength 405 nm, BP 420–480 + LP 750,
grey), pDNA (YOYO-1 Iodide, excitation wavelength 488 nm,
BP 495–550 + LP 750, green), polymer P3 (Cy-5 labeling, excitation
wavelength 642 nm, LP 655, blue) and lysosome (CellLight
Lysosomes-RFP BacMam 2.0, excitation wavelength 561 nm,
BP 570–620 + LP 750, red). The grating position and axial
position of the sample table were controlled by piezo controllers.
Images were recorded with a sCMOS camera (pco.edge, Kehlheim,
German), cooled to 5 1C. Reconstructions and deconvolution
were performed with the commercial ZEN2 software installed
on the system (Zeiss, Oberkochen, Germany).
Statistical analysis
The values represent the mean  SD. For the calculation of
the standard derivation of two or more different groups, the
two sample t-test (student’s t-test) or the ANOVA was used.
Statistical significance was defined as * for p-values of o0.05
and # for p-values o0.005.
Results and discussion
Polymer synthesis
As chain transfer reactions are more likely to occur during poly-
merization of 2-methyl-2-oxazoline,39 2-ethyl-2-oxazoline was used
as monomer for the polymerization of the precursor homopolymer,
being able to decrease cytotoxicity of aspired copolymers.40
PEtOx was synthesized according to a literature procedure by
microwave supported cationic ring-opening polymerization
(CROP).41 The degree of polymerization of 575 was calculated
from the tosylate 1HNMR signals of MeOTos before purification.
In order to ensure the absence of water, the polymerization
solutions were prepared in a glove box under nitrogen atmo-
sphere yielding PEtOx with a dispersity Ð of 1.3 (SEC: DMAc,
0.21% LiCl, standard: PS, Table 1). This homopolymer served as
precursor for the subsequent copolymer synthesis.
PEtOx was hydrolyzed in a microwave synthesizer (Scheme 1a)
to yield the copolymer poly(2-ethyl-2-oxazoline-stat-ethylene
imine) (P(EtOx-stat-EI)) with an EtOx content of 54% (calc.
from 1H NMR).38
To introduce primary amines to the polymers, a fraction of
the ethyleneimine units was functionalized with N-succinimidyl-
4-pentenate to introduce alkene functionalities (Scheme 1b).42
While the synthesis of poly(2-butenyl-2-oxazoline) is possible via
the polymerization of the respective monomers,36 these units
do not withstand the conditions of the acidic hydrolysis of
PEtOx. Three different copolymers of P(EtOx-stat-EI-stat-ButEnOx)
(preP1 to preP3) with varying ratios of secondary amines and
2-(3-butenyl-2-oxazoline)s (1 : 3, 1 : 2, 1 : 1) were synthesized
while maintaining a constant EtOx content of 54% (Table 1). The
introduction of primary amines was performed by thiol–ene photo-
addition. Hence, the copolymers P(EtOx-stat-EI-stat-AmButOx)
(P1 to P3) were synthesized by reaction of the corresponding
precursor copolymers (preP1 to preP3) with a protected aminothiol
under UV irradiation and subsequent deprotection to yield the
primary amine group (Scheme 1c and d).
Characterization by 1H NMR spectroscopy confirms the
presence of 2-ethyl-2-oxazoline (EtOx) as well as ethylene imine
(EI) units (Fig. 2, PEtOx and P(EtOx-stat-EI)). The integrals of
the signals of the EtOx side chain (A, B) as well as the signals of
the backbone (C) remain constant during further reactions and
are, therefore, used as reference.
The successful functionalization with the activated acid
N-succinimidyl-4-pentenate is exemplified by the proton signals
of the double bond (ButEnOx) that appear at 5.9 ppm (–HCQCH2,
H) and 5.1 ppm (–HCQCH2, I) for the copolymer preP3. The
first signal is used to calculate the composition of the formed
copolymer by comparing the signals of the ethylene imine
backbone (between 3.00 to 2.66, NH–CH2–CH2, D) and the methyl
protons of the EtOx side chain (between 1.22 to 0.97, CH2–CH3, A).
The successful functionalization of preP1 to preP3 with the thiol
is shown by the disappearance of the double bond signals after
the photoaddition (bocP3). The signals of the newly formed CH2
groups appear at 2.40 (I0) and 1.70 ppm (H0), respectively.
Furthermore, a singlet of the tert-butyloxycarbonyl (boc) pro-
tecting group is obtained at 1.50 ppm (L). After treatment with
Table 1 Composition and molar masses for PEtOx, P(EtOx-stat-EI), preP1 to preP3 and P1 to P3
Compositiona Amine ratio NMRb AF4 SEC
Abbr. Name X [%] Y [%] secX : primY Mn [g mol
1] Mn [g mol
1] Ð Mn [g mol
1] Ð
PEtOx PEtOx575 — — — 57000 57 000 1.2 69 000 1.3
P(EtOx-stat-EI) P(EtOx54%-stat-EIX) 46 — — 42100 31 300 1.3 48 000 1.3
preP1 P(EtOx54%-stat-EIX-ButEnOxY) 12 34 — 58100 25 500 1.4 36 000 2.1
preP2 P(EtOx54%-stat-EIX-ButEnOxY) 17 29 — 55800 30 900 1.3 34 500 1.6
preP3 P(EtOx54%-stat-EIX-ButEnOxY) 23 23 — 53000 30 400 1.3 36 000 1.6
P1 P(EtOx54%-stat-EIX-AmButOxY) 12 34 1 : 2.8 73 200 35 300 1.7 30 500 1.6
P2 P(EtOx54%-stat-EIX-AmButOxY) 17 29 1 : 1.7 68 600 43 700 1.7 39 000 1.6
P3 P(EtOx54%-stat-EIX-AmButOxY) 23 23 1 : 1 63 100 30 500 1.6 31 500 1.5
a Determined by 1HNMR (calculated from the ratio of EtOx, ButEnOx signals and EI backbone). b Determined by 1H NMR (calculated from tosylate
signals of MeOTos before purification).
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trifluoroacetic acid (TFA) and precipitation into diethyl ether,
the signal of the protecting group disappears, indicating the
successful deprotection of bocP1 to bocP3 and, consequently,
the synthesis of P(EtOx-stat-EI-stat-AmButOx) (P1 to P3).
A comparison of the composition and molar masses of
the prepared copolymers obtained by asymmetric flow field-
flow fractionation (AF4) and size exclusion chromatography
(SEC) is shown in Table 1. Although a trend is clearly visible,
the obtained values should be handled with care due to the
fact that the introduction of double bond containing ButEnOx
units as well as the cationic amine units (primary and secondary)
could lead to undesired column and membrane interactions
and, hence, to a change in the elution behavior. SEC traces,
exemplified for the synthesis of P2, are depicted in the ESI†
(Fig. S1).
To enable in vitro imaging, copolymer P3 was labeled using
one equivalent of Cy5–NHS per polymer chain. Successful dye
functionalization and purification via dialysis (3500 g mol1
cut-off) was verified by size exclusion chromatography (SEC),
revealing no trace of unbound dye (ESI,† Fig. S2).
Bio- and hemocompatibility
Biocompatibility represents a critical parameter for PEI based
polymers. One option to reduce the known cytotoxicity of PEI12,13,43
Scheme 1 Schematic representation of the synthesis of cationic copolymers. (a) Partial hydrolysis of poly(2-ethyl-2-oxazoline) in a microwave
synthesizer, (b) post-polymerization functionalization with N-succinimidyl-4-pentenate, (c) thiol–ene photo-addition of 2-(boc-amino)ethanethiol at
365 nm and (d) deprotection using trifluoroacetic acid.
Fig. 2 Comparison of 1H NMR spectra of PEtOx, P(EtOx-stat-EI), preP3, bocP3 and the final product P3 (* side product N-hydroxysuccinimide)
(300 MHz, MeOD).
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is the introduction of EtOx units.31 The copolymers introduced
here (P1 to P3) possess an oxazoline content of 54%, expected to
decrease severe cytotoxic effects. The cytotoxicity of P1 to P3 was
investigated in comparison to lPEI (Fig. 3A), obtained by full
hydrolysis of P(EtOx-stat-EI). Besides lPEI, commercial available
linear poly(ethylene imine) (comlPEI, 25 kDa, Polyscience) was
used as internal control. The results of the following in vitro
experiments performed with comlPEI are summarized in the
ESI† (Fig. S18–S20).
As assumed, lPEI leads to a significant reduction of cell
viability at low concentrations (IC50 of 3.6 mg mL
1), which is
in accordance to literature data.3 Despite a high molar mass
(425 kDa), P(EtOx-stat-EI) as well as P1 to P3 showed no
cytotoxicity after 24 h using polymer concentrations up to
1 mg mL1 (IC50 4 1 mg mL
1, Fig. 3A). This improvement
on cell viability is attributed to the introduced EtOx content of
54% within the copolymers and is consistent with literature
reports on partially hydrolyzed POx.32
The blood compatibility of the copolymers was further
investigated by assessment of the hemolytic activity (Fig. 3B)
as well as the aggregation of erythrocytes. The treatment of
P(EtOx-stat-EI) and P1 to P3 did not show any hemolytic activity in
a concentration range from 10 to 50 mg mL1. A slight hemolysis
(B1% hemoglobin release) could be revealed at higher concen-
trations of P(EtOx-stat-EI) and P1 (100 mg mL1). In contrast, lPEI
revealed an increased interaction with the cellular membranes
of the blood cells resulting in hemoglobin releases above 2%
(100 mg mL1) and, moreover, in a strong agglomeration of
erythrocytes (see ESI,† Fig. S3 and S4). The later was not
observed with EtOx containing copolymers (P(EtOx-stat-EI),
P1 to P3) indicating a good hemo- and biocompatibility.
Characterization of the polyplexes
Despite the beneficial impact of EtOx on the biocompatibility
of the polymers, their impact on the polyplex formation was
investigated. For this purpose, the ethidium bromide quenching
assay (EBA) was used to investigate the condensation of plasmid
DNA (pDNA) by P1 to P3 as well as P(EtOx-stat-EI), at different
nitrogen (polymer) to phosphate (DNA) ratios (N/P). Ethidium
bromide is excluded from its binding sites within the oligo-
nucleotides because of the electrostatic and hydrophobic inter-
actions between polymer and the nucleic acid, leading to a
reduction in fluorescence that can be correlated to the affinity
of the complexation.44,45 All copolymers (P1 to P3) revealed
decreasing fluorescence intensities below 40% relative fluores-
cence units (RFU, Fig. 4A). Stable polyplexes indicated by a
plateau were reached at higher N/P ratios 5 to 40, whereby no
significant differences between P1, P2, P3 and lPEI were
observed. In contrast, the precursors PEtOx (data not shown)
and P(EtOx-stat-EI) did not form appropriate polyplexes. It can
be assumed that the EtOx units prevent a strong binding
of the DNA to the secondary amines of the PEI backbone.
This reduced complexation affinity is compensated by the
introduction of the more flexible side chains consisting of
AmButOx (primary amines) within P1 to P3, which apparently
are essential for the polyplex formation. Interestingly, the combi-
nation of EI and AmButOx seems to be beneficial, since a
comparable copolymer P(MeOx-stat-AmButOx) without ethylene
imine units revealed reduced pDNA complexation around 60% RFU
in a previous study.17 A synergistic effect between both, primary
amines in the side chain and secondary amines in the backbone,
leads to an improved binding of DNA despite an EtOx content of
54%. The following studies of P1 to P3 were performed with
polyplexes formed at N/P 30 as this guarantees stable polyplex
formation.
To analyze the stability and the dissociation properties
of the formed polyplexes, the heparin dissociation assay was
performed.46–48 Heparin, a sulfated glycosaminoglycan, has
an anionic character and competes with the nucleic acid of
the polyplex. With increasing amount of heparin, the pDNA
dissociates from the polymer and the polyplex dissolves. As
indicated in Fig. 4B, polyplexes formed with partially hydro-
lyzed PEtOx (P(EtOx-stat-EI)) as well as P2 and P3 polymers
revealed a reversible binding, achieving 80% dissociation at
5 U mL1 heparin. A higher heparin concentration (20 U mL1)
was required for P1 reaching 80% dissociation. One reason for
Fig. 3 Determination of bio- and hemocompatibility. (A) Relative viability of L929 cells after 24 h incubation with the polymers at different
concentrations according to ISO10993-5. (B) Hemolysis assay of erythrocytes after incubation with polymers at the indicated concentrations. Triton
X-100 served as positive control (98.8% hemolysis) and PBS as negative control (0.2%). A value less than 2% hemolysis rate was classified as non-
hemolytic, 2 to 5% as slightly hemolytic and values 45% as hemolytic. Values represent the mean  S.D. (n = 3).
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this might be the higher amount of AmButOx, responsible for
an enhanced binding to the genetic material. However, a full
release from the copolymers P1 to P3 could not be achieved using
heparin. Therefore, another polyanion, namely poly(methacrylic
acid) (PMAA, DP = 200), was successfully used as competitor
(Fig. S5, ESI†). lPEI required an increased amount of heparin
(40 U mL1) as compared to the copolymers. These results
confirm the weakening of the electrostatic interactions caused
by the presence of EtOx units, which are beneficial for a fast
release of the genetic material.
As polyplexes are usually internalized into cells via endocytic
pathways, the size as well as the charge of the complexes is of
crucial importance. For efficient delivery, critical sizes of poly-
meric nanocarriers up to 200 nm are recommended.33,49
As depicted in Table 2, the polyplexes formed with P1 to P3 at
N/P 30 exhibit a favorable size of approximately 150 nm with a
positive net charge, as determined by dynamic and electro-
phoretic light scattering. P(EtOx-stat-EI) formed complexes
with a z-average of 242  73.4 nm and high polydispersity
(0.46) supporting the inefficient polyplex formation as observed
by EBA.50 Polyplexes formed with lPEI revealed a smaller
complex size of 80 nm with a positive net charge comparable
to previous studies.46 These results support our assumption that
the EtOx units impede the compact packaging of the genetic
material into small polyplexes. This can be compensated by the
presence of AmButOx units resulting in polyplex sizes between
lPEI and loosely bound P(EtOx-stat-EI) polyplexes. Therefore,
the tailored combination of EtOx and AmButOx units within
the copolymer structure can be used to design polyplexes with
required properties.
Transfection efficiency
Based on the previous results, the polymers P1 to P3 appear
to be promising candidates as non-viral gene delivery agents
and were, therefore, analyzed regarding their transfection
efficiency (TE) using human embryonic kidney (HEK) cells
and pDNA containing a enhanced green fluorescence protein
reporter gene (egfp). The TE was determined by flow cytometry
analyzing all viable cells (PI staining) which successfully
express EGFP (see ESI,† Fig. S6 and S7). To investigate
the interaction with serum proteins, a side effect of cationic
polymers, the cells were transfected in serum reduced media
(OptiMEM) and in serum containing media (RPMI1640 supple-
mented with 10% FCS) (Fig. 5). The use of serum offers
test conditions more comparable to an in vivo situation and
represents a known challenge for the performance of the
polymers due to the inhibitory effect of serum proteins on
the cellular uptake process.51,52
It should be noted that higher N/P ratios were required for
the copolymers as all nitrogen atoms were taken into account
for the N/P calculations. This includes also the amide function-
alities of EtOx and AmButOx although they are not capable to
interact with the pDNA. P1-based polyplexes were less efficient
as indicated by a TE below 50%. High TEs over 60% were
achieved in serum reduced conditions for P2 and P3 polyplexes
at N/P 30 to 50. Comparable TEs were obtained for lPEI at
N/P20. Compared to the transfection in OptiMEM, the EGFP
transfection level of P1 to P3 at N/P 50 in serum containing
media did not change considerably. Due to the cytotoxic effect
of lPEI and the influence of serum proteins the cell viability as
well as the TE decreased rapidly with increasing N/P ratios.
The combination of high cell viability (no cyto-/hemotoxicity)
and formidable transfection performance even in the presence
of proteins underlines the potential of P2 and, in particular, P3
as preferable gene delivery vectors. Moreover, P3 also withstands
Fig. 4 Polyplex formation and stability with pDNA using the polymers P(EtOx-stat-EI), P1, P2, P3 as well as lPEI, which was used as positive control.
(A) Complexation affinity (ethidium bromide quenching assay) of all polymers at the indicated N/P ratios. (B) Dissociation assay of polyplexes formed at
N/P 30 using heparin. Values represent the mean  S.D. (n = 3).
Table 2 Size and surface charge (zeta potential) of pDNA complexes at
N/P 30measured via dynamic light as well as electrophoretic light scattering
Polymeric system z-Average [d, nm] PDI Zeta potential [mV]
P(EtOx-stat-PEI) 242  73.4 0.46 20  0.44
P1 158  1.0 0.23 27  0.25
P2 143  1.4 0.21 23  0.11
P3 154  1.4 0.23 23  0.12
lPEI 80  2.3 0.17 33  4.23
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a comparison to lPEI and the literature known ‘gold standard for
transfection’, comlPEI (see ESI,† Fig. S18).
Uptake mechanism
For cationic polyplexes, the internalization into cells by endo-
cytosis followed by the endosomal release of the pDNA into
the cytosol and the subsequent transport into the nucleus
is reported.53,54 To clarify this process and to understand
the excellent transfection performance of the copolymers,
the uptake mechanism was investigated. An uptake kinetic
using polyplexes formed with YOYO-1 labeled pDNA was
performed to detect the internalization within cells by flow
cytometry (Fig. 6). All tested polymers exhibited a fast and time-
dependent cellular uptake. In detail, almost 90% of measured
cells internalized polyplexes after 4 h when medium is changed
Fig. 5 Transfection efficiency of copolymers P1 to P3 and lPEI for adherent HEK cells in serum reduced (OptiMEM, light grey) and serum containing
media (RPMI + 10% FCS, dark grey) at different N/P ratios after 24 h. Values represent the mean  S.D. (n = 3).
Fig. 6 Uptake study. Polyplexes formed with YOYO-1 labeled pDNA were incubated with HEK cells in OptiMEM for indicated time points using the
copolymers P1 to P3 and lPEI (N/P ratio 30) as control. Statistical analysis (t-test) was used to compare the MFI after 4 h of P1 with P3 and lPEI,
* represents p o 0.05 and # p o 0.005 of MFI values using student’s t-test. Values represent the mean  S.D. (n = 3).
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according to standard transfection protocol. In particular, P1 as
well as lPEI showed an enhanced uptake efficiency after 30 min
(B60%) compared to P2 and P3 (40%). Although most of the
cells internalized polyplexes, the quantities (mean fluorescence
intensities, MFI) differ significantly after 4 h (Fig. 6). Higher
internalized polyplex concentrations were detected in cells
using P2, P3 (twofold) and P1 (threefold) compared to lPEI.
An explanation might be the introduction of AmButOx to
the copolymers for enhanced complexation with the genetic
material and cellular uptake, while the EtOx content possessing
reduced membrane disruption.
To preclude an uptake by passive membrane diffusion, the
uptake of YOYO-1 stained polyplexes was performed at 4 1C and
37 1C, respectively (Fig. S8B, ESI†). Polyplexes of all tested
polymers were internalized into cells at 37 1C with approxi-
mately 90% efficiency. In contrast, the uptake efficiency was
significantly decreased to approximately 10% at 4 1C for all
samples. This indicates an energy-dependent uptake (endocytotic
process). Furthermore, bafilomycin, a proton pump (H+-ATPase)
inhibitor, was used to prevent endosomal release caused by
acidification (Fig. S8A, ESI†). The inhibition of an endosomal
escape prevents the release of pDNA into the cytoplasm, the
transfer into the nucleus and the EGFP expression. As expected,
the TE significantly decreased after treatment with bafilomycin
for all tested polymers too5%. This indicates the involvement
of the endosomal uptake and release as critical steps during the
transfection mechanism, as it is reported for PEI.43,55
High resolution microscopy of polyplex–cell interactions
Deeper insights into the uptake mechanism and the fate of
polyplexes within the cells were obtained with microscopic studies
including confocal microscopy, structured illuminationmicroscopy
(SIM) and high-angular annular dark-field scanning transmission
electron microscopy (HAADF-STEM).
Confocal microscopy as well as SIM studies were performed
with HEK cells and polyplexes based on YOYO-1 labeled pDNA
and Cy5-labeled P3 representing the polymer with the overall
highest transfection efficiency compared to lPEI. Fluorescence
imaging of cells, in particular SIM images, revealed a co-localization
of pDNA-bound P3 polyplexes (blue) within the lysosomes/late
endosomes (red, RFP labeling, Fig. 7 and Fig. S9 and S10, ESI†).
The detection of the YOYO-signal within the cytoplasm that was
not co-localized with lysosomal structures reveals that pDNA
is released from the polyplex itself. Considering the low con-
centration of heparin required to destabilize the polyplex, an
efficient release of pDNA into the cytoplasm can be assumed. As
SIM provides a resolution of approx. 100 nm, a more detailed
insight into the polyplex behavior within the lysosomes/late
endosomes was obtained compared to conventional confocal
imaging. A non-centrically localization of P3 polyplexes
Fig. 7 High resolution imaging. (A) Structured illumination image of P3-based polyplexes within cells (deconvolved data). White arrows indicate
co-localization of P3-pDNA polyplexes within lysosomes. (B and C) Magnified view of the yellow and red, dash-lined frame in (A): P3-Cy5 polyplex within
the endosome. 63 Oil Obj. 1.4 NA. Grey: Hoechst 33342. Red: lysosomal membrane (RFP). Green: plasmid DNA labeling (YOYO-1). Blue: polymer
labeling (Cy-5). (D–F) HAADF-STEM images of P3-based polyplexes taken up by HEK cells. The following letters correspond to cell organelles: N = cell
nucleus, M = mitochondria, E = endosomal compartment, P = polyplex.
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(Cy5 and YOYO-1 signal) within the endosome (red) was
observed, being in close vicinity to the endosomal membrane
(Fig. 7A and zoom-in Fig. 7B and C, single channel splitting:
Fig. S11, ESI†). This could be attributed to a strong interaction
between the polyplex and the cytoplasmic membrane at the time
of the cellular uptake or a strong interaction of the polyplex with
the endosomal membrane caused by acidification. However, also
lPEI polyplexes (Cy5 and YOYO-1 signal) were localized in close
vicinity to the endosomal membrane (Fig. 8A and zoom-in Fig. 8B
and C, single channel splitting: Fig. S12, ESI†). Interestingly, a
higher number of larger endosomes bearing polyplex signals
with an apparent larger spatial dimension was found for lPEI
in contrast to P3. To study the interaction of both polymers
with the endosomal membrane in more detail, STEM on
embedded sections was carried out to confirm this assumption.
STEM provides a resolution in the low nanometer range,
elucidating the subcellular ultrastructural context, and particularly,
highlighting membrane structures. EM images revealed an uptake
of single P3 polyplexes into vesicles with sizes of 200 to 500 nm
(n 4 10 vesicles of different sections were analyzed, Fig. S13,
ESI†). Although, the polyplexes themselves provide only poor
electron contrast, their structures were highlighted efficiently
within the cellular environment (Fig. 7D–F) in the sample by
sample staining. This can be explained by the strong affinity
of the amines of the polymer and phosphates of the DNA to
the heavy metal stains (OsO4 and uranylacetate, respectively).
The close vicinity between P3 polyplex and the endosomal
membrane was confirmed. We attribute this observation to a
preceding active cell membrane-driven uptake event, initiated
by strong interaction of a single polyplex with the membrane.
We observed an uptake event involved by membrane ruffles
and lamellipodia-like structures (Fig. 7E and F), supporting our
previous findings concerning an energy-dependent uptake,
such as by macropinocytosis. We therefore investigated cells after
incubation with P3 polyplexes in the presence of the inhibitor,
5-(N-ethyl-N-isopropyl)amiloride (EIPA, 100 mM). Our experiments
support the assumption, since only 25% of the cells internalized
P3 polyplexes after 4 h (see ESI,† Fig. S14). Performing STEM
imaging, we observed no P3 polyplexes within the cytoplasm
(see ESI,† Fig. S15A and B). This underlines an uptake mechanism
via macropinocytosis.
STEM images of lPEI polyplexes revealed larger endosomes
with sizes of 500 to 1500 nm (n 4 10 vesicles of different
sections were analyzed, Fig. S16, ESI†) bearing more than a
single polyplex as well as increased cellular membrane rupture
(Fig. 8D–F). The presence of multiple polyplexes within large
endosomes explains the large spatial dimension of the polyplex
signals as being found in SIM images (Fig. 8F). STEM images
of cells, which were incubated with lPEI polyplexes in the
presence of a macropinocytosis inhibitor (EIPA), revealed indeed
a cellular internalization (see ESI,† Fig. S15C and D). However,
the uptake efficiency was apparently lower compared to the
Fig. 8 High resolution imaging. (A) Structured illumination image of lPEI-based polyplexes within HEK cell, white arrows indicates full co-localization
(deconvolved data). (B and C) Magnified zoom of yellow and red, dash-lined frame in (A): lPEI-Cy5 polyplex within the endosome. 63 oil obj. 1.4 NA.
Grey: Hoechst 33342. Red: lysosomal membrane (RFP). Green: plasmid DNA labeling (YOYO-1). Blue: polymer labeling (Cy-5). (D–F) HAADF-STEM
images of lPEI-based polyplex taken up by HEK-293 cell. The following letters correspond to cellular structures: N = cell nucleus, M = mitochondria,
E = endosomal compartment, P = polyplex.
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standard uptake protocol (B65% YOYO-positive cells after 4 h)
and hints towards alternative uptake mechanisms in addition
to macropinocytosis. It was already demonstrated that lPEI
possesses a high membrane activity (see erythrocyte aggrega-
tion, Fig. S3 and S4, ESI†), which is in association with polymer
aggregation in serum containingmedia5 and could lead to enhanced
uptake of multiple polyplexes within single endosomes. Aggregated
polyplexes could be also responsible for a reduced uptake
because of a size-limited uptake mechanism, e.g. endocytosis.
The presence of EtOx subunits within P3 shields the formed
polyplexes from aggregation caused by protein interaction prior
to uptake. This might be a reason for a more efficient cellular
uptake and the high transfection efficiency of the respective
copolymer. Based on this data, the efficient endosomal release of
single P3 polyplexes is impressive compared to agglomerated
lPEI polyplexes. Due to the high buffer capacity of lPEI, an
enhanced protonation of amines followed by the swelling of
the endosomesmight occur, as it is hypothesized for the ‘‘proton
sponge’’ effect.6,51,53,54,56 In case of P3, the full protonation of the
primary/secondary amines could lead to a destabilization of the
membrane indicating a membrane rupture and the subsequent
release of the cargo into the cytosol. A previous study of Zuhorn
and co-workers describes a similar process for PEI polyplexes
supporting these findings.52 Additionally, the authors showed
that the release did not come along with a complete rupture
of the endosome. As the polymers P1 to P3 possess a content of
12 to 23% secondary amines and a content of primary amines of
34 to 23%, they do not show such a severe swelling of endosomal
compartments like lPEI polyplexes. Nevertheless, it can be assumed
that a protonation of the primary amines in the side chain
within the endosomal compartments forces the interaction of
the polymers with the endosomal membrane leading to an
efficient endosomal release. These results indicate that not only
the buffer capacity and the swelling of endosomal compartments
but also the interaction of the polymer with the endosomal
membrane facilitate the escape from the endosome, which is in
accordance to literature data and visualized in detail.51,52
siRNA delivery
To further investigate the potential of the modified PEI
copolymers, the delivery efficiency for siRNA was determined.
Although DNA and siDNA represent genetic material they differ
in certain characteristics. Most importantly, siRNA is smaller
(o30 base pairs (bp) compared to 4700 bp pDNA) and more
rigid. From a biological point of view, pDNA has to be trans-
ferred across the nuclear barrier to the cell nuclei, whereas
siRNA has to be released from the polyplex in the cytoplasm to
form the RNA-induced silencing complex (RISC).57
The copolymers P1 to P3 were further investigated regarding
the influence of primary and secondary amines for siRNA delivery.
High binding affinity to siRNA (o40%) of all tested polymers was
observed by EBA (Fig. 9A). Positively charged polyplexes with a size
of o200 nm were formed, whereas lPEI polyplexes exhibited
a compact size of around 83 nm (Table 3). This trend was also
observed for the pDNA based polyplexes (see Table 2).
A GFP-expressing CHO cell line was used to estimate the
knockdown efficiency (Fig. 9B). Interestingly, P1 showed superior
knockdown efficiency for siRNA (244  50.3 MFI), compared
to P3 (317  19.3 MFI), which was identified as best performer
for pDNA transfection. Both, P1 and P2, led to a significant
reduction of around 40% of the fluorescence intensity of
EGFP-expressing cells. In contrast, P3 showed only 10 to 20%
reduction of MFI. Interestingly, lPEI as well as branched PEI
Fig. 9 Investigations of the siRNA delivery. (A) Binding affinity of siRNA to P1 to P3 and lPEI at different N/P ratios measured by the fluorescence
quenching of ethidium bromide. The fluorescence of pure siRNA represents 100% RFU. (B) siRNA knockdown mediated by P1 to P3, lPEI and jetPRIME
polyplexes at N/P 30 after 72 h. Stable EGFP-expressing CHO cells were transfected with polyplexes formed using siRNA able to knock down egfp.
Statistical analysis (t-test) was used to compare the mean fluorescence intensity (MFI) of the control with P1 to P3 and lPEI, * represents p o 0.05 and
# p o 0.005. The values represent the mean  S.D. (n Z 3).
Table 3 Size and surface charge (zeta potential) of the siRNA complexes
at N/P 30 measured via dynamic light as well as electrophoretic light
scattering in water-based HBG buffer
Polymeric system z-Average [d, nm] PDI Zeta potential [mV]
P1 102  1.2 0.15 21  1.2
P2 124  1.5 0.13 25  1.0
P3a 149  12.6 0.49 22  0.1
lPEI 83  2.3 0.23 33  1.6
a Intensity weighted size distribution revealed a mean peak of 257 nm
(68%).
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(bPEI) revealed high knockdown potentials of around 60%
(Fig. 9B). ComlPEI was less efficient and exhibited comparable
efficiencies to the copolymers P1 and P2 (Fig. S20, ESI†). However,
the highest knockdown (480%,B68 3.9MFI) was achieved with
the positive control jetPRIME (cationic, polymeric transfection
reagent, Polyplus). The fluorescence intensities were not reduced
when using scrambled siRNA (negative control, see ESI,† Fig. S17).
The polymers P1 and P2 revealed adequate knockdown levels, but
are not as effective as commercially available siRNA transfection
agents. Nevertheless, the promising performance and high bio-
compatibility of these 3rd generation PEIs could be developed in
future studies by optimizing the polymeric design and composition
as a higher AmOx content shows improved performance.
To understand the different performances of the copolymers
depending on the genetic material, the endosomal release has
to be considered. For successful delivery of siRNA a fast and
efficient release from the endosome into the cytosol is bene-
ficial, whereas the transfection efficiency of pDNA is increased,
when it is transported to the perinuclear region inside endo-
somal compartments.58
From the titration of the polymers P1 to P3 (Fig. 10A) the
buffer capacities of the respective copolymers were calculated
(b = dn(OH)/dpH) and expressed as a function of the pH value
(Fig. 10B). The copolymers show considerable higher buffer
capacities with increasing EI content for pH values between
5 and 7 (endosomal release environment). As P3 revealed the
Fig. 10 (A) Acid–base titration curves of an acidified solution of the cationic copolymers P1 to P3 (B5 mg mL1) dissolved in 4 mL hydrogen chloride
(HCl, 0.06 M) and neutralized with sodium hydroxide (0.1 M). For comparison, 0.06 M HCl was titrated accordingly. Precipitation of lPEI at pH 7 prevents
the interpretation of the respective titration curve. (B) The buffer capacities of the cationic copolymers P1 to P3 were calculated from A utilizing the
relation b = dn(OH)/dpH and presented as a function of the pH value. For comparison, the buffer capacity of HCl is included.
Fig. 11 Schematic representation of the polyplex formation illustrating the interaction of 3rd generation poly(ethylene imine) with pDNA or siRNA.
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highest buffer capacity at acidic conditions, this could be an
explanation for the diminished performance for siRNA delivery
due to a delayed endosomal escape. In contrast, P1 showed
the highest degree of protonation at endosomal pH values
facilitating a faster endosomal release into the cytosol by inter-
action of the charged amines with the endosomal membrane. It
should be kept in mind, that P1 and P2 revealed also a high
buffer capacity at a pH value around 9, in contrast to P3, which
could be a hint for different performances.
Moreover, it could be assumed that the different physico-
chemical parameters of the genetic material (size, topology)
play a crucial role for the interaction with the 3rd generation
PEIs (Fig. 11). siRNA is small and stiff preferentially interacting
with the primary amines in the polymer side chain. In contrast
to that, the large pDNA requires the interaction with the primary
amines (flexible side chains) as well as the secondary amines
(backbone). This enabled an tremendous enhancement of
pDNA delivery compared to literature reported polymer systems,
e.g. P(EtOx-stat-MeOx).17
Conclusion
The introduced 3rd generation PEI copolymers has shown to
present several advantages in contrast to 1st (PEI) and 2nd
(single PEI modifications) generation approaches in terms of
efficient polymeric gene delivery. Starting from high molar
mass PEtOx, partially hydrolyzed P(EtOx-stat-EI) copolymers were
synthesized. Subsequently, different amounts of the ethylene
imine subunits were functionalized, introducing alkene groups
which, in turn, could be used to attach primary amine groups
in the side chains using thiol–ene chemistry. While the EtOx
content of these polymers remained constant, the ratio between
primary and secondary amine groups was varied to obtain a
series of copolymers. It should be highlighted that no adverse
effects on the cell viability was observed for polymer concentra-
tions up to 1 mg mL1 in contrast to lPEI (IC50 = 3.6 mg mL
1).
Remarkably, these 3rd generation PEIs were, in contrast to the
2nd generation P(EtOx-stat-EI), able to form well-defined com-
plexes with various genetic materials, in detail pDNA and siRNA.
Besides a fast uptake, the delivery of pDNA revealed comparable
transfection efficiencies to lPEI. In serum containing media,
the performance of copolymer-based polyplexes could even
exceed the efficiency of lPEI. Furthermore, the copolymers (in
particular P1 and P2) revealed siRNA delivery capability as well.
Nevertheless, an optimization of this approach should be further
pursued in future studies. Noteworthy, a different ratio of
primary to secondary amines is required to form appropriate
polyplexes with siRNA emphasizing the multivalence and potential
of the presented polymeric system.
Using live cell confocal microscopy, super-resolution micro-
scopy as well as transmission electron microscopy of ultrathin
sections of embedded cell samples, the transfection mechanism
was elucidated in more detail. In contrast to lPEI, where endo-
somes contained multiple polyplexes in swollen endosomes,
copolymer based polyplexes present themselves individually
within the endosomal compartments. This was attributed to a
lower protein interaction of PEtOx containing vectors, preventing
agglomeration in serum containingmedia prior to uptake as well
as to a diminished membrane interaction. This feature also
leads to a release process based on membrane interactions of
the described polyplexes in contrast to the ‘‘proton sponge’’
effect hypothesized for PEI. The 3rd generation PEI outperforms
PEI of former generations (1st and 2nd) concerning an overall
concept in terms of toxicity as well as transfection efficiency for a
wide range of genetic materials. Thus, it represents a promising
alternative for more complex transfection approaches including
hard-to-transfect cells or in vivo studies.
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Figure S1. Size exclusion chromatography traces of the starting homopolymer PEtOx and the copolymers 
P(EtOx-stat-EI), preP2 and P2 (N,N-dimethylacetamide, 0.21% LiCl, calibration: polystyrene).
Figure S2. Size exclusion chromatography elugrams of the labeled copolymer P3 (P3-Cy5) in comparison to the 
unlabeled starting material (P3) (N,N-dimethylacetamide, 0.21% LiCl, calibration: polystyrene).
Hemocompatibility of PEI-based polyplexes
The erythrocyte aggregation of the PEI copolymers was performed in parallel with high molar 
mass lPEI polymers as positive controls. lPEI show membrane-perturbing activity at high 
concentrations (100 µg mL-1) leading to the aggregation of erythrocytes as indicated in the 
photospectrometrically measurement and by light microscopy. This effect was not seen with 
the copoly mers P1 to P3.
Figure S3. Erythrocyte aggregation of the tested polymers at indicated concentrations. bPEI (25 kDa) served as 
positive control resulting in high aggregation formation and PBS as negative control. Values represent the mean 
± S.D. (n=3).
Figure S4. Light microscopy of erythrocyte aggregation of the polymers P1 to P3, PEtOx and both lPEI 
polymers. PBS served as negative control, while bPEI (25kDa) was served as positive control. Scale bar = 50 µm.
Interaction of polymers with genetic material
The polyplex dissociation assay was performed aside from heparin with poly(methacrylic acid) 
(PMAA) (DP = 200) as competing factor. To keep equal conditions, same PMAA 
concentrations as for heparin were used during the measurement. 
Figure S5. Dissociation assay of polyplexes formed with pDNA at N/P 30 and with increasing PMAA 
concentrations, which correlates to heparin concentrations.
Analysis of polyplex uptake and transfection of cells
The uptake and transfection studies were performed with HEK cells and pDNA encoding the 
EGFP (enhanced green fluorescence protein) or with YOYO-labeled pDNA. Transfection 
efficiency was determined by measuring the amount of viable cells (PI stained) expressing 
EGFP after 24 h via flow cytometry, whereas non-transfected cells served as negative control. 
To determine the amount of EGFP expressing cells, the histogramm of control cells was used 
and the percentage of cells within the gated area was defined as transfection efficiency in 
percentage.
Figure S6. Flow cytometry measurements. A) Dot-plot of PI stained HEK cells for determining cell viability. 
FL2 Log represents red fluorescence of PI stained cells. All cells within the specified area G represent all measured 
viable cells. B) Histogramm of non-transfected cells served as control. FL1 Log represents green fluorescence by 
EGFP expression.
Figure S7. Histograms of flow cytometry measurements determining positive EGFP-expressing HEK cells after 
24 h post-transfection with P1 to P3 and lPEI (N/P 30). Only viable HEK cells (PI staining) were gated. FL1 Log 
represents green fluorescence by EGFP expression.
To investigate the uptake mechanism in detail, cells were treated at different conditions with 
bafilomycin (proton pump inhibitor) or at 4 °C and 37 °C.
Figure S8. A) Uptake study: amount of cells taken up YOYO-1 labeled pDNA after 4 h at different temperatures 
(4 °C and 37 °C) using the copolymers P1 to P3 and lPEI (N/P ratio 30) as controls. Values represent the mean 
(n = 3). B) Comparison of the transfection efficiency of P1 to P3 and lPEI for adherent HEK cells in serum 
reduced (OptiMEM) and serum containing media (RPMI + 10% FCS) as well as after bafilomycin treatment at 
N/P 30. Values represent the mean (n = 3).
Live cell imaging
Confocal as well as structured illumination microscopy were used to investigate the uptake 
process of polyplexes in more detail and for visualization purposes. Therefore, non-treated 
control HEK cells as well as P3 polyplexes added to HEK cells in serum reduced media were 
analyzed.
Control: pDNA transfection
Figure S9. Uptake studies: HEK cells in serum reduced media without polyplexes served as negative controls. 
The cells were analyzed after 4 h via confocal laser scanning microscopy. The cell nucleus was stained with 
Hoechst 33342, the lysosomes with LysoTracker Red.
P3-Cy5: pDNA transfection
Figure S10. Uptake studies: Pure YOYO-labeled pDNA was added to HEK cells in serum reduced media. The 
cells were analyzed after 4 h via confocal laser scanning microscopy. The cell nucleus was stained with 
Hoechst 33342, the lysosomes with LysoTracker Red.
Structured illumination microscopy (SIM)
Figure S11. Magnified SIM images of endosome bearing polyplexes formed with P3 in the presence of DNA 
(SIM data, deconvolved, acquired with 63x Oil Obj. 1.4 NA). Red; Lysosomal membrane (RFP). Green: pDNA 
labeling (YOYO-1). Blue: Polymer labeling (Cy5). A and E: Merged channels. B-D, F-H: split channels. Scale 
bars = 1 µm,
Figure S12. Magnified SIM images of endosome bearing polyplexes formed with lPEI in the presence of DNA 
(SIM data, deconvolved, acquired with 63x Oil Obj. 1.4 NA). Red; Lysosomal membrane (RFP). Green: pDNA 
labeling (YOYO-1). Blue: Polymer labeling (Cy5). A and E: Merged channels. B-D, F-H: split channels. Scale 
bars = 1 µm,
Scanning transmission electron microscopy (STEM)
To obtain deeper insights into the uptake mechanism and the fate of polyplexes inside the cell 
as well as the endosomal environment, scanning transmission electron microscopy (STEM) 
were performed. The images display a section (thickness of the resin slice: 80 nm) through the 
cell and sizes are determined by a two-dimensional section through the cell. This can only 
conditionally make a statement of the actual size of the three-dimensional vesicle. More than 
5 sections (and ~ 10 vesicles) of different cells were analyzed to evaluate our findings.
Figure S13. STEM images of polyplex uptake in HEK cells at standard conditions. Polyplexes were formed with 
P3 and pDNA. Cells were harvested after 4 h.
Macropinocytosis inhibitor
For inhibition experiments, cells were treated with 100 µM 5-(N-ethyl-N-isopropyl)amiloride 
(EIPA) in standard culture media 30 min prior to polyplex addition. Subsequently, P3 and lPEI 
polyplexes were added to the cells and incubated for further 4 h. Afterwards, the cells were 
harvested and analyzed as described above via flow cytometry or were further prepared for 
STEM imaging. 
 Figure S14. Polyplex uptake (YOYO-labeled pDNA) in HEK cells after treatment with EIPA (macropinocytosis 
inhibitor). 
Figure S15. STEM images of polyplex uptake in HEK cells after treatment with EIPA (macropinocytosis 
inhibitor). A-B) Uptake of P3 polyplexes. C-D) Uptake of lPEI polyplexes. White arrows indicate vesicles with 
polyplexes.
 Figure S16. STEM images polyplex uptake in HEK cells at standard conditions. Polyplexes were formed with 
lPEI and pDNA. Cells were harvested after 4 h.
siRNA delivery
A stable GFP-expressing CHO cell line was transfected with the polymers P1 to P3 as well as 
PEI using scrambled siRNA as negative control. The knockdown of EGFP was analyzed via 
flow cytometry by measuring the MFI of all viable cells (PI staining).
Figure S17. siRNA transfection efficiency mediated by P1 to P3 as well as PEI polyplexes at N/P 30 after 72 h. 
Stable EGFP-expressing CHO cells were transfected with scrambled siRNA served as negative control. The 
values represent the mean ± S.D., n ≥ 3.
Comparison of lPEI and commercial lPEI25k (comlPEI, Sigma Aldrich)
The cytotoxicity tests of the PEI copolymers were performed in parallel with high molar mass 
lPEI polymers as positive controls. Fully hydrolyzed PEtOx, thus lPEI as well as the 
commercially available lPEI (25 kDa, comlPEI) obtained from Polysciences were used. The 
synthesized lPEI shows a higher cytotoxicity (IC50 at ~ 4 µg mL-1), whereas the commercial 
PEI reaches 50% cell viability at 25 µg mL-1. The reduced cytotoxicity could be attributed to 
residual, N-acyl groups from polymerization, which is also stated by the supplier.[39] 
Furthermore, the hemolysis and the erythrocyte aggregation assay were performed with both 
PEIs. Both polymers show membrane-perturbing activity at high concentrations (100 µg mL-1) 
leading to hemoglobin release and the aggregation of erythrocytes. This effect was not seen 
with the copolymers P1 to P3.
Figure S18. Comparison of lPEI and commercially available PEI (comlPEI, Polysciences). A) Cytotoxicity assay 
treating L929 cells with the synthesized lPEI as well as comlPEI at indicated concentrations. B) Hemolysis assay 
of erythrocytes after incubation with polymers at indicated concentrations. Triton X-100 served as positive control 
(100% hemolysis) and PBS as negative control. C) Erythrocyte aggregation of the tested polymers at indicated 
concentrations. bPEI (25 kDa) served as negative control resulting in high aggregation formation and PBS as 
negative control. Values represent the mean ± S.D. (n=3).  
Figure S19. Comparison of lPEI and commercially available PEI (comlPEI, Polysciences). A) Complexation 
affinity (EBA) of mentioned polymers using pDNA at the indicated N/P ratios. B) Dissociation assay with heparin 
of polyplexes formed with pDNA at N/P 30. C-D) Transfection efficiency of both PEI polymers for adherent HEK 
cells in serum reduced (C) as well as serum containing (D) media at different N/P ratios after 24 h. Values 
represent the mean ± S.D. (n=3).
Besides the synthesized lPEI, comlPEI was used as control for the ethidium bromide quenching 
assay (Figure S18A). Both polymers show a high complexation affinity with pDNA, while a 
faster polyplex formation of lPEI could be detected at N/P 5. Regarding the heparin dissociation 
assay, comlPEI achieved a full decomplexation of genetic material at a heparin concentration 
of 10 U mL-1 (Figure S19B). For the complete release of pDNA (100% RFU) from lPEI 
polyplexes, 40 U mL-1 heparin was required. The uptake and transfection studies were 
performed with HEK cells and pDNA encoding the EGFP (enhanced green fluorescence 
protein). Transfection efficiency was determined by measuring the amount of cells expressing 
EGFP after 24 h via flow cytometry. ComlPEI shows high TE > 80% at N/P ratios of 20 to 50 
in serum reduced media, which is comparable to other studies. It has to be mentioned that with 
increasing N/P ratio, i.e. the polyplex concentration, the cell viability is reduced. This effect 
could be prevented using serum containing media for transfection, whereas a significant 
reduction of up to 70% (at N/P 20) of TE is occured. 
Figure S20. siRNA transfection efficiency mediated by PEI polyplexes at N/P 30 after 72 h. Stable EGFP-
expressing CHO cells were transfected with polyplexes formed using siRNA able to knock down egfp. Statistical 
analysis (t-test) was used to compare the MFI of the control with PEI, * represents p < 0.05 and # p < 0.005. The 
values represent the mean ± S.D., n ≥
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The targeted drug delivery to the central nervous system represents one of the major challenges in pharmaceu-
tical formulations since it is strictly limited through the highly selective blood-brain barrier (BBB). L-Glutathione
(GSH), a tripeptide and well-known antioxidant, has been studied in the last years as potential candidate to fa-
cilitate the receptor-mediated transcytosis of nanocarriers.We thus testedwhether GSH decoration of a positive-
ly charged polymer, poly(ethylene imine), with this vector enables the transport of genetic material and,
simultaneously, the passage through the BBB. In this study, we report the synthesis of GSH conjugated cationic
poly(ethylene imine)s via ecologically desirable thiol-ene photo-addition. The copolymers, containing 80% pri-
mary or secondary amine groups, respectively, were investigated concerning their bio- and hemocompatibility
as well as their ability to cross a hCMEC/D3 endothelial cell layer mimicking the BBB within microﬂuidically per-
fused biochips. We demonstrate that BBB passage depends on the used amino-groups and on the GSH ratio.
Thereby the copolymer containing secondary amines showed an enhanced performance. We thus conclude
that GSH-coupling represents a feasible and promising approach for the functionalization of nanocarriers
intended to cross the BBB for the delivery of drugs to the central nervous system.
© 2016 Elsevier B.V. All rights reserved.
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1. Introduction
Discovered by Paul Ehrlich in 1885 and named by Max
Lewandowsky in 1900, the blood-brain barrier (BBB) is known as one
of the most challenging obstacles concerning the delivery of drugs and
therapeutic nucleic acids [1,2]. Within the BBB, specialized endothelial
cells of the cerebral vasculature (cerebral microvascular endothelial
cell, CMEC) form an endothelial layer that strictly regulates the passage
of small molecules. The tightness of the BBB is furthermore regulated by
astrocytes and pericytes that are in direct contact with the CMECs [3].
The BBB passage ofmolecules depends on several parameters, including
themolecular size, lipid solubility, hydrophilicity, and the degree of dis-
sociation. The passage of macromolecules as well as of 98% of small
molecules (b400 g mol−1) is prevented under physiological conditions
[4]. Besides the passive transport, which comprises the diffusion of
small molecules [5], the active transport of amino acids and macromol-
ecules such as transferrin is described to bemediated by carrier proteins
or transcytosis [6]. While the transport of different amino acids is well-
investigated [7], the transport of L-glutathione (GSH), a tripeptide
which is known as antioxidant that lowers the oxidative stress level
within the brain, is currently under investigation [8–10].
In order to circumvent the BBB, several methods including the inva-
sive direct injection into the central nervous system (CNS) and the non-
invasive nasal delivery of nanoparticular and liposomal carriers as well
as of covalently targeted small molecules have been investigated [11,
12]. However, nasal delivery possesses the difﬁculty to adjust the ther-
apeutic delivery due to individually varying absorption proﬁles, limited
volume and long term side effects [11].
Introducing targetingmolecules to nanocarriers is the key to beneﬁt
from the active transporting systems and to enable also the passage of
larger drugs. Non-viral receptor- and adsorptive-initiated transcytosis,
as well as carrier-mediated transport can be used for an active transcel-
lular vector-based drug delivery. By using larger biomolecules like anti-
bodies and peptides [13,14], additional surface modiﬁcations like
PEGylation and polysorbate 80 (“Tween 80” or polyoxyethylene(20)
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sorbitanmonooleate) [15] or smallmolecule conjugation (such asGSH),
BBB passage could be revealed successfully [16–19]. The latter has been
successfully used to modify nanoparticles for drug delivery resulting in
an enhanced passaging ability of the BBB [20,21]. Recently, Grover et al.
combined two known techniques to create a novel nanoparticle system
(PEGylation andGSH coating), while Gaillard et al. showed the improve-
ment of the BBB passage using liposomal carrier systems [20,21]. The 2-
BBB company has already startedwith two clinical trials regarding lipo-
somal based PEGylated and GSH decorated particles bearing doxorubi-
cin and methylprednisolone [22]. At the end of 2014 positive results
from phase 1 were announced showing a BBB passage and anti-tumor
properties. This reveals that the decoration with GSH seems to be a
promising targeting approach also for other carrier systems. While the
choice of targeting molecules inﬂuences the transcytosis efﬁciency, the
nanocarrier material should be adopted to the transported drug. There-
fore, synthetic as well as natural polymers (e.g. polysaccharides, pro-
teins) have been used for the transport of drugs and genetic material
[23]. Among others, polybutylacrylate (polysorbate 80) [24] and PLA/
PGA or PLGA (TAT [25] or polysorbate 80 [26]) have been successfully
established in in vivo tests for the encapsulation of hydrophobic drugs.
In order to enable nucleic acid delivery to the central nervous system
(as novel treatment option of neuronal-related diseases), there is an ur-
gent need for appropriate binding nanocarriers. Cationic polymers, in
particular poly(ethylene imine) (PEI), represent a class of suitable can-
didates for the complexation of geneticmaterial by electrostatic interac-
tions [27]. Due to its superior buffering ability enabling endosomal
escape, PEI is known as the gold standard of polymeric carriers for
gene delivery in vitro [28]. However, its potential is accompanied with
high cytotoxicity and non-biodegradability [29]. The functionalization
of the linear PEI backbone [30] and the addition of side chains, creating
copolymers, represent a powerful strategy to overcome these limita-
tions and have been extensively studied attaching various carbohy-
drates [31–33] or polymers like poly(ethylene glycol) [34].
However, these in vitro studies were based on standard cell culture
techniques under static culture conditions. Shear forces as observed in
vivo and their impact on endothelial cells [35] as ﬁrst cells to come in
contactwith administereddrugs have not been addressed.Microﬂuidics
can serve as a tool to reduce this transferability gap. Recently, we report-
ed a microﬂuidically supported biochip model of the BBB with the
proof-of-concept of the modulation of the BBB permeability by inﬂam-
matory cytokines [36]. To mimic the cerebral endothelial cell layer of
the BBB, hCMEC/D3 cell layers have been used that speciﬁcally express
cerebral endothelial marker proteins including cell adhesion and tight
junction proteins as well as CNS related transporter proteins. In vitro
the cell line forms a tight endothelial cell layer that shows similarities
with the BBB even in the absence of astrocytes or pericytes [37–39].
Thus HCEMC/D3 cells were already used in various BBB models [40,
41] for mechanistically studies on leukocyte transmigration [42], nano-
particle uptake and transcytosis [43,44].
In this study, we describe for the ﬁrst time a nanocarrier design that
combines vector as well as charge optimized properties for crossing the
BBB and that enables complexation of nucleic acids. We focused on the
installation of GSH moieties on the backbone of high molar mass linear
PEI. A post-polymerization functionalization process was applied to ob-
tain double bond functionalities and deﬁned quantities of cationic ethyl-
ene imine units. Since reduced GSH provides a free thiol end group,
thiol-ene photo-additionwas used tomodify the PEI backbone avoiding
potentially hazardous metal catalysts. Comparable amounts of primary
amine groups in the polymer side chain were installed in a second ap-
proach on the PEI backbone for an enhanced polyplex stability. The co-
polymers were characterized concerning their polyplex formation,
toxicity, hemocompatibility and their potential to deliver nucleic acids
across the BBB. We want to demonstrate that polyplexes, formed by
GSH-modiﬁed PEI-based polymers and plasmid DNA, are able to cross
an endothelial cell model of the BBB under physiological shear stress
of 4 dyn cm−2.
2. Results and discussion
To conjugate GSH to a cationic polymer backbone (using a poly(eth-
ylene imine)-derivative), the thiol-ene photo-addition reactionwas uti-
lized. It can be performed undermild conditions (no thermal energy, no
toxic metal catalysts) without generating harmful side products. The
solubility properties of GSH limits the click reaction to water. To inves-
tigate the inﬂuence of different amine functionalities on the balance be-
tween stable polyplex formation and BBB passage, materials either
containing solely secondary amines or bearing additional primary
amines were synthesized.
2.1. Polymer synthesis
The homopolymer poly(2-ethyl-2-oxazoline) (PEtOx) was synthe-
sized according to literature procedure [9]. For this purpose, the cationic
ring-opening polymerization (CROP) of the monomer 2-ethyl-2-
oxazoline was performed in a microwave reactor. The precursor re-
vealed a degree of polymerization of 575 (calculated from the tosylate
1H-NMR signal integrals ofMeOTos before puriﬁcation) and a dispersity
of 1.3 (SEC: DMAc, 0.21% LiCl, calibration: polystyrene). PEtOx was fur-
ther treated with half-concentrated hydrochloric acid and heated to re-
ﬂux overnight [45]. The resulting linear poly(ethylene imine) (P1)
exhibited a degree of hydrolysis of N 95% (calculated from 1H-NMR).
P1 served as the main polymer for the installation of all functionalities
including the GSHmoieties. To investigate the inﬂuence of different cat-
ionic charges on the biocompatibility and the DNA binding afﬁnity, pri-
mary as well as secondary amine functionalities were introduced to the
polymer backbone besides the GSH functionalities [46]. This versatile
approach required two different synthesis pathways (see Scheme 1).
The ﬁrst one comprises of the partial functionalization of linear
poly(ethylene imine) (P1) with N-succinimidyl-4-pentenate to intro-
duce double bond functionalities yielding the P(EI-stat-ButEnOx) copol-
ymer (P2) (see Scheme 1a, strategy I) [47]. Since the homopolymer
poly(2-butenyl-2-oxazoline) (which can be synthesized by a CROP of
the respective monomers) does not withstand the conditions of acidic
or basic hydrolysis, the mentioned post-polymerization modiﬁcation
strategy was applied. Preliminary studies of copolymers consisting of
varying contents of ethylene imine (EI) and 2-butenyl-2-oxazoline
units (ButEnOx) resulted in a critical amount of EI units required for
the formation of stable polyplexes [47]. Therefore, a ButEnOx content
of 27% was installed onto the backbone of P1, resulting in an EI content
of 78% (2) (see Table 1). The introduction of GSH (reduced state, for the
schematic representation of the structure see Scheme 1)was performed
by a thiol-ene photoaddition while maintaining a constant EI content of
78% (Scheme 1c). Since GSH shows only limited solubility properties,
the click reaction was performed in water utilizing the photoinitiator
Irgacure® 2959. The full conversion resulted in the copolymer P(EI73%-
stat-GluButOx27%) (3).
In a second approach primary amine moieties were installed on the
polymer backbone to investigate their inﬂuence on the interaction with
DNA.While primary amine groups are known to promote superior com-
plexation of nucleic acids [48,49], secondary amines reveal an enhanced
buffer capacity resulting in a fast endosomal release [50]. The previously
mentioned modiﬁcation strategy was used (Scheme 1a, strategy II) to
synthesize a fully functionalized poly(2-butenyl-2-oxazoline) (P4).
Subsequently, the protected aminothiol was added to P4 under UV irra-
diation (Scheme 1b) to yield the copolymer P(bocAmButOx82%-stat-
ButEnOx18%) (P5) (Table 1). In a second photo-addition step, reduced
GSH was introduced to the backbone of P5 analog to the previously de-
scribed ﬁrst synthesis route (Scheme 1c, strategy II). Under these condi-
tions, the conversion of the double bonds was incomplete (56% of the
origin double bond functionalities remained), even after an additional
functionalization step. Almost certainly, the content of ﬂexible side
chains containing sterically demanding protection groups hinders the
full modiﬁcation. Furthermore, the introduction of a deﬁned amount
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of bulkyGSH (~8%) could result in an additional hindrance, which limits
the degree of functionalization. The deprotection of bocP6 (Scheme 1d)
resulted in the ﬁnal polymer P(AmButOx82%-stat-ButEnOx10%-stat-
GluButOx8%) (P6). Focusing on the amount of amine groups within
the copolymers, a comparison of P3 and P6 concerning this point is
part of further investigations.
Characterization by 1H-NMR spectroscopy (Fig. 1) conﬁrmed the al-
most complete hydrolysis of PEtOx revealing one main signal for the
backbone of P1 between 3.70 and 3.20 ppm (NR\\CH2\\CH2, A). In ad-
dition, 5% remaining 2-ethyl-2-oxazoline units can be found. The ap-
pearance of the double bond signals for P2 at 5.81 ppm (CH2_CH\\,
E) and 4.95 ppm (CH2_CH\\, F) conﬁrm the successful
functionalization with N-succinimidyl-4-pentenate. The former signal
is compared to the unaffected ethylene imine backbone to determine
the composition of the formed copolymer P2 (degree of
functionalization: 27%). The disappearance of the double bond signals
after the thiol-ene photoaddition conﬁrmed the complete
functionalization with GSH. Besides the additional protons observed
after the click reaction (E′ and F′), the signals of GSH can be assigned
to the respective protons (see Fig. 1). The very speciﬁc GSH signal for
the CH group of the cysteine unit appears at 4.54 ppm
(NR\\CH\\CH2\\S, H).
The complete functionalization of P1 resulted in polymer P4, indi-
cated by the disappearance of the signals assigned to the ethylene
imine backbone (between 3.70 and 3.20 ppm) (see Fig. 2). Instead, the
signals assigned to the double bonds at 5.8 ppm (CH2_CH\\, D) and
4.96 ppm (CH2_CH\\, E) as well as to the backbone (3.45–3.53,
NR\\CH2\\CH2, A) could be observed. The successful attachment of
side chains bearing primary amine groups and GSH moieties is shown
by the CH2 signals nearby the amine group around 2.8 ppm
(NH2\\CH2\\CH2), the signal of the boc-protecting group which disap-
pears after deprotection (1.4 ppm, CH3 boc) and the speciﬁc GSH pro-
tons of P6.
The composition of the prepared polymers (and respective interme-
diates) is depicted in Table 1. Asymmetric ﬂow ﬁeld-ﬂow fractionation
(AF4) was utilized to determine the molar masses of the starting poly-
mer P1 and the ﬁnal products P3 and P6. Since the intermediates reveal
different solubility behaviors, another characterization method had to
be chosen. Therefore, size exclusion chromatography (SEC) was used
to determine the molar masses of P2, P4, P5 and bocP6. However, in
both cases the presence of cationic amine units (primary or secondary)
and/or double bond functionalities resulted in undesired column and
membrane interactions and, therefore, a change in the elution behavior
(increased dispersities) [51,52]. Although the obtained values indicate
lowermolarmasses compared to the calculated values, a trend is visible.
To conﬁrm the successful photo-addition of GSH and the formation
of a single (polymeric) species (P3, P6), diffusion-ordered NMR spec-
troscopy (DOSY NMR) was performed. GSH clearly revealed a higher
diffusion coefﬁcient compared to the polymeric species. The decreasing
values for the GSH decorated P2 indicate an increase of the hydrody-
namic radius of P3 in solution (Fig. 3A). This can be explained by the
bulky GSH moiety. Comparable results are obtained for P6 (Fig. 3B).
2.2. Bio- and hemocompatibility
Biocompatibility represents a critical parameter for potential non-
viral vectors in biomedical applications. In vitro studies were performed
using the precursor P2 and the ﬁnal GSH-conjugated polymers P3 and
P6 in comparison to the linear PEI (P1) to evaluate their bio- and
hemocompatibility (Fig. 4A and Supporting information Fig. S1). P4
and P5were excluded due to their insolubility in aqueousmedia. P1 ex-
hibited a high cytotoxicity at low polymer concentrations (IC50 of
~4 μgmL−1) because of its highmolarmass and cationic charge density
(leading to membrane damages followed by the possible initiation of
apoptosis [53,54]). Interestingly, the attachment of 27% GSH resulted
in a strong reduction of the cytotoxicity. P3 revealed an IC50 value of
Scheme 1. Schematic representation of the synthesis of I) P(EI-stat-GluButOx) (P3) and II) P(AmButOx-stat-ButEnOx-stat-GluButOx) (P6), respectively. a) Functionalization of linear
poly(ethylene imine) (P1). b) Thiol-ene photo-addition of tert-butyl-(2-mercaptoethyl)carbamate to the copolymer backbone. c) Thiol-ene photo-addition of L-glutathione to the
copolymer backbone. d) Deprotection of primary amine side chains.
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~270 μg mL−1 and even polymer concentrations up to 150 μg mL−1 re-
vealed nearly no cytotoxic effects (relative viability ≥ 85%). The precur-
sor P2 also exhibited a lower cytotoxicity compared to P1 (see
Supporting information Fig. S1A). The replacement of the ethylene
imine units by ﬂexible primary amine containing side chains for P6
led to an increased cytotoxicity (IC50 value of ~44 μg mL
−1) compared
to P3. Furthermore, the incomplete thiol-ene photoaddition resulted
in a lower content of GSH and, likewise, unmodiﬁed double bond func-
tionalities, which could both inﬂuence the biocompatibility. However,
Table 1
Composition and molar masses for (co-)polymers P1 to P6.
Abr. Name
Compositiona NMRb AF4 SECc,d
X
[%]
Y 
[%]
Z
[%]
Mn
[gmol–1]
Mn Ð Ð
[gmol–1]
Mn
[gmol–1]
P1 LPEIx >98 0 0 24,800 9900 1.4 n.d. n.d.
P2 P(EIx–stat–ButEnOxy) 73 27 0 37,500 n.d. n.d. 31,400
c 1.2
P3 P(EIx–stat–GluButOxz) 73 0 27 85,200 21,000 2.0 n.d. n.d.
P4 PButEnOxy 0 >98 0 71,900 n.d. n.d. 44,000
c 1.5
P5 P(bocAmButOxx–stat–ButEnOxy) 82 18 0 155,300 n.d. n.d. 23,400
d 1.9
bocP6 P(bocAmButOxx–stat–ButEnOxy–stat–GluButOxz) 82 10 8 169,500 n.d. n.d. 38,400
d 1.7
P6 P(AmButOxx–stat–ButEnOxy–stat–GluButOxz) 82 10 8 122,300 63,300 1.8 n.d. n.d.
a Determined by 1H NMR (calculated from the ratio of x, y and z signals)
b Determined by 1H NMR (calculated from tosylate signals of MeOTos before purification)
c SEC 1: CHCl3/iPrOH/NEt3 94:2:4, polystyrene calibration
d SEC 2: DMAc, 0.21% LiCl, polystyrene calibration
n.d. – not determined. All polymers soluble in aqueous media and /or insoluble in organic solvents were measured at 
AF4 – MALS system.
Fig. 1. Comparison of 1H-NMR spectra of P1 to P3 (# side productN-hydroxysuccinimide)
(400 MHz, D2O/MeOD). Fig. 2. Comparison of
1H-NMR spectra of P4 and P6 (400 MHz, D2O/MeOD and D2O).
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polymer concentrations of P3 and P6 from 2 to 5 μgmL−1were used for
the preparation of polyplexes, which are in an acceptable range beyond
the cytotoxicity-inducing concentrations. The cytotoxicity test was not
only performed with L292 cells according to the ISO protocol 10993-5
but the assay was also performed with HEK as well as hCMEC/3D cells
for a detailed determination of the causal relation of toxicity and related
interactions (see Supporting information Fig. S2 A). In static culture the
hCMEC revealed a different performance during cytotoxicity tests and
showed only 10% relative viability for P1 at a concentration of
2 μg mL−1 and also a decreased viability for P6 whereas P3 revealed
no cytotoxic effects up to 500 μg mL−1. While the IC50 values of P1
and P6 decreased up to a 2-fold higher concentration,P3 showed no cy-
totoxic effect at all independent of the used cell line (Fig. S2B).
To investigate the blood compatibility ofP2, P3 and P6, the hemolyt-
ic activity as well as the aggregation of erythrocytes was assessed (Fig.
4B, Supporting information Figs. S3 and S4). All investigated copolymers
did not show any hemolytic activity in a concentration range from 10 to
100 μgmL−1. P1 aswell as P2 (SI Fig. S1B) revealed a slightly hemolytic
activity at higher concentrations (50 to 100 μgmL−1) indicated by a he-
moglobin releases of 2% aswell as strong agglomeration of erythrocytes
(see Supporting information, Fig. S3). While no agglomeration for P3
was observed, indicating a good hemocompatibility, P6 showed distinct
interactions with cellular membranes of erythrocytes leading to aggre-
gation. Obviously, the type of amineswithin the polymer side chain rep-
resents a crucial factor for the interaction with cells, in particular with
the plasma membrane, and is therefore linked to the biocompatibility
properties. This fact was also assumed by Dekie et al. concluding this
from glutamic acid derivatives [55]. However, Fischer et al. mentioned
that these effects have to be mentioned relative to the polymer class
and can also be inﬂuenced by factors like charge density (number of
amines and three dimensional arrangements) [54].
As reported earlier, primary amines revealed an increased afﬁnity to
cellular membranes compared to secondary amines, indicated by a
higher toxicity [56]. Tripathi et al. demonstrated the successful reduc-
tion of the cytotoxicity by pyridoxyl derivatization of primary amines
of branched PEI [57]. This behavior supports the ﬁndings observed for
P3 and P6.
2.3. Characterization of the polyplexes
An efﬁcient delivery of nucleic acids, like plasmid DNA, into cells de-
pends on several parameters. They comprise of the compact condensa-
tion of the genetic material, the masking of negative charges, the
prevention of degradation and the efﬁcient dissociation from the vector
after transfer into the cellular cytoplasm or nucleus. PEI derivatives, in
particular PEI disulﬁde linked rabies virus glycoprotein, have been
shown to enable the delivery of neurogenic microRNA into the brain
[58]. To investigate the binding afﬁnity of P1, P2 (SI Fig. S1C), P3 as
Fig. 3. Diffusion ordered NMR spectra of: A) P2, P3 and L-glutathione and B) P6 and L-
glutathione (400 MHz, D2O).
Fig. 4. Bio- & hemocompatibility. A) Relative viability of L929 cells after 24 h incubationwith the respective polymers at indicated concentrations. B) Hemolysis assay of erythrocytes after
incubationwith polymers at indicated concentrations. Triton X-100was used as positive and PBS as negative control. A value b 2%hemolysis is classiﬁed as non-hemolytic, 2–5% as slightly
hemolytic and values N 5% as hemolytic. Values represent the mean ± S.D. (n = 3).
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well as P6 with plasmid DNA as model system, the ethidium bromide
quenching assay (EBA) was utilized. Polyplexes were formed at different
nitrogen (polymer) to phosphate (DNA) ratios (N/P). Due to the electro-
static and hydrophobic interactions between the polymer and the pDNA,
ethidiumbromide is excluded from its binding siteswithin the oligonucle-
otides resulting in a reduction of ﬂuorescence intensity [59,60].
All polymers revealed a decreasing ﬂuorescence intensity with in-
creasing N/P ratios that resulted in a plateau, indicating stable polyplex for-
mation (Fig. 5A and Supporting information Fig. S1D). While the positive
control P1 exhibited a fast polyplex formation starting at N/P 5, P2, P3
and P6 revealed a stable polyplex formation at higher N/Ps from 20 to 40
reaching 60%, 45% and 30% relative ﬂuorescence units (RFU), respectively.
A possible explanation for the slightly lower binding afﬁnity could be the
ethylene imine units which are shielded by the bulky GSH moieties as
well as a lower zeta potential of P3 (4.06 mV) compared to P6 (28.4 mV)
(see Table S5). For P6, primary amine groups are attached through ﬂexible
side chains, which are easier accessible for the pDNA. Additionally primary
amines are known to promote pDNA compensation [61].
The heparin dissociation assaywas used to analyze the stability and the
dissociation behavior of the formedpolyplexes [62,63]. Heparin is a natural
polyanion with one of the highest density of negative charges and can ef-
fectively bind to the positive charged polymers P3 and P6. It competes
with the pDNA within the polyplex and forces the release of the nucleic
acid. The free nucleic acid is able to rebind free ethidium bromide (added
in the same concentration as for the EBA) causing an increase of the ﬂuo-
rescence intensity (Fig. 5B). In the case of the P3 and P6 polyplexes, the
pDNA was released very fast at low heparin concentrations. While P3 re-
vealed a reversible binding, reaching 90% dissociation at 10 UmL−1 hepa-
rin, P6 showed full dissociation (~100% RFU at 10 UmL−1). In contrast, P1
required higher concentrations of heparin (40 UmL−1) for almost full re-
lease (~95% RFU), which underlines the stability of P1/pDNA polyplexes
and is in accordance to literature data [46].
An efﬁcient delivery, comprising of the internalization of polyplexes
into cells via endocytic pathways, requires deﬁned sizes and charges of
the complexes. Therefore, critical sizes of polymeric carriers up to
200 nm are recommended [64]. As shown in Table 2, the formed
polyplexes of P3 and P6 revealed z-averages of 282 nm and 117 nm at
a N/P ratio of 20, respectively, which are calculated from the correlation
function. Since the intensity of the particle scattering is proportional to
the sixth power of its diameter (Rayleigh approximation), larger parti-
cles or agglomerates of free polymer chains result in comparatively
more light scattering and higher intensity than smaller ones. Therefore,
the intensity-weighted diameters (z-averages) determined by dynamic
light scattering are supplemented by the number-weighted sizes re-
vealing a calculated number percentage over 95. Although the calculat-
ed sizes can only be seen as informative basis, they are in good
agreement with the favorable size of polyplexes. The zeta potential
changes during the synthesis from well-known positive charged P1
(28.4 mV) to the GSH bearing conjugate P3 (−6.9 mV). In this case, a
potential explanation could be that the positive charge of the former
PEI backbone is complexing the DNA meanwhile the GSH carboxylic
acid moieties are present at the outside of the polyplex resulting in a
negative value of−6.9 mV while the precursor P2 showed comparable
size and zeta potential as P1. The results of P2 can be found in the
Supporting information, Table S6. The change in charge cannot be ob-
served in the case of P6. Here, the lower content of GSH and the side
chains with more ﬂexible primary amines reduce the effect of the GSH
functionalities.
2.4. Uptake efﬁciency
To investigate the potential of the different polymers to deliver
nucleic acids, cellular uptake studies were performed with adherent
human embryonic kidney (HEK) cells as well as hCMEC/3D in OptiMEM
and EndoGro media (see Supporting information, Figs. S7 and S8). For
this purpose, YOYO-1 labeled pDNA was used for the polyplex forma-
tion at N/P 20 to detect the time-depended cellular internalization by
ﬂow cytometry. A fast polyplex uptake in HEK cells was revealed for
P6 polyplexes exhibiting ~50% internalization after 15 min, N80% inter-
nalization after 1 h, and a nearly complete uptake of polyplexes after 2
to 4 h similar to P1. Taking the aggregation data of P6 into account,
the strong interaction with the cellular membrane, led to enhanced up-
take efﬁciency. In contrast, P3polyplexes exhibited only poor uptake ef-
ﬁciencies with b10% of HEK cells positive for internalized P3 polyplexes
(Fig. 6A). These results were also conﬁrmed by life cell imaging after 1 h
(Fig. 6B). Interestingly, the precursor of P3without GSH, P2, exhibited
Fig. 5.Polyplex formation and stabilitywith pDNAusing thepolymersP1,P3 andP6. A) Complexation afﬁnity (ethidiumbromidequenching assay) of respective polymers at indicatedN/P
ratios. B) Dissociation assay of polyplexes formed at N/P 40 using heparin (0 to 60 U mL−1). Values represent the mean ± S.D. (n = 3).
Table 2
Size and zeta potential measured in 20 mM 4-(2-hydroxethyl) piperazine-1-
ethanesulfonic acid (HEPES) and 5% (w/v) glucose, pH 7.2 of pDNA complexes of P1, P3
and P6 at N/P 20 measured by dynamic light scattering.
Polymeric
system
z-Average
[d/nm]
PDI Number-weighted size
[d/nm]
Zeta potential
[mV]
P1 132 ± 28 0.24 61 ± 18 28.4 ± 2.7
P3 282 ± 5 0.38 109 ± 18 −6.9 ± 0.1
P6 117 ± 1 0.31 61 ± 16 33.2 ± 1.5
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an enhanced polyplex uptake comparable to P6 (see Supporting infor-
mation, Fig. S1E). Compared to HEK cell experiments the uptake of P6
decreased in hCMEC/3D cells independently from the culture media
used to 20 to 40%. In contrast, the results of P1 and P3 uptake did not
changed signiﬁcantly.
Taking the MFI of uptaken pDNA into account, comparable results
were also obtained for the transfection efﬁciencies of the polymers P1,
P3 and P6 in HEK cells. A transfection efﬁciency of over 60% of HEK
cells was achieved for P1, whereas reduced transfection efﬁciencies
were found for P3 and P6 of around 30% and 5%, respectively (see
Supporting information, Fig. S9).
2.5. Blood-brain barrier passaging performance within the biochip
approach
The GSH modiﬁed polyplexes were subsequently investigated to-
wards their ability to cross the endothelial layer of the BBB. HCMEC/
D3 cells resembling the cerebral endothelial cell layer of the BBB were
cultured on a suspended membrane within MOTiF biochips that were
recently shown to enable an improved culture of endothelial cells
under physiological perfusion conditions [65]. Here, the membrane
serves as a cell substrate that is perfused from the apical side of the en-
dothelial cell layer. The cells were grown until full conﬂuence to form a
densely packed layer (see Supporting information, Fig. S10). Additional-
ly, immunoﬂuorescence staining for characteristic adherens and tight
junction proteins was performed to conﬁrm the integrity of the
microvascular endothelial layer before perfusion (see Fig. 7, ﬁrst row).
HCMEC exhibit prominent staining of VE-Cadherin, a key component
of adherens endothelial junction and mediator of Claudin-5 expression
[66]. Claudin-5 is themain claudin-class protein expressed in BBB endo-
thelial cells and a key regulator of its permeability [67]. Another VE-
Cadherin regulated protein is β-Catenin, which plays an important
role in maintenance of the BBB integrity and related signaling [68,69].
In addition,we investigated thedistributionof occludin, another protein
important for tight junction formation and for regulating paracellular
permeability [70]. Occludin is associated with cytoplasmic scaffolding
and regulatory protein ZO-1 [3]. Claudin-5, β-Catenin, ZO-1 and
occludin were found all expressed and localized to intercellular junc-
tions formed by hCMEC. Perfusion with precursor polymer P1 resulted
in a signiﬁcant loss of endothelial junctionalmarkers (see Fig. 7). Arrow-
heads indicate a reduced staining of the proteins at the intercellular
contacts. This observation is in accordance to the results obtained for
the biocompatibility of P1 on L929 cells (see Fig. 4A) as well as on
hCMEC (see Supporting information S2). In ﬂow experiments hCMEC
seem to be renderedmore susceptible to PEI uptake since already a con-
centration of 0.1 μg mL−1 revealed a strong impact on the cell viability
(see Fig. 4A). In 2006Mennesson et al. already showed that an increase
in the polyplex-cell membrane interaction and binding capabilities
under ﬂow conditions is altered by shear and sedimentation velocity
forces [71]. As demonstrated in hemocompatibility tests, P1 leads to
erythrocyte aggregation and, therefore, to strong membrane interac-
tions. We speculate that in the presence of ﬂow this interaction could
Fig. 6. Cellular uptake study of P1, P3 and P6 polyplexes (N/P 20) using YOYO-1 labeled pDNA. A) HEK cells were treated with polyplexes for 15 min to 4 h and uptake was analyzed via
ﬂow cytometry (MFI –mean ﬂuorescence intensity). Values represents the mean ± S.D. (n = 3). B) Confocal microscopy of HEK cells, which were incubated for 1 h with polyplexes
(green). Cell nuclei were stained with Hoechst (blue), lysosomes with LysoTracker Red (red). Scale bar = 10 µm.
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be promoted which results in a disruption of tight junctions and in-
creased cytotoxicity. In contrast, perfusion with polyplex P3 as well as
free pDNA, serving as control, revealed no impact on adherens or tight
junction formation (see Fig. 7). We thus conclude that under ﬂow con-
ditions the tightness of the hCMEC layers is not impaired by the
polyplexes, except for polyplex P1.
The biochip design allows the quantiﬁcation of nanoparticles taken
up by the endothelial layer through ﬂuorescence measurements as
well as the exact determination of the total amount of polyplexes that
crossed the endothelial barrier. The imperviousness of the model sys-
tem, in particular for the endothelial cell layer, was proven for YOYO-1
labeled pDNA without nanocarrier (see Supporting information, Fig.
S11). In order to demonstrate the need of glutathionemoieties for a suc-
cessful passage, the precursor P2was investigated for comparison rea-
sons. For the polyplex P6, we observed the highest uptake into the
endothelial cell layer that was associated with a polyplex aggregation
(Fig. 8A; see also Supporting information Fig. S3), which was also ob-
served in kinetic studies using HEK cells. In contrast, polyplexes P1
and P2 show a lower enrichment at the endothelial layer. P3 exhibited
theweakest enrichmentwithin the endothelial layer compared to other
polymers. An image analysis of the quantitative uptake revealed that
the internalization of the polyplex P6 within the endothelial barrier
was signiﬁcantly higher compared to the internalization of the
polyplexes P1 and P2, respectively (Fig. 8B). Interestingly, the highest
difference in the endothelial uptake of all polyplexes tested was ob-
served for P3, even with a signiﬁcant difference regarding the GSH
free precursor P2 (see Fig. S12).
To further elucidate the trans-endothelial transport of the different
polyplexes, we measured its enrichment in the lower chamber under-
neath the endothelial barrier of the biochip (Fig. 8C). GSH was reported
to facilitate a crossing of the nanocarriers through the BBB [21].We thus
testedwhether pDNAbound toP3 could be delivered through the endo-
thelial barrier more efﬁciently than polyplexes P1, P2 or P6 (high up-
take efﬁciency and strong interaction with endothelial layer). After
30 min of perfusion we observed a signiﬁcant increase of polyplex P1
translocation through the endothelial that remained at this level up to
60 min of perfusion. A viability test revealed that P1was toxic already
at low concentrations (Fig. 4A). A similar effect was further conﬁrmed
by immunoﬂuorescence staining of several endothelial adherens and
tight junction proteins involved in maintenance of barrier integrity. Ac-
cordingly, P1 induced a leakage of hCMEC/D3 cell layers under ﬂow
conditions. The difference in our observations under ﬂow conditions
compared to static culture conditions, where the ﬁnal concentration of
0.5 μg mL−1 was still in an acceptable range, can likely be explained
by a signiﬁcantly increased total amount of polyplexes presented to
the cells within the similar incubation time compared to the static cell
culture. This could be an explanation to the unexpected polyplex pas-
sage after 30 min. In contrast, we observed a continuously increasing
transport of the polyplex P3 through the endothelial layer reaching a
maximum at 60min. Indeed, a signiﬁcantly difference is observed com-
pared to the non-passaging precursor polyplex P2without glutathione
modiﬁcation. Taking the results of the uptake studies into account, a
highly “active” polymer like P6within HEK cells can perform in a differ-
ent way compared to microvascular endothelial cell interactions. It is
not beneﬁcial for a passage through the BBB due to its strong interaction
with any kind of cells, independent of proper uptake or not. These re-
sults indicate that in vivo P6 would probably adhere to and might be
partly internalized by endothelial blood vessel cells, followed by cargo
release instead of passing the cell layer. Importantly, the pure pDNA, the
precursor polyplex using P2 without GSH and P6 containing only 8%
Fig. 7. Expression of BBB relevant junctionalmarker proteins before and after polyplexperfusion. pDNA served as control group. Arrowheads showbreakdown or diminished expression of
adherens (VE-Cadherin) and tight junction components evoked by polyplex P1. Nuclei are stained in blue (scale bar 20 nm, n = 3).
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coupled GSHwere virtually prevented from crossing the endothelial layer.
Only P3 showed no interaction neitherwith HEK cells nor endothelia cells,
but was able to pass the BBB and, therefore, was identiﬁed as a promising
candidate as BBB nanocarrier. These results further indicate the strong in-
ﬂuence of the polymer design/composition for a BBB carrier balancing the
GSH content, DNA binding potential and cellular interactions.
3. Conclusion
In this study, the synthesis of L-glutathione (GSH) bearing cationic
polymers is described. To enable the transport of genetic material,
~80% amine functionalities of different nature (primary amines in side
chains and secondary amine groups in polymer backbones) were
installed within a poly(ethylene imine) derivative. A post-polymeriza-
tion modiﬁcation technique followed by a thiol-ene photo-addition in
water was used to attach the GSH moieties. The cationic polymers in-
vestigated in this study exhibited cytotoxic side effects. The insertion
of different types of amines in combination with GSH improved the
cell viability compared to poly(ethylene imine). While the presence of
primary amines in P6 still revealed adverse effects on the cell viability
combinedwith a strong interactionwith cellular membranes, P3 exhib-
ited a superior cell viability as well as a good hemocompatibility. De-
spite the functionalization with negatively charged GSH, the
copolymers were able to bind and release plasmid DNA. These features
supported the potential application as attractive gene delivery agents
for the passage of the BBB.
Studies with biochip embedded cerebral microvascular endothelial
cell layers perfused under physiological shear stress conditions revealed
a signiﬁcantly enhanced passage of the BBB for the GSHmodiﬁed candi-
date containing secondary amine functionalities. Interestingly, the pri-
mary amines led to strong interactions with cells combined with
remarkable high uptake efﬁciency independent of the utilized cell
types. However, this functionalization likely mediates an intracellular
incorporation within the BBB and, thus, renders the nanocarriers (P6)
unsuitable to efﬁciently cross the endothelial layer of the BBB. While
P1 showed an unexpected cell layer passaging effect which is probably
due to a reduced tightness of the cell layer, the nanocarrier precursor
(P2) as well as the uncomplexed plasmid DNA nanocarriers revealed
signiﬁcantly reduced ability to cross the endothelial BBB compared to
GSH-coupled nanocarriers with higher GSH amounts (P3). The GSH-
coupling of nanocarriers thus represents a promising approach to efﬁ-
ciently cross the BBB while avoiding cellular toxicity as shown in this
ﬁrst proof-of-concept study in vitro. However, follow-up studies are re-
quired to further characterize trans-endothelial transport across the
BBB. To proof the feasibility of GSH-coupled nanocarriers as novel ther-
apeutic option for drug-delivery to the CNS also more complex in vivo
models will be investigated in the future.
4. Experimental part
4.1. Materials
Unless otherwise stated, the chemicals were used without further
puriﬁcation. Triﬂuoroacetic acid, ethanol, methanol, Irgacure® 2959,
tert-butyl-(2-mercaptoethyl)carbamate and reduced L-glutathione
were purchased from Sigma Aldrich. The following chemicals were or-
dered from the suppliers in brackets: 2-Ethylen-2-oxazoline (Acros Or-
ganics), 4-dimethylaminopyridine (Merck Millipore), 2,2-dimethoxy-
1,2-diphenylethan-1-one (TCI America), hydrochloric acid (VWR
Chemicals). N-succinimidyl-4-pentenate was synthesized according to
literature procedures [72]. AlamarBlue, YOYO-1 iodide, Hoechst 33342
trihydrochloride (10 mg mL−1 solution) as well as LysoTracker Red
Fig. 8. Performance of the GSH-conjugated polyplexes P1, P2, P3 and P6 in a microﬂuidically supported biochip assay mimicking permeability of the BBB. A) Microscopic images display
polyplexuptake (green)with thehCMEC/D3 cells (nuclei stainedwithDAPI (blue)) under a physiologic shear stress of 4 dyn cm−2. B) Quantiﬁcational analysis of polyplexes at the cellular
barrier. C) Passage of polyplexes P1, P2, P3 and P6 through BBB-like hCMEC/D3 cell layer over time. * signiﬁcances vs. P3; ***p b 0.001; n = 3; scale bar 100 nm.
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DND-99were obtained from Life Technologies (Thermo Fisher, Germany).
If not stated otherwise, cell culture media and supplements (L-glutamine,
antibiotics) were obtained from Lonza (Basel, Switzerland) and Biochrom
(Merck Millipore, Germany), respectively. All other chemicals were pur-
chased from standard suppliers and used without further puriﬁcation.
4.2. General methods and instrumentation
An Initiator Sixty single-mode microwave synthesizer from Biotage,
equipped with a noninvasive IR sensor (accuracy: 2%), was used for po-
lymerization under microwave irradiation.
Proton (1H) nuclear magnetic resonance (NMR) spectra were re-
corded in deuterated water or methanol, at room temperature using a
Bruker Advance I (300 MHz) or a Bruker Advance III HD (400 MHz)
spectrometer; chemical shifts (δ) are expressed in parts per million rel-
ative to TMS. Size exclusion chromatography (SEC) was measured on a
Agilent 1200 series system equipped with a PSS degasser, a G1310A
pump, a G1362A refractive index detector and a PSS GRAM guard col-
umn running with dimethylacetamide (DmAc) with 0.21% of lithium
chloride. For further measurements a Shimadzu system using a SCL-
10A VP controller equipped with a DGU-14A degasser, a LC-10AD VP
pump, a RID-10A refractive index detector and a PSS SDV guard and lin-
ear S column running with chloroform/iso-propanol/triethylamine
(94:2:4) was utilized. The Techlab oven used for both systems was set
to 40 °C and the molar masses were calculated using polystyrene (PS)
standards. Asymmetric ﬂow ﬁeld-ﬂow fractionation (AF4) was per-
formed on an AF2000 MT system (Postnova Analytics, Landberg, Ger-
many) coupled to an UV (PN3211, 260 nm), RI (PN3150), MALS
(PN3070, 633 nm) detector. The eluent is delivered by two different
pumps (tip and focus-ﬂow) and the sample is injected by an
autosampler (PN5300) into the channel. The channel has a trapezoidal
geometry and an overall area of 31.6 cm2. The nominal height of the
spacer was 500 μm and a regenerated cellulose membrane with a
molar mass cut-off of 10,000 g mol−1 (Mn) was used as the accumula-
tion wall. All experiments were carried out at 25 °C and the eluent
was 20mMNaCl in 25mMsodiumacetate buffer at pH3.5. The detector
ﬂow rate was set to 0.5 mL min−1 for all samples and 50 μL
(10 mg mL−1) were injected with an injection ﬂow rate of
0.2 mL min−1 for 7 min. For all samples the cross-ﬂow was set to
2 mL min−1. After the focusing period and a transition time of 1 min,
the cross ﬂow was kept constant for 1 min and was then decreased
under a power function gradient 0.40 to zerowithin 15min. Afterwards
the cross-ﬂowwas kept constant at zero for 20 min to ensure complete
elution. For the calculation of themolarmass a Zimmplot was used. The
refractive index increment (dn/dc) of all samples was measured by
manual injection of a known concentration directly into the channel
without any focusing or cross-ﬂow. The dn/dcwas calculated as the av-
erage of at least three injections from the area under the RI curve. The
cytotoxicity studies as well as ethidium bromide and heparin assays
were performed using a microplate reader (Tecan Inﬁnite M200 Pro,
Crailsheim, Germany). For the uptake studies of HEK-293 and hCMEC/
D3 cells a ﬂow cytometer, Cytomics FC 500 (Beckman Coulter, Krefeld,
Germany) and a confocal laser scanning microscope LSM880 (Carl
Zeiss, Jena, Germany) were used (see below).
4.3. Synthesis of linear poly(ethylene imine) (P1)
The polymerization of the monomer 2-ethyl-2-oxazoline using the
initiator methyl tosylate was performed in a microwave synthesizer ac-
cording to literature procedures [9]. The resulting poly(2-ethyl-2-
oxazoline) (PEtOx, DP= 575, 5.0 g) was further hydrolyzed in 6 M hy-
drochloric acid (HCl) at 100 °C for 16 h under heating to reﬂux [73]. The
excess of HCl and formed propionic acid was removed under reduced
pressure. After dissolving in water, the solution was neutralized by the
addition of 3 M sodium hydroxide (pH N 8). The precipitated linear
poly(ethylene imine) was ﬁltered off and, subsequently, redissolved in
15mLN,N-dimethylformamide to remove the formed salt. After repeat-
ed precipitation in 400 mL ice-cold diethyl ether, the obtained product
was dried under reduced pressure at 85 °C for three days. 1H-NMR
was used to determine the degree of hydrolysis of the resulting polymer
1 (yield: 1.85 g, 85%).
PEtOx: DP = 575. 1H-NMR (300 MHz, D2O): δ 3.70–3.20
(\\NR\\CH2\\CH2), 2.41–2.08 (CH2\\CH3), 1.09–0.79 (CH2\\CH3)
ppm.
P1: EtOx:EI [%] = 5:95. 1H-NMR (300 MHz, MeOD): δ 3.58–3.41
(NR\\CH2\\CH2), 2.91–2.61 (NH\\CH2\\CH2), 2.56–2.36
(CH2\\CH3), 1.18–1.06 (CH2\\CH3) ppm. AF4: Mn =
9900 g mol−1, Ð = 1.4.
4.4. Synthesis of P(EI-stat-ButEnOx) (P2, P4)
Double bond functionalities were installed on the backbone of P1 by
a post-polymerization modiﬁcation process. For this purpose, P1 (for
P2: 751 mg, for P4: 765 mg) and the catalyst 4-N,N-dimethylamino-
pyridine (DMAP, for P2: 120 mg, 0.98 mmol, for P4: 360 mg,
2.95 mmol) were dissolved in pyridine (V= 5mL) at 80 °C. In a second
vial, N-succinimidyl-4-pentenate (for P2: 707 mg, for P4: 4.012 g) was
dissolved in pyridine (V=5mL) and heated to 80 °C. The two solutions
were combined to a 5 wt% mixture (5 mL pyridine were added) of P1.
The reactionmixture was stirred for 21 h at 80 °C. The polymer solution
was precipitated in 500 mL ice-cold diethyl ether. The ﬁltered product
waswashedwith 50mLdiethyl ether and dried under reduced pressure
to constant weight (yield: P2: 0.83 g, 73%, P4: 1.29 g, 58%).
P2: EI:ButEnOx [%] = 73:27. 1H-NMR (400 MHz, D2O): δ 2.28–2.46
(m, CH2 ButEnOx), 2.63–2.85 (m, NH\\CH2\\CH2), 3.35–3.62 (m,
NR\\CH2\\CH2), 4.9–5.0 (dd, CH2_CH\\), 5.76–5.86 (m,
CH2_CH\\) ppm. SEC (CHCl3/iPrOH/NEt3): Mn = 31,400 g mol
−1,
Ð = 1.20.
P4: EI:ButEnOx [%] = 0:100. 1H-NMR (400 MHz, D2O): δ 2.27–2.44
(m, CH2 ButEnOx), 3.45–3.53 (m, NR\\CH2\\CH2), 4.92–5.04 (dd,
CH2_CH), 5.76–5.84 (m, CH2_CH) ppm. SEC (CHCl3/iPrOH/NEt3):
Mn = 44,000 g mol
−1, Ð = 1.53.
4.5. Synthesis of P(EI-stat-GluButOx) via thiol-ene photo-addition (P3)
In a microwave vial, P(EI73%-stat-ButEnOx27%) (P2: 740 mg) and a
1.2-fold excess per double bond of reduced L-glutathione (1.11 g,
3.6 mmol) were dissolved in 15 mL Milli-Q water (5 wt% of P2).
The radical photoinitiator Irgacure® 2959 (100 mg, 0.45 mmol)
was added and the reaction mixture was degassed with argon for
30 min. The clear solution was stirred in a UV-chamber (λ= 365 nm)
for 17 h and, subsequently, dialyzed against water using Spectra/Por 1
dialysis membrane (6000 to 8000 g mol−1 cut-off). The product P3
was lyophilized and obtained as a yellowish powder (yield: 770mg, 44%).
P3: EI:GluButOx [%] = 73:27. 1H-NMR (400MHz, D2O): δ 1.60–1.71
(m, CH2\\CH2\\S\\), 2.12 (q, NCH\\CH2\\CH2\\C_O), 2.45–2.64
(m, NCH\\CH2\\CH2\\C_O, CH2 ButOx), 2.87–3.30 (m,
CH2\\S\\CH2\\CH2, NH\\CH2\\CH2), 3.63–3.95 (m, NR\\CH2\\CH2,
NR\\CH2\\COOH, NH2\\CH), 4.54 (m, NR\\CH\\CH2\\S) ppm. AF4:
Mn = 21,000 g mol
−1, Ð = 2.0.
4.6. Synthesis of P(bocAmButOx-stat-ButEnOx) via thiol-ene photo-addi-
tion (P5)
In a similar procedure, PButEnOx (P4, 1.13 g) and 2-(boc-
amino)ethanethiol (1.19 g, 6.7 mmol) were dissolved in 15 mL metha-
nol (7.5 wt% of P4). 2,2-Dimethoxy-2-phenylacetophenone (DMPA,
88 mg, 0.40 mmol) was added as photoinitiator and the reaction
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mixturewasdegassedwith argon for 30min. Subsequently, the solution
was stirred in a UV-chamber (λ = 365 nm) for 17 h. Precipitation in
400 mL ice-cold diethyl ether, washing with 50 mL of diethyl ether
and drying under reduced pressure for three days resulted in a yellow-
ish powder P5 (yield: 1.94 g, 80%).
P5: bocAmButOx:ButEnOx [%]= 82:18. 1H-NMR (300MHz,MeOD):
δ 1.42 (s, CH3 boc), 1.65 (s, CH2\\S\\CH2\\CH2\\NR), 2.37–2.63 (m,
m, CH2 ButEnOx, S\\CH2\\CH2\\NR), 3.50 (m, NR\\CH2\\CH2,
S\\CH2\\CH2\\NR), 4.96–5.09 (dd, CH2_CH), 5.84 (m, CH2_CH)
ppm. SEC (DMAc, 0.21% LiCl): Mn = 23,400 g mol
−1, Ð = 1.86.
4.7. Synthesis of P(bocAmButOx-stat-ButEnOx-stat-GluButOx) via thiol-
ene photo-addition (bocP6)
The conjugation of reduced L-glutathione (GSH) to the copolymerP5
was performed similar to the conjugation to P3. For this purpose, P5
(1.01 g) was dissolved in 17 mL ethanol (6 wt% of P5). The
photoinitiator Irgacure® 2959 (321 mg, 1.4 mol) and a 1.2-fold excess
per double bond of GSH (252 mg, 0.82 mmol) was added, the reaction
mixture was degassed with argon for 30min and stirred in a UV-cham-
ber (λ=365 nm) for 48 h. An aliquot of 50 μL was taken and character-
ized via 1H-NMR. Due to still incomplete photo-addition, additional GSH
(150 mg, 0.49 mmol) was added to the reaction mixture and irradiated
for further 48 h. The copolymer was puriﬁed by dialysis against ethanol
using Spectra/Por 1 dialysis membrane (6000 to 8000 g mol−1 cut-off)
and dried under reduced pressure for four days (yield: 735 mg, 67%).
bocP6: bocAmButOx:ButEnOx:GluButOx [%] = 82:10:8. 1H-NMR
(300 MHz, MeOD): δ 1.32–1.48 (s, CH3 boc), 1.67 (m,
CH2\\S\\CH2\\CH2\\NR), 2.20 (m, NCH\\CH2\\CH2\\C_O),
2.17–2.60 (m, NCH\\CH2\\CH2\\C_O, CH2 ButOx), 3.08–3.91 (m,
CH2\\S\\CH2\\CH2, NR\\CH2\\CH2, NR\\CH2\\COOH, NH2\\CH),
4.58 (m, NR\\CH\\CH2\\S), 5.02 (CH2_CH), 5.34 (CH2_CH) ppm.
SEC (DMAc, 0.21% LiCl): Mn = 38,400 g mol
−1, Ð = 1.74.
4.8. Synthesis of P(AmButOx-stat-ButEnOx-stat-GluButOx) via
deprotection (P6)
The protected copolymer bocP6 (615mg)was dissolved in dichloro-
methane (24mL) and triﬂuoroacetic acid (40mL) was added. The reac-
tion mixture was stirred for 20 h at room temperature and,
subsequently, precipitated in 300mL ice-cold diethyl ether. The residue
was ﬁltered off, washedwith 30mL diethyl ether, re-dissolved inmeth-
anol and shaken overnight with Amberlyst® A21 (free base) (~0.5 mg).
After ﬁltration, the solvent was removed and the copolymer P6
lyophilized.
P6: AmButOx:ButEnOx:GluButOx [%] = 82:10:8. 1H-NMR
(400 MHz, D2O): δ 1.60 (CH2\\S\\CH2\\CH2\\NR), 2.05
(NCH\\CH2\\CH2\\C_O), 2.32–3.73 (NCH\\CH2\\CH2\\C_O,
CH2 ButOx, CH2\\S\\CH2\\CH2, NR\\CH2\\CH2, NR\\CH2\\COOH,
NH2\\CH2\\CH2), 4.38 (NR\\CH\\CH2\\S), 5.06 (CH2_CH), 5.84
(CH2_CH) ppm. AF4: Mn = 63,300 g mol
−1, Ð = 1.82.
4.9. Determination of the cytotoxicity
Cytotoxicity studies were performed with the mouse ﬁbroblast cell
line L929 (CCL-1, ATCC), as recommended by ISO10993-5 as well as
with HEK-293 and hCMECs/D3 cells. The cells were routinely cultured
in Dulbecco's modiﬁed eagle's medium (DMEM, Lonza) supplemented
with 10% fetal calf serum (FCS), 100 U mL−1 penicillin and
100 μg mL−1 streptomycin at 37 °C in a humidiﬁed 5% (v/v) CO2 atmo-
sphere. In detail, cellswere seeded at 104 cells perwell in a 96-well plate
and incubated for 24 h, whereas no cells were seeded in the outer wells.
Afterwards, the substances to be tested (polymers) at indicated concen-
trations (from 10 μg mL−1 to 500 μg mL−1) were added to the cells and
the plates were incubated for further 24 h. Control cells were incubated
with fresh culture medium. Subsequently, themediumwas replaced by
a mixture of fresh culture medium and Alamar-Blue solution, prepared
according to themanufacturer's instructions. After an additional incuba-
tion of 4 h at 37 °C, the ﬂuorescence was measured at Ex 570/Em
610 nm, with untreated cells on the samewell plate serving as negative
controls. The negative control was standardized as 0% ofmetabolism in-
hibition and referred as 100% viability. Cell viability below 70%was con-
sidered indicative of cytotoxicity. Data are expressed as mean ± S.D. of
three determinations.
4.10. Hemolysis assay
The interaction of polymers with cellularmembranes was examined
by analyzing the release of hemoglobin from erythrocytes. Blood from
sheep, collected in heparinized tubes, were provided by the Institute
of Laboratory Animal Science and Animal Welfare, Friedrich Schiller
University Jena. The blood was centrifuged at 4500 ×g for 5 min, and
the pellet was washed three times with cold 1.5 mM phosphate buff-
ered saline (PBS, pH 7.4). After dilution with PBS in a ratio of 1:7, ali-
quots of erythrocyte suspension were mixed 1:1 with the polymer
solution and incubated in a water bath at 37 °C for 60 min. After centri-
fugation at 2400 ×g for 5min, the hemoglobin release into the superna-
tant was determined spectrophotometrically using a microplate reader
at 544 nmwavelength. Complete hemolysis (100%) was achieved using
1% Triton X-100 serving as positive control. Pure PBS was used as nega-
tive control (0% hemolysis). The hemolytic activity of the polycations
was calculated as follow (Eq. (1)):
%Hemolysis ¼ 100 
ASample−ANegative control
 
APositive control
ð1Þ
A value b 2% hemolysis rate was considered as non-hemolytic, 2 to
5% as slightly hemolytic and values N 5% as hemolytic. Experiments
were run in triplicates andwere performedwith three different batches
of donor blood.
4.11. Erythrocyte aggregation
The erythrocyte suspension was mixed 1:1 with the polymer solu-
tions (100 μL total volume) in a clear ﬂat bottomed 96-well plate. The
cells were incubated at 37 °C for 2 h, and the absorbance wasmeasured
at 645 nm in a microplate reader. Cells, which were treated with PBS
served as negative control and 25 kDa bPEI (50 μg mL−1, Polyscience)
was used as positive control. Absorbance values of the test solutions
lower than the negative control were regarded as aggregation. Experi-
ments were run in triplicates and were performed with three different
charges of donor blood from sheep.
4.12. Polyplex preparation
Polyplexes of pDNA and polymers were prepared by mixing stock
solutions of 15 μg mL−1 pDNA and different amounts of polymers
(1mgmL−1) to obtain various N/P ratios (nitrogen of polymer to phos-
phate of pDNA) in HBG buffer (20mM4-(2-hydroxethyl) piperazine-1-
ethanesulfonic acid (HEPES) and 5% (w/v) glucose, pH 7.2). The solu-
tions were vortexed for 10 s at maximal speed and incubated at room
temperature for 20 min to ensure complex formation.
4.13. Ethidium bromide quenching assay
The formation of polyplexes with pDNA was examined by
quenching of the ethidium bromideﬂuorescence as described previous-
ly [56]. Brieﬂy, 15 μgmL−1 pDNA in a total volume of 100 μL HBG buffer
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(HEPES buffered glucose) were incubated with ethidium bromide
(0.4 μg mL−1) for 10 min at room temperature. Afterwards, polyplexes
with increasing amounts of indicated polymers (regarding N/P ratio)
were prepared in black 96-well plates (Nunc Thermo Fisher). The sam-
ples were incubated at room temperature for 15 min before ﬂuores-
cence measurements. The ﬂuorescence of the samples was measured
at an excitation wavelength of 525 nm and an emission wavelength of
605 nm using a microplate reader. A sample solely containing pDNA
and EtBr was used to calibrate the device to 100% ﬂuorescence against
a background of 0.4 μg mL−1 of EtBr in HBG solution. The percentage
of dye displaced upon polyplex formation was calculated using Eq. (2):
RFU %½  ¼
Fsample−F0
FpDNA−F0
 100 ð2Þ
RFU is deﬁned as the relative ﬂuorescence and Fsample, F0, and FpDNA
are theﬂuorescence intensities of a given sample, the ethidiumbromide
in HBG alone, and the ethidium bromide intercalated into pDNA alone.
4.14. Heparin dissociation assay
To investigate the release of pDNA from the polyplexes, the heparin
dissociation assay was performed. Polyplexes with a N/P ratio of 40
were prepared as described above in a total volumeof 100 μLHBGbuffer
containing ethidium bromide (0.4 μg mL−1). After incubation in the
dark at room temperature for 15 min, the polyplexes were transferred
into a black 96-well plate, and heparin of indicated concentrations
was added. The solution was mixed and incubated for further 30 min
at 37 °C in the dark. The ﬂuorescence of ethidium bromide was mea-
sured at Ex 525 nm/Em 605 nm with a Tecan microplate reader. The
percentage of intercalated ethidium bromide was calculated as de-
scribed before.
4.15. Dynamic and electrophoretic light scattering
Dynamic light scattering (DLS) was performed on a Zetasizer Nano
ZS (Malvern Instruments, Herrenberg) with a He-Ne laser operating at
a wavelength of λ = 633 nm. All measurements (30 runs, triplicate)
were carried out at 25 °C after an equilibration time of 120 s. The counts
were detected at an angle of 173°. The mean particle size was approxi-
mated as the effective (z-average) diameter and thewidth of the distri-
bution as the polydispersity index of the particles (PDI) obtained by the
cumulants method assuming a spherical shape. Electrophoretic light
scattering (ELS) was used to measure the zeta potential (ζ). The mea-
surement was performed on a Zetasizer Nano ZS (Malvern Instruments,
Herrenberg, Germany) by applying laser Doppler velocimetry. For each
measurement, 20 runs were carried out using the slow-ﬁeld reversal
and the fast-ﬁeld reversal mode at 150 V. Each experiment was per-
formed in triplicate a 25 °C. The zeta potential was calculated from the
electrophoretic mobility (μ) according to the Henry Equation. Henry co-
efﬁcient f(ka) was calculated according to Oshima.
4.16. Polyplex uptake
HEK-293 cells (CRL-1573, ATCC) were cultured in RPMI 1640 medi-
um supplemented with 10% FCS, 100 μg mL−1 streptomycin,
100 IU mL−1 penicillin and 2 mM L-glutamine at 37 °C in a humidiﬁed
5% (v/v) CO2 atmosphere. For uptake studies, cellswere seeded at a den-
sity of 105 cells per mL in 24-well plates and cultured for 24 h. One hour
prior to the addition of the polyplexes, the medium was changed to
OptiMEM (Thermo Fisher, Germany). For the uptake kinetic studywith-
in 4 h, pDNAwas labeledwithYOYO-1 iodide prior to thepolyplex prep-
aration. For labeling of 1 μg pDNA, 0.026 μL of 1 M YOYO-1 solution was
mixedwith pDNA and incubated for 20min at 4 °C protected from light.
Afterwards, HBG buffer and the polymers were added at the indicated
N/P ratio and the polyplexes were formed as described previously. The
cells were harvested 15 min, 30 min, 1 h, 2 h and 4 h after polyplex ad-
dition and 10% trypan blue was added to quench the outer ﬂuorescence
of the cells. To determine the relative uptake of the polyplexes, 10,000
cells were measured by ﬂow cytometry using a Cytomics FC 500
(Beckman Coulter) and the amount of viable cells showing YOYO-1 sig-
nal were gated. Dead cells were identiﬁed via counterstaining with
propidium iodide. The experiments were performed at least three
times independently. The uptake studies of hCMECs were performed
in OptiMEM and EndoGro media, respectively. For live cell imaging
HEK cells (105 cells mL−1) were seeded in glass-bottomed, 4-chamber
dishes (CELLVIEW, Greiner Bio-One, Germany) and cultured for 24 h.
One hour prior to polymer addition, the cells were rinsed with phos-
phate buffered saline (PBS) and the media were changed to OptiMEM.
Polyplexes were prepared at N/P 20 as described above and incubated
for further 1 h. Afterwards, the media were replaced with fresh culture
media supplementedwith LysoTracker Red DND-99 andHoechst 33342
for lysosome and nucleus staining, respectively. The living cells were
imaged with a LSM880 using the following excitation wavelengths/
laser lines 405 nm (for Hoechst), 488 nm (for YOYO-1) and 561 nm
(for LysoTracker Red).
4.17. Transfection of adherent cells
For transfection of adherent HEK-293 cells, the cells were seeded at a
density of 105 cellsmL−1 in 24-well plates and incubated for 24 h at 37 °
C, 5% (v/v) CO2. One hour prior to transfection, the cells were washed
with PBS and supplemented with serum-reduced media (OptiMEM).
Polyplexes were prepared as described above, and were added to the
cells (50 μL per well). After an incubation time of 4 h at 37 °C, the super-
natant was replaced by fresh growthmedium and the cells were further
incubated for 20 h. For analysis via ﬂow cytometry (Cytomics FC 500,
Beckman Coulter), the cells were harvested by trypsinization and 104
cells were analyzed. For determination of the viability during ﬂow cy-
tometry, dead cells were identiﬁed via counterstaining with propidium
iodide. For determination of the transfection efﬁciency, viable cells ex-
pressing EGFP were gated. The experiments were performed indepen-
dently three times.
4.18. Immunoﬂuorescence microscopy.
Cells were ﬁxed with ice cold methanol for 10 min at −20 °C,
permeabilized with 0.1% Saponin and blocking was done with 3% nor-
mal donkey serum. Antibody staining was performed using mouse-
anti-human VE-Cadherin, mouse-anti-human β-Catenin (both BD Bio-
sciences, Heidelberg, Germany), mouse-anti-human Claudin-5, rabbit-
anti-human ZO-1 and rabbit-anti-human Occludin (all Life Technolo-
gies, Karlsruhe, Germany) overnight. Secondary antibodies donkey-
anti-rabbit Cy3 (Dianova, Hamburg, Germany) and donkey-anti-
mouse AlexaFluor647 (Life Technologies) as well as DAPI (Life Technol-
ogies) were applied for 1 h at room temperature. Samples were embed-
ded in ﬂuorescencemountingmedium (Dako, Hamburg, Germany) and
imaged on an Axio Observer.Z1 ﬂuorescencemicroscope (Carl Zeiss AG,
Jena, Germany). Image analysis was performed using ImageJ2 software
(Fiji).
4.19. Dynamic cell culture assay
MOTiF biochips were made by injection moulding of polystyrene
and manufactured by microﬂuidic Chip Shop (Jena, Germany) as de-
scribed previously [65]. Chip geometry and embedded structures are
shown in Supporting information, Fig. S10. The human cerebral micro-
vascular endothelial cell line hCMEC/D3 (BIOZOL, Eching, Germany)
was cultured in EndoGRO-MV Basal Medium supplemented with 5%
(v/v) FCS, 0.2% (v/v) EndoGRO-LS supplement, 5 ng/mL recombinant
human epidermal growth factor, 10mM L-glutamine, 1 μgmL−1 hydro-
cortisone-hemisuccinate, 0.75 U mL−1 heparin-sulfate, 50 μg mL−1
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ascorbic acid (all additives were obtained fromMerck-Millipore, Darm-
stadt, Germany), and 100 U mL−1 penicillin and 100 μg mL−1 strepto-
mycin at 37 °C in a humidiﬁed 5% (v/v) CO2 atmosphere. The
membrane within the biochip was coated with 150 μg mL−1 collagen A
(Biochrom, Berlin, Germany) for at least 1 h prior to cell seeding. hCMEC/
D3 were seeded at a density of 0.75 × 105 cm−2 in the upper channel to
grow on top of the membrane. Cells were cultured until fully conﬂuent
after four to ﬁve days. Afterwards, biochips were connected to an Ismatec
peristaltic pump (Cole Parmer,Wertheim,Germany) via gas permeable sil-
icon tubing (Cole Parmer andmicroﬂuidic Chip Shop) at 37 °C in a humid-
iﬁed 5% (v/v) CO2 atmosphere and accustomed to ﬂow conditions with a
ﬂow rate of 175 μL min−1 (corresponding shear stress of 2 dyn cm2) for
30min.Meanwhile polyplex formation at a N/P ratio of 20was performed
in hCMEC/D3 cell culturemediumas stated abovewith additionally apply-
ing YOYO-1 as reporter dye. As corresponding controls polyplex solutions
without dye were used. Subsequently shear stress was increased to
4 dyn cm2 and polyplex solutions were applied for 1 h. For sampling
30 μL from the lower channel system were taken whereas the ﬁrst 15 μL
were discarded to ensure sampling from under the membrane and not
just from the microchannels. Samples were taken every 15 min. After-
wards, cells were washed gently by ﬂushing the upper and lower
microchannels three times with PBS. Nuclei were stained with Hoechst
33342. Membranes and supernatants were analyzed using an Axio
Observer.Z1 ﬂuorescence microscope (Carl Zeiss AG, Jena, Germany) ap-
plying a ﬁlter with 470 nm excitation and 525 nm emission wave
lengths. At least three images per sample were taken. Fluorescence im-
ages were analyzed with the ImageJ2 software whereas controls were
subtracted for quantiﬁcation.
4.20. Statistical analysis
The values represent the mean± S.D. Direct comparison of two dif-
ferent groups was done with two-tailed, non-paired student's test. For
multiple comparisons analysis by two-way ANOVA was performed
using Turkey's multiple testing as post-test. Statistical signiﬁcant was
deﬁned with p-values of b0.05.
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grades and types.[2] The number of specific targets is high, 
in which 60%–80% of all cases are hormone receptors of 
the human epidermal growth factor receptor (HER) family 
that can be targeted by endocrine therapy.[3] By lacking 
progesterone and estrogene receptor overexpression as 
well as amplification of HER2 genes at the same time, a 
tumor type with a shorter median time from relapse to 
death was identified in 1987 and is nowadays treated 
with Trastuzumab, a monoclonal antibody.[4] Triple-
negative tumors are described by the lack of hormone 
receptor expression as well as HER2 receptors, an aggres-
sive type with insufficient therapy options and poor prog-
nosis, which represents roughly 15% of all breast cancer 
tumors.[3] Besides the treatment with the monoclonal 
antibody Bevacizumab, that blocks angiogenesis by inhib-
iting vascular endothelial growth factor A, there are more 
than 50 clinical trials ongoing, which address various tar-
gets such as the epidermal growth factor,[5] Src tyrosine 
kinase,[6] and heat shock protein 90 to develop strategies 
against this aggressive kind of breast cancer.[7]
Another target, which is controversially discussed in 
the present literature, is the GLUT5 transporter, a highly 
affine D-fructose transporter.[8] While Gowrishankar 
The high affinity of GLUT5 transporter for D-fructose in breast cancer cells has been discussed 
intensely. In this contribution, high molar mass linear poly(ethylene imine) (LPEI) is function-
alized with D-fructose moieties to combine the selectivity for the GLUT5 transporter with the 
delivery potential of PEI for genetic material. The four-step synthesis of a thiol-group bearing 
D-fructose enables the decoration of a cationic polymer backbone with D-fructose via thiol-ene 
photoaddition. The functionalization of LPEI is confirmed by 2D NMR techniques, elemental 
analysis, and size exclusion chromatography. Importantly, a D-fructose decoration of 16% ren-
ders the polymers water-soluble and eliminates the cytotox-
icity of PEI in noncancer L929 cells, accompanied by a reduced 
unspecific cellular uptake of the genetic material. In contrast, 
the cytotoxicity as well as the cell specific uptake is increased 
for triple negative MDA-MB-231 breast cancer cells. Therefore, 
the introduction of D-fructose shows superior potential for 
cell targeting, which can be assumed to be GLUT5 dependent.
D-Fructose-Decorated Poly(ethylene imine) for 
Human Breast Cancer Cell Targeting
Christoph Englert, Michael Pröhl, Justyna A. Czaplewska, Carolin Fritzsche, 
Elisabeth Preußger, Ulrich S. Schubert, Anja Traeger, Michael Gottschaldt*
C. Englert, M. Pröhl, Dr. J. A. Czaplewska, C. Fritzsche,  
E. Preußger, Prof. U. S. Schubert, Dr. A. Traeger,  
Dr. M. Gottschaldt
Laboratory of Organic and Macromolecular Chemistry (IOMC)
Friedrich Schiller University Jena
Humboldtstrasse 10, 07743 Jena, Germany
E-mail: michael.gottschaldt@uni-jena.de
C. Englert, M. Pröhl, Dr. J. A. Czaplewska, C. Fritzsche,  
E. Preußger, Prof. U. S. Schubert, Dr. A. Traeger,  
Dr. M. Gottschaldt
Jena Center for Soft Matter (JCSM)
Friedrich Schiller University Jena
Philosophenweg 7, 07743 Jena, Germany
1. Introduction
With around 1.65 million new cases of cancer and around 
590 thousand deaths resulted from cancer in 2015 in the 
United States, human breast cancer represents the second 
leading death cause after heart diseases. Among them, 
230 thousand new cases derive from breast cancer from 
which around 41 thousand ended deadly.[1] It is described 
as a highly heterogeneous type of cancer with manifold 
Macromol. Biosci. 2017, DOI: 10.1002/mabi.201600502
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et al. declined the overexpression of GLUT5 in all breast 
cancer tissues,[9] Nualart and co-workers claimed GLUT5 
as overexpressed in 85% of 33 tested breast cancer cell 
lines,[10] also confirmed for estrogen-receptor posi-
tive MCF-7 and triple-negative MDA-MB-231 breast 
cancer cell lines.[11] Nevertheless, that implies a possible 
enhanced selectivity of anticancer agents by the attach-
ment of D-fructose and its derivatives. Previous studies 
revealed that modifications at C1- and C6-position of the 
sugar are tolerated by the GLUT5 transporter.[12] For this 
reason, D-fructose was successfully attached to dyes,[13] 
metal complexes,[14] polymers,[15] and nanoparticles[16] 
and tested with various breast cancer cell lines, revealing 
an increased uptake for the D-fructose conjugated com-
pounds and structures.
Nowadays, one opportunity of cancer treatment is the 
manipulation of the pathways in tumors on the level 
of the cellular genetic information, e.g., by the intro-
duction of genetic material. This promising anticancer 
approach has gained increasing interest over the last 
decade and various potential carriers have been inves-
tigated.[15] Since viral vectors possess considerable cyto-
toxicities and immunological concerns, nonviral vectors 
like cationic cell penetrating peptides,[17] antibodies[18] 
and lipid-based carriers[19] have been intensively investi-
gated. Cationic polymers, e.g., poly(ethylene imine) (PEI), 
represent another class of suitable candidates to com-
plex genetic material by electrostatic interactions.[20] Due 
to its superior buffering ability leading to endosomal 
escape (“proton sponge effect”), PEI is known as the gold 
standard of polymeric carriers for gene delivery.[21] How-
ever, its full potential is restricted through its high cyto-
toxicity and non-biodegradability.[22] One useful strategy 
to overcome these limitations is the modification of the 
PEI backbone[23] and/or the introduction of side chains. 
The latter approach has been extensively studied, e.g., by 
functionalization of PEI with various carbohydrates[24] or 
stealth polymers, like poly(ethylene glycol).[25]
Herein, we focused on the installation of D-fructose 
moieties at side chains of high molar mass linear PEI to 
combine the selectivity for the GLUT5 transporter and 
the delivery potential of genetic material. To remain a 
defined quantity of cationic ethylene imine units, a post-
polymerization functionalization using N-succinimidyl-
4-pentenate was chosen. This enables the synthesis of 
glycopolymer structures[26] by the reaction with thiol 
sugars utilizing the metal-free thiol-ene photoaddition. 
The designed copolymer and respective precursors were 
investigated concerning their bio- and hemocompat-
ibility, their affinity for binding and release of genetic 
material (exemplified for plasmid DNA) and their specific 
cellular uptake (MDA-MB231 breast cancer vs. noncancer 
L929 and primary human umbilical vein endothelial cells, 
HUVEC).
2. Experimental Section
2.1. Materials
2-Ethyl-2-oxazoline (EtOx) and methyl tosylate were obtained 
from Acros Organics, distilled (over barium oxide (BaO) in the case 
of EtOx), and stored under argon atmosphere. Pyridine, meth-
anol, dichloromethane, 4-N,N-dimethylamino-pyridine (DMAP), 
2,2-dimethoxy-2-phenylacetophenone (DMPA) and rhodamine B 
isothiocyanate were obtained from Sigma-Aldrich (Steinhausen, 
Germany) and are of analytical grade and are used without fur-
ther purification. Acetonitrile was purified on a MBraun solvent 
purification system (MB SPS-800). N-Succinimidyl-4-pentenate 
was prepared according to literature procedures.[27] Ethidium 
bromide solution (1%, 10 mg mL−1) was purchased from Carl 
Roth (Karlsruhe, Germany). AlamarBlue, YOYO-1 iodide, Hoechst 
33342 trihydrochloride, heparin and Cy5 dye were obtained from 
Thermo Fisher (Germany). Plasmid pEGFP-N1 (4.7 kb, Clontech, 
USA encoding green fluorescent protein (EGFP) was isolated with 
the Giga Plasmid Kit provided by Qiagen (Hilden, Germany). If 
not stated otherwise, cell culture materials, cell culture media 
and solutions were obtained from Biochrom (Berlin, Germany).
2.2. General Methods and Instrumentation
The polymerizations as well as the hydrolysis of poly(2-ethyl-
2-oxazoline) were performed under microwave irradiation in an 
Initiator Sixty single-mode microwave synthesizer from Biotage, 
equipped with a noninvasive IR sensor (accuracy 2%). Chroma-
tographic separations were performed using normal phase (NP) 
silica RediSep Cartridges by Teledyne Isco. The reaction progress 
was monitored by thin-layer chromatography (TLC) using glass 
plates precoated with silica gel 60 (Merck).
Proton (1H) nuclear magnetic resonance (NMR) spectra were 
recorded at room temperature using spectrometers from Bruker 
(300, 600 MHz). 13C NMR was recorded at 100 MHz. Chemical 
shifts (δ) are expressed in parts per million relative to tetra-
methylsilane (TMS).
Size exclusion chromatographic (SEC) investigations were per-
formed on an Agilent Technologies 1200 Series gel permeation 
chromatography system equipped with a G1329A auto sampler, 
a G131A isocratic pump, a G1362A refractive index detector, and 
both a PSS Gram 30 and a PSS Gram 1000 column placed in series. 
As eluent a 0.21% LiCl solution in N,N-dimethylacetamide (DMAc) 
was used at 1 mL min−1 flow rate and a column oven tempera-
ture of 40 °C. Molar masses were calculated using poly(styrene) 
standards. High-resolution electron spray ionization mass spec-
trometry (HR-ESI-MS) was measured with a Bruker MicroQTof 
and elemental analysis were measured with a Leco CHN-932.
2.2.1. Synthesis of 1-(2-(Benzyloxy)ethyl)-
2,3:4,5-di-O-isopropylidene-β-D-fructopyranoside (2)
6.5 g (25 mmol) of 2,3:4,5-di-O-isopropylidene-β-D-fructopy ranoside 
1 was dissolved in 150 mL of dry THF, 4 g NaH (166.7 mmol) 
were added and the mixture stirred for 20 min under nitrogen. Sub-
sequently, benzyl 2-bromoethyl ether (10 g, 43.6 mmol) was added 
dropwise and reaction was conducted for 7 d (controlled during 
this time with TLC). After no starting material had remained (TLC, 
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SiO2, EtOAc/cyclohexane, v/v, 1:2), 50 mL of methanol were slowly 
added and the reaction mixture was evaporated. The crude product 
was dissolved in 200 mL of ethyl acetate and washed twice with 
each 200 mL of saturated NaHCO3 solution and once with 200 mL 
of water. The organic phase was dried with Na2SO4 and the solvent 
was removed. The product 2 was purified by column chromatog-
raphy (SiO2, EtOAc/cyclohexane, v/v, 1:2) and collected as light 
yellow oil. Yield: 8.69 g (70%).
1H-NMR (300 MHz, CDCl3, δ): 7.39–7.24 (m, 5H, Bn), 4.62–
4.58 (dd, J = 7.92 Hz, 2.61 Hz, 1H, H-4), 4.56 (s, 2H, Bn-CH2), 4.44 
(d, J = 2.6 Hz, 1H, H-3), 3.92 (dd, J = 7.9 Hz, 1.1 Hz, 1H, H-5), 3.81 
(dd, J = 13 Hz, J = 1.85 Hz, 1H, H-6), 3.77–3.68 (m, 3H, H-1, H-1′, 
H-6′), 3.67–3.58 (m, 4H, CH2), 1.54, 1.47, 1.43, 1.35 (4s, 12H, CH3); 
13C-NMR (CDCl3, 75 MHz, δ): 138.26 (Bn-Cq), 128.33, 127.66, 127.56 
(Bn), 108.90 (isopropylidene-Cq), 108.54 (isopropylidene-Cq), 
102.72 (C2), 73.23 (Bn-CH2), 72.47 (CH2), 71.38 (C1), 71.03 (C5), 
70.22 (C4), 69.99 (C3), 69.37 (CH2), 61.01 (C6), 26.56, 25.87, 25.29, 
24.03 (CH3). MS (ESI) m/z: [M+Na]
+ calcd for C21H30O7Na, 417.19; 
found, 417.18; [M+K]+ calcd for C21H30O7K, 433.16; found, 433.16. 
Anal. calcd. for C21H30O7: C 63.94, H 7.67; found: C 63.90, H 7.69.
2.2.2. Synthesis of 1-(2-(Hydroxyl)ethyl)-2,3:4,5-di-O-
isopropylidene-β-D-fructopyranoside (3)
8.38 g (21.2 mmol) of 2 were dissolved in 300 mL of methanol and 
0.23 g of palladium on charcoal (3 wt%) were added to the reac-
tion mixture. The reaction flask was evacuated and refilled with 
hydrogen several times. After stirring for 48 h, the catalyst was 
filtered off and the solvent was evaporated to obtain the product 
as colorless oil. Yield: 6.03 g (95%).
1H-NMR (300 MHz, CDCl3, δ): 4.62–4.56 (dd, J = 8.0 Hz, 2.5 Hz, 
1H, H-4), 4.35 (d, J = 2.5 Hz, 1H, H-3), 4.26–4.21 (dd, J = 8.0 Hz, 
1.1 Hz, 1H, H-5), 3.90 (dd, J = 13.0 Hz, J = 1.8 Hz, 1H, H-6), 
3.80–3.56 (m, 5H, H-6, H-1, H-1′, CH2), 2.18 (s, 1H, OH), 1.53, 1.49, 
1.41, 1.34 (4s, 12H, CH3); 
13C-NMR (CDCl3, 75 MHz, δ): 108.98 
(Cq), 108.44 (Cq), 102.59 (C2), 73.26 (CH2), 72.20 (C1), 70.76 (C5), 
70.69 (C3), 70.14 (C4), 61.49 (CH2), 60.97 (C6), 26.44, 25.70, 25.18, 
23.89 (CH3). MS (ESI) m/z: [M+Na]
+ calcd for C14H24O7Na, 327.14; 
found, 327.14; [M+K]+ calcd for C14H24O7K, 343.12; found, 343.12; 
[2M+Na]+ calcd for C28H48O14Na, 631.29; found, 631.29. Anal. 
calcd. for C14H24O7: C 55.25, H 7.95; found: C 55.24, H 8.14.
2.2.3. Synthesis of 1-(2-(Methanesulfonyl)ethyl)-2,3:4,5-di-
O-isopropylidene-β-D-fructopyranoside (4)
5 g (16.4 mmol) of 3 were dissolved in 30 mL of CH2Cl2 and 
6.825 mL (49.24 mmol) of Et3N and 20 mg 4-DMAP (0.16 mmol) 
were added. The reaction mixture was cooled to 0 °C and 3 mL 
(38.8 mmol) of mesyl chloride were added dropwise to the solu-
tion.[28] The reaction mixture was left to slowly warm to room 
temperature and stirred for 2 h. After no starting material had 
remained (TLC, SiO2, EtOAc/cyclohexane, v/v, 2:1), 50 mL CH2Cl2 
were added and the mixture was washed thrice with each 
200 mL of water and twice with each 200 mL of saturated, aqueous 
NaHCO3 solution. The organic layer was dried over Na2SO4 and the 
solvent was removed. The crude product was dissolved in 10 mL of 
ethyl acetate, filtered over silica gel and collected as yellowish oil.
Yield: 5.78 g (92%). 1H-NMR (CDCl3, 300 MHz, δ): 4.63–4.58 
(dd, J = 7.9 Hz, 2.6 Hz, 1H, H-4), 4.40–4.33 (m, 3H, H-3, CH2), 
4.26–4.21 (dd, J = 7.9 Hz, 0.9 Hz, 1H, H-5), 3.94–3.64 (m, 6H, H-1, 
H-1′, H-6, H-6′, CH2), 3.05 (s, 3H, SCH3), 1.54, 1.47, 1.42, 1.34 
(4s, 12H, CH3); 
13C-NMR (CDCl3, 75 MHz, δ): 108.95 (Cq), 108.68 
(Cq), 102.38 (C2), 72.84 (CH2), 70.91 (C5), 70.11 (C4, C3), 69.70 (C1), 
68.61 (CH2), 61.06 (C6), 37.34 (SCH3), 29.33 (CH2), 26.52, 25.88, 
25.33, 24.00 (CH3). MS (ESI) m/z: [M+Na]
+ calcd for C15H26O9SNa, 
405.12; found, 405.12. Anal. calcd. for C15H26O9S: C 47.11, H 6.85, 
S 8.38; found: C 47.22, H 6.96, S 8.25.
2.2.4. Synthesis of 1-O-(2-Mercapto-ethyl)-2,3:4,5-di-O-
isopropylidene-β-D-fructopyranoside (5)
1.311 g (3.43 mmol) of 4 was dissolved in 15 mL 2-butanone, 
0.78 g (10.25 mmol) thiourea was added, and the mixture was 
heated to 95 °C under reflux for 7 h.[29] After no starting mate-
rial had remained (TLC, SiO2, EtOAc/cyclohexane, v/v, 2:1), the 
solvent was evaporated, 15 mL CH2Cl2, 15 mL H2O and 0.874 g 
K2S2O5 (3.93 mmol) were added and the mixture was heated to 
reflux for 12 h. The organic layer was washed thrice with each 
200 mL of water, dried with anhydrous Na2SO4, filtered, and 
evaporated to effort after column chromatography (SiO2, EtOAc/
cyclohexane, v/v, 1:1) the pure product.
Yield: 0.842 g (76.7%). 1H-NMR (600 MHz, CDCl3, δ): 4.61 
(dd, J = 7.92 Hz, 2.58 Hz, 1H, H-4), 4.39 (d, J = 2.58 Hz, 1H, H-3), 4.23 
(dd, J = 7.92 Hz, 1.32 Hz, 1H, H-5), 3.90 (dd, J = 12.99 Hz, 3J = 1.83 Hz, 
1H, H-6) 3.74–3.70 (m, 2H, H-6′, H-1), 3.65–3.56 (m, 3H, H-1′, 
CH2), 2.71–2.68 (m, 2H, CH2), 1.59 (t, J = 8.25 Hz, 1H, SH), 1.53–1.34 
(4s, 12H, CH3); 
13C-NMR (150 MHz, CDCl3, δ): 109.07 (Cq), 108.71 
(Cq), 102.64 (C2), 73.62 (CH2),72.36 (C1), 71.11 (C5), 70.30 (C4), 
70.23 (C3), 61.16 (C6), 26.69, 26.02, 25.52, 24.27 (CH3), 24.14 (CH2). 
HRMS (ESI) m/z: [M+Na]+ calcd for C14H24O6SNa, 343.1186; found, 
343.1200. Anal. calcd. for C14H24O6S: C 52.48, H 7.55, S 10.01; 
found: C 52.77, H 7.64, S 10.39.
2.2.5. Synthesis of Linear Poly(ethylene imine) (P1)
Poly(2-ethyl-2-oxazoline) (PEtOx) used as starting material in this 
study was synthesized according to literature procedures.[30] The 
monomer 2-ethyl-2-oxazoline (3.965 g) and the initiator methyl 
tosylate (12.42 mg, 0.067 mmol) were dissolved in dry acetoni-
trile (6.0 mL) under inert conditions in a glovebox. After stirring 
for a few minutes the microwave vial was heated in a microwave 
synthesizer for 128 min at 140 °C. The polymerization mixture 
was diluted with 5 mL dichloromethane and precipitated in 
250 mL ice-cold diethyl ether. Subsequently, the precipitate was 
filtered off and lyophilized (yield: 3.720 g, 94%).
Accordingly, PEtOx (degree of polymerization (DP) = 575, 
2.7 g) was treated with an excess of 6 M aqueous hydrochloric 
acid (250 mL) at 100 °C for 16 h under reflux.[31] The excess of 
hydrochloric acid and the resulting propionic acid were removed 
under reduced pressure. The residue was dissolved in water fol-
lowed by the addition of 3 M NaOH to reach pH = 8. Precipitation 
occurred and the precipitated, hydrolyzed linear poly(ethylene 
imine) was filtered off. The residue was redissolved in 10 mL 
of N,N-dimethylformamide and precipitated two times into 
300 mL ice-cold diethyl ether. The obtained product was dried 
in vacuo at 85 °C. The degree of hydrolysis of the resulting linear 
poly(ethylene imine) P1 was determined by 1H NMR spectroscopy 
(yield: 1.0 g, 85%).
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PEtOx: DP = 575. 1H NMR (300 MHz, D2O, δ): 3.70–3.20 
(NRCH2CH2), 2.41–2.08 (CH2CH3), 1.09–0.79 (CH2CH3). SEC 
(DMAc, LiCl): Mn = 69 000 g mol
−1, Ð = 1.3.
P1: EtOx:EI [%] = 2:98. 1H NMR (300 MHz, MeOD, δ): 3.58–3.41 
(NRCH2CH2), 2.91–2.61 (NHCH2CH2), 2.56–2.36 (CH2CH3), 
1.18–1.06 (CH2CH3).
2.2.6. Synthesis of P(EI-stat-ButEnOx) (P2)
P1 (500 mg) and the catalyst 4-N,N-dimethylamino-pyridine 
(DMAP, 50 mg, 0.41 mmol) were dissolved in pyridine (5 mL) 
at 80 °C. A defined quantity of N-succinimidyl-4-pentenate 
(465 mg) was dissolved in pyridine (5 mL) and heated up to 
80 °C. The two solutions were combined and 2 mL pyridine 
added to obtain a 3 wt% mixture of P1 and stirred for 16 h at 
80 °C. Afterward, the mixture was filtered and precipitated into 
300 mL ice-cold diethyl ether (Et2O). The precipitated copoly mer 
was filtered off and washed with 30 mL of diethyl ether. 
The purified product P2 was dried under reduced pressure 
(yield: 860 mg, 89%).
EI:ButEnOx [%] = 73:27. 1H NMR (600 MHz, DMSO-d6, δ): 5.89–
5.74 (HCCH2), 5.06–4.91 (HCCH2), 3.58–3.20 (NRCHCH2), 
2.80–2.45 (NHCH2CH2), 2.44–2.34 (CH2CH2C2H3), 2.27–
2.16 (CH2CH2C2H3). SEC (DMAc, LiCl, polystyrene): Mn = 
8000 g mol−1, Ð = 1.3. Anal. calcd. for C1927H3811N575O155: C 61.69, 
H 10.24, N 21.47; found: C 60.90, H 10.43, N 22.91.
2.2.7. Synthesis of P(EI-stat-ButEnOx-stat-isoFruButOx) 
via Thiol-Ene Photoaddition (isoP3)
P2 (558 mg) was dissolved in 5 mL methanol. In a second vial, the 
photoinitiator DMPA (6.5 mg, 0.025 mmol) and a 1.2-fold excess 
per double bond of 5 (840 mg) were dissolved in methanol (5 mL). 
The combined solution (5 wt% of P2) was deoxygenated with 
argon for 20 min and stirred in a UV chamber (λ = 365 nm) for 
18 h. Subsequently, the copolymer was precipitated two times in 
300 mL ice-cold diethyl ether. After filtration, the copolymer was 
dried under reduced pressure at 40 °C (yield: 980 mg, 70%).
EI:ButEnOx:isoFruButOx [%] = 73:11:16. 1H NMR (600 MHz, 
DMSO-d6, δ): 5.90–5.74 (HCCH2), 5.07–4.88 (HCCH2), 4.57 
(H-4), 4.27 (H-3), 4.22 (H-5), 3.73 (H-6), 3.66 (CH2), 3.55 (H-6, 
CH2), 3.48 (H-1), 3.43 (H-1), 3.40–3.12 (NRCH2CH2), 2.78–2.46 
(NHCH2CH2), 2.42–2.16 (CH2CH2C2H3), 1.53 (CH2CH2C
H2CH2), 1.47–1.26 (isopropylidene). SEC (DMAc, LiCl): Mn = 11 
600 g mol−1, Ð = 1.9. Anal. calcd. for C3123H5835N575O707S92: C 57.09, 
H 8.95, N 12.26, S 4.49; found: C 57.39, H 9.23, N 13.35, S 4.18.
2.2.8. Synthesis of P(EI-stat-ButEnOx-stat-FruButOx) via 
Deprotection (P3)
The cleavage of the isopropylidene groups was performed under 
acidic conditions.[32] The copolymer isoP3 (685 mg) was dis-
solved in a THF/H2O mixture (22.5/22.5 mL) and acidified with 
2 M hydrochloric acid (6.75 mL). The solution was heated to 
40 °C for 12 h. Subsequently, the mixture was neutralized with 
1.2 g NaHCO3 and THF as well as formed acetone were evapo-
rated under reduced pressure. Purification of the deprotected 
D-fructose conjugate was performed by dialysis against water 
using a Spectra/Por 3 dialysis membrane (3500 g mol−1 cutoff). 
Finally, the product was lyophilized and obtained as a yellowish 
powder (yield: 324 mg, 53%). EI:ButEnOx:FruButOx [%] = 73:11:16. 
SEC (DMAc, LiCl): Mn = 9800 g mol
−1, Ð = 1.2. Anal. calcd. for C2571
H5099N575O707S92: C 52.94, H 8.81, N 13.81, S 5.06; found: C 53.60, 
H 9.13, N 14.91, S 4.66.
2.3. Polymer Labeling with Cy5 (P1-Cy5)
P1 (40 mg) and triethylamine (360 µL) were dissolved in meth-
anol (10 mL). After addition of the cyanine-5-NHS-ester (1 mg) 
the reaction was stirred at room temperature overnight. The 
labeled polymer was precipitated in 250 mL ice-cold diethyl 
ether, filtered, and redissolved in methanol (15 mL). Further puri-
fication was performed by dialysis against a mixture of water/
methanol using a Spectra/Por 3 dialysis membrane (3500 g mol−1 
cutoff). Finally, the product was dried under reduced pressure 
(yield: 15 mg, 37%; labeling efficiency: 2.0% of dye).
2.4. Copolymer Labeling with Rhodamine  
(P2-Rho, P3-Rho)
The copolymer (P2: 35 mg, P3: 40 mg) and triethylamine (200 µL) 
were dissolved in DMF (4 mL). After addition of Rhodamine B 
isothiocyanate (0.7 mg) the reaction was stirred at room tem-
perature for 18 h. Purification was performed by dialysis against 
water using a Spectra/Por 3 dialysis membrane (3500 g mol−1 
and subsequently 6–8000 g mol−1 cutoff). Finally, the product 
was lyophilized and obtained as a reddish powder. The calcu-
lated labeling efficiency (via UV–vis spectroscopy) for conjuga-
tion was 1.4% of dye for the P2-Rho (yield: 23 mg, 66%) and 30.4% 
of dye for the labeled P3 (yield: 26 mg, 65%). To achieve compa-
rable fluorescence intensities, the labeled P3 was mixed with the 
unlabeled P3 (1:19) to obtain P3-Rho (new label efficiency: 1.5% 
of dye).
2.5. Polyplex Preparation
Polyplexes of plasmid desoxyribonucleic acid (pDNA) and 
selected polymers were prepared by mixing stock solutions of 
15 µg mL−1 pDNA and the respective polymers (1 mg mL−1) in dif-
ferent amounts to obtain various N/P ratios (nitrogen of polymer 
to phosphate of pDNA) in HBG (HEPES buffered glucose)  buffer 
(20 × 10−3 M 4-(2-hydroxethyl) piperazine-1-ethanesulfonic acid 
and 5% (w/v) glucose, pH 7.2). The solutions were vortexed for 
10 s at maximal speed and incubated at room temperature for 
20 min to ensure a complex formation.
2.6. Determination of Cytotoxicity
Cytotoxicity studies were performed with the mouse fibroblast 
cell line L929 (CCL-1, ATCC), as recommended by ISO10993-5. Fur-
thermore, the breast cancer cell line MDA-MB-231 and the HUVEC 
cells were used. The cells were routinely cultured in Dulbecco’s 
modified eagle’s medium (Lonza, Basel) supplemented with 10% 
fetal calf serum (FCS), 100 U mL−1 penicillin, and 100 µg mL−1 
streptomycin at 37 °C in a humidified 5% (v/v) CO2 atmosphere. 
HUVEC cells were cultured in M199 Medium (Lonza, Basel) sup-
plemented with 17.5% FCS, 680 × 10−6 M L-glutamin, 25 µg mL−1  
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heparin, 7.5 g mL−1 endothelial mitogenic, Vitamin C (5 µg mL−1), 
human serum and 100 U mL−1 penicillin, and 100 µg mL−1 strep-
tomycin at 37 °C in a humidified 5% (v/v) CO2 atmosphere. In 
detail, cells were seeded at 1 × 104 cells per well in a 96-well 
plate and incubated for 24 h, whereas no cells were seeded in 
the outer wells. Subsequently, P1, P2, and P3 were added to the 
cells in fresh media at indicated concentrations and the plates 
were incubated for 24 h. Control cells were incubated only with 
fresh culture medium. Subsequently, media was replaced by a 
mixture of fresh culture medium and AlamarBlue solution, pre-
pared according to the manufacturer’s instructions. After a fur-
ther incubation of 4 h at 37 °C, the fluorescence was measured 
at Ex 570/Em 610 nm, with untreated cells on the same well plate 
serving as negative controls. The negative control was set as 0% 
of metabolism inhibition and referred as 100% viability. Cell via-
bility below 70% was considered indicative of cytotoxicity. Data 
are expressed as mean ± standard deviation (SD) of three inde-
pendent determinations of six data points each.
2.7. Hemocompatibility and Erythrocyte Aggregation
The interaction of polymers with cellular membranes was inves-
tigated by analyzing the release of hemoglobin from erythro-
cytes. Blood from sheep, collected in heparinized tubes, was 
provided by the Institute of Laboratory Animal Science and 
Animal Welfare, Friedrich Schiller University Jena. The blood 
was centrifuged at 4500 × g for 5 min, and the pellet was washed 
three times with cold 1.5 × 10−3 M phosphate buffered saline 
(PBS, pH 7.4). After dilution of erythrocytes with PBS in a ratio 
of 1:7, aliquots of erythrocyte suspension were mixed 1:1 with 
the indicated polymer solution up to 100 µg mL−1 and incu-
bated in a water bath at 37 °C for 60 min. After centrifugation 
at 2400 × g for 5 min, the hemoglobin release into the superna-
tant was determined spectrophotometrically at a wavelength 
of 544 nm using a microplate reader (TECAN Infinite M200 Pro, 
Crailsheim, Germany). Complete hemolysis (100%) was achieved 
using 1% Triton X-100 serving as positive control. Pure PBS was 
used as negative control (0% hemolysis). The hemolytic activity 
of the polycations was calculated using Equation (1)
= ×
−
−
A A
A A
%Hemolysis 100
( )
( )
Sample Negative control
Positive control Negative control  
(1)
A value less than 2% hemolysis rate was classified as non-
hemolytic, 2%–5% as slightly hemolytic and >5% as hemolytic. 
Experiments were run in triplicates and were performed with 
three different batches of donor blood.
To study the influence of aggregation, erythrocytes were iso-
lated as described above. The erythrocyte suspensions were 
mixed 1:1 with the polymer solutions (100 µL total volume) in 
a clear flat bottomed 96-well plate. The cells were incubated at 
37 °C for 2 h, and the absorbance was measured at 645 nm in 
a microplate reader. Cells, which were treated with PBS, served 
as negative control and 25 kDa branched PEI (BPEI) (50 µg mL−1, 
Sigma-Aldrich) was used as positive control. Absorbance values 
of the test solutions lower than the negative control were 
regarded as aggregation. Experiments were run in triplicates and 
were performed with three different batches of donor blood.
2.8. Ethidium Bromide Quenching Assay (EBA)
The formation of polyplexes with pDNA was examined by 
quenching of the ethidium bromide fluorescence. Briefly, 
15 µg mL−1 pDNA in a total volume of 100 µL HBG buffer were 
incubated with ethidium bromide (0.4 µg mL−1) for 10 min at 
room temperature. Subsequently, polyplexes with different 
amounts of polymer (various N/P ratios) were prepared in black 
96-well plates (Nunc Thermo Fisher). The samples were incu-
bated at room temperature for 15 min before fluorescence meas-
urements. The fluorescence of the samples was measured at an 
excitation wavelength of 525 nm and an emission wavelength 
of 605 nm using a Tecan Genios Pro fluorescence plate reader 
(Tecan, Crailsheim, Germany). A sample containing only pDNA 
and ethidium bromide was used to calibrate the device to 100% 
fluorescence against a background of 0.4 µg mL−1 of ethidium 
bromide in HBG solution. The percentage of dye displaced upon 
polyplex formation was calculated using Equation (2)
[ ] = ×F
F
RFU % 100
sample
pDNA  
(2)
Here, RFU is the relative fluorescence and Fsample and FpDNA are 
the fluorescence intensities of a given sample and the ethidium 
bromide intercalated into pDNA alone.
2.9. Heparin Dissociation Assay
To investigate the release of pDNA from polyplexes, the heparin 
dissociation assay was performed. Polyplexes with an N/P ratio 
of 30 were prepared as described above in a total volume of 
100 µL HBG buffer containing ethidium bromide (0.4 µg mL−1). 
After incubation in the dark at room temperature for 15 min, 
the polyplexes were transferred into a black 96-well plate, and 
heparin solutions of indicated concentrations were added. The 
solutions were mixed and incubated for further 30 min at 37 °C 
in the dark. The fluorescence of ethidium bromide was measured 
at Ex 525 nm/Em 605 nm with a Tecan microplate reader. The 
percentage of intercalated ethidium bromide was calculated as 
described above.
2.10. Dynamic and Electrophoretic Light Scattering (ELS)
Dynamic light scattering was performed on a Zetasizer Nano ZS 
(Malvern Insturments, Herrenberg) with an He-Ne laser oper-
ating at a wavelength of λ = 633 nm. All measurements (30 runs, 
triplicate) were carried out at 25 °C after an equilibration time 
of 120 s. The counts were detected at an angle of 173°. The 
mean particle size was approximated as the effective (z-average) 
diameter and the width of the distribution as the polydisper-
sity index of the particles (PDI) obtained by the cumulants 
method assuming a spherical shape. ELS was used to measure 
the zeta potential (ζ). The measurement was performed on a 
Zetasizer Nano ZS (Malvern Instruments, Herrenberg, Germany) 
by applying laser Doppler velocimetry. For each measurement, 
20 runs were carried out using the slow-field reversal and the 
fast-field reversal mode at 150 V. Each experiment was per-
formed in triplicate at 25 °C. The zeta potential was calculated 
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from the electrophoretic mobility (µ) according to the Henry’s 
equation. Henry coefficient f(ka) was calculated according 
to Oshima.
2.11. Uptake Studies
For uptake studies, cells were cultured as described above. Sub-
sequently, cells were seeded at a density of 105 (HUVEC, 3 × 105) 
cells per mL in 24-well plates and cultured for 24 h. One hour 
prior to the addition of the polyplexes, the medium was changed 
to OptiMEM (Life Technologies, Darmstadt, Germany). The poly-
plexes were prepared as described above and at least 50 µL poly-
plex solution of N/P 50 were added to the cells cultured with 
500 µL media. The plates were incubated for 1 h at 37 °C under 
5% CO2 atmosphere.
For flow cytometry studies the pDNA (pEGFP-N1) was labeled 
with YOYO-1 iodide prior to the polyplex preparation. For labe-
ling of 1 µg pDNA, 0.026 µL of 1 M YOYO-1 solution was mixed 
with pDNA and incubated for 20 min at 4 °C protected from 
light. Afterward, HBG buffer and polymers were added at 
the indicated N/P ratio and the polyplexes were formed as 
described previously. The cells were washed and harvested 
after 1 h and 10% trypan blue was added to quench the outer 
fluorescence of the cells. To determine the relative uptake of 
the polyplexes, 10 000 cells were measured by flow cytometry 
using a Cytomics FC 500 (Beckman Coulter) and the amount 
of viable cells showing YOYO-1 signal (FL1) were gated. Dead 
cells were identified via counterstaining with propidium 
iodide. The experiments were performed at least three times 
independently.
Live cell imaging was performed for uptake studies. In detail, 
cells (105 cells mL−1) were seeded on glass-bottomed dishes 
(Greiner, Germany) and cultivated for 24 h in a humidified 
atmosphere. One hour prior to the polymer addition, the cells 
were rinsed with PBS and the medium was changed to OptiMEM. 
The polyplexes were formed with P1-Cy5, or P2-Rho, and P3-Rho, 
added to the cells, and incubated for one additional hour. Sub-
sequently, the medium was replaced by fresh culture medium 
or PBS supplemented with Hoechst 33342 for nucleus staining. 
Imaging was performed with LSM880, Elyra PS.1 system (Zeiss, 
Oberkochen, Germany) applying a 63× 1.4 NA plan apochromat 
oil objective.
2.12. Transfection Studies
For transfection studies HUVEC cells were seeded at a density 
of 2 × 105 cells mL−1 in 24-well plates 1 d before transfection. 
One hour prior to transfection, cells were rinsed with PBS and 
supplemented with 1 mL of OptiMEM (Life Technologies). Poly-
plexes (50 µL) were added to the cells and the plates were incu-
bated for 4 h in the incubator. Afterward, the supernatant was 
replaced by 1 mL of fresh growth medium and the cells were 
further incubated for 20 h. For analysis, adherent cells were 
harvested by trypsinization. The relative expression of EGFP 
fluorescence of 104 cells was quantified via flow cytometry 
using a Cytomics FC 500 (Beckman Coulter). For determination 
of the transfection efficiency viable cells expressing EGFP were 
gated.
3. Results and Discussion
To conjugate a D-fructose derivative to a cationic polymer 
backbone, the thiol-ene photoaddition was utilized as the 
method of choice since it can be performed under mild 
conditions (low temperature, no toxic metal catalysts) 
in high yields.[33] Previous studies revealed that overex-
pressed D-fructose receptors of various breast cancer cell 
lines tolerate only defined positions of the introduced func-
tional groups.[12] Several modifications at the C1 position 
of fructopyranose have been reported to be tolerated by 
GLUT5.[13,14,34] Since 1-deoxy-1-mercapto-fructopyranose 
did not react with the respective copolymers by thiol-ene 
photoaddition, an ethyl spacer had to be installed at the C1 
position between the D-fructose moiety and the thiol group.
3.1. Synthesis of Thio-Functionalized D-Fructose
The D-fructose derivative bearing a thiol-group was 
obtained in a four-step synthesis from commercially avail-
able 2,3:4,5-di-O-isopropylidene-β-D-fructopyranoside (1). 
First, a benzyl ether group was introduced by the conversion 
of 1 with benzyl-2-bromoethyl ether (Scheme 1) resulting 
in 1-(2-(benzyloxy)ethyl)-2,3:4,5-di-O-isopropylidene-β- 
D-fructopyranoside (2). In a second step, the benzyl group 
of 2 was cleaved under standard conditions with H2/palla-
dium on activated charcoal to obtain 3 in high yield (95%). 
The OH-group was transformed into a leaving group by 
mesylation with mesyl chloride under argon atmosphere 
analog to a literature procedure.[28] In a substitution reac-
tion, the thiol functionality was introduced stepwise 
by transformation to the isothioronium salt and, subse-
quently, hydrolysis to yield the product 1-O-(2-mercapto-
ethyl)-2,3:4,5-di-O-isopropylidene-β-D-fructopyranoside (5).
Characterization of the synthesis pathway by 1H 
NMR spectroscopy for the compounds 1–5 is illustrated 
in Figure 1. The successful introduction of the “benzyl 
ethyl” substituent (1–2) can be followed by the proton 
signals in the aromatic region (7.24–7.39 ppm), the ben-
zylic CH2 signal (4.56 ppm), and the disappearance of the 
OH-quadruplet (2.09 ppm). After cleavage of the benzyl 
group (3), the disappearance of the aromatic and the ben-
zylic CH2 signals is observed. The successful substitution 
with mesyl chloride is characterized by the appearance 
of a sharp singlet at 3.02 ppm (4). The disappearance of 
the mesyl singlet and the appearance of a quadruplet 
(1.58 ppm) confirm the successful introduction of the 
thiol group (5). For the subsequent polymer modification, 
the protected thio-fructose 5 was used.
3.2. Synthesis of a D-Fructose Bearing Cationic Copolymer
The homopolymer poly(2-ethyl-2-oxazoline) (PEtOx) 
was synthesized according to a literature procedure by 
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ABSTRACT: We describe the synthesis of matrix supported
hydrogel structures based on amine containing poly(2-
oxazoline)s and their use to bind and release genetic material
for potential applications in diagnostics or pathogen detection.
Amine containing poly(2-oxazoline)s were synthesized by
copolymerization of 2-ethyl-2-oxazoline with a monomer
bearing a tert-butyl oxycarbonyl (Boc) protected amine
group in the 2-position and subsequent deprotection. The
statistical copolymers were used to generate hydrogels and
matrix supported hydrogels by cross-linking of a certain
fraction of the amine groups with epichlorhydrin. Supported
structures were prepared by soaking porous polyethylene (PE)
or polypropylene (PP) ﬁlter materials in a copolymer/
epichlorhydrin solution, which was cross-linked upon heating. Scanning electron microscopy (SEM) of the composites revealed
a bead like structure of the gel phase, which could be attributed to a lower critical solution temperature (LCST) behavior of the
initial polymer prior to gelation. The dependency of the LCST behavior on the content of amine groups was investigated.
Swelling values and the ratio of hydrogel per composite was determined using water sorption analysis. Subsequently, the ability of
the systems to absorb and release labeled DNA was tested. Uptake and stimulated release, triggered by changes in pH,
temperature, and heparin concentration, were investigated using ﬂuorescence microscopy. Polymerase chain reaction (PCR)
proved the successful recovery of the DNA, demonstrating the potential of the presented system for a broad range of molecular
biological applications.
■ INTRODUCTION
The isolation of nucleic acids from biological samples, such as
cells, tissues, and viruses, is of signiﬁcant importance for DNA-
based applications in modern clinical diagnostics,1 genetic
analysis,2 drug discovery,3 and pathogen detection.4 To
guarantee a successful and speciﬁc detection of DNA sequences
in downstream processes, puriﬁcation of the genetic material is
the main requirement. An optimal DNA extraction system
comprises the fast and eﬃcient isolation of DNA ideally directly
from complex biological samples, the avoidance of toxic
reagents and inhibitory substances, and a cost-eﬀective
fabrication enabling disposable devices.5,6 However, the low
amount of DNA in cell/tissue extracts and its structural and
chemical similarity to other cell components (size, negative
charge, molecular mass, and hydrophobicity)7 results in poor
selectivity and considerable coelution.8
A broad diversity of DNA puriﬁcation and extraction
techniques have been developed in the past decades, and up
to now, no universal puriﬁcation method exists.9 Well
established approaches are based on, e.g., phenol−chloroform
extraction or CsCl/ethidium bromide density gradient
centrifugation. These extraction techniques, performed in
liquid phases, are time-consuming and associated with the use
of toxic, hazardous reagents.10,11 Solid phase extraction (SPE)
techniques using mostly glass ﬁber, silicon dioxide, diatoma-
ceous earth, nitrocellulose, polyamide, or anion exchange resins
as solid phases have become the most common method to
prepare DNA samples for genetic analysis and other biomedical
techniques.12−17
In consideration of the fact that the potential of common
SPE is fairly exhausted, future developments need to involve
new materials. A highly promising alternative approach is the
catch and release of DNA molecules within a three-dimensional
hydrogel matrix. Hydrogels possess a high water content,
resulting in a mobility of guest molecules by diﬀusion,18 are
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tunable in pore size19 and chemical functionality,20 and most
importantly, they provide a large surface area for binding of
targeted molecules. To make use of these systems for DNA
puriﬁcation processes, hydrogels can be endowed with, e.g.,
cationic functionalities, which enables electrostatic interactions
with the negatively charged DNA. The advantage of this
approach over SPE is the avoidance of chaotropic salt solutions
and alcohols, which can contaminate the samples and, e.g.,
inhibit polymerase chain reactions (PCR).21 In addition,
hydrogels exhibit an inherent wettability enabling the eﬃcient
interaction with the DNA containing solution in contrast to the
often relatively hydrophobic solid surfaces. Elution from the
hydrogel can be performed either speciﬁcally, using a
competitive ligand, or nonspeciﬁcally, by changing the pH,
ionic strength, or polarity of the solvent depending on the
matrix used and the chemical characteristics of the
biomolecules.
Poly(2-oxazoline)s (POx) represent a highly promising
platform for the synthesis of functional materials. The living
cationic ring-opening polymerization (CROP) of 2-oxazolines,
which was discovered in 1966,22−25 enables the design of well-
deﬁned (co)polymers with tailored molar mass and function-
alities.26 The polymer properties are mainly determined by the
choice of the monomer and can be further ﬁne-tuned by the
introduction of functional groups that are able to be modiﬁed
in postpolymerization reactions.27,28 The ﬁrst examples of POx-
based hydrogels were reported in 1989 by Saegusa and co-
workers. The authors copolymerized conventional monomers
with bis-functional oxazolines.29 In the following years, their
method of choice was the partial hydrolysis of POx and the
subsequent esteriﬁcation of the resulting poly(ethylene imine)
units. Using this approach, it was possible to introduce several
functionalities and to cross-link the polymers via secondary
interactions30−32 or covalent bonds.33−35 More than one
decade later, other groups continued studying POx-based
networks and reported diﬀerent approaches for the network
synthesis, e.g., by the preparation of methacrylate functionalized
POx macromonomers and their use as cross-linker in radical
polymerizations.36−39 The ﬁrst example of amine bearing POx
and their general ability to form hydrogels was reported by
Cesana et al. in 2006.40 In more detail, we recently studied the
kinetics of a 2-oxazoline monomer with a protected amine
functionality and were able to produce polymers and networks
with deﬁned compositions. Furthermore, we could show that
these systems are able to reversibly bind genetic material from
solution.18 However, before these systems can be used in the
above-mentioned applications, two problems have to be solved:
(i) the lack of mechanical stability of the hydrogels (in
particular relevant for common extraction protocols requiring
centrifugation steps that cause considerable shear forces) and
(ii) the dependence of the release process on high
concentrations of heparin, which would interfere with
subsequently performed PCR. To overcome the former issue,
the use of a supportive inert polymer-based matrix in which the
hydrogel component is localized represents a promising
approach. While the (amine-containing) hydrogel network is
meant to bind and release DNA, the second network introduces
additional stability and protects it from mechanical degradation.
The latter issue can be overcome by a change in the release
stimuli, using temperature and pH changes or by a reduction of
the initial heparin concentration.
In this contribution, we report on the fabrication of
composite materials composed of a polyethylene (PE) or
polypropylene (PP) matrix and amine containing POx
hydrogels. To gain insights into the phase conditions during
formation of the POx hydrogels, the LCST behavior of the
precursor polymer in dependence of the amine content was
studied. The microstructure of the produced hydrogels was
investigated via SEM, and the ability of the substrates to absorb
water from the gas phase was determined using TGA. The
potential of the material for binding and release of DNA in
dependence of the heparin concentration was studied using
ﬂuorescence microscopy.
■ EXPERIMENTAL SECTION
Materials and Instrumentation. All chemicals and solvents were
purchased from Sigma-Aldrich, Merck, Fluka, and Acros. 2-Ethyl-2-
oxazoline (EtOx) and methyl tosylate (MeTos) were distilled to
dryness prior to use.
2-(4-((tert-Butoxycarbonyl)amino)butyl)-2-oxazoline (BocOx) was
synthesized as described in our previous work.41 Filter substrates
consisting of PE (90 μm pore size) or PP (120 μm pore size) were
purchased from Porex technologies GmbH and perforated to pills with
a diameter of 7 mm and a thickness of 1.6 mm. Cy5 labeled DNA was
provided by Analytik Jena.
The Initiator Sixty single-mode microwave synthesizer from
Biotage, equipped with a noninvasive IR sensor (accuracy 2%), was
used for polymerizations under microwave irradiation. Microwave vials
were heated overnight to 110 °C and allowed to cool to room
temperature under argon atmosphere before usage. All polymer-
izations were carried out under temperature control. Size-exclusion
chromatography (SEC) of protected polymers was performed on a
Shimadzu system equipped with a SCL-10A system controller, a LC-
10AD pump, a RID-10A refractive index detector, and a PSS SDV
column with chloroform/triethylamine (NEt3)/2-propanol (94:4:2) as
eluent. The column oven was set to 50 °C. SEC of the deprotected
statistical copolymers was performed on a Shimadzu system with a LC-
10AD pump, a RID-10A refractive index detector, a system controller
SCL-10A, a degasser DGU-14A, and a CTO-10A column oven using
N,N-dimethylacetamide with 2.1 g/L LiCl as the eluent and the
column oven set to 50 °C. Poly(styrene) (PS) samples were used as
calibration standards for both solvent systems. Proton NMR
spectroscopy (1H NMR) measurements were performed at room
temperature on a Bruker AC 300 and 400 MHz spectrometer, using
CDCl3 or MeOD as solvents. The chemical shifts are given in ppm
relative to the signal from the residual nondeuterated solvent. Fourier
transform infrared (FTIR) spectroscopy was performed on an Aﬃnity-
1 FT-IR from Shimadzu, using the reﬂection technique. Gas
chromatography (GC) was performed on a GC-2010 from Shimadzu.
Acetonitrile was used as an internal standard to determine the
monomer conversion. Scanning electron microscopy (SEM) was
measured using a ﬁeld emission scanning electron microscope Gemini
1530 type LEO from Carl Zeiss AG, Germany. Investigated samples
were freeze-dried matrix supported hydrogels. Cloud points were
determined in a Crystal 16 from Avantium Technologies connected to
a chiller (Julabo FP 40) at a wavelength of 500 nm.
Copolymerization of EtOx and BocOx (P(EtOx-stat-BocOx))
(1−5). In a microwave vial, EtOx (181.7 μL, 1.8 mmol), MeTos (90.8
μL, 0.600 mmol), and acetonitrile (11.5 mL) were mixed under inert
conditions. After heating in the microwave at 140 °C for 16 min, EtOx
(2543 μL, 25.2 mmol) and BocOx (749 μL, 3 mmol) were added
under argon stream and the mixture was heated again in the
microwave synthesizer (140 °C, 11 min). The solution was diluted
with dichloromethane (100 mL) and extracted with saturated aqueous
solution of sodium bicarbonate (3 × 100 mL) and water (3 × 100
mL). Subsequently, the solution was concentrated and the polymer
was precipitated in 400 mL ice-cold diethyl ether. The white
precipitate was ﬁltered and dried in high vacuum (2.77 g, 78%).
1H NMR (CDCl3, 300 MHz): δ = 4.99 (s, 0.2 H, NH), 3.45 (s, 4 H,
backbone), 3.11 (s, 0.3 H, CH2−CH2−NH (BocOx)), 2.40 (s, 1.9 H,
CH2 (EtOx)), 1.92 (s, 0.3 H, CH2−CH2−CO (BocOx)), 1.64 (s, 0.3
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H, CH2−CH2−CH2 (BocOx)), 1.53 (s, 0.3 H, CH2−CH2−CH2
(BocOx)), 1.42 (s, CH3 (BocOx)), 1.21 (s, 1.3 H, CH3 (EtOx)) ppm.
SEC (9) (eluent: CHCl3/2-propanol/NEt3, PS-standard): Mn =
5300 g/mol, Mw = 5700 g/mol, PDI = 1.08.
Deprotection of P(EtOx-stat-BocOx) (P(EtOx-stat-AmOx) (6−
10). Exemplarily, P(EtOx-stat-BocOx) (1, 2 g) was dissolved in
triﬂuoroacetic acid (TFA) (5 mL) and heated at 60 °C for 1 h. After
stirring for 24 h at room temperature, the mixture was diluted with 10
mL of methanol and precipitated in 400 mL of cold diethyl ether. The
yellowish precipitate was redissolved in methanol (200 mL) and
stirred with Amberlyst A21 for 24 h. Subsequently, the solution was
concentrated and the polymer was precipitated in cold diethyl ether
(400 mL), ﬁltered, dried in high vacuum, and obtained as a yellowish
powder (1.58 g, 87%).
1H NMR (MeOD, 400 MHz): δ = 3.52 (s, 4 H, backbone), 2.96
(0.23 H, s, CH2−CH2−NH2), 2.42 (2 H, s, CH2 (EtOx) + CH2−
CH2−CO (AmOx)), 1.69 (0.41 H, s, CH2−CH2−CH2−CH2
(AmOx)), 1.11 (2,8 H, s, CH3 (EtOx)) ppm.
SEC (18) (eluent: DMAc/LiCl, PS-standard): Mn = 8,100 g/mol,
Mw = 10,200 g/mol, PDI = 1.26.
Investigation of the Cloud Point Behavior of P(EtOx-stat-
PAmOx). To determine the temperature responsive solubility changes
of P(EtOx-stat-AmOx), the polymer was dissolved in distilled water at
diﬀerent concentrations ranging from 0.4 to 100 mg/mL. The
solutions were heated from 2 to 100 °C under stirring with a heating
rate of 1 °C/min. The turbidity of the solution was recorded as a
function of the temperature. The cloud point was deﬁned as the
temperature where the solution reaches 50% of transmission. Three
heating cycles were performed, and the average value was used. For
one measurement point, four samples of identical concentrations were
investigated in parallel.
Synthesis of Matrix Supported (11−16) and Nonsupported
Hydrogels (17−19). In a typical experiment, the ﬁlter substrates were
swollen in a 1 mL solution of 9 (200 mg, 0.034 mmol, 0.51 mmol
based on amine groups) and epichlorhydrin (6.66 μL, 0.085 mmol) in
5 wt % sodium hydroxide (NaOH) solution. After 10 min, the mixture
was heated to 50 °C for 1 h. The ﬁlter substrates were separated from
the residual gel, washed in water (3 × 100 mL, 1 day), and freeze-
dried.
Water Uptake Measurements. The swelling of the matrix
supported hydrogels was investigated using a TGA Q5000 SA
thermogravimetric analyzer from TA Instruments Eschborn, Germany.
For data evaluation the “Universal Analysis Software” was used.
Substrates were dried in the machine at 60 °C and 0% relative
humidity until weight constancy was reached. Water uptake was
performed at room temperature and 90% relative humidity. The
measurement was stopped when the samples were saturated with
water.
The weight fraction of hydrogel in the composite materials was
determined using eq 1.
=
−
−
×m
Q Q
Q Q
(wt%) 100%HG
ges F
HG F (1)
where Qges = swelling value of the composite, QHG = swelling value of
the hydrogel, and QF = swelling value of the host matrix.
DNA Binding and Release of Composite Materials. DNA
absorption of matrix supported hydrogels was measured using labeled
DNA (Cy5) and a ﬂuorescence microscope (Cell Observer Z1, Carl
Zeiss, Jena, Germany) equipped with a mercury arc UV lamp and the
appropriate ﬁlter combinations for excitation and detection of
emission. Images of a series (11 × 11 pictures per well) were
captured with a 10× objective using identical instrument settings (e.g.,
UV lamp power, integration time, and camera gain), and spots of the
96-well plate were addressed using an automated XY table.
The matrix supported gels were swollen in HBG-buﬀer (HEPES
buﬀered glucose, pH 7) for 30 min and, subsequently, in a DNA
solution (500 μL, 10 μg/mL) for 30 min. After washing with buﬀer
solution for another 30 min, the ﬂuorescence of the substrates was
detected. The release was accomplished applying a 2 mL of a 6 mg/
mL heparin solution in water for 30 min. Surface adherent water was
removed before each measurement. Fluorescence pictures were taken
from the buﬀer-swollen material after DNA binding and washing and
after the release took place.
Stimuli Responsive Release. The temperature, pH, and heparin
concentration dependency of the release process was investigated by
measuring the ﬂuorescence of the supernatant of the matrix supported
hydrogel after treatment with the respective condition for 1 h. Samples
were swollen in a solution of Cy5-labled DNA (200 mL, 10 ng/mL).
Subsequently, the solution was removed and the gel was washed using
200 μL of water. Again, the water was removed and replaced with
either water, buﬀer (pH = 4), or heparin solution of varying
concentration. After 1 h, the supernatant was analyzed using the Tecan
M200 Pro ﬂuorescence microplate reader (Crailsheim, Germany) at
the following wavelengths: Ex 649 nm/Em 670 nm.
DNA Extraction and Real-Time PCR Assay. The gDNA
extraction of a laboratory isolated strain of Escherichia coli K12 was
performed with a magnetic particle based system for fully automated
isolation and puriﬁcation of nucleic acids (AJ InnuPure C16). The
real-time PCR assay was realized in a AJ TOptical Real-time
Thermocycler and was carried out in a 20 μL of reaction mixture
with the follow compositions: DNA extract (5 μL), 0.025 units Taq
DNA polymerase (AJ innuTaq Hot-A DNA polymerase), 4 mM
magnesium chloride, 1.0 mM of deoxy-nucleotriphosphate, 2.5 mM
buﬀer, 1× EvaGreen Fluorescent DNA Stain, and 0.5 μM of each
primer. For ampliﬁcation, an initial denaturation for 2 min at 95 °C
was followed by 45 cycles of 95 °C for 30 s, 57 °C for 30 s, and 72 °C
for 30 s. In this study, a DNA fragment of E. coli LacZ was used as
positive control and without DNA as negative control. The PCR
products were analyzed by agarose gel electrophoresis using 2.0%
agarose gel containing ethidium bromide, and the gels were viewed on
a UV transilluminator (AJ Biometra UVsolo TS). Additional
information about the primers can be found in the Supporting
Information.
■ RESULTS AND DISCUSSION
Polymer and Hydrogel Synthesis. The synthesis of
amine containing poly(2-oxazoline)s (POx)s was carried out, as
described previously (Scheme 1).41 2-Ethyl-2-oxazoline (EtOx)
was copolymerized with 2-(4-((tert-butoxycarbonyl)amino)-
butyl)-2-oxazoline (BocOx), a 2-oxazoline monomer bearing
a Boc-protected amine group in the side chain. To ensure that
the initiator, namely methyl tosylate (MeTos), does not attack
the Boc-protected amine group of the comonomer, an
Scheme 1. Schematic Representation of the Polymer and Hydrogel Synthesis
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macroinitiator containing three repeating units EtOx was
synthesized in the ﬁrst step. The increased sterically hindrance
of the oxazolinium species is expected to diminish the reaction
with the functional group. The respective primary amine
containing copolymers (P(EtOx-stat-AmOx)) were obtained
after deprotection of the amine group using TFA (Table 1).
The gelation reaction was performed using epichlorhydrin
(ECH) as cross-linker. Under the basic conditions applied (pH
14), ECH undergoes a ring-opening reaction with the amine
groups of the copolymers. The resulting OH group and the
chlorine group of ECH can reform an epoxide moiety by the
elimination of hydrochloric acid. This functionality can undergo
a second reaction to covalently cross-link the polymers.
Matrix Supported Hydrogels. For the fabrication of
matrix supported hydrogels, polymer 9 was selected as it
demonstrated good DNA binding capabilities.41 A host network
(PE or PP based porous ﬁlter substrate) was swollen in an
aqueous solution of polymer (9), cross-linker (ECH), and
sodium hydroxide for 30 min. The linker concentration was
chosen to react with 33% (11, 14), 66% (12, 15), and 100%
(13, 16) of the available amine groups. Gelation occurred after
1 h at 50 °C. Subsequently, the ﬁlter substrates were separated
from the supernatant gel and cleaned from surface adherent gel
particles using a spatula. The composite material and the
residual gels (17−19) were puriﬁed by washing with distilled
water (3 × 5 mL per substrate, 24 h) and freeze-drying (Figure
1). Six diﬀerent matrix supported gels were prepared
comprising two host materials (PP and PE) with the three
diﬀerent degrees of cross-linking. The stoichiometry was
calculated in assumption that every amine group reacted once
with ECH resulting in a secondary amine. However, the real
case is a mix of unreacted, secondary, and tertiary amines within
the network.
A ﬁrst evidence for the successful incorporation of the POx
gel within the host matrix could be obtained by the
investigation of the water uptake from the gas phase. This
measurement was carried out using a special TGA setup where
the sample weight can be determined in dependency of the
relative humidity and temperature of the surrounding
atmosphere. To exclude swelling prior to the measurement,
the samples were annealed at 60 °C and 0% humidity for 2 h.
After weight constancy was reached, the measurement was
started by an increase of the relative humidity to 90% at room
temperature. As depicted in Figure 2, the weight of the
substrate increases upon this environmental change. The
measurement was stopped when no further change of the
sample weight could be detected.
The composition of hydrogels and matrix supported gels as
well as the results of the water uptake studies are summarized in
Table 2. The pure POx gels show a good swelling behavior
from humid air and absorb up to 66% of their own weight of
water. A trend is clearly visible; the higher the degree of cross-
linking of the network, the lower the swelling value of the gel.
Table 1. Selected Analytical Data of the Amine Containing
POx
sample
no. polymer
Mn (SEC)
[g/mol] PDI
yield
[%]
AmOx
[%]
6 P(EtOx43-stat-
PAmOx5)
8100 1.26 95 10
7 P(EtOx39-stat-
PAmOx7)
8200 1.24 90 15
8 P(EtOx32-stat-
PAmOx9)
8700 1.25 93 22
9 P(EtOx38-stat-
PAmOx15)
9500 1.23 89 27
10 P(EtOx32-stat-
PAmOx16)
9400 1.24 96 33
Figure 1. Synthesis of matrix supported gels from POx (green) within a host structure (blue): (A) Host material swollen in polymer solution, (B)
gelated polymer within the pores of the host, (C) matrix supported gel separated from residual gel, and (D) isolated as well as freeze-dried product.
Figure 2. Water uptake measurement of composite 11.
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In contrast, the material based on the PE and PP host
substrates only show minimal water uptake of 1.9 to 4.5%. In
combination with the water uptake of the bare substrates (0.0%
for PP and 0.2% for PE), this clearly indicates the presence of a
second, hydrophilic component within the host matrix.
It was possible to calculate the mass of the entrapped gel
from the swelling value of the composite and the water uptake
of the single components. The fact that the PP-based materials
contains more hydrogel is attributed to the pore size of the
material which is larger than the one of PE (PP = 120 μm, PE =
90 μm). Therefore, the swelling in the polymer solution prior
to gelation is more eﬃcient and results in a higher weight
fraction.
A further proof of the proposed structure of the matrix
supported gels could be obtained by SEM investigations
(Figure 3). The large pore structure of the host material is
visible in the ﬁrst picture (PP). The images of the composites
clearly show the existence of a second component within the
host matrix consisting of a network of hydrogel beads. The
bead size is similar for all diﬀerent cross-linking degrees. Only
the shape becomes more regular with increasing amount of
linker. SEM pictures of the PE-based supported hydrogels can
be found in the Supporting Information (Figure S2).
LCST of the Copolymers. The appearance of gel particles
instead of a homogeneous network was unexpected. To
understand this eﬀect, the behavior of the polymer during the
process of gelation (aqueous solution of sodium hydroxide (pH
14), 50 °C) was investigated in more detail. Poly(2-ethyl-2-
oxazoline) (PEtOx) based systems are known to exhibit lower
critical solution temperature (LCST) behaviors in aqueous
solution, i.e., EtOx-containing copolymers show a coil-to-
globular transition at elevated temperatures.42 If the polymers
reported here reveal a cloud point behavior where the
homogeneous solution separates into two phases with diﬀerent
polymer concentrations, gelation of only one phase would lead
to gel particles as observed. This phase transition can be
investigated measuring the transmission of the solution in
dependence of the applied temperatures because the turbidity
of the solution increases by the light scattering of one phase.43
As depicted in Figure 4, all polymers exhibited cloud points
in the investigated concentration range in aqueous solution
(pH 14). Furthermore, an inﬂuence of the polymer
composition on the cloud point temperature was observed.
An increased AmOx content resulted in increased cloud point
temperature, with values between 25 and 65 °C. However,
PEtOx itself exhibits a LCST behavior but only at higher molar
masses and higher temperatures (61−69 °C for PEtOx with Mn
of 20,000 g/mol−1).42 Therefore, the AmOx monomer seems
Table 2. Overview of the Synthesized Composite Materials and Hydrogelsa
11 12 13 14 15 16 17 18 19 PP PE
substrate PP PP PP PE PE PE
ratio ECH/amine (%) 33.0 66.0 100.0 33.0 66.0 100.0 33.0 66.0 100.0
swelling value (%) 3.3 4.5 3.3 2.2 3.0 1.9 66.5 61.5 53.0 0.0 0.2
gel component (wt %) 5.0 7.3 6.2 3.0 4.6 3.2 100.0 100.0 100.0 0.0 0.0
aPolymer 9 was used for the gelation of the hydrophilic component.
Figure 3. SEM pictures of PP-based composites. The magniﬁed images show the appearance of hydrogel beads with a diameter of 5 to 10 μm.
Figure 4. Concentration dependent evaluation of the cloud points of
P(EtOx-stat-AmOx) at pH 14.
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to have a signiﬁcant eﬀect on the thermal properties of these
systems. The incorporation of 10 mol % AmOx causes a
decrease of the cloud point temperature to almost as low as
room temperature. A further increase of the AmOx amount
should lead to a faster response and, therefore, to an even lower
cloud point temperature. However, a contrary behavior was
observed. This could be attributed to two competing trends.
The polymer side chain exhibits two diﬀerent domains: the
hydrophobic alkyl chain and the hydrophilic amine group,
which is not protonated at the pH values studied. While the
hydrophobic domain induces the phase transition, the amine
group promotes the water solubility. A stronger increase of the
inﬂuence of the amine in comparison to the hydrophobic
behavior of the alkyl chain could explain a rising cloud point
with increasing amounts of comonomer, as observed. A
diﬀerent explanation could be the chaotropic inﬂuence of the
high OH− concentration resulting in a lowering of the cloud
point of the PEtOx part.
All investigated polymers exhibit LCSTs between 40 and 80
mg/mL under the conditions of the gelation reaction.
Therefore, the polymer solution is phase separated before the
gelation occurs. The cross-linking then proceeds in the phase
with the high polymer concentration, forming small gel beads
as visible in the SEM pictures.
This behavior is favorable for the foreseen application in
several aspects. First of all, a bead-like structure provides a large
surface to volume ratio, which is beneﬁcial for the purpose of
DNA capture and release because the diﬀusion control of the
process is decreased. Moreover, the porous structure of the host
material is not completely ﬁlled by the gel. This increases the
ability of a sample solution to pass through the ﬁlter matrix in a
given time without the need of intense force which is also
beneﬁcial for the targeted application where a sample solution
should be pumped through the ﬁlter matrix on a short time
scale.
DNA Binding and Release. To investigate the ability of
the synthesized composites to absorb and release genetic
material, Cy5 (Abs, 649 nm; Em, 670 nm) labeled DNA was
used. The location and concentration of this DNA derivative
can be measured directly by spectroscopic and microscopic
techniques tracking the ﬂuorescence of the attached dye. In a
general procedure, the matrix supported gels were swollen in
HBG-buﬀer (HEPES buﬀered glucose, pH 7, 2 mL) for 30 min.
Afterward, the samples were transferred into a DNA solution
for 30 min. The prior swelling limits the penetration of the gel
by DNA to passive diﬀusion. Subsequently, the gels were
cleaned from adhered liquid and washed in buﬀer solution for
another 30 min to exclude the detection of DNA which is not
bound (Figure 5).
The samples were investigated using ﬂuorescence micros-
copy. The results of the measurements for the PP-based
composites are depicted in Figure 6 (uptake and release studies
of all other supported hydrogels can be found in the Supporting
Information, Figure S3).
The ﬁrst row shows ﬂuorescence images of the samples
which were swollen in buﬀer solution. The slightly increased
intensity of the red color in comparison to the initial PP
material resembles the autoﬂuorescence of the hydrogel which
is bound to the substrate. After the addition of DNA and a
washing step, a bright ﬂuorescence of the composite is visible
while the bare PP matrix shows online some bright spots which
are attributed to the encapsulation of DNA solution droplets
within the pores of the material. Treatment of the ﬁlters with
heparin solution (6 mg/mL) for 30 min caused a fraction of the
bound DNA to be released again as depicted in the last row.
Heparin is a polyanion able to replace genetic material in
electrostatic complexes. In the enlargement of the picture, the
microstructure of the hydrogel beads is clearly visible and
provides a further proof that the POx hydrogel is responsible
for the binding of DNA because only the beads light up under
the ﬂuorescence microscope.
While the release using heparin is an eﬃcient method to
regain the bound DNA, it has also drawbacks. The most
prominent one is that heparin acts as an inhibitor in a PCR.
Therefore, other stimuli for the release of DNA from the gels
were tested. The most obvious trigger for this purpose is a
change of the temperature. To investigate this inﬂuence, the
DNA loaded substrates (13) were placed in water (500 μL)
and heated to a speciﬁc temperature between 30 and 90 °C.
Figure 5. Schematic representation of the DNA uptake and release by
the composite materials. (A) Uptake of ﬂuorescently labeled DNA by
the hydrogel component and (B) release of DNA by the addition of
heparin.
Figure 6. DNA uptake and release of PP-based composite 13.
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After 1 h, the supernatant was transferred into a well plate and
the ﬂuorescence was measured using a plate reader. The data
were related to reference samples which were treated with the
same temperature program but without the presence of a
composite. Unfortunately, no release could be detected up to a
temperature of 80 °C. At 90 °C, about 1.5% of the labeled
DNA was detected in the supernatant (Figure 7). Also a change
of pH to lower or higher values did not lead to a suﬃcient
release.
Another possibility to minimize the heparin concentration in
the ﬁnal DNA solution is the variation of the initial heparin
amount added to the composite. The DNA is set free from the
gel by a replacement with heparin, which blocks the cationic
binding site of the network. Because of its higher charge
density, heparin has a higher aﬃnity to the gel than the genetic
material. If the concentration of heparin is low enough for a
complete absorption into the gel but high enough for a partially
replacement of DNA, the resulting sample solution would be
suitable for a PCR. An increase of the heparin concentration
resulted, as expected, in a higher DNA release, although this
enhancement is not linearly increasing with the concentration
of polyanion. Also, a combination of the three triggers did not
result in an increased release of DNA.
PCR Results. To prove the suitability of the presented
system for the aimed application, DNA fragments released by
heparin were ampliﬁed in a real-time PCR process. For this
purpose, the three diﬀerent samples, which were released for
each concentration, were pooled and an aliquot was
subsequently subjected to PCR. The ampliﬁcation curves are
depicted in the Supporting Information (Figure S4). Addition-
ally, the resulting PCR products were analyzed using conven-
tional agarose gel electrophoresis (Figure 8). The size of the
sample products and the positive control matches with the
theoretical value of the gene aimed at (LacZ; approximately 228
base pairs). Exclusively, the DNA sample, which was released
using 2 mg/mL heparin, was not ampliﬁed in the PCR. This is
most probably attributed to the inhibitory eﬀect of the higher
heparin content. It seems reasonable that in all other cases the
heparin concentration is suﬃciently low (0.031 to 1 mg/mL)
that the majority of the heparin added to the DNA loaded
hydrogel is entrapped within the polymer network and hence
does not interfere with the subsequent PCR. This assumption is
supported by the fact that already very low heparin
concentrations around 0.02 mg/mL inhibit the ampliﬁcation
of genetic material in the reported protocol (Supporting
Information, Figure S5). For a heparin concentration of 2 mg/
mL, the gel sample is saturated with anionic material and hence
Figure 7. Release studies of the composites varying the temperature, pH value, and heparin concentration.
Figure 8. Agarose gel of the heparin released DNA samples after PCR and electrophoresis (M = DNA ladder standard, P = positive control, N =
negative control).
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further excess of heparin cannot be hold back. Therefore, no
PCR product could be obtained. Having in mind that the DNA
release using 1 mg/mL is almost as high as with 2 mg/mL
(Figure 7), this eﬀect is negligible for the PCR application
presented here.
■ CONCLUSION AND OUTLOOK
In summary, we demonstrated the successful combination of
functional POx hydrogels and polymeric ﬁlter substrates. The
presence of a gel component within the host material could be
proven by an increased water uptake and scanning electron
microscopy studies. Furthermore, the amount of incorporated
gel could be determined indirectly by the swelling values.
The cloud point behavior of the precursor polymer was
investigated to gain insights of the state of dissolution during
the hydrogel synthesis. All polymers showed LCST behavior in
dependency of the amount of amine containing comonomer in
aqueous solution (pH 14). The phase separation of the
polymer solution at the conditions of the gelation resulted in
the formation of hydrogels with bead-like microstructure as
detected by SEM.
It was shown that the composites are able to absorb DNA
from solution and that the release was accomplished via a
replacement of the genetic material by heparin. Furthermore,
the inﬂuence of the heparin concentration was examined. PCR
studies demonstrated that recovered DNA, which was released
with heparin concentrations up to 1 mg/mL, was still intact and
could be ampliﬁed. Moreover, temperature and pH value were
investigated as stimuli for the release of DNA from the
hydrogels. However, both resulted in low amounts of free
DNA.
Because the release of genetic material from all the hydrogels
synthesized so far is rather restricted, further studies will focus
on diﬀerent release stimuli, as well as systems which are able to
immobilize DNA on surfaces without the absorption into a
three-dimensional substrate. Using this approach, it could be
possible to perform a PCR directly on the surface to
accumulate DNA copies in the surrounding solution without
any need for a DNA release.
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on the spot, however, operating with the 
same accuracy as laboratory tests. [ 2 ] More-
over, cost effi ciency is a major require-
ment in this context, rendering the design 
of new bioanalytical devices a highly chal-
lenging task. [ 3 ] The detection of diseases 
based on bacterial, fungal, or viral infec-
tions can be accomplished by the inves-
tigation of the pathogens nucleic acid 
profi les, [ 4 ] providing the opportunity of a 
fast determination and a targeted medi-
cation. [ 5 ] The recognition of the genetic 
material can be accomplished via special-
ized DNA assays, [ 6 ] e.g., based on micro-
chip systems. [ 7 ] However, this presents 
only the last step in bioanalytics. The iso-
lation of nucleic acids from whole tissue 
and cell samples and, in particular, the 
separation from proteins is still a prereq-
uisite for downstream analytical processes. 
The general steps of nucleic acid purifi ca-
tion include 1) tissue and/or cell lysis, 
2) inactivation of cellular nucleases, and 
3) separation of the desired nucleic acids 
from the cell debris. [ 8 ] To separate proteins from genetic mate-
rial, phenol-chloroform extraction and density gradient cen-
trifugation displayed the method of choice for many years. [ 8a , 9 ] 
Besides the use of toxic substances, [ 9 ] these liquid phase based 
methods had the drawback of very time consuming and labo-
rious working steps. [ 10 ] An enormous improvement was 
achieved in 1989, when the fi rst solid phase extraction (SPE) 
system for DNA purifi cation was described by McCormick 
et al . [ 8b ] It has the advantage to separate nucleic acids from 
proteins more effectively, and without the generation of toxic 
by-products. Since its introduction, the SPE system evolved to 
the most common and easily adaptable purifi cation method for 
genetic material. [ 11 ] Still, there are remaining disadvantages, 
such as the labor-intensive multiple washing procedures, the 
limited loading capacity of the silica matrix, as well as limita-
tions in the extraction effi ciency. [ 8a ] 
 To overcome these restrictions, a challenging alternative 
approach is the binding of DNA within polymer matrices. Such 
scaffolds can be considered as a potential alternative for DNA 
immobilization, based on the fact that they have the potential 
of low cost production at large scales and mostly exhibit a bio-
compatible character. [ 12 ] Furthermore, they can be functionalized 
easily, [ 13 ] e.g., with positively charged groups, able to interact with 
the negatively charged phosphate backbone of polynucleotides. [ 14 ] 
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 1.  Introduction 
 A reliable and time saving point-of-care diagnostic is one of the 
most important targets in bioanalytical science. [ 1 ] The optimal 
method would comprise an analysis of sample material directly 
Adv. Funct. Mater. 2015, 25, 2458–2466
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 However, these polymers are mostly water soluble and, 
therefore, an assignment in biological, water based systems 
is not possible, since a separation from solution is diffi cult. 
For this reason, polymer-based hydrogels offer a great oppor-
tunity for a reversible DNA binding and release. [ 15 ] Because 
of their high water content and the resulting permeability of 
the 3D matrix, as well as the adjustable functionalities and a 
high surface to volume ratio, hydrogels represent attractive 
candidates for DNA immobilization. The suitability of poly(2-
oxazoline) (POx) based hydrogels [ 16 ] and networks composed 
of POx–poly(ethylenimine) copolymers [ 17 ] was already investi-
gated. The amine content and, therefore, the affi nity to DNA 
are adjustable in both systems, resulting in a tunable DNA 
binding behavior. The combination of charged moieties with 
hydrophilic monomers such as 2-ethyl-2-oxazoline (EtOx) 
results in water swellable networks able to interact with genetic 
material. Furthermore, a release can be induced by the addition 
of heparin which replaces the DNA, generating eluates compat-
ible with subsequent polymerase chain reaction (PCR) based 
DNA amplifi cation. [ 16 ] However, the diffusion of genetic mate-
rial within the gel is the limiting factor preventing fast purifi ca-
tion procedures. Additionally, also non- or low-charged residues 
from cell lysis could be entrapped within the pores of the gel 
and, hence, interfere with downstream processes. 
 Surface bound polymer coatings are a potential way to over-
come the drawbacks discussed above and combine the advan-
tages of hydrogels with diffusion independent, surface medi-
ated processes. The covalent immobilization of POx on glass 
substrates was already demonstrated in the context of low-
fouling coatings; [ 18 ] however, to the best of our knowledge, 
no investigations regarding their bioanalytical potential are 
reported. A major requirement for DNA purifi cation systems 
is their compatibility with subsequent PCR processes which 
are indispensable for a later detection. The PCR was invented 
by Mullis in 1983 and enveloped to one of the most important 
methods in bioanalytical science. [ 19 ] Via PCR, a few copies of 
a specifi c sequence of genetic material can be amplifi ed by 
the naturally thermostable enzyme polymerase, [ 20 ] using spe-
cifi cally, synthesized oligonucleotides (primers) for the gene-of-
interest. [ 19 ] The process itself consists of three steps: [ 21 ] 1) The 
denaturation (melting), 2) the primer annealing to the specifi c 
gene sequences, and 3) the elongation at a polymerase-specifi c 
temperature. Without PCR, DNA detection would be impos-
sible due the low amounts of genetic material in biological 
samples. [ 22 ] However, the PCR process is limited by the purity 
of the bioanalytical samples, as well as by the template DNA 
amount. [ 23 ] Cellular components, remaining from cell lysis or 
other impurities, can interfere with the process and lead to 
nonexponential amplifi cation or even a complete inhibition of 
the process. Therefore, pure polynucleotide solutions with a 
high concentration are preferable. 
 In this contribution we describe the synthesis of POx based 
surface coatings, containing a defi ned amount of amine groups 
for DNA binding and release. The polymers are covalently 
immobilized in a layer-by-layer (LbL) approach, generating 
fi lms of defi ned thicknesses, and DNA binding/release pro-
fi les. The coating procedure is established on glass and, sub-
sequently, transferred to poly(propylene) (PP), being one of the 
most common and important materials in bioanalytics. After 
investigation of the DNA interaction on plain substrates, PCR 
tubes are coated on the inside, creating a system able to sepa-
rate DNA from impurities and, moreover, amplify and detect 
specifi c sequences by quantitative real-time PCR (qPCR). 
Exploiting the temperature dependent DNA binding behavior 
of POx multilayers it is possible to extract and detect DNA 
directly from cell lysate rendering this “lab in a tube” system 
a highly versatile and likewise easy to use tool for pathogen 
detection. 
 2.  Results and Discussion 
 2.1.  Polymerization and Fluorescent Labeling 
 The synthesis of amine containing POx was reported previously 
by our group. [ 15 ] Briefl y, a 2-oxazoline bearing a Boc protected 
amine group (BocOx) was used in a copolymerization with 
EtOx to yield a statistical copolymer having 24% of functional 
comonomer incorporated (P(EtOx 35 - stat -BocOx 11 ,  1 ). Deprotec-
tion using trifl uoroacetic acid (TFA) was applied to obtain amine 
containing POx (P(EtOx 37 - stat -AmOx 9 ,  2 ) with a molar mass 
( M n ) of 4600 and a narrow size distribution. Recalculation of the 
composition by NMR measurements after deprotection resulted 
in a fi nal AmOx content of 20% ( Table  1 ). Since this polymer 
should be used as a surface coating material, labeling was con-
ducted using fl uorescent dyes (fl uorescein-5- N -hydroxysuccin-
imide ester for polymer  3 or rhodamine B  iso -thiocyanate for 
polymer  4 ) which are able to react with amine groups to enable 
a later detection of deposits. The coupling reaction was per-
formed using one equivalent of dye per polymer chain, leaving 
a suffi cient amount of free amine groups for surface attachment 
and DNA interaction. The success of the dye functionalization 
was verifi ed by size-exclusion chromatography (SEC) meas-
urements, comparing the signal from the refractive index (RI) 
Adv. Funct. Mater. 2015, 25, 2458–2466
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 Table 1.  Selected characteristics of the synthesized polymers. 
Polymer Compound Dye  M n 
[g M −1 ]
 Ð Degree of func. 
[%]
Absorption maximum
[nm]
Emission maximum
[nm]
 1 P(EtOx 35 - stat -BocOx 11 ) − 4600 
a) 1.30 − − −
 2 P(EtOx 37 - stat -AmOx 9 ) − 9300 
b) 1.13 − − −
 3 P(EtOx 37 - stat -AmOx 8 - stat -FAmOx 1 ) Fluorescein 11 000 
b) 1.16 78 485 530
 4 P(EtOx 37 - stat -AmOx 8 - stat -RAmOx 1 ) Rhodamine B 12 000 
b) 1.19 5 555 590
 a) SEC measurements in chloroform;  b) SEC measurements in DMAc. 
F
U
L
L
 
P
A
P
E
R
2460 wileyonlinelibrary.com © 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
detector with the UV–vis signals. Purifi cation (precipitation, 
and in the case of polymer  4 preparative size exclusion chro-
matography) was conducted until no trace of unbound dye was 
detected in the SEC traces. Overlapping RI and UV–vis traces 
prove a homogeneous functionalization of the polymeric mate-
rial (Figure S1, Supporting Information). The effi ciency of the 
labeling reaction was quantifi ed by NMR spectroscopy (Table  1 ). 
 2.2.  Surface Functionalization 
 The covalent attachment of amine functionalized POx to (acti-
vated) glass substrates was already reported by our group. [ 24 ] 
The method comprises the cleaning and activation by plasma 
and the subsequent deposition of a siloxane monolayer using 
3-glycidyloxypropyl trimethoxysilane (GOPTMS). The epoxide 
groups of the siloxane layer react readily with the amine groups 
of the POx material to form a polymeric monolayer on the 
surface. While glass is a substrate frequently used for func-
tionalization by silanization, also PP was utilized as a support 
material in this study since it is cheap, fl exible, and relatively 
inert regarding biological processes. For this reason, the surface 
chemistry described before was transferred to PP. An overview 
over the performed coating procedures is depicted in  Scheme  1 . 
 To generate oxygen based functionalities 
on the highly inert substrate, O 2 -plasma was 
applied. The oxidative conditions lead to the 
formation of OH groups and other oxygen 
based functionalities on the surface. [ 25 ] These 
functional groups can be used to attach a 
siloxane monolayer of GOPTMS. The present 
epoxide groups were subsequently quenched 
by the reaction with the amine groups of pol-
ymers  2 ,  3 , or  4 . The success of the reaction 
could be verifi ed by contact angle (CA) meas-
urements determining the surface energy, as 
well as by fl uorescence using confocal laser 
scanning microscopy (CLSM). 
 To optimize the amount and homogeneity of the deposited 
POx, the O 2 -plasma treatment time, as well as the GOPTMS 
incubation temperature was altered since coating experi-
ments with conditions described for glass resulted in hetero-
geneous coated surfaces. Additionally, the incubation time of 
the polymer was varied between 1, 2, and 24 h. The success 
of coating experiments was analyzed via CA and CLSM meas-
urements ( Figure  1 ). The CA measurements revealed that the 
hydrophobic character of untreated PP (CA = 88°) decreases 
after activation with O 2 plasma (CA = 36°), most probably due 
to the formation of hydroxyl groups. These oxygen functionali-
ties react with GOPTMS to form a monolayer on the surface 
(CA = 25). After coating with polymer  4 , the hydrophilicity 
increases (CA < 20°) as a result of the covalently bound mac-
romolecules. According to the CA results, there are no differ-
ences in the coating effi ciencies for varying incubation times. 
CLSM measurements at  λ ex = 543 nm ( λ em : 560–615 nm) were 
performed for all coated slides, as well as for the blank sub-
strates measuring an increase of fl uorescence after coating with 
fl uorescently labeled POx ( 4 ). The fl uorescence intensity does 
not change signifi cantly by varying either coating conditions 
or POx incubation time; however, the fi lm homogeneity does, 
which is indicated by the standard deviation of the signal. An 
O 2 plasma treatment of 30 min and 1 h GOPTMS incubation at 
Adv. Funct. Mater. 2015, 25, 2458–2466
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 Scheme 1.  Schematic representation of the deposition of P(EtOx 37 - stat -AmOx 9 ) on substrates 
by LbL immobilization.
 Figure 1.  Optimization of the coating conditions for POx ( 3 ) on PP. The plasma incubation time was investigated using A,B) 15 min or C,D) 30 min of 
treatment. GOPTMS incubation was performed for A,C) 60 min at RT, or B,D) with an additional heat treatment for 5 min at 85 °C. POx coating was 
performed for 1, 2, or 24 h at 50 °C. Success and homogeneity of the coating procedure was verifi ed by CA and CLSM.
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room temperature (RT) were chosen as the best activation and 
functionalization conditions because of a high mean fl uores-
cence in combination with the most homogenous distribution 
of polymer on the surface within a reasonable time (Figure  1 C). 
 2.3.  LbL Assembly 
 The aim of this work is the production of POx coatings having 
a defi ned thickness to tailor the strength of interaction with the 
genetic material. To this end, an LbL deposition method was 
conducted to produce multilayers of amine containing POx 
on PP. The general procedure is shown in Scheme  1 , starting 
with the already described deposition of a POx coating on a 
GOPTMS monolayer. Subsequently, the remaining amine 
groups were activated by the use of an excess of epichlorohy-
drin (ECH). The epoxide groups of this cross-linker molecule 
react with primary and secondary amines present in the fi rst 
POx layer resulting in tertiary amine groups. In a second step, 
alkaline conditions are applied, leading to a reformation of an 
epoxide ring, based on the elimination of hydrochloric acid. 
The generated epoxide groups can be used to attach a second 
layer of POx as described before. This cycle can be repeated to 
immobilize a defi ned amount of POx layers on the substrate. 
Within this study fi lms composed of up to three layers were 
produced. A fi rst indication of a successful layer deposition was 
generated by CA measurements ( Table  2 ). The blank PP sub-
strate produced high CA values due to the hydrophobicity of 
the material. 
 Plasma activation, as well as GOPTMS deposition reduces 
the CA signifi cantly, indicating an effective functionalization. 
Upon the attachment of POx, the CA decreases below 20° 
which displays the minimum measurable CA. The activation 
using ECH cross-linker yields CA values above 50° which is 
decreased again below 20° upon the addition of another POx 
layer. This behavior of surface energy changes is in perfect 
agreement with the successful deposition of POx in an LbL 
approach. 
 To gain further insights into the system, thermogravimetric 
analysis (TGA) experiments were conducted. Pure PP sub-
strates, as well as POx ( 2 ) were subjected to thermal combus-
tion. The weight loss as a function of temperature was recorded 
revealing different decomposition temperatures (Figure S2, 
Supporting Information). 
 Using this information it is possible to calculate the amount 
of deposited POx on PP from the TGA measurements of the 
coated samples (Table  2 ). The relatively linear mass increase 
per POx layer indicates a homogeneous LbL deposition. 
 Further analysis of the POx coating was conducted using 
refl ectometric interference spectroscopy (RIFS) measurements. 
The method determines the thickness of layers on glass sub-
strates having a refl ective Ta 2 O 5 layer on the opposite site of 
the coating by measuring the peak shift of light refl ected by 
the polymer layers. [ 26 ] For this purpose, glass slides were coated 
applying the conditions used for PP and analyzed accordingly 
(Table S1, Supporting Information). During the measurements, 
a water fl ow was channeled over the POx surface continuously 
to generate information about the swollen layers. The exponen-
tial increase of the layer thickness is, at fi rst sight, inconsistent 
with the information obtained from TGA. A varying cross-
linking density of individual layers could be an explanation for 
this discrepancy. The fi rst layer is attached to the substrate via 
the reaction with epoxide groups directly on the surface, gener-
ating a fl at fi lm of polymer chains. With every additional layer 
the mobility of the epoxide binding sites increases generating 
more loosely bound and mobile POx layers able to incorporate 
more water into the polymeric matrix, describing the transition 
from a surface coating to an immobilized hydrogel ( Figure  2 ). 
 As a fi nal proof of the LbL deposition, fl uorescence analyses 
were performed using polymer  3 . All investigated PP slides 
were coated with three POx layers; however, fl uorescently 
labeled POx was only used in the fi rst, second, or third coating 
step, respectively. For the other two layers, polymer  2 was 
used. In this way samples with one fl uorescently labeled POx 
layer and two unlabeled layers are obtained. Every coating step 
was investigated using CLSM measurements ( Figure  3 ). The 
pictures illustrate the control over the layer deposition by the 
applied method. A signifi cant increase in fl uorescence upon 
coating with polymer  3 shows the successful immobilization 
of the material (e.g., A1). The fl uorescence signal remains 
relatively constant upon the addition of further layers (e.g., 
A2 and A4) proving the existence of LbL structures on the 
surfaces. 
 2.4.  DNA Binding and Release 
 The ability of the presented POx fi lms to adsorb genetic mate-
rial in a reversible manner is a prerequisite for the aimed 
application. First tests were conducted using the RIFS method 
(BIAffi nity) as described before, however, using DNA solutions 
instead of pure water to swell the POx layers. Differences at the 
peak minimum (500 nm) enable information about the layer 
Adv. Funct. Mater. 2015, 25, 2458–2466
www.afm-journal.de
www.MaterialsViews.com
 Table 2.  Analytical data of the multilayer POx coatings. 
Coating step CA 
[°]
POx amount by TGA 
[wt%]
Layer thickness (on glass) 
[nm]
Blank 100 − 0.0
O 2 plasma 80 − 0.6
GOPTMS 48 − 0.8
1st POx layer <20 0.7 3.5
ECH 57 n. d. n. d.
2nd POx layer <20 1.3 28.4
ECH 72 n.d. n.d.
3rd POx layer <20 1.8 109.4
 Figure 2.  Schematically representation of water-swollen POx multilayers.
F
U
L
L
 
P
A
P
E
R
2462 wileyonlinelibrary.com © 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
thickness which, in the end, allows a conclusion about the rela-
tive amount of bound DNA ( Figure  4 ). 
 Slides containing a POx monolayer do not show a signifi cant 
swelling upon addition of DNA while the thickness of coat-
ings with two as well as three polymer layers increases. This 
trend correlates well with the increase of the hydrogel character 
per deposited layer. A weaker interconnection between the 
polymer chains of a fi lm leads to a higher DNA adsorption due 
to the incorporation of DNA molecules within the layer and 
an increased interaction between amine groups and the DNA 
backbone. However, the presence of DNA as a polyanion could 
also lead to an alteration of the swelling behavior without a dis-
tinct binding. 
 To track the fate of the genetic material in the presence of 
POx multilayers directly by CLSM investigations, Cy5-labeled 
DNA strands were used. These measurements allow a quantifi -
cation of the amount of bound DNA on the substrate assuming 
that the fl uorescence emission increases proportional to the 
amount of immobilized genetic material. Cy5-labeled DNA lacZ 
segments were synthesized via PCR using Cy5-labeled primers. 
After amplifi cation, the PCR products were purifi ed and ana-
lyzed via gel electrophoresis. The DNA amount was determined 
using UV–vis spectroscopy (ScanDrop250). 
 The time required to establish an equilibrium between 
bound and unbound DNA is crucial for a later application since 
it determines the velocity of the fi rst step of, e.g., pathogen 
detection. To this end, the immobilization of labeled DNA on 
POx multilayers was investigated ( Figure  5 A). PP chips with 
a defi ned surface (78 mm 2 ) were covered with a water droplet 
(15 µL) containing 1.5 µg of DNA for a defi ned time. To exclude 
an unspecifi c interaction, the chips were subsequently washed 
with water at RT. 
 The CLSM measurements show an increase of fl uores-
cence emission that is proportional to the incubation time of 
Cy5-labeled DNA strands. Chips containing one POx layer do 
not show a pronounced uptake behavior which is assumedly a 
result of the diminished swelling of this monolayer preventing 
an effi cient uptake of the oppositely charged species. In con-
trast, PP chips with two POx layers reveal an increase in fl uo-
rescence up to 5 min incubation time. PP chips with three POx 
layers show a constant increase in emission up to 2 h. Those 
results indicate a correlation between the amount of polymer 
layers and the total DNA adsorption. It is assumable that the 
hydrogel-like character of chips coated with three layers of POx 
results in an increasing impact of diffusion processes on the 
DNA adsorption which is not pronounced for the two-layered 
systems. 
 As the polymer associated DNA will be used for surface 
mediated PCR experiments, the ability of a controllable DNA 
release behavior is likewise important. Since the genetic mate-
rial must be available for the polymerase to be amplifi ed, a 
quantitative release is preferable. 
 For these experiments, chips loaded for 1 h with the above 
described procedure were subjected to a temperature dependent 
washing process (Figure  5 B). DNA release studies were not per-
formed for chips containing one polymer layer, due to the fact 
that the long incubation times necessary for binding makes 
them unfavorable for further studies. All samples were inves-
tigated regarding Cy5 fl uorescence before and after the release 
was accomplished resulting in a percentage amount of released 
genetic material. The measurements show a release of around 
40% of the initially bound DNA at a temperature of 65 °C or 
above representing ideal conditions for PCR experiments, since 
the temperature in the amplifi cation cycles varies between 57 
and 95 °C. Since no signifi cant improvement regarding DNA 
binding and release is achieved by the deposition of three 
instead of two POx layers, further experiments were conducted 
using a POx double layer. 
 2.5.  PCR Experiments 
 One major advantage of the presented method is the possibility 
of coating PP substrates enabling a larger variety in the design 
of analytical systems. Up to now, only 2D PP slides were used 
for polymer immobilization. For detection applications, how-
ever, it would be favorable to apply POx layers on the inside of 
PCR reaction vessels. For this reason, PP-tubes (RoboStrip PP 
white 8-well strips low profi le) were coated using the already 
described procedure. The success of the coating was verifi ed 
using CLSM measurements of layers deposited using polymer  3 
(Figure S3, Supporting Information). However, for qPCR exper-
iments, unlabeled polymers ( 2 ) were used to avoid interference 
with fl uorescence based detection process. To demonstrate the 
Adv. Funct. Mater. 2015, 25, 2458–2466
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 Figure 3.  CLSM pictures of fl uorescently labeled POx multilayers. 
Polymer  3 was used for the A) fi rst, B) second, or C) third polymer layer. 
Pictures were captured of blank PP (0), and after the fi rst (1), second 
(2), as well as third (3) coating step at a wavelength between 505 and 
530 nm. Scale bar: 200 µm.
 Figure 4.  RIFS measurements using a DNA solution of 100 ng µL −1 to 
swell POx multilayers.
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convenience of the “lab in a tube“-approach, qPCR assays were 
performed using coated PCR tubes. 
 In fi rst experiments, DNA from  Escherichia coli BL21 ( E. coli ) 
was extracted with innuPREP DNA Mini Kit (AJ Innuscreen 
GmbH, Berlin), bound within POx coatings for 1 h at RT, and 
washed thoroughly. The DNA loaded tubes were fi lled with 
10 µL of qPCR master mix and subjected to qPCR. The assay 
detects specifi c gene sequences, like the LacZ-Gene as  E. coli 
specifi c target, by the use of specifi c primer sequences which 
only bind to the desired gene. A schematic representation of 
the whole process is displayed in  Scheme  2 . 
 The cycle threshold ( c t ) value of the qPCR assay shows at 
which cycle the DNA has reached a defi ned concentration pro-
viding an indication about the effi ciency of the process and the 
amount of available template. After amplifi cation, a positive 
result is reported by the melting peak of the PCR product, as 
detected by the use of intercalating dyes. In the case of LacZ, the 
melting curve of the product should exhibit a peak around 87.5 
°C. This melting-point is equivalent to the expected product 
of 224 base pairs (GenBank sequence accession number: 
AM946981.2). The results of the detection of extracted  E. coli 
samples are shown in  Table  3 and the amplifi cation curves as 
well as melting points are depicted in Figure S4, Supporting 
Information. Uncoated tubes with additional template served as 
a positive control, whereas, a PCR experiment without sample 
DNA was used as a negative control. 
 The qPCR result of surface bound DNA is positive for the 
specifi c  E. coli- target and the amplicon shows the same charac-
teristic melting point as the positive control. Also the assay is 
able to detect  E. coli DNA in the presence of a background of 
Herring testes DNA, proving the working principle in the pres-
ence of undesired genetic material. 
 However, for an easy and cost-effective sample analysis it 
is necessary to bind DNA directly from a cell lysate instead of 
using already purifi ed genetic material. Consequently, the pres-
ence of other (charged) cellular components has to be tolerated. 
Therefore, an  E. coli suspension (1.36 × 10 9 cfu mL −1 ) was incu-
bated for 10 min at 95 °C to lyse the cells by heat induction. 
Each 50 µL of this cell lysate were fi lled in POx modifi ed tubes 
and incubated for 1 h. To investigate the infl uence of tempera-
ture to the binding behavior during the incubation, the tubes 
were incubated at 25, 35, 45, 55, and 65 °C (incubation per-
formed on BioShake iQ with adapter for 96 × 0.2 mL tubes) and 
the supernatant solution was removed at the specifi c tempera-
ture. Every incubation temperature step was tested positive for 
 E. coli DNA with a melting point around 87.3 °C with no detect-
able melting point on negative control ( Figure  6 ). 
 As shown in the box-plot the  c t values of the qPCR decrease 
with increasing temperature which indicates a faster ampli-
fi cation process. Generally, the  c t value is dependent on the 
amount of accessible template (a higher initial DNA concen-
trations leads to lower values) and the presence of inhibitors 
Adv. Funct. Mater. 2015, 25, 2458–2466
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 Figure 5.  Adsorption and release of Cy5 labeled DNA by POx multilayers. A) Time dependent uptake of labeled genetic material determined by mean 
fl uorescence of POx multilayers after treatment. B) Temperature dependent release of POx multilayers loaded with DNA for 1 h displayed as percentage 
of the initially bound DNA amount.
 Scheme 2.  Working principle of the “lab in a tube” approach. Cells are lysed by heat treatment and genetic material is adsorbed in POx surface coat-
ings. After addition of a specifi c primer and a PCR master mix, amplifi cation and detection is accomplished in a qPCR process.
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which increase the  c t value by lowering the effi ciency of the 
reaction. Since the amount of bound DNA is not increasing at 
higher temperatures (Figure  5 B) the latter reason is presum-
ably responsible for the faster amplifi cation. A further indica-
tion is given by a narrowing of the value distribution at higher 
temperatures. 
 To explain this behavior, the complex composition of the 
cell lysate can be accounted. While DNA has a high density of 
negative charge, also other former cell components have poten-
tially negative charges and can interact with the POx layers. The 
presence of these compounds leads to a disturbance or inhibi-
tion of the PCR process, resulting in high  c t values. However, 
the binding affi nity of negatively charged material decreases 
with increasing temperature, as already demonstrated by tem-
perature dependent release studies (Figure  5 B). It is likely that 
these compounds are released from the POx layers at lower 
temperatures than the DNA with its multiple negative charges. 
At 65 °C, the majority of contaminants are present unbound in 
solution and can be washed away while a considerable amount 
of genetic material is still adsorbed to the polymer layers, acces-
sible for a subsequent amplifi cation. The performed experi-
ments demonstrate the suitability of POx modifi ed surfaces for 
a qPCR detection of DNA. Due to the compatibility of the modi-
fi ed PP surface with the qPCR process a combination of sample 
purifi cation and detection in a single tube or cavity is possible. 
 3.  Conclusion 
 We demonstrated the production of a poly(2-oxazoline) (POx)-
based separation and detection system for pathogen analysis 
without prior purifi cation steps. Covalent amine containing 
POx multilayers was deposited on PP substrates in a layer-by-
layer process. The affi nity of DNA to the surface coatings was 
studied in detail and the binding and release was found to be 
temperature dependent. PCR tubes, coated with POx were 
used to bind and purify DNA directly from cell lysates and the 
amplifi cation of genetic material can be accomplished directly 
from the adsorbed DNA templates. Moreover, detection can be 
performed using a qPCR assay. The presented system displays 
an easy and elegant way to collect sample DNA from biological 
materials, as well as to perform purifi cation, amplifi cation, and 
detection within just one coated PCR tube. The method is like-
wise effective and easy-to-use while requiring only low amounts 
of functional polymer coating. The straight forward prepara-
tion of the layer system and the cost effi ciency of the support 
material should enable for large scale production and automa-
tion of detection processes. For this reason, this “lab-in-a-tube” 
displays a promising tool for bioanalytics. Further studies have 
to show how reliable the method is concerning varying sam-
ples sources, primers and in which concentration ranges a suc-
cessful detection is possible. 
 4.  Experimental Section 
 Material and Instrumentation : All chemicals were purchased from 
Sigma-Aldrich and Merck. 2-Ethyl-2-oxazoline (EtOx) and methyl tosylate 
(MeTos) were distilled to dryness under argon atmosphere prior to usage. 
PCR ingredients as well as polypropylene (PP) substrates were provided 
by Analytik Jena. PP slides (1 × 3 cm) were used for optimization of the 
coating procedure and verifi cation of the LbL deposition (CA and CLSM 
measurements). Round PP-chips with a diameter of 0.5 cm were utilized 
for TGA investigations as well as DNA binding and release studies. For 
PCR experiments, PCR-tubes (RoboStrip PP white 8–well strips low profi le) 
were coated on the inside. 2-(4-(( tert -Butoxycarbonyl)amino)butyl)-2-
oxazoline (BocOx) was synthesized according to a published procedure. [ 15 ] 
 The polymerization was performed under microwave irradiation, 
using an Initiator Sixty single-mode microwave synthesizer from Biotage, 
equipped with a noninvasive IR sensor (accuracy: 2%). Microwave vials 
were heated overnight to 100 °C under vacuum and allowed to cool to 
RT under argon before usage. Polymerizations were performed under 
temperature control. 
 SEC of the protected statistic copolymers was performed on a 
Shimadzu system equipped with a SCL-10A system controller, a 
Adv. Funct. Mater. 2015, 25, 2458–2466
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 Table 3.  Results of  E. coli detection from extracted DNA using the LacZ-gene as target. The amount of bound DNA within the POx coatings could not 
be determined. 
Template Sample Amount of DNA 
[ng]
Melting point 
[°C]
Mean  c t value Sample count
 E. coli Positive control 0.6 87.3 16.4 3
Negative control 0 − − 3
Surface bound n. d. 87.5 20.5 4
 E. coli + Herring testes Positive control 1 87.5 13.7 3
Negative control 0 − − 4
Surface bound n. d. 87.2 20 4
 Figure 6.  Box-plot of qPCR experiments, performed in POx coated reac-
tion vessels. The tubes were loaded with genetic material from cell 
lysates at different temperatures and the  c t value of the amplifi cation was 
recorded.
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LC-10AD pump, a RID-10A RI detector, and a PSS SDV column with 
chloroform-triethylamine (TEA)-2-propanol (94:4:2) as eluent. The 
column oven was set to 50 °C. 
 SEC measurements of the deprotected statistic copolymers and 
the fl uorescently labeled macromolecules were accomplished an a 
Shimadzu system equipped with a LC-10AD pump, a RID-10A RI 
detector, a degasser DGU-14A, and a CTO-10A column oven utilizing 
 N,N -dimethylacetamide with 2.1 g L −1 LiCl as eluent. The column oven 
was set to 50 °C. Poly(styrene) (PS) samples were used as calibration 
standards for both solvent systems. 
 Proton NMR spectroscopy ( 1 H-NMR) measurements were performed 
at RT on a Bruker AC 300 MHz spectrometer, using CDCl 3 or D 2 O as 
solvents. The chemical shifts are given in ppm relative to the signal from 
the residual nondeuterated solvent. 
 Absorption and emission spectra of the fl uorescently labeled POxs 
were recorded using the Tecan M200 Pro fl uorescence microplate reader 
(Crailsheim, Germany) at wavelengths from  λ = 350 to 800 nm. 
 Fluorescence images were obtained using a confocal laser-scanning 
microscope (CLSM 510 Meta, Zeiss, Jena, Germany), equipped with a 
10× objective. Fluorescein-labeled polymers were excited with the 488 nm 
line of the argon laser. The emitted fl uorescence was collected using a 
505–530 nm band-pass fi lter. Scans for the rhodamine-labeled polymers 
were accomplished using the 543 nm line of the He/Ne laser. The 
fl uorescent emission was recorded with a 560–615 nm band-pass fi lter. 
To excite the Cy5-labeled DNA, the He/Ne 633 nm laser was used. 
Fluorescence was recorded using a 650 nm long-pass fi lter. To allow a 
comparison, all images were captured under identical conditions and 
instrument settings (laser power, pinhole diameter and detector gain). 
Quantitative image analysis was performed on grayscale converted 
images using the ImageJ software. 
 The hydrophilicity of the substrate surfaces was determined using a 
CA measuring system (OCA 30, Dataphysics, Germany) with droplets of 
distilled water having a volume of about 10 µL. The measurements were 
performed in triplicates on different positions of the surface area of the 
substrates at RT. 
 TGA was performed under a nitrogen atmosphere on a Netzsch 
TG 209 F1 Iris in the range from RT to 800 °C with a heating rate of 
10 K min −1 . The amount of surface bound POx was calculated at a 
temperature of 280 °C comparing uncoated and coated samples. 
 The RIFS (BIAffi nity) the swelling and DNA binding measurements 
were accomplished in a new set up, the parallel fl ow device (Analytik 
Jena AG), using a fl ow rate for polymer swelling of 20 µL min −1 and for 
the gDNA binding a fl ow rate of 5 µL min −1 at RT. During DNA binding 
experiments 100 µL of a gDNA  E. coli BL21 solution (100 ng µL −1 ) was 
injected and channeled in Channel 1 over the coated chip surface and 
in Channel 2 over the coated chip surface parallel with pure water. 
The residual DNA content was determined by UV–vis spectroscopy 
(ScanDrop250). 
 Synthesis of P(EtOx 35 -stat-BocOx 11 ) ( 1 ) : In a microwave vial EtOx 
(35.3 µL, 0.35 × 10 −3  M) , MeTos (17.7 µL, 0.12 × 10 −3  M ), and acetonitrile 
(2.6 mL) were mixed under inert conditions. After heating in the 
microwave synthesizer at 140 °C for 19 min EtOx (530 µL, 5.95 × 10 −3  M ) 
and BocOx (350 µL, 0.70 × 10 −3  M ) were added under inert conditions 
and the reaction mixture was heated to 140 °C for another 13 min. The 
solution was diluted in CH 2 Cl 2 (10 mL) and precipitated in cold diethyl 
ether (300 mL). The white solid was fi ltered off and dried in high vacuum 
to obtain the product as a white powder (810 mg, 88%).  1 H NMR (CDCl 3 , 
300 MHz):  δ = 4.99 (s, 0.2 H, NH), 3.45 (s, 4 H, backbone), 3.11 (s, 0.3 
H, CH 2 -CH 2 -NH (BocOx)), 2.40 (s, 1.9 H, CH 2 (EtOx)), 1.92 (s, 0.3 H, 
CH 2 -CH 2 -CO (BocOx)), 1.64 (s, 0.3 H, CH 2 -CH 2 -CH 2 (BocOx)), 1.53 (s, 
0.3 H, CH 2 -CH 2 -CH 2 (BocOx)), 1.42 (s, CH 3 (BocOx)), 1.21 (s, 1.3 H, 
CH 3 (EtOx)) ppm. SEC (eluent: CHCl 3 -i-propanol-TEA, PS-standard): 
 M n = 4600 g  M 
−1 ,  M w = 6000 g  M 
−1 ,  Ð = 1.30. 
 Synthesis of P(EtOx 37 -stat-AmOx 9 ) ( 2 ) : TFA (10 mL) was added to 
solid P(EtOx 37 -stat -BocOx 11 ) (810 mg), heated to 60 °C, and stirred for 1 
h. Subsequently, the solution was cooled to RT, stirred for another 12 h, 
and was diluted by the addition of 10 mL methanol (MeOH) followed by 
precipitation in cold diethyl ether (500 mL). The white solid was fi ltered 
and redissolved in MeOH (50 mL). Amberlyst A21 free base was added 
and the mixture was stirred at RT for 24 h. The solid phase was fi ltered 
off and the solvent was evaporated under reduced pressure. The product 
was obtained as a slightly yellow powder (450 mg, 60%).  1 H-NMR (D 2 O, 
300 MHz):  δ = 3.48 (s, 4 H, backbone), 2.98 (0.23 H, s, CH 2 -CH 2 -NH 2 ), 
2.23 (2 H, s, CH 2 (EtOx) + CH 2 -CH 2 -CO (AmOx)), 1.53 (0.41 H, s, CH 2 -
CH 2 -CH 2 -CH 2 (AmOx)) 1.11 (2.8 H, s, CH 3 (EtOx)) ppm. SEC (eluent: 
DMAc-LiCl, PS-standard):  M n = 9300 g  M 
−1 ,  M w = 12 000 g  M 
−1 ,  Ð = 1.13. 
 Fluorescent labeling of P(EtOx 37 -stat-AmOx 9 ) ( 2 ) with fl uorescein-5-
N-hydroxysuccinimide ester (Fluorescein-NHS-ester) ( 3 ) : P(EtOx 37 - stat -
AmOx 9 ) ( 2 , 1.35 g, 0.24 × 10 
−3  M ) was dissolved in dimethylformamide 
(DMF, 50 mL) followed by the addition of the fl uorescein-NHS-ester 
(112 mg, 0.24 × 10 −3  M ) and TEA (2.5 mL, 18 × 10 −3  M ). The reaction 
mixture was stirred at RT for 3 h. Subsequently, the solvent was 
evaporated and the crude product was redissolved in MeOH (10 mL). 
The polymer was precipitated in cold diethyl ether (800 mL), fi ltered 
and redissolved in MeOH (50 mL). The solvent was evaporated and the 
product was obtained as yellow powder (1.17 g, 80%).  1 H-NMR (D 2 O, 
300 MHz):  δ = 6.60–6.78 (m, 4.7 H, dye), 3.48 (s, 4 H, backbone), 2.98 
(0.23 H, s, CH 2 -CH 2 -NH 2 ), 2.23 (2 H, s, CH 2 (EtOx) + CH 2 -CH 2 -CO 
(AmOx)), 1.53 (0.41 H, s, CH 2 -CH 2 -CH 2 -CH 2 (AmOx)) 1.11 (2.8 H, s, 
CH 3 (EtOx)) ppm. SEC (eluent: DMAc-LiCl, PS-standard):  M n = 11 000 g 
 M −1 ,  M w = 13 000 g  M 
−1 ,  Ð = 1.16 
 Fluorescent Labeling of P(EtOx 37 -stat-AmOx 9 ) ( 2 ) with Rhodamine B iso-
thiocyanate ( 4 ) : P(EtOx 37 -stat -AmOx 9 ) ( 2 , 300 mg, 0.05 × 10 
−3   M ) was 
dissolved in DMF (20 mL). After addition of rhodamine B  iso -thiocyanate 
(26.1 mg, 0.05 × 10 −3  M ), the reaction was stirred at RT for 48 h. 
Subsequently, the solvent was evaporated and the crude product was 
redissolved in MeOH (10 mL). The polymer was precipitated in cold 
diethyl ether (800 mL), fi ltered and redissolved in MeOH (50 mL). After 
evaporation of the solvent, the crude product was purifi ed via preparative 
size exclusion chromatography (SEC) using bio beads SX-1 and DMF 
used as eluent. The product was obtained as a pink powder (280 mg, 
86%).  1 H-NMR (D 2 O, 300 MHz):  δ = 6.70–6.88 (m, 0.3 H, aromatic 
peaks), 3.48 (s, 133.2 H, backbone), 1.56 (s, 37.7 H, CH 2 (AmOx)), 1.11 
(s, 111.0 H, CH 3 (EtOx)) ppm. SEC (eluent: DMAc-LiCl, PS-standard): 
 M n = 12 000 g  M 
−1 ,  M w = 14 000 g  M 
−1 ,  Ð = 1.19. 
 Surface Coating : PP slides (3 × 1 cm), PP Chips (diameter = 0.5 cm), 
and PCR tubes were washed in a water/ethanol (EtOH) mixture (1:1) 
for 24 h. The dried material was treated with O 2 plasma for 30 min. 
Subsequently, the slides were incubated in an excess of GOPTMS 
molten on the substrates at RT for 1 h and cleaned by washing with 
DMF repeatedly. 
 The epoxide functionalized PP was coated in a layer-by-layer (LbL) 
approach. First, the substrates were incubated in a POx solution (10 wt%, 
DMF) at 50 °C for 1 h and washed with DMF to create the fi rst polymer. 
Subsequently, the material was incubated in an ECH solution (1 wt%, 
DMF) at 50 °C for 1 h and washed with DMF as well as water. Afterwards, 
the slides were incubated in an aqueous sodium hydroxide solution 
(5 wt%) at 50 °C for 1 h and washed with water and DMF. This cycle 
was repeated, until the desired amount of POx layers were deposited on 
the glass slides. The same procedure was used for BIAffi nity glass slides 
(10 mm × 10 mm; thickness: 1.1 mm; single-sided coated with Ta 2 O 5 ). 
 DNA Binding and Release : DNA binding and release experiments were 
performed using Cy5-labeled lacZ amplifi cates that were synthesized by 
standardized PCR experiments from lacZ transfected  E. coli BL21 using 
Cy5-labeled primers (SI). All experiments were conducted using PP 
chips coated with one, two, or three POx layers. In each case the fi rst 
polymer layer was fl uorescein labeled (polymer  3 ). DNA solution (15 µL) 
containing 100 ng µL −1 Cy5 labeled lacZ DNA was added to the POx 
coated PP chips and incubated at RT for different times (10, 30 s, 2, 5 
min, 1, 2 h). Afterwards, the chips were washed with water (5 × 500 µL) 
and dried using compressed air. Subsequently, the mean fl uorescence 
was determined by LSM measurements ( λ ex = 633 nm,  λ em ≥ 650 nm). 
 For release, the PP chips were loaded with DNA as described 
above for 1 h and, subsequently, incubated in water for 1 h at different 
temperatures. After separation from the solution and drying using 
compressed air, the mean fl uorescence was determined via CLSM 
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( λ ex = 633 nm,  λ em ≥ 650 nm) before and after treatment and the relative 
DNA release was determined by comparison of the two values. 
 PCR Experiments : The qPCR assay was designed to detect DNA of 
 E. coli in a POx coated and uncoated cavities. Therefore, every qPCR 
experiment had a minimum three PP POx modifi ed tubes with qPCR 
master mix and no template as negative control and 1 µL of DNA 
extract out of 10 7 cfu mL −1  E. coli as positive control. The qPCR master 
mix contains: 3 × 10 −3  M of MgCl 2 , 1 × Hot Start Buffer w/o MgCl 2 
pH 8.5, 0.1 × 10 −3  M dNTPs each, 0.025 U µL −1 InnuTaq HOT-A DNA 
polymerase (provided by AJ Innuscreen GmbH, Berlin), one EvaGreen 
(Jena BioScience GmbH, Jena), 1 × 10 −6  M Primer ( Table  4 ) each 
(Eurofi ns Genomics, Ebersberg), 3% dimethyl sulfoxide (DMSO) (Carl 
Roth GmbH + Co. KG, Karlsruhe). The qPCR protocol was optimized 
for sensitivity and specifi city up to <10 1 cfu (data not shown). For 
amplifi cation an initial denaturation for 2 min at 95 °C was followed 
by 10 cycles 95 °C for 5 s, 72 °C for 15 s and 30 cycles 95 °C for 5 s, 
67 °C for 5 s, 72 °C for 10 s with one fi nal amplifi cation of 2 min at 72 °C. 
The qPCR products were analyzed by melting curve measurements with 
a temperature range from 60 to 95 °C. The whole qPCR was performed 
using a TOptical Gradient Thermocycler (Biometra GmbH, Göttingen) 
 Supporting Information 
 Supporting Information is available from the Wiley Online Library or 
from the author. 
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 Table 4.  Used primer sequences. 
Label Target Sequence Nucleotides Guanin and 
Cytosin 
content [%]
 T m 
[°C]
SekuLZF LacZ 5′-cgcagcctgaatggc-
gaatg-3′
20 60 61.4
SekuLZR LacZ 5′-gtgagcgagtaacaaccc-
gtcg-3′
22 59.1 64.0
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Figure S1: SEC elugrams of labeled polymers (3 and 4) in comparison to the unlabeled staring 
material (2). 
 
 
Figure S2: TGA graphs of uncoated PP, pure POx, as well as substrates coated with one, two 
or three layers of POx. 
 
 
Table S1: CA values for POx deposition on biaffinity glass. * CA values below 20 ° cannot be measured and are, therefore, 
specified as < 20 °. 
Coating step CA (°) 

PCR of DNA from lacZ transfected Escherichia coli BL21  
Target Sequence Product size  (base pairs) Label 
LacZ 5’-Cy5-GGA TTG ACC GTA ATG GGA TAG-3’ 228 Cy5 
LacZ 5’-biotin-CTG GCG TAA TAG CGA AGA GG-3’ 228 Biotin 
 
DNA was isolated using the innuPREP DNA/RNA Mini Kit, according to the manufacturer’s 
instructions (Analytik Jena AG). An E. coli BL21 pellet was re-suspended in 100 ȝL TE-buffer to 
induce cell lysis. Subsequently, 450 ȝL lysis buffer RL were added and the mixture was incubated at 
room temperature for 3 min. The mixture was centrifuged at 14,000 rpm for 1 min to separate the 
lysed from the unlysed parts. A spin filter D was placed on a receiver tube, the supernatant was added 
and centrifuged at 12,000 rpm for 2 min. 500 ȝL HS washing solution was added and the mixture was 
centrifuged for at 12,000 rpm for 1 min. Afterwards, 700 ȝL lysis buffer were added and the combined 
solution was centrifuged at 12,000 rpm for 1 min. The filtrate was discarded and the spin filter D 
containing the extract was added to another receiver tube and centrifuged at 14,000 rpm for another 
2 min. Subsequently, a spin filter D was added to an elution tube and, after addition of 100 ȝL elution 
buffer, it was incubated at room temperature for 1 min. The mixture was centrifuged at 8,000 rpm for 
1 min to obtain the DNA extract into the elution tube. Finally, the DNA concentration was determined 
via UV/VIS spectroscopy (ScanDrop®250) (Ȝ1, ex = 260 nm, Ȝ2, ex = 280 nm).  
The PCR assay was carried out in a 50 ȝL reaction mixture containing the following compounds: 
DNA extract (0.5 ȝL of ~10 ng ȝL-1), 1.00 units Taq DNA polymerase (AJ innuTaq DNA 
polymerase), 0.25 mM desoxy-nucleotriphosphates (dNTPs), 0.5 ȝM of each primer. The PCR was 
started with an initial denaturation for 3 min at 95 °C followed by 45 cycles with 95 °C for 30 s 
(denaturation), 57 °C for 30 s (annealing) and 72 °C for 30 s (amplification). At the end of the 
repeated PCR cycles, the mixture was heated to 72 °C for another 5 min to ensure the completion of 
the amplificates elongation. The purity of the crude PCR product was controlled by gel 
electrophoresis, which was performed using a 2% agarose gel containing GelRed (1:25,000). The gels 
were run for 30 min at 100 V with TAE-buffer, which consists of Tris acetate (2 mol L
-1
) and EDTA 
(0.05 mol L
-1
), dissolved in deionized water and has a pH value of 8.2 to 8.4 at RT. The gels were 
imaged on a UV transilluminator (AJ Biometra UVsolo TS).  
All PCR and qPCR products were purified using the innuPREP PCRpure Kit, according to the 
manufacturer’s instructions (Analytik Jena). 500 ȝL binding buffer were added to a spin filter 
positioned on an elution tube and then spin coated at 12,000 rpm for 2 min. Subsequently, the spin 
filter was placed into a receiver tube, 10 ȝL of elution buffer were added and incubated at RT for 1 
min, before spin coating at 8,000 rpm for 1 min. Finally, the DNA concentration was determined via 
UV/VIS spectroscopy (ScanDrop
®
250) (Ȝ1, ex = 260 nm, Ȝ2, ex = 280 nm). Since the generated PCR 
products contained both, biotin- and Cy5-labeled DNA, the biotin-labeled DNA amplificates could be 
used for the horseradish peroxidase assay and the Cy5-labeled DNA sequences for DNA binding and 
release determinations based on the DNA derived fluorescence emission intensity. 
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Core cross-linked nanogels based on the self-
assembly of double hydrophilic poly(2-oxazoline)
block copolymers†
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and Ulrich S. Schubert*ab
The synthesis of poly(2-oxazoline)-based block copolymers consisting of a cationic and a hydrophilic
segment is described. The self-assembly of these macromolecules in organic solvents results in the
formation of micelles and vesicles, respectively, depending on the solvent used. To transfer the systems
into water, cross-linking using glutaraldehyde was applied, followed by the consumption of excessive
aldehyde functions by either diethylamine or 6-aminoﬂuorescein (6AF). The cross-linked assemblies
were analyzed regarding their size and shape by electron microscopy and light scattering methods, as
well as for their chemical composition by solid state NMR spectroscopy. 6AF associated samples were
examined with respect to their absorption and ﬂuorescence behavior in aqueous environment, revealing
an alkaline microenvironment within the presented nanostructures. The toxicity of the systems against
mouse ﬁbroblast cell line L929 was examined by the XTT assay and was found to be insigniﬁcant for
concentrations of up to 2.5 mg mL1. Flow cytometry and ﬂuorescence microscopy analysis revealed an
eﬃcient concentration and time dependent cellular uptake of the nanogels.
Introduction
The term nanomedicine refers to the use of nanoscopic objects
in medical applications like drug delivery and has received
considerable attention in recent years.1,2 The utilization of drug
carriers, such as liposomes, polymeric micelles, vesicles,
nanoparticles, and dendrimers oﬀers numerous advantages.
Besides potential control over pharmacokinetics and toxicity,
the solubilization and protection of the drug is of paramount
interest. In particular, polymeric micelles are frequently studied
for the administration of hydrophobic compounds.3 Such
micelles are formed via the aqueous self-assembly of block
copolymers consisting of hydrophilic and hydrophobic
segments.4 While the hydrophilic shell reduces non-specic
interactions with tissue and blood components, the hydro-
phobic core contains and protects the therapeutic and/or
diagnostic molecule. The critical micelle concentration (CMC)
of polymeric micelles is rather low (106 to 107 mol L1) as
compared to surfactant based nanocarriers (103 to 104 mol
L1).5However, even above their CMC a component exchange or
a disassembly is possible. As a consequence, Lammers and co-
workers have recently proposed that cross-linking of such
systems and covalent attachment of the cargo are paramount
prerequisites for their successful application.6 Nanogels are
covalently cross-linked structures in the nanometer size range
and combine benecial properties of hydrogels (e.g. tissue-like
structure, biocompatibility, and stimuli responsiveness)1 with
the solubility properties of nano-assemblies, such as nano-
particles or micelles. There are several ways for the production
of these structures such as the use of inverse emulsions7 or via
polymerization induced phase separation, respectively.8 One
particularly elegant way is the cross-linking of self-assembled
structures.
In this context, type and properties of the polymeric material
serving as precursor for nanogels are highly important. Besides a
well-controlled polymerization process as a prerequisite to yield
highly dened block copolymers, the biocompatibility and
functionality of the resulting polymers is of outstanding interest.
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Poly(2-oxazoline)s (POx) represent a promising class of materials
for biomedical applications. Such as poly(ethylene glycol) (PEG),
poly(2-methyl oxazoline) (PMeOx) and poly(2-ethyl-2-oxazoline)
(PEtOx) are highly soluble in water and organic solvents, bio-
comaptible9,10 and exhibit stealth properties.11,12
The cationic ring-opening polymerization (CROP) of 2-oxa-
zolines provides access to multifunctional polymers with a wide
range of possible structural variations, using diﬀerent func-
tional initiators, terminating agents and functional mono-
mers.13 This versatility, in combination with the possibility to
combine diﬀerent monomers in distinct architectures,
including statistical, gradient or block copolymers, renders the
CROP of 2-oxazolines a powerful toolbox to produce functional
polymers for biological applications.14
POx-based micellar structures were investigated thoroughly
over the past decades.15–21 This includes also studies on the
incorporation of anti-cancer drugs.22–24 However, up to date only
a limited number of reports are available on the synthesis and
potential of cross-linked POx aggregates. The type of cross-
linking reaction is of central interest for designing drug delivery
systems with suﬃcient stability and the ability to release their
cargo on demand.25 Covalently cross-linked POx micelles,
stabilized by thiol-yne chemistry,26,27 epoxide-amine cross-link-
ing,28 UV mediated cross-linking29,30 as well as electron beam
irradiation31,32 have been described. To the best of our knowl-
edge only one reversible system using a disulde bond linker, is
reported so far.33
Herein, we describe the synthesis of double hydrophilic POx-
based block copolymers including a neutral (PEtOx) as well as a
cationic (PAmOx) block and their self-assembly in organic
solvents. The polymerization of 2-oxazolines carrying a pro-
tected amine group was rst introduced by Cesana et al.34 and is
continuously developed.35 The self-assembly of the polymers in
organic solvents is investigated and the structures are cross-
linked by Schiﬀ-base chemistry and covalently loaded with 6-
amino uorescein as a model compound. This connection is
known to be reversible36 enabling a later disassembly. The
nanogels were characterized intensively and their interaction
with cells was investigated. They exhibit low toxicity and an
endosomal localization.
Results and discussion
Polymer synthesis
In this study we describe the synthesis of block copoly(2-oxazo-
line)s and their self-assembly into nano-scaled objects. The
block copolymer P(EtOx-b-AmOx) consists of a hydrophilic
(EtOx) and a hydrophilic/cationic segment (AmOx). While PEtOx
is known to be biocompatible37,38 and soluble in a wide range of
solvents, including water, the second block is (aer depro-
tection) cationically charged due to the primary amine groups in
the side chain and, therefore, lacks solubility in organic solvents.
The synthesis of P(EtOx-b-AmOx) is depicted in Scheme 1.
The polymerization of EtOx, which constitutes the rst block,
was initiated by methyl tosylate (MeOTos) at 140 C under
microwave irradiation (see ref. 39 for optimized polymerization
conditions). Aer close to full conversion (ln([M]0/[M]t) ¼ 4) of
the rst monomer, the living polymer was chain extended with
2-(4-((tert-butoxycarbonyl)amino)butyl)-2-oxazoline (BocOx), the
Boc-protected precursor of the cationic AmOx segment, which
was deprotected aer termination of the polymerization using
triuoroacetic acid (TFA) and Amberlyst A21 solid phase catalyst
to remove triuoroacetate salts. By changing initiator-to-
monomer ratios and polymerization times, block copolymers of
Scheme 1 Schematic representation of the synthesis of amphiphilic block copolymers (P(EtOx-b-AmOx)).
Table 1 Analytical data and composition of the prepared block copolymers
Sample Composition
NMR SEC (CHCl3) SEC (DMAc) AF4
Co-monomer [%]Mn [g mol
1] Mn [g mol
1] Đ Mn [g mol
1] Đ Mn [g mol
1] Đ
1 P(EtOx104) 10 300 9900 1.11 20 600 1.17 0
2 P(EtOx112-b-BocOx6) 12 600 7700 1.18 5
3 P(EtOx92-b-BocOx10) 11 600 7400 1.16 10
4 P(EtOx85-b-BocOx15) 12 100 8900 1.20 15
5 P(EtOx84-b-BocOx20) 13 200 8900 1.17 20
6 P(EtOx70-b-BocOx22) 12 300 7600 1.18 22
7 P(EtOx113-b-AmOx5) 12 000 14 500 1.34 11 700 1.10 5
8 P(EtOx92-b-AmOx10) 10 600 16 800 1.23 9200 1.14 10
9 P(EtOx72-b-AmOx18) 9700 16 100 1.22 13 300 1.10 18
10 P(EtOx82-b-AmOx23) 11 400 18 100 1.23 13 600 1.09 22
11 P(EtOx64-b-AmOx26) 10 100 15 600 1.30 12 500 1.26 29
This journal is © The Royal Society of Chemistry 2015 J. Mater. Chem. B, 2015, 3, 1748–1759 | 1749
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diﬀerent compositions were prepared, as summarized in Table
1. To investigate the length of the polymer chains, 1H NMR
investigations were conducted directly aer polymerization and
the integral of the initiator tosylate peaks was compared to the
integral of the polymer backbone revealing total degree of
polymerization (DP) values of around 100 for all macromole-
cules. The block ratios were calculated from the 1HNMR spectra
before and aer deprotection, respectively (ESI: Fig. S1 and S2†).
The diﬀerence in the calculated values can be explained by the
overlap of solvent peaks with the EtOx–CH3-group for polymers
2 to 6, limiting the accuracy of the determination. Aer depro-
tection, these solvent peaks disappear and, thus, we refer in the
following to the values obtained from the deprotected polymers.
Size exclusion chromatography (SEC) measurements of pro-
tected polymers indicated Mn values around 10 000 g mol
1.
Low dispersity (Đ) values prove a narrow molar mass distribu-
tion of the synthesized block copolymers. Aer deprotection,
SEC measurements of the block copolymers were performed in
N,N-dimethyl acetamide (DMAc), a non-selective solvent for
both blocks, showing an increase inMn and Đ. However, due to
the lack of cationic SEC standards a precise determination of
Mn and Đ is hardly possible. The comparison of the SEC derived
Mn and Đ values of the PEtOx homopolymer (which increases
when changing the solvent to DMAc) indicated a similar size
and uniformity of the protected and the deprotected polymers.
As a consequence, to gain further information about the size
distribution of the cationic P(EtOx-b-AmOx) copolymers, asym-
metric ow eld-ow fractionation (AF4) investigations were
performed. The measurements were carried out at a low pH
value (3.5) to ensure a neutral or cationic charge of the
membrane resulting in an electrostatic repulsion of the cationic
samples to reduce adsorption phenomena. The obtained size
values t well with the expected values based on the monomer-
to-initiator ratio and the Mn values derived from the
1H NMR
experiments. Since the determination of the molar masses was
carried out using a multi-angle laser light scattering detector
(MALLS) to obtain absolute molar mass values, the AF4 results
are more reliable than the data derived from SEC measure-
ments without available cationic calibration standards. Again,
small Đ values indicate narrow size distributions of the block
copolymers. Nevertheless, the molar masses obtained by AF4
might be slightly overestimated as most probably some low
molar mass fractions are washed out through the membrane
(nominal cut-oﬀ 10 000 g mol1). This is supported by a
recovery rate of around 75 to 85% (ESI: Table S1†).
Self-assembly, cross-linking and labeling of block copolymers
Since the LCST behavior of the polymers in aqueous solution
could not be utilized for a self-assembly (ESI Fig. S3†) of P(EtOx-
b-AmOx), the low solubility of the cationic block in organic
solvents was exploited. First, the self-assembling behavior of
P(EtOx-b-AmOx) (7–11) was screened in three organic solvents
(MeOH, iPrOH and CHCl3) using dynamic light scattering (ESI:
Fig. S4†). The results of these measurements are summarized in
Table 2. As expected, pure PEtOx showed no aggregation in
these solvents. All block copolymers however formed structures
in the range between 4 and 112 nm depending on the solvent
and the composition. Surprisingly, the ratio between the two
blocks did not inuence the size of the aggregates as much as
the polarity of the solvents used. All samples assembled in
CHCl3 formed structures with radii between 4 and 17 nm.
In iPrOH, size distributions between 68 and 105 nm were
detected, and MeOH led to structures with even larger radii (77
to 113 nm). In dependence on the solvent and block ratio, most
of the samples show rather high polydispersity indices, which
can be traced back to the formation of a small fraction of
aggregates. Therefore, only samples with low PDI values indi-
cating narrow size distributions are selected for further
experiments.
To transfer these structures into aqueous solution, the core
of the agglomerates has to be cross-linked, as both polymer
blocks are readily water soluble. For this purpose, two samples,
exhibiting the most uniform size distribution in organic
solvents were chosen (labeled with a in Table 2) and cross-linked
with glutaraldehyde (GA) (Scheme 2). As a bis-aldehyde, GA is
able to form imine bonds with the amine groups present in the
core and, consequently, lock the structure of the assemblies.
However, a direct transfer of the micelles into water yielded only
hydrogels, which indicated that even though GA was added in
stoichiometric amounts, a suﬃcient number of free amine and
aldehyde groups remained to cross-link the colloidal structures
among each other. As demonstrated by Lecommandoux and co-
workers, the amount of cross-linked amine groups for such
reactions is only about 35%, when aiming for a full conver-
sion.40 To overcome this drawback, lowmolar mass amines have
to be added in large excess aer the cross-linking step to
consume the residual aldehydes. This strategy, in turn, does not
only enable the stabilization of the self-assembled structure, but
also allows the simultaneous incorporation of drug molecules
or uorescence labels into the system. Here, diethylamine
Table 2 DLS screening of the self-assembling behavior of the block copolymers in organic solvents (5mgmL1; size indication in radius; number
plot; no size value is speciﬁed, if the number weighted plot shows only the polymer precursor)
Solvent
0% AmOx (1) 5% AmOx (7) 10% AmOx (8) 18% AmOx (9) 22% AmOx (10) 29% AmOx (11)
Rh [nm] PDI Rh [nm] PDI Rh [nm] PDI Rh [nm] PDI Rh [nm] PDI Rh [nm] PDI
MeOH — — — — — — 113 0.334 83 0.646 77 0.335
iPrOH — — 71 0.550 105 0.714 99 0.561 92 0.509 68a 0.111
CHCl3 — — 4 0.360 8 0.217 16 0.256 13 0.376 17
a 0.048
a Samples selected for further cross-linking.
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(DEA) and 6-amino uorescein (6AF), respectively, were used as
model substances to quench the cross-linking process. Aer
this treatment the assembled structures could be transferred
into aqueous solution, successfully.
Characterization of self-assembled structures by light
scattering and electron microscopy
To purify the systems from unbound amine or cross-linker
molecules, the crude products were precipitated in diethyl ether
and dialyzed in a water–methanol mixture (4 : 1), where meth-
anol acted as a solubility mediator for 6AF, which is barely
soluble in water. A rst indication of successfully cross-linked
structures was provided by DLS experiments, which indicated
distributions in the same size range as observed in organic
solvents (Table 3, ESI: Fig. S5†). The PDI values of the locked
systems increased slightly, which suggests an agglomeration
caused by unconsumed aldehyde groups in the core.
However, the values are still in a good range for synthetic
nano-sized objects. The zeta potential of all cross-linked
assemblies was found to be positive, indicating the presence of
free amine groups in the colloid.
A further investigation of size and uniformity was conducted
using asymmetric ow eld-ow fractionation measurements.
Utilizing this technique it is possible to separate the samples by
the diﬀusion coeﬃcient and to determine the hydrodynamic
radius (Rh, by online DLS measurements) and the radius of
gyration (Rg, by multi-angle laser light scattering (MALLS)
measurements). The data depicted in Table 3 (Graphs in ESI:
Fig. S6†) are similar to the values obtained by DLS measure-
ments. For samples originating from iPrOH the obtained AF4-
DLS values are signicantly smaller than the collected sizes
from the DLSmeasurements, which can be attributed to the AF4
separation technique. While DLS investigations provide a
radius comprising also small fractions of aggregates, aer
separation by AF4 single colloidal structures are examined. An
additional information provided by this analysis is an indica-
tion of the particle shape by the comparison of both, hydrody-
namic radius and radius of gyration, expressed in the ratio r
(r¼ Rg/Rh). For particles assembled in CHCl3, the Rg value could
not be determined since they were too small for detection via
the MALLS detector (limit around 15 nm).41 This indicates a Rg
below 15 nm and, hence, a r ratio less than 0.8, which is
characteristic for hard spheres and, therefore, indicated a
compact structure like a micellar architecture of the assembled
particles.42 Larger ratios (around 1) as obtained for iPrOH
derived structures are usually attributed to less dense and so
structures, which might indicate vesicles.42 A possible explana-
tion for this trend is a swelling of the selective block induced by
the diﬀerent polarity of the solvents used. While the amine
group has a potentially cationic charge, the side chain and the
backbone of the block can be readily solubilized by organic
solvents resulting in a gel-like core instead of a complete
collapse of the AmOx segment. Upon increase of polarity of the
applied solvent, swelling should concommittantly increase,
resulting in a higher steric demand of the selective block, while
Scheme 2 Schematic representation of the self-assembly of P(EtOx-b-AmOx) followed by cross-linking and quenching/loading.
Table 3 Characterization data for cross-linked nanostructures (DLS: 5 mg mL1, size indication in radius). Polymer 11 served as precursor for all
assemblies. The content of ﬂuorescein was determined by the absorbance at 470 nm
Sample
Solvent for
self-assembly Capping agent
DLS in solvent DLS in water AF4
Content of capping
agent (wt%)Size, Rh [nm] PDI Size, Rh [nm] PDI z [mV] Rg Rh r
12 CHCl3 DEA 17 0.048 17 0.093 +7 — 19 <0.8 N. d.
13 6AF 15 0.199 +17 — 20.0 <0.8 29
14 iPrOH DEA 68 0.111 59 0.246 +17 41 37 1.11 N. d.
15 6AF 50 0.179 +23 40 40.0 1.00 29
This journal is © The Royal Society of Chemistry 2015 J. Mater. Chem. B, 2015, 3, 1748–1759 | 1751
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the hydrophilic PEtOx block reveals a similar solubilization in
all solvents used. Thus, the transition from a micellar to a
vesicular structure might be attributed to the change in the ratio
between the volume of the two segments.43 Considering the
block architectures of P(EtOx-b-AmOx) and the fact that a fully
stretched polymer chain is with roughly 32 nm length (calcu-
lated from the bond length; C–C ¼ 154 pm, C–N ¼ 135 pm
under consideration of the bond angles) shorter than the radius
of the assemblies, support a vesicular morphology of these
samples.
To further investigate the proposed structures, (cryo) trans-
mission electron microscopy (cryoTEM) measurements were
performed. Samples in aqueous media (Fig. 1A–C and F) as well
as non-cross-linked polymers in organic solvents were investi-
gated (Fig. 1D and E). The non-cross-linked systems could be
examined only in the dried state as vitrication of the solutions
was not successful. However, structures found in samples
derived from MeOH and iPrOH (Fig. 1D and E) might originate
from the collapse of a vesicle shell, supporting the assumption
of a vesicular architecture. The cryoTEM picture of the cross-
linked equivalent (Fig. 1F) does not show a hollow sphere which
could be attributed to hydrophilicity of the nanogel. The
swelling of the structure in water reduces the contrast of the
picture compared to TEM investigations in organic solvents.
Based on the combined investigations the larger nanostructures
will henceforth be referred to as vesicles. Nevertheless, we are
aware, that this interpretation of AF4 and TEM data has to be
treated with caution and that the hypothesis of a vesicular
nanostructure is not fully proven.
Determination of 6AF loading and release
For samples which were loaded with 6AF, the amount of cova-
lently bound dye was determined using its absorption and
uorescence properties. The absorption and emission spectra
of 6AF-containing samples were measured in water at a pH
value of 7 in order to compare the data to pure 6AF, which was
measured in the presence of a 100-fold excess of GA to ensure a
quantitative conversion to the imine form (Fig. 2). While 6AF
shows the typical absorption and emission spectra of the lacton
derivative at a pH value of 7 (low absorption, maximum at 440
nm), both, micelles as well as vesicles absorb and emit similar
to the ring-opened di-anionic carboxy isomer state of the dye
(Fig. 2A). This behavior seems best explained by the high
density of amine groups in the core of the assemblies leading to
a locally increased pH value, which, in turn, causes the forma-
tion of the di-anionic species characterized by a strong
absorption at 490 nm.44 A closer look at the photochemical
behavior of the nano-assemblies shows that even at a pH value
of 4 still a signicant amount of 6AF emits indicating a alkaline
microenvironment within the core of the nanostructures.
To determine the amount of loaded dye, samples were
investigated in aqueous NaOH solution (0.1 mol L1) to ensure
the quantitative presence of the carboxy-form of uorescein in
the 6AF calibration. For a better comparison with the bound
dye, a 100-fold excess of GA was added to the free 6AF gener-
ating the imine derivative in situ as described before. Both,
absorption as well as uorescence spectra showed equal
maxima and shape for the samples as well as calibration. The
amount of incorporated 6AF was found to be 29 wt% of dye per
total mass for the micelles, as well as for the vesicles. This is
equivalent to 12 6AF molecules per polymer chain, which
complies with the conversion of amine groups by GA in similar
systems (35%).40 An equal loading for both nano-architectures
was expected as the chemical composition of both systems
should be identical, while only the shape varies.
Liquid and solid state (ss) NMR spectroscopy
While light scattering and electron microscopy experiments
shed light on size and shape of the assemblies, they do not
provide insights into their chemical composition. Liquid and
solid state NMR spectroscopy were employed for a more
detailed characterization. Both, micelles and vesicles yield non-
turbid solutions in solvents such as water or chloroform. In the
liquid state 1H NMR spectra of non-cross-linked polymers in
Fig. 1 TEM images of the dried structures assembled in methanol (D) and iPrOH (E), and cryoTEM images of self-assembled as well as cross-
linked structures (A–C and F).
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CHCl3 (ESI: Fig. S7†) solely signals of the PEtOx block are
visible, probably as they represent highly mobile groups once in
contact with the solvent. In contrast, cross-linking of the core is
likely to physically link the mobility of individual core compo-
nents to the overall rotational correlation time of the vesicle/
micelle, thereby increasing the relaxation rate of the core
components signicantly and, hence, leading to an absence of
signals attributable to the AmOx side chain, GA and DEA or 6AF,
respectively.
To qualitatively assess the cross-linked system, natural
abundance CP MAS solid state 13C NMR spectroscopy was
employed (Fig. 3). We assigned the prominent signals to the
carbonyl functions (A), the backbone (D), and to the side groups
(F) and (H), respectively of the abundant PEtOx units. Further-
more, the resonance (E) detectable at 30 ppm represents two
methylene groups of the AmOx side chain. The presence of the
AmOx part is also supported by a resonance at 60 ppm (C). The
shoulder at 20 ppm (G) is attributed to the outer methylene
groups of the AmOx spacer and the GA methylenes. The GA
gives in addition rise to a broad resonance at 160 ppm (B)
assigned to its C]N bond. It should also be noted that the GA
groups are the least abundant ones in the cross-linked system.
Taken together, these tentative assignments are compatible
with the relative abundance, and hence, the observed relative
intensities of the respective chemical groups. However, a bona
de quantitative assessment via integration of signals of the
individual chemical groups, as typically performed in liquid
state NMR, is not reliable due to the non-uniform eﬃciency of
the cross-polarization transfer (CP) step in the ssNMR experi-
ment and the signicant line broadening observed which, in
turn, preclude to identify individual groups. In addition, the
comparably low intensities of the broad signals (B) and (C),
suggest an under-representation of the core, which might be
due to a conformational heterogeneity with concomitant line
broadening in the cross-linked region. Likewise, signals for the
6AF are of an intensity lower than expected from the quantita-
tive uorescence analysis (Table 3). To assign resonances
arising from the 6AF moiety, we compared commercial micro-
crystalline 6AF with amorphous and with KOH treated, ring-
opened 6AF (ESI: Fig. S8†). From this comparison, we
concluded that the signals detectable at 155 ppm, at 120 to 100
ppm and a shied signal at 75 ppm arise from 6AF. Notably,
already the conversion of microcrystalline into amorphous 6AF,
produced by dissolving in MeOH, ash-freezing and lyophili-
sation, caused a severe line broadening in the ssNMR spectra of
some of the 6AF resonances and other lines become virtually
indetectable. This clearly indicates that a certain degree of
conformational heterogeneity (‘amorphousness’) of the 6AF
moiety causes severe line-broadening or in-detectability of some
groups in the ssNMR spectra. In summary, we interpret the low
intensity signal pattern of the 6AF moiety as resulting from
diﬀerences in the CP transfer eﬃciency, severe line broadening
and the mainly ring-open form (see Fluorescence experiments)
and a residual proportion of amorphous 6AF, the latter giving
rise to the signals at 155, 100 to 120 and 80 ppm, respectively.
Biocompatibility of self-assembled structures
The evaluation of the biocompatibility is one of the rst steps to
assess the applicability of the micellar/vesicular structures
presented herein for potential biomedical applications. Hence,
Fig. 3 Solid state 13C NMR spectra of cross-linked micelles (samples
12 and 13) and vesicles (samples 14 and 15).
Fig. 2 (A) Absorption and ﬂuorescence spectra of 6AF (pH dependent) and dye quenched nanostructures; (B) pH dependent absorbance and
ﬂuorescence of compound 15 (0.05 mg mL1).
This journal is © The Royal Society of Chemistry 2015 J. Mater. Chem. B, 2015, 3, 1748–1759 | 1753
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adverse eﬀects on the cellular metabolism upon incubation
with 6AF labeled micelles (sample 13) and vesicles (sample 15)
were evaluated using the established L929 cell line, which is
characterized and documented by its sensitivity towards cyto-
toxic agents.45
The in vitro cytotoxicity experiments were performed via a
XTT assay according to the German standard institution
guideline DIN ISO 10993-5 as a reference for biomaterial
testing. Aer 24 h of incubation with diﬀerent micelle/vesicle
concentrations (0.005, 0.05, 0.5, 2.5 and 5 mg mL1) the meta-
bolic activity of the treated cells was found to be at the level of
the untreated controls, with the exception that only the highest
concentration of micelles (5 mg mL1) led to a signicant
reduction of cell viability (50%). Interestingly, the vesicular
structures did not show any cytotoxic potential even at the
highest concentration (Fig. 4 top). One possible explanation for
this behavior could be related to the size of the vesicles. The
larger diameter of the structures in comparison to micelles
leads to a smaller surface/volume ratio. Furthermore, related to
the vesicular architecture, half of the surface faces the inside of
the nano-assembly. However, the micelle concentrations which
did not show an overt toxicity eﬀect were more than adequate
for potential applications.
Microscopic assessment of the proportion of live and dead
cells conrmed the ndings from the XTT assay – the
membrane integrity of viable cells was proven by the exclusion
of red uorescent propidium iodide (PI) from cell nuclei indi-
cating their excellent viability (Fig. 4 bottom panel; B3). In
addition, the microscopic investigations provided rst hints for
a cellular internalization of the uorescein containing micelles
(Fig. 4, B5).
In the case of the highest micelle concentration, images
revealed a disintegration of the cell membrane (PI positive cell
nuclei) accompanied by a reduced intracellular localization of
micelles, which might be caused by a diﬀusion of the micelles
through the leaky membrane out of the dead cells (Fig. 4, A3
and A4). These results conrm the low cytotoxicity generally
observed for PEtOx-basedmaterials with diﬀerent molar masses
and PEtOx-containing block copolymers, which were evaluated
before.9
Flow cytometric (FC) investigations on time and
concentration dependent uptake
The time and concentration dependent uptake of the uores-
cein containing micelles/vesicles was quantied by FC
measurements. For this purpose, cells were incubated either
with diﬀerent concentrations (0.05, 0.1, 0.25, and 0.5 mg
mL1) of the materials for 24 h at 37 C or with one concen-
tration (0.5 mg mL1) for diﬀerent time scales (0.5, 1, 3, 12,
and, 24 h; 37 C). Following the incubation, the excess of
micelle/vesicle material was removed by washing with PBS.
Subsequently, the cells were trypsinized and subjected to FC
analysis.
Fig. 4 (Top) Cell viability of L929 mouse ﬁbroblasts after incubation
with micelles (13)/vesicles (15) up to 5 mg mL1 for 24 hours. (Bottom)
Representative bright ﬁeld and ﬂuorescence microscopy images of
Hoechst 33342/PI stained L929 mouse ﬁbroblast cells cultured for 24
h in the presence of sample 13 (A1–A5; 5mgmL1) and sample 15 (B1–
B5; 0.5 mg mL1). Blue ﬂuorescent Hoechst dye labels nuclei of all
cells present (A2 and B2), while red ﬂuorescent PI signals (A3 and B3)
indicate nuclei of dead cells. Green ﬂuorescence originates from the
dye containing nanostructures (A4 and B4). Additionally, image
superimpositions for all four channels are displayed (A5 and B5). Scale
bar: 100 mm.
Fig. 5 Flow cytometry investigation on the time and concentration
dependent uptake of 6AF containing micelles/vesicles by L929 mouse
ﬁbroblasts at 37 C. For time dependent uptake cells were incubated
between 0.5 and 24 h with micelles (13)/vesicles (15) with a concen-
tration of 0.5 mg mL1, whereas the concentration dependent uptake
was investigated over an incubation time of 24 h using micelle/vesicle
concentrations in the range between 0.05 and 0.5 mg mL1. Cells
incubated only with culture medium served as control. For histogram
plots the ﬂuorescence intensity on the x-axis is plotted against the
number of events on the y-axis. A shift of the histogram toward the
right side demonstrates an increasing amount of dye containing
micelles/vesicles associated to the cells. The bar charts depict the
results for the corresponding normalized mean ﬂuorescence intensi-
ties, obtained from ﬂow cytometry of the analyzed cell populations.
The data are expressed as mean  SD of triplicates.
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The uorescence intensity distributions (histogram plots in
Fig. 5) clearly display a concentration-dependent right-shi to
higher uorescence intensity for both, the micellar and vesic-
ular structures indicating a concentration-dependent uptake.
Interestingly, the increase in uorescence intensity wasmore
pronounced for the vesicle samples, suggesting an increased
cellular accumulation/association as compared to micelles.
This becomes evident in quantitative terms when the mean
uorescence intensities (MFI) of the cell populations are eval-
uated as depicted in the bar charts (Fig. 5). An up to three-fold
uptake of the vesicles was obtained as compared to micelles
with the same concentration. These results were also conrmed
by uorescence microscopic observations of the treated cell
populations (ESI: Fig. S9†). Interestingly, the proportion of
“positive cells” having associated micelles or vesicles did not
only increase at higher material concentrations but was also
higher for vesicular compared to micellar samples, e.g. at 0.05
mg mL1 83 to 13% and at 0.5 mg mL1 98 to 88% (data not
shown).
For the time-dependent uptake trends similar to the
concentration-dependent internalization were observed. The
cellular accumulation of material proceeds over time for both
the micelles and vesicles without reaching a plateau aer 24 h.
Additionally, the cellular uptake of the vesicular formulation
exceeds the internalization rate of the micelles by a factor of 3
and, again, supports the interpretation of a higher cellular
internalization of the vesicles. It should be noted that the
initially conducted uorescence measurements of the micelle
and vesicle suspensions at equivalent concentrations (weight/
volume) demonstrated that both show similar uorescence
values (Fig. 3). Therefore, the observed increase in cell associ-
ated uorescence can clearly be attributed to an enhanced
vesicle uptake.
The diﬀerent cellular internalization eﬃciencies could be
caused by the cellular uptake mechanism. It is known that very
large particles enter cells by phagocytosis, whereas, in the case
of nanoparticles, most internalization occurs via various endo-
cytotic pathways, which can be diﬀerent with regard to the
nature of the surface and the structural properties of nano-
particles (e.g. clathrin or caveolin dependent pathways).46
Depending on the particular pathway and also its energy
dependent or independent nature, diﬀerent internalization
rates are achieved47 – this could also impact the uptake eﬃ-
ciency of the presented micelles and vesicles. To elucidate these
phenomena further investigations are required, e.g. by assess-
ing or blocking certain uptake pathways using specic
inhibitors.
Internalization and co-localization with cellular
compartments
The cellular internalization and intracellular localization of
micelles and vesicles in L929 cells was further elucidated by
epiuorescence and confocal laser scanning microscopy
(CLSM) investigations. For this purpose, the cells were incu-
bated for 24 h with 0.5 mg mL1 of the respective substance at
37 C and, in order to assign the localization of the uorescent
micelles/vesicles to cellular compartments, the living adherent
or suspended cells were stained with specic dyes for the cell
plasma membrane (Cell Mask Orange), the nuclei (Hoechst
33342 or SytoRed59) or the acidic late endosomes and lyso-
somes (LysoTracker), respectively.
A representative distribution of uorescent vesicles in the
context of cellular structures in adherent cells is presented in
Fig. 6. The epiuorescence images suggest an intracellular
localization of the vesicles, since no green uorescent signal
(from the 6AF labeled structures) is detectable at the outer cell
membrane, which would be the case when vesicles are
adsorbed to, but not transported through the membrane
(Fig. 6: A2, A3 and A5). Additionally, no vesicles were observed
within the nuclear compartment: They were rather associated
with distinct outer nuclear membrane regions (Fig. 6: A5).
Fig. 6 Representative bright ﬁeld (A1 and B1) and epiﬂuorescence images of adherent L929 cells after 24 h incubation at 37 C with vesicles (15)
at a concentration of 0.1 mg mL1. Cell nuclei (A2 and B2), cell membranes (A3) or late endosomes/lysosomes (B3) were speciﬁcally stained and
their ﬂuorescence signal was captured in addition to the ﬂuorescence signal originating from the internalized 6AF labeled vesicles (A4 and B4).
Co-localization was examined by superimposing all four channels (A5 and B5). Identical results were obtained for micelles (ESI: Fig. S10†). Scale
bar: 20 mm.
This journal is © The Royal Society of Chemistry 2015 J. Mater. Chem. B, 2015, 3, 1748–1759 | 1755
Paper Journal of Materials Chemistry B
Pu
bl
ish
ed
 o
n 
13
 Ja
nu
ar
y 
20
15
. D
ow
nl
oa
de
d 
by
 T
hu
er
in
ge
r U
ni
ve
rs
ita
ts 
La
nd
es
bi
bl
io
th
ek
 Je
na
 o
n 
30
/0
8/
20
16
 1
2:
02
:4
3.
 
View Article Online
Hypothesizing that internalization of the vesicles/micelles
proceeds via endocytotic pathways, an appearance of the
internalized structures in the late endosomes or lysosomes
was very likely. Indeed, co-localization of stained acidic
endosomes and uorescent vesicles was observed (Fig. 6: B2,
B3 and B5). CLSM investigations on cells treated as mentioned
above but additionally detached aer incubation and sub-
jected to microscopic analysis with precise optical z-sectioning
through the cell body conrmed an extra-nuclear presence and
the complete internalization of the vesicles into the lysosomal
compartment (Fig. 7: A1 to C3).
Identical results for internalization and lysosomal localiza-
tion were obtained for the micellar forms suggesting similar
endocytotic uptake and distribution mechanisms for both,
vesicles and micelles. It should be noted that only intact nano-
structures can be detected by uorescence in an intracellular
environment since the emission intensity of the free dye is
strongly diminished at neutral and acidic pH values (Fig. 2).
Therefore, the co-localization studies clearly suggest an endo-
somal location and, hence, a internalization by endocytosis can
be assumed. For further studies this behavior could be benecial
because the low pH value within these cellular compartments
should lead to a disassembly of the nanostructures and might
result in a release of the cargo. With the presented loading,
however, no pH dependent release can be investigated due to the
low solubility of the dye at neutral and acidic pH values.
Conclusion
In this contribution we describe the synthesis of block copoly-
mers with a neutral hydrophilic (EtOx) and a cationic hydro-
philic (AmOx) segment as well as the self-assembling behaviour
of the system into micelles and vesicles in organic solvents.
Glutaraldehyde mediated cross-linking resulted in the
formation of nanogels, which were covalently loaded with 6-
amino uorescein. A detailed characterization of these nano-
structures led to the conclusion that formation of either
micellar or vesicular structures, respectively, is signicantly
dependent upon the nature of the solvent used for assembly.
The presented nanogels exhibit a good biocompatibility for
concentrations of up to 5 mg mL1 and reveal a concentration
and time dependent uptake by cells, presumably by endocy-
tosis, as investigated by co-localization studies.
Further studies will focus on the immobilization of drugs
like cytostatica and the investigation of the release of these
compounds. Moreover, a variation of the zeta potential by
changing the degree of cross-linking will be studied in order to
control the interaction with cells and the rate of the uptake.
Experimental section
Information about materials and instrumentation can be found
in the ESI.†
Block copolymers of 2-ethyl-2-oxazoline (EtOx) and 2-(4-((tert-
butoxycarbonyl)amino)butyl)-2-oxazoline (BocOx) (P(EtOx-b-
BocOx)), (2–6)
In a microwave vial, EtOx (606 mL, 6 mmol), MeOTos (12.1 mL,
0.08 mmol) and acetonitrile (2.9 mL) were mixed under inert
conditions. Aer heating in the microwave synthesizer at 140 C
for 28 min, a solution of BocOx (500 mL, 2 mmol) in acetonitrile
(1.5 mL) was added through a syringe and the mixture was
heated again in the microwave synthesizer (140 C, 22 min). The
solution was precipitated in cold (80 C) diethyl ether. The
white precipitate was ltered and dried in high vacuum (994
mg, 92%).
1H NMR (CDCl3, 300 MHz) (6): d ¼ 7.67, (d, 8.1 Hz, 0.018H,
tosylate), 7.14 (d, 8.21 Hz, 0.018H, tosylate), 3.46 (s, 4H, back-
bone), 3.10 (s, 0.5H, CH2–CH2–NH (BocOx)), 2.50–2.15 (m,
1.96H, CH2 (EtOx)/CH2–CH2–NHBoc), 1.62 (s, 0.46H, CH2–CH2–
CH2 (BocOx)), 1.52 (s, 0.46H, CH2–CH2–CH2 (BocOx)), 1.42 (s,
2.1H, CH3 (BocOx)), 1.21 (s, 2.1H, CH3 (EtOx)) ppm.
Size exclusion chromatography (SEC) (6) (eluent: CHCl3/iso-
propanol/NEt3, PS-standard):Mn ¼ 7.600 g mol
1,Mw ¼ 9.000 g
mol1, Đ ¼ 1.18.
Deprotection of P(EtOx-b-BocOx) P(EtOx-b-AmOx), (7–11)
Exemplarily, P(EtOx-b-BocOx) (6, 500 mg) was dissolved in TFA
(5 mL) and heated to 60 C for 1 h. Aer stirring for 12 h at room
temperature, the mixture was diluted with 10 mL methanol and
precipitated in 200 mL of cold (80 C) diethyl ether. The
precipitate was re-dissolved in methanol (100 mL) and stirred
with Amberlyst A21 for 48 h. Subsequently, the solvent was
Fig. 7 Representative CLSM images of detached L929 cells after 24 h
incubation at 37 C with vesicles (15) at a concentration of 0.1 mg
mL1. Cell membranes (A2), cell nuclei (B2), or late endosomes/lyso-
somes (C2) were speciﬁcally stained and correlated with the ﬂuores-
cence signal of 6AF labeled vesicles (A1, B1, and C1). Superimposition
of both channels (A3, B3 and C3) proves an intracellular (A3) but extra-
nuclear (B3) localization of the vesicles and their apparent co-locali-
zation with endosomal structures (C3). Identical results were obtained
for micelles (ESI: Fig. S11†). Scale bar: 10 mm.
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removed, the polymer was dissolved in de-ionized water and
freeze dried (80 C, 0.003 mbar). The polymer was obtained as
white powder (456 mg, 91%).
1HNMR (N,N-dimethyl formamide (DMF)-D7, 300 MHz) (11):
d ¼ 5.37 (s, 1.7H, NH2),3.69 (s, 4H, backbone), 3.23 (s, 0.55H,
CH2–CH2–NH2), 2.78–2.45 (m, 2.1H, CH2 (EtOx)/CH2–CH2–CO
(AmOx)), 2.06–1.72 (m, 1.1H, CH2–CH2–CH2–CH2 (AmOx)), 1.2
(s, 2.5H, CH3 (EtOx)) ppm.
SEC (11) (eluent: DMAc/LiCl, PS-standard): Mn ¼ 15 600 g
mol1, Mw ¼ 20 300 g mol
1, Đ ¼ 1.30.
Determination of cloud point behavior in aqueous sodium
hydroxide solution
To investigate the cloud point behavior, P(EtOx-b-AmOx) was
dissolved in an aqueous solution of sodium hydroxide (5 wt%)
in concentrations varying from 2.5 to 20 mgmL1. The turbidity
was recorded as a function of the temperature, which was
modulated between 2 and 98 C in three cycles (1 C min1).
The cloud point was determined at 50% transmission. Cloud
points were measured in a Crystal 16 from Avantium Technol-
ogies connected to a chiller (Julabo FP 40) at a wavelength of 500
nm.
Self-assembly and cross-linking
To create nanostructures, the block copolymer (11, 150 mg,
0.015 mmol, 0.39 mmol of amine) was dissolved in the
respective solvent (MeOH, iPrOH or CHCl3, 5 mg mL
1) and
stirred for 3 h. Subsequently, glutaraldehyde (19.5 mg, 0.195
mmol, 0.5 eq. per amine) was added and the solution was
stirred for another 3 h. With proceeding reaction time the color
of the solution changed from colorless to yellow. To quench the
excess aldehyde function, diethylamine or 6-amino uorescein
was added, respectively, and stirred for 12 h. Subsequently, the
amount of solvent was reduced under an argon stream and the
residual was precipitated in 100 mL cold diethyl ether (80 C).
To purify the self-assembled structures from residual amine
and cross-linker, dialysis in MeOH–water (1 : 4) was applied
using a membrane with a molar mass cut oﬀ of 3500 g mol1
(Roth Zellutrans). Aer the extraction was nished, the dialysis
medium was changed to pure water and the aqueous solution
was freeze dried to yield an orange powder (140 mg). The size
distribution of all intermediate steps was examined by dynamic
light scattering (DLS) measurements.
Determination of dye loading content by absorbance/
uorescence
The absorbance/uorescence of nanostructures was investi-
gated under alkaline conditions (1 mol L1 NaOH in water) in
diluted solution (0.1, 0.05 and 0.025 mg mL1). The absorbance
was determined at a wavelength of 490 nm and compared to a
dilution series of 6AF in the same aqueous NaOH solution. To
the 6AF stock solution a 100 fold excess of glutaraldehyde was
added to ensure that only the imine species of 6AF is present.
Emission was detected at an excitation wavelength of 450 nm.
Micellar samples as well as 6AF calibration exhibit an emission
maximum at 510 nm. All measurements were carried out in a 96
well-plate format with 200 mL per well and double determina-
tion for each measuring point. The read out was accomplished
using a Tecan M200 Pro uorescence micro plate reader
(Crailsheim, Germany). DEA loaded nanostructures served as a
reference for all measurements.
Cytotoxicity assay
For the cytotoxicity screening, the mouse broblast cell line
L929 was purchased from a commercial cell bank (Cell line
service, Eppelheim, Germany). The cells were routinely cultured
as follows: cell culture media Dulbecco's modied eagle's
medium (DMEM) was supplemented with 10% fetal calf serum,
100 U mL1 penicillin, and 100 mg mL1 streptomycin (all
components from Biochrom, Berlin, Germany) at 37 C in a
humidied atmosphere with 5% (v/v) CO2. The cytotoxicity was
determined using a XTT assay following the ISO/EN 10993 part 5
protocol: cells were seeded in 96-well plates at a density of 1 
104 cells per well and grown as monolayer cultures for 24 h. The
cells were subsequently incubated separately with diﬀerent
concentrations of the micelles and vesicles (from 0.005 to 5 mg
mL1) for 24 h. Control cells were incubated with fresh culture
medium. Aer incubation, the cells were washed once with PBS
and a mixture of 100 mL fresh medium and 50 mL of a XTT
solution, prepared according to the manufacturer's instruc-
tions, were added to each well. Aer 4 h at 37 C, 100 mL of each
solution were transferred to a new micro titer plate and the
optical density (OD) was measured photometrically. The control
was standardized as 0% of metabolism inhibition and referred
as 100% viability. Cell viability below 70% was considered
indicative of cytotoxicity. Data are expressed as mean SD of six
determinations.
Photometrical and microscopical methods
For the photometric absorbance measurements, a TECAN
Innite M200 PRO plate reader (TECAN, Crailsheim, Germany)
was used to measure the absorption of samples from the XTT
cytotoxicity assay (570 nm with a background correction of the
optical density (OD) at 690 nm). Each well containing the
sample was measured in four diﬀerent spots each with 25
ashes per scan.
The evaluation of micelles/vesicles uptake was performed by
ow cytometry (FC) measured on a Beckmann Coulter Cytomics
FC-500 equipped with Uniphase Argon ion laser, 488 nm, 20
mW output and analyzed with the Cytomics CXP soware. For
time dependent uptake, cells (L929) were incubated between 30
min and 24 h with micelles (13)/vesicles (15) at a concentration
of 0.5 mg mL1, whereas the concentration dependent uptake
was investigated over an incubation time of 24 h using micelle/
vesicle concentrations in the range between 0.05 and 0.5 mg
mL1. Cells incubated with culture medium only served as
control. Data are expressed as mean  SD of three determina-
tions. To visualize the viability of cells aer incubation with the
micelles/vesicles as well as for the time/concentration depen-
dent kinetic studies on cellular uptake, the blue/red/green
uorescence signal of cells cultured in a 96 well plate and
stained with Hoechst 33342 and propidium iodide (PI) was
This journal is © The Royal Society of Chemistry 2015 J. Mater. Chem. B, 2015, 3, 1748–1759 | 1757
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observed on a Cell Observer Z1 uorescence microscope (Carl
Zeiss, Jena, Germany) equipped with amercury arc UV lamp and
the appropriate lter combinations for excitation and detection
of emission. Images of a series were captured with a 40
objective using identical instrument settings (e.g. UV lamp
power, integration time, camera gain) and cell-spots in the 96
well plate were addressed using an automated XY table.
For CLSM analysis of uptake and co-localization with cell
organelle, the nuclei, late endosomes/lysosomes and cell
membranes were either stained with SYTO®Red 59, Lyso-
Tracker Red or Cell Mask Orange. CLSM images were acquired
using a Zeiss LSM 510 META (Carl Zeiss) with excitation wave-
lengths/emission lters of 633 nm/LP 650 nm for SYTO®Red
and 543 nm/BP 585 to 615 nm for LysoTracker Red and Cell
Mask Orange respectively.
Images were captured with a Plan-Apochromat 63 objective
and in multitrack mode, enabling single excitation and emis-
sion of uorescence dyes. Co-localization was visualized in
overlay images of the multiple channels.
Microscopic evaluation of cell viability. In addition to the
above described measurement of the metabolic cell activity by
the XTT assay, viability of the cells aer exposure to the micelles
and vesicles was examined microscopically using a propidium
iodide (PI)/Hoechst staining assay. Aer incubation with the
test substances, the cells were washed once with PBS,
submerged with medium containing PI (10 mg mL1) and
Hoechst 33342 (10 mg mL1) and incubated for 10 min at 37 C.
During that time, PI enters into the nuclei of dead cells via the
leaky cell membrane, whereas the dye is kept outside of viable
cells. Hoechst dye is capable of uorescently labeling nuclei of
dead and viable cells and was used to tag the entire cell
collective. The blue (Hoechst), red (PI), and green (6AF labeled
vesicles and micelles) uorescence signals of cells were
captured on a uorescence microscope.
Fluorescence microscopy for kinetic studies on cellular uptake
of micelles (13)/vesicles (15)
For kinetic investigations concerning a concentration depen-
dent uptake, the cells, growing as a semiconuent cell layer in 6
well plates, were incubated separately with diﬀerent concen-
trations (0.05, 0.1, 0.25 and 0.5 mg mL1) of micelles and
vesicles for 24 h at 37 C under 5% CO2 atmosphere. Control
cells were incubated with fresh culture medium. Aer incuba-
tion, the solutions were aspirated from the wells and any excess
materials were removed by washing the cell layer three times
with PBS. For ow cytometry, the adherent cells were detached
by trypsin treatment and 10.000 cells were analyzed using gates
of forward and side scatters to exclude debris and cell aggre-
gates. For microscopic analysis, the adherent cells were addi-
tionally stained with Hoechst 33342 (10 mg mL1) and
immediately subjected to uorescence imaging.
For kinetic investigation concerning a time dependent
uptake, cells were treated with 0.5 mg mL1 of micelles or
vesicles for 0.5 h, 1 h, 3 h, 12 h and 24 h at 37 C under 5% CO2
atmosphere. Subsequent analysis was performed as mentioned
above.
Co-localization study
In order to analyze the micelle/vesicle uptake and co-localiza-
tion with cell organelle, adherent cells were treated with 0.1 mg
mL1 of micelles/vesicles for 24 h at 37 C under 5% CO2
atmosphere. Subsequently, the nuclei, late endosomes/lyso-
somes and cell membranes were stained with Hoechst 33342
and LysoTracker Red or Cell Mask Orange according to manu-
factures instructions (all dyes from Life Technologies, Darm-
stadt, Germany) and the adherent cell populations were,
subsequently, subjected to microscopic investigation immedi-
ately using an epiuorescence microscope. In order to prove an
eﬀective internalization of the uorescent micelles (13)/vesicles
(15) and to exclude a false positive uorescence signal by a
simple adsorption on the extracellular leaet of the cell
membrane, CLSM was utilized to perform an optical z-
sectioning through the cells. For that purpose, adherent cells
were enzymatically detached aer the above mentioned incu-
bation with the micelles/vesicles. The nuclei, late endosomes/
lysosomes and cell membranes were stained with SYTO®Red
59, LysoTracker Red or Cell Mask Orange according to manu-
factures instructions and, subsequently, xed with 4% para-
formaldehyde dissolved in PBS. Aliquots of the cell suspensions
were then transferred onto microscopic slides, decorated with
coverslips and subjected to CLSM analysis.
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I Materials and instrumentation
Chemicals and solvents were purchased from Sigma-Aldrich, Merck, Fluka, and Acros. 2-
Ethyl-2-oxazoline (EtOx) and methyl tosylate (MeOTos) were distilled to dryness prior to use. 
EtOx was dried using barium oxide before distillation. 2-(4-((tert-Butoxycarbonyl)amino)butyl)-
2-oxazoline (BocOx) was synthesized as described in a previous publication.1
The Initiator Sixty single-mode microwave synthesizer from Biotage, equipped with a non-
invasive IR sensor (accuracy: 2%), was used for polymerizations under microwave irradiation. 
1
Electronic Supplementary Material (ESI) for Journal of Materials Chemistry B.This journal is © The Royal Society of Chemistry 2015
Microwave vials were heated overnight to 110 °C and allowed to cool to room temperature under 
argon atmosphere before use. All polymerizations were carried out under temperature control. 
Size-exclusion chromatography (SEC) of protected polymers was performed on a Shimadzu 
system equipped with a SCL-10A system controller, a LC-10AD pump, a RID-10A refractive 
index detector and a PSS SDV column with chloroform/triethylamine (NEt3)/iso-propanol 
(94:4:2) as eluent. The column oven was set to 50 °C. SEC of the deprotected statistical 
copolymers was performed on a Shimadzu system with a LC-10AD pump, a RID-10A refractive 
index detector, a system controller SCL-10A, a degasser DGU-14A, and a CTO-10A column 
oven using N,N-dimethyl acetamide (DMAc) with 2.1 g L-1 LiCl as the eluent and the column 
oven set to 50 °C. Poly(styrene) (PS) samples were used as calibration standards for both solvent 
systems. Proton NMR spectroscopy (1H NMR) measurements were performed at room 
temperature on a Bruker AC 300 and 400 MHz spectrometer, using CDCl3 or N,N dimethyl 
formamide (DMF)-D7 as solvents. The chemical shifts are given in ppm relative to the signal of 
the residual non-deuterated solvent.
Batch dynamic light scattering (DLS) was performed on a Zetasizer Nano ZS (Malvern 
Instruments, Herrenberg, Germany). All measurements were performed in folded capillary cells 
(DTS1071, Malvern Instruments, Herrenberg, Germany). After an equilibration time of 180 s, 
3 × 30 s runs were carried out at 25 °C (λ = 633 nm). The counts were detected at an angle of 
173°. Each measurement was performed in triplicate. Apparent hydrodynamic radii, Rh, were 
calculated according to the Stokes–Einstein equation.
Laser Doppler velocimetry was used to measure the electrokinetic potential, also known as 
zeta potential. The measurements were performed on a Zetasizer Nano ZS (Malvern Instruments, 
Herrenberg, Germany) in folded capillary cells (DTS1071). For each measurement, 15 runs were 
2
carried out using the fast-field and slow-field reversal mode at 150 V. Each experiment was 
performed in triplicate at 25 °C. The zeta potential (ζ) was calculated from the electrophoretic 
mobility (μ) according to the Henry Equation.2 The Henry coefficient, f(ka), was calculated 
according to Ohshima.3
Cryo-TEM investigations were conducted with a FEI Tecnai G2 20 at 200 kV acceleration 
voltage. Specisms were vitrified by a Vitrobot Mark V system on Quantifoil grids (R2/2). The 
blotting time was 1 s with blotting force offset of 0. The amount of solution was 7 µL. Samples 
were plunge frozen in liquid ethane and stored under liquid nitrogen until transferred to the 
Gatan ncryo-holder and brought into the microscope. Images were acquired with a 4k × 4k CCD 
Eagle camera.
Solid state (ss) NMR spectroscopy
One-dimensional (1D) natural abundance 13C cross polarization magic angle spinning ssNMR 
spectroscopy was carried out using a Bruker Avance II spectrometer operating at 1H (13C) 
frequencies of 500 (125) MHz and using a 3.2 mm triple resonance probe. Sample temperature 
was 293 K at 20 kHz spinning frequency. Cross polarization (CP) contact time was 1.5 ms, and 
1H decoupling was performed using 90 kHz decoupling field strength. Final spectra were 
collected with 295006 scans and a 2 s recycle time, processed (exponential window function; 
line broadening 20 Hz) and evaluated with Bruker Topspin. Referencing was relative to 
Adamantan, setting the methine line to 29.46 ppm relative to neat trimethylsilane.4
3
Asymmetric flow field-flow fractionation (AF4)
Asymmetric flow field-flow fractionation (AF4) was performed on an AF2000 MT System 
(Postnova Analytics, Landsberg, Germany) coupled to an UV (PN3211, 260 nm), RI (PN3150), 
MALLS (PN3070, 633 nm) and DLS (ZetaSizerNano ZS, 633 nm) detector. The eluent is 
delivered by two different pumps (tip and focus-flow) and the sample is injected by an auto-
sampler (PN5300) into the channel. The channel has a trapezoidal geometry and an overall area 
of 31.6 cm². The nominal height of the spacer was 500 µm and a regenerated cellulose 
membrane with a molar mass cut-off of 10,000 g mol-1 was used as accumulation wall. All 
experiments were carried out at 25 °C. For molar mass determination of the polymers, the eluent 
was composed of 25 mM acetate buffer at a pH value of 3.5 and 20 mM NaCl. The detector flow 
rate was set to 0.5 mL min-1 for all samples and 50 µL (5 mg mL-1) were injected with an 
injection flow rate of 0.2 mL min-1 for 7 min. For all samples the cross-flow was set to 
1.8 mL min-1. After the focusing period and a transition time of 1 min, the cross flow was kept 
constant for 3 min and then decreased under a power function gradient (0.4) to 0 within 15 min. 
Afterwards, the cross-flow was kept constant at zero for at least 20 min to ensure complete 
elution. For characterization of the colloidal structures, the eluent was 0.025% NovaChem 
Surfactant 100 detergents mix. The detector flow rate was set to 0.5 mL min-1 for all samples and 
20 µL (5 mg mL-1) were injected with an injection flow rate of 0.2 mL min-1 for 7 min. For all 
samples the cross-flow was set to 1.0 mL min-1. After the focusing period and a transition time of 
1 min, the cross flow was kept constant for 2 min and then decreased under a power function 
gradient (0.4) to 0 within 18 min. Afterwards, the cross-flow was kept constant at zero for at 
least 25 min to ensure complete elution. For calculation of the molar mass and the radius of 
gyration, a Zimm plot was used. All measurements were repeated three times. The refractive 
4
index increment (dn/dc) of all samples was measured by manual injection of a known 
concentration directly into the channel without any focusing or cross-flow. The dn/dc was 
calculated as the average of at least three injections from the area under the RI curve (AUCRI).
II Analytics of P(EtOx)-b-(BocOx) and P(EtOx)-b-(AmOx)
Figure S1. 1H NMR spectra (300 MHz, CDCl3) and size exclusion chromatograms 
(chloroform/NEt3/iso-propanol) of the protected block copolymers (P(EtOx-b-BocOx, 2-6) with 
BocOx-contents between 5 and 22%.
5
Figure S2. 1H NMR spectra (300 MHz, DMF-D7) and size exclusion chromatograms (N,N-
dimethyl acetamide) of the deprotected block copolymers (P(EtOx-b-AmOx, 7-11) with AmOx-
contents between 5 and 29%.
Table S1. Asymmetric flow field flow fractionation (AF4) data of the deprotected block 
copolymers.
Sample dn/dc [mL g-1]
Mn  
[g mol-1]
Error 
[g mol-1]
Mw 
[g mol-1]
Error 
[g mol-1]
Mz 
[g mol-1]
Error 
[g mol-1] Ð Error
Rec 
[%]
Error 
[%]
7 0.153 11,700 670 12,900 530 14,000 560 1.10 0.024 73.7 0.1
8 0.160 9,200 360 10,500 840 11,300 860 1.14 0.065 74.9 0.9
9 0.153 13,300 340 14,600 270 15,900 260 1.10 0.008 77.6 0.3
10 0.156 13,600 430 14,900 450 16,600 820 1.09 0.003 77.1 0.5
11 0.139 12,500 500 15,700 180 18,100 380 1.26 0.039 75.9 0.9
6
Figure S3. Cloud-points of P(EtOx-b-AmOx) in dependency of the concentration.
In a recent publication we described the formation of cationic hydrogels, originating from 
statistical copolymers P(EtOx-stat-AmOx) with comparable compositions, which were formed 
due to phase separation during the gelation leading to micron-sized hydrogel beads.5 Such a 
behavior was observed under strong alkaline conditions (5 wt% aqueous NaOH) at elevated 
temperatures (50 °C). As a consequence, the prepared P(EtOx-b-AmOx) block copolymers were 
investigated regarding their LCST behavior at the conditions described earlier, revealing a 
similar phase transition (Figure S3). However, also a PEtOx homopolymer was included into the 
study and exhibited a lower Tcp than any of the copolymers. This prompted us to conclude that 
PEtOx is the segment which undergoes phase separation upon heating. This can be explained by 
a chaotropic influence of the high hydroxyl ion concentration in solution.6, 7 Therefore, the phase 
separation at these conditions cannot be exploited to create micellar systems with the cationic 
building block in the core since PEtOx collapses at increasing temperatures.
7
III Analytics of cross-linked and non-cross-linked self-assembled structures.
Figure S4. DLS size distributions and correlation functions of P(EtOx-b-AmOx) in organic 
solvents (1 mg mL-1).
8
Figure S5. DLS size distributions of cross-linked nanostructures in water.
Figure S6. AF4 elugrams of cross-linked nanostructures (in 0.025% NovaChem Surfactant 
100 detergents mix).
9
Figure S7. Comparison of the 1H NMR spectra of polymer 11 in CDCl3 (self-assembly) and 
DMF-D7 (no assembly).
10
Figure S8. Solid state 13C NMR spectra of different 6AF forms and micelles with (13) and 
without (12) 6AF. Commercial, microcrystalline 6AF, amorphous 6AF and KOH-induced ring-
opened 6AF were analyzed by natural abundance 13C CP MAS ssNMR. All MAS ssNMR 
spectra were acquired at 293 K, with 295006 scans, 2 s recycle time and a CP contact time of 
1.5 ms. Microcrystalline 6AF was used as commercially supplied, amorphous 6AF was produced 
by dissolving commercial 6AF in MeOH, flash-freezing in liquid N2 and subsequent 
lyophilisation; ring-open 6AF was derived from microcrystalline material by dissolving it in 1 M 
KOH, subsequent flash-freezing and lyophilisation.
11
IV Cellular uptake and co-localization studies of nano-assemblies.
Figure S9. Fluorescence microscopy images on the concentration dependent uptake of dye 
containing micelles (13)/vesicles (15) by L929 mouse fibroblasts. Cells were incubated for 24 h 
using micelle/vesicle concentrations in the range between 0.05 and 0.5 mg mL-1. Cells incubated 
with culture medium only served as control. The cell nuclei were stained with blue fluorescent 
Hoechst 33342. Shown are fluorescence images resulting from superimposing the blue and green 
channels. Increasing green fluorescence emitted by the dye-containing micelles/vesicles indicates 
a concentration dependent internalization of both structures with an elevated uptake of vesicles 
vs. micelles. Scale bar 50 µm.
12
Figure S10. Representative bright field (A1 and B1) and epifluorescence images of adherent 
L929 cells after 24 h incubation at 37 °C in the presence of micelles (13) at a concentration of 
0.1 mg mL-1. Cell nuclei (A2 and B2), cell membranes (A3) or late endosomes/lysosomes (B3) 
were specifically stained and their fluorescence signal was captured in addition to the 
fluorescence signal originating from the internalized 6AF labeled vesicles (A4 and B4). 
Superimposition of all four channels (A5 and B5). Scale bar: 20 µm.
13
Figure S11. Representative CLSM images of detached L929 cells after 24 h incubation at 37 °C 
in the presence of micelles (13) at a concentration of 0.1 mg mL-1. Cell membranes (A2), cell 
nuclei (B2), or late endosomes/lysosomes (C2) were specifically stained and correlated with the 
fluorescence signal of 6AF labeled micelles (A1, B1, and C1). Superimposition of both channels 
(A3, B3 and C3) proves intracellular (A3) but extra-nuclear (B3) localization of the vesicles and 
their apparent co-localization with lysosomal structures (C3). Scale bar: 10 µm.
14
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